IARC MONOGRAPHS
ON THE
EVALUATION OF CARCINOGENIC RISKS TO HUMANS

Pharmaceutical Drugs

VOLUME 50

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 17-24 October 1989

1990
In 1969, the International Agency for Research on Cancer (IARC) initiated a programme on the evaluation of the carcinogenic risk of chemicals to humans involving the production of critically evaluated monographs on individual chemicals. In 1980 and 1986, the programme was expanded to include the evaluation of the carcinogenic risks associated with exposures to complex mixtures and other agents.

The objective of the programme is to elaborate and publish in the form of monographs critical reviews of data on carcinogenicity for agents to which humans are known to be exposed, and on specific exposure situations; to evaluate these data in terms of human risk with the help of international working groups of experts in chemical carcinogenesis and related fields; and to indicate where additional research efforts are needed.

This project is supported by PHS Grant No. 6 U01 CA33193–06 awarded by the US National Cancer Institute, Department of Health and Human Services. Additional support has been provided since 1986 by the Commission of the European Communities.

©International Agency for Research on Cancer 1990

ISBN 92 832 1250 9
ISSN 0250–9555

All rights reserved. Application for rights of reproduction or translation, in part or in toto, should be made to the International Agency for Research on Cancer.

Distributed for the International Agency for Research on Cancer by the Secretariat of the World Health Organization

PRINTED IN THE UK
CONTENTS

NOTE TO THE READER ............................................. 5
LIST OF PARTICIPANTS .............................................. 7
PREAMBLE
- Background ...................................................... 11
- Objective and Scope ........................................... 11
- Selection of Topics for Monographs ......................... 12
- Data for Monographs .......................................... 13
- The Working Group ............................................ 13
- Working Procedures ........................................... 14
- Exposure Data .................................................. 14
- Biological Data Relevant to the Evaluation of Carcinogenicity to Humans ............................................. 16
- Evidence for Carcinogenicity in Experimental Animals .... 17
- Other Relevant Data in Experimental Systems and in Humans ......................................................... 19
- Evidence for Carcinogenicity in Humans .................... 21
- Summary of Data Reported ................................... 24
- Evaluation ....................................................... 25
- References ...................................................... 29
GENERAL REMARKS ............................................... 33
THE MONOGRAPHS
- Antineoplastic and immunosuppressive agents
  - Azacitidine ................................................... 47
  - Chlorozotocin ................................................ 65
  - Ciclosporin .................................................. 77
  - Prednimustine ............................................... 115
  - Thiotepa ..................................................... 123
  - Trichlormethine (Trimustine hydrochloride) ............... 143
# CONTENTS

## Antimicrobial agents
- Ampicillin .................................................. 153
- Chloramphenicol .......................................... 169
- Nitrofural (Nitrofurazone) .............................. 195
- Nitrofurantoin ............................................. 211

## Other drugs
- Cimetidine .................................................. 235
- Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone) ..................... 265
- Furosemide (Frusemide) .................................... 277
- Hydrochlorothiazide ....................................... 293
- Paracetamol (Acetaminophen) ................................ 307

## SUMMARY OF FINAL EVALUATIONS .................. 333

## APPENDIX 1. SUMMARY TABLE OF GENETIC AND RELATED EFFECTS .................. 335

## APPENDIX 2. ACTIVITY PROFILES FOR GENETIC AND RELATED EFFECTS ........... 337

## SUPPLEMENTARY CORRIGENDA TO VOLUMES 1-49 .................. 385

## CUMULATIVE INDEX TO THE MONOGRAPHS SERIES ........... 387
NOTE TO THE READER

The term 'carcinogenic risk' in the IARC Monographs series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the Monographs does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.
LIST OF PARTICIPANTS

Members

I.N. Chernozemsky, National Oncological Centre, Medical Academy, Darvenitza, Sofia 1156, Bulgaria
L. Fiore-Donati, Istituto di Anatomia e Istologia Patologica, Verona University, Policlinico Borgo Roma, 37100 Verona, Italy
G.D. Friedman, Division of Research, Kaiser Permanente Medical Care Program, Northern California Region, 3451 Piedmont Avenue, Oakland, CA 94611, USA
B. Holmberg, Department of Toxicology, National Institute of Occupational Health, 171 84 Solna, Sweden
L.J. Kinlen, Cancer Research Campaign Epidemiology Unit, University of Edinburgh, 15 George Square, Edinburgh EH8 9JZ, UK
M. Marselos, Department of Pharmacology, Medical School, University of Ioannina, Ioannina 45110, Greece
M. Mattila, Department of Clinical Pharmacology, University of Helsinki, Department of Clinical Pharmacology, University of Helsinki, Paasikivenkatu 4, 00250 Helsinki, Finland
G. Obe, Universität GSH Essen, Fachbereich 9, Department of Genetics, PO Box 103 764, 4300 Essen 1, Federal Republic of Germany
J.H. Olsen, Danish Cancer Registry, Rosenvængets Hovedvej 35, Box 839, 2100 Copenhagen Ø, Denmark
N.V. Popova, Laboratory of Carcinogenic Substances, All-Union Cancer Research Centre, Kashirskoye Shosse 24, 115478 Moscow, USSR
J.P. Seiler, Swiss Federal Research Station for Fruit-Growing, Viticulture and Horticulture, 8820 Wädenswil, Switzerland

S. Shapiro, Boston University Medical School, Slone Epidemiology Unit, 1371 Beacon Street, Brookline, MA 02146, USA

S.M. Sieber, Division of Cancer Etiology, National Cancer Institute, Building 31, Room 11A03, Bethesda, MD 20892, USA

M. Sorsa, Institute of Occupational Health, Topeliuksenkatu 41 a A, 00250 Helsinki, Finland (Vice-Chairperson)

R. Stahlmann, Institut für Toxikologie und Embryonal Pharmakologie der Freien Universität Berlin, Garystrasse 1-9, 100 Berlin 33, Federal Republic of Germany

B. Stewart, Children’s Leukaemia and Cancer Research Unit, The Prince of Wales Children’s Hospital, High Street, Randwick, NSW 2031, Australia

F.M. Sullivan, Department of Pharmacology, Guy’s Hospital Medical School, London SE1 9RT, UK

J. Weissinger, Office of Drug Evaluation (HFD-502), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, USA

G.M. Williams, American Health Foundation, Dana Road, Valhalla, NY 10595, USA (Chairman)

K. Yokoro, Hiroshima University, Institute of Nuclear Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan

Representatives and observers

Representative of the International Federation of Pharmaceutical Manufacturers’ Associations

E. Longstaff, Safety Medicines Department, ICI Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK

Representative of the US Pharmaceutical Manufacturers’ Association

M.J. Tidd, Norwich Eaton Pharmaceuticals Inc., PO Box 191, Norwich, NY 13815-0191, USA

---

1 Present address: Interkantonale Kontrollstelle für Heilmittel (IKS), Erlachstrasse 8, 3000 Bern, Switzerland

2 Unable to attend, M.-Th. van der Venne, Commission of the European Communities, Health and Safety Directorate, Bâtiment Jean Monnet (C4/83), BP 1907, 2920 Luxembourg, Grand Duchy of Luxembourg
Secretariat

A. Aitio, Laboratory of Biochemistry, Institute of Occupational Health, Arinatie 3, 00370 Helsinki, Finland

H. Bartsch, Unit of Environmental Carcinogenesis and Host Factors

X. Bosch, Unit of Field Intervention Studies

E. Cardis, Unit of Biostatistical Research and Informatics

J. Cheney, Editorial, Translation and Publication Services

M. Coleman, Unit of Descriptive Epidemiology

M. Friesen, Unit of Environmental Carcinogenesis and Host Factors

E. Heseltine, Montignac, France

J. Jongen, Unit of Mechanisms of Carcinogenesis

J. Kaldor, Unit of Biostatistics Research and Informatics

V. Krutovskikh, Unit of Mechanisms of Carcinogenesis

K. L’Abbé, Unit of Analytical Epidemiology

D. McGregor, Unit of Carcinogen Identification and Evaluation

D. Mietton, Unit of Carcinogen Identification and Evaluation

R. Montesano, Unit of Mechanisms of Carcinogenesis

S. Narod, Unit of Mechanisms of Carcinogenesis

G. Nordberg, Unit of Carcinogen Identification and Evaluation

C. Partensky, Unit of Carcinogen Identification and Evaluation

I. Peterschmitt, Unit of Carcinogen Identification and Evaluation, Geneva, Switzerland

D. Shuker, Unit of Environmental Carcinogenesis and Host Factors

L. Shuker, Unit of Carcinogen Identification and Evaluation

L. Tomatis, Director

H. Vainio, Unit of Carcinogen Identification and Evaluation

J. Wilbourn, Unit of Carcinogen Identification and Evaluation

Secretarial assistance

J. Cazaux

M. Lézère

S. Reynaud
IARC MONOGRAPHS PROGRAMME ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS

PREAMBLE

1. BACKGROUND

In 1969, the International Agency for Research on Cancer (IARC) initiated a programme to evaluate the carcinogenic risk of chemicals to humans and to produce monographs on individual chemicals. The Monographs programme has since been expanded to include consideration of exposures to complex mixtures of chemicals (which occur, for example, in some occupations and as a result of human habits) and of exposures to other agents, such as radiation and viruses. With Supplement 6(1), the title of the series was modified from IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans to IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, in order to reflect the widened scope of the programme.

The criteria established in 1971 to evaluate carcinogenic risk to humans were adopted by the working groups whose deliberations resulted in the first 16 volumes of the IARC Monographs series. Those criteria were subsequently re-evaluated by working groups which met in 1977(2), 1978(3), 1979(4), 1982(5) and 1983(6). The present preamble was prepared by two working groups which met in September 1986 and January 1987, prior to the preparation of Supplement 7(7) to the Monographs and was modified by a working group which met in November 1988(8).

2. OBJECTIVE AND SCOPE

The objective of the programme is to prepare, with the help of international working groups of experts, and to publish in the form of monographs, critical

---

1This project is supported by PHS Grant No. 5 U01 CA33193-07 awarded by the US National Cancer Institute, Department of Health and Human Services, and with a subcontract to Tracor Technology Resources, Inc. Since 1986, this programme has also been supported by the Commission of the European Communities.
reviews and evaluations of evidence on the carcinogenicity of a wide range of human exposures. The *Monographs* may also indicate where additional research efforts are needed.

The *Monographs* represent the first step in carcinogenic risk assessment, which involves examination of all relevant information in order to assess the strength of the available evidence that certain exposures could alter the incidence of cancer in humans. The second step is quantitative risk estimation, which is not usually attempted in the *Monographs*. Detailed, quantitative evaluations of epidemiological data may be made in the *Monographs*, but without extrapolation beyond the range of the data available. Quantitative extrapolation from experimental data to the human situation is not undertaken.

These monographs may assist national and international authorities in making risk assessments and in formulating decisions concerning any necessary preventive measures. The evaluations of IARC working groups are scientific, qualitative judgements about the degree of evidence for carcinogenicity provided by the available data on an agent. These evaluations represent only one part of the body of information on which regulatory measures may be based. Other components of regulatory decisions may vary from one situation to another and from country to country, responding to different socioeconomic and national priorities. Therefore, no recommendation is given with regard to regulation or legislation, which are the responsibility of individual governments and/or other international organizations.

The *IARC Monographs* are recognized as an authoritative source of information on the carcinogenicity of chemicals and complex exposures. A users' survey, made in 1988, indicated that the *Monographs* are consulted by various agencies in 57 countries. Each volume is generally printed in 4000 copies for distribution to governments, regulatory bodies and interested scientists. The *Monographs* are also available via the Distribution and Sales Service of the World Health Organization.

3. SELECTION OF TOPICS FOR MONOGRAPHS

Topics are selected on the basis of two main criteria: (a) that they concern agents and complex exposures for which there is evidence of human exposure, and (b) that there is some evidence or suspicion of carcinogenicity. The term agent is used to include individual chemical compounds, groups of chemical compounds, physical agents (such as radiation) and biological factors (such as viruses) and mixtures of agents such as occur in occupational exposures and as a result of personal and cultural habits (like smoking and dietary practices). Chemical analogues and compounds with biological or physical characteristics similar to those of suspected carcinogens may also be considered, even in the absence of data on carcinogenicity.
The scientific literature is surveyed for published data relevant to an assessment of carcinogenicity; the IARC surveys of chemicals being tested for carcinogenicity(9) and directories of on-going research in cancer epidemiology(10) often indicate those exposures that may be scheduled for future meetings. An ad-hoc working group convened by IARC in 1984 gave recommendations as to which chemicals and exposures to complex mixtures should be evaluated in the IARC Monographs series(11,12).

As significant new data on subjects on which monographs have already been prepared become available, re-evaluations are made at subsequent meetings, and revised monographs are published.

4. DATA FOR MONOGRAPHS

The Monographs do not necessarily cite all the literature concerning the subject of an evaluation. Only those data considered by the Working Group to be relevant to making the evaluation are included.

With regard to biological and epidemiological data, only reports that have been published or accepted for publication in the openly available scientific literature are reviewed by the working groups. In certain instances, government agency reports that have undergone peer review and are widely available are considered. Exceptions may be made on an ad-hoc basis to include unpublished reports that are in their final form and publicly available, if their inclusion is considered pertinent to making a final evaluation (see pp. 25 et seq.). In the sections on chemical and physical properties and on production, use, occurrence and analysis, unpublished sources of information may be used.

5. THE WORKING GROUP

Reviews and evaluations are formulated by a working group of experts. The tasks of this group are five-fold: (i) to ascertain that all appropriate data have been collected; (ii) to select the data relevant for the evaluation on the basis of scientific merit; (iii) to prepare accurate summaries of the data to enable the reader to follow the reasoning of the Working Group; (iv) to evaluate the results of experimental and epidemiological studies; and (v) to make an overall evaluation of the carcinogenicity of the exposure to humans.

Working Group participants who contributed to the considerations and evaluations within a particular volume are listed, with their addresses, at the beginning of each publication. Each participant who is a member of a working group serves as an individual scientist and not as a representative of any organization, government or industry. In addition, representatives from national and international agencies and industrial associations are invited as observers.
6. WORKING PROCEDURES

Approximately one year in advance of a meeting of a working group, the topics of the monographs are announced and participants are selected by IARC staff in consultation with other experts. Subsequently, relevant biological and epidemiological data are collected by IARC from recognized sources of information on carcinogenesis, including data storage and retrieval systems such as CHEMICAL ABSTRACTS, MEDLINE and TOXLINE—including EMIC and ETIC for data on genetic and related effects and teratogenicity, respectively.

The major collection of data and the preparation of first drafts of the sections on chemical and physical properties, on production and use, on occurrence, and on analysis are carried out under a separate contract funded by the US National Cancer Institute. Efforts are made to supplement this information with data from other national and international sources. Representatives from industrial associations may assist in the preparation of sections on production and use.

Production and trade data are obtained from governmental and trade publications and, in some cases, by direct contact with industries. Separate production data on some agents may not be available because their publication could disclose confidential information. Information on uses is usually obtained from published sources but is often complemented by direct contact with manufacturers.

Six months before the meeting, reference material is sent to experts, or is used by IARC staff, to prepare sections for the first drafts of monographs. The complete first drafts are compiled by IARC staff and sent, prior to the meeting, to all participants of the Working Group for review.

The Working Group meets in Lyon for seven to eight days to discuss and finalize the texts of the monographs and to formulate the evaluations. After the meeting, the master copy of each monograph is verified by consulting the original literature, edited and prepared for publication. The aim is to publish monographs within nine months of the Working Group meeting.

7. EXPOSURE DATA

Sections that indicate the extent of past and present human exposure, the sources of exposure, the persons most likely to be exposed and the factors that contribute to exposure to the agent, mixture or exposure circumstance are included at the beginning of each monograph.

Most monographs on individual chemicals or complex mixtures include sections on chemical and physical data, and production, use, occurrence and analysis. In other monographs, for example on physical agents, biological factors, occupational exposures and cultural habits, other sections may be included, such
The Chemical Abstracts Services Registry Number, the latest Chemical Abstracts Primary Name and the IUPAC Systematic Name are recorded. Other synonyms and trade names are given, but the list is not necessarily comprehensive. Some of the trade names may be those of mixtures in which the agent being evaluated is only one of the ingredients.

Information on chemical and physical properties and, in particular, data relevant to identification, occurrence and biological activity are included. A separate description of technical products gives relevant specifications and includes available information on composition and impurities.

The dates of first synthesis and of first commercial production of an agent or mixture are provided; for agents which do not occur naturally, this information may allow a reasonable estimate to be made of the date before which no human exposure to the agent could have occurred. The dates of first reported occurrence of an exposure are also provided. In addition, methods of synthesis used in past and present commercial production and different methods of production which may give rise to different impurities are described.

Data on production, foreign trade and uses are obtained for representative regions, which usually include Europe, Japan and the USA. It should not, however, be inferred that those areas or nations are necessarily the sole or major sources or users of the agent being evaluated.

Some identified uses may not be current or major applications, and the coverage is not necessarily comprehensive. In the case of drugs, mention of their therapeutic uses does not necessarily represent current practice nor does it imply judgement as to their clinical efficacy.

Information on the occurrence of an agent or mixture in the environment is obtained from data derived from the monitoring and surveillance of levels in occupational environments, air, water, soil, foods and animal and human tissues. When available, data on the generation, persistence and bioaccumulation are also included. In the case of mixtures, industries, occupations or processes, information is given about all agents present. For processes, industries and occupations, a historical description is also given, noting variations in chemical composition, physical properties or levels of occupational exposure with time.

Statements concerning regulations and guidelines (e.g., pesticide registrations, maximal levels permitted in foods, occupational exposure limits) are included for some countries as indications of potential exposures, but they may not reflect the most recent situation, since such limits are continuously reviewed and modified.
The absence of information on regulatory status for a country should not be taken to imply that that country does not have regulations with regard to the exposure.

The purpose of the section on analysis is to give the reader an overview of current methods cited in the literature, with emphasis on those widely used for regulatory purposes. No critical evaluation or recommendation of any of the methods is meant or implied. Methods for monitoring human exposure are also given, when available. The IARC publishes a series of volumes, *Environmental Carcinogens: Methods of Analysis and Exposure Measurement* (13), that describe validated methods for analysing a wide variety of agents and mixtures.

8. BIOLOGICAL DATA RELEVANT TO THE EVALUATION OF CARCINOGENICITY TO HUMANS

The term 'carcinogen' is used in these monographs to denote an agent or mixture that is capable of increasing the incidence of malignant neoplasms; the induction of benign neoplasms may in some circumstances (see p. 18) contribute to the judgement that the exposure is carcinogenic. The terms 'neoplasm' and 'tumour' are used interchangeably.

Some epidemiological and experimental studies indicate that different agents may act at different stages in the carcinogenic process, probably by fundamentally different mechanisms. In the present state of knowledge, the aim of the Monographs is to evaluate evidence of carcinogenicity at any stage in the carcinogenic process independently of the underlying mechanism involved. There is as yet insufficient information to implement classification according to mechanisms of action (6).

Definitive evidence of carcinogenicity in humans can be provided only by epidemiological studies. Evidence relevant to human carcinogenicity may also be provided by experimental studies of carcinogenicity in animals and by other biological data, particularly those relating to humans.

The available studies are summarized by the Working Group, with particular regard to the qualitative aspects discussed below. In general, numerical findings are indicated as they appear in the original report; units are converted when necessary for easier comparison. The Working Group may conduct additional analyses of the published data and use them in their assessment of the evidence and may include them in their summary of a study; the results of such supplementary analyses are given in square brackets. Any comments are also made in square brackets; however, these are kept to a minimum, being restricted to those instances in which it is felt that an important aspect of a study, directly impinging on its interpretation, should be brought to the attention of the reader.

For experimental studies with mixtures, consideration is given to the possibility of changes in the physicochemical properties of the test substance during collection, storage, extraction, concentration and delivery. Either chemical
or toxicological interactions of the components of mixtures may result in nonlinear
dose-response relationships.

An assessment is made as to the relevance to human exposure of samples
tested in experimental systems, which may involve consideration of: (i) physical and
chemical characteristics, (ii) constituent substances that indicate the presence of a
class of substances, (iii) tests for genetic and related effects, including genetic
activity profiles, (iv) DNA adduct profiles, (v) oncogene expression and mutation;
suppressor gene inactivation.

9. EVIDENCE FOR CARCINOGENICITY IN EXPERIMENTAL ANIMALS

For several agents (e.g., 4-aminobiphenyl, bis(chloromethyl)ether,
diethylstilboestrol, melphalan, 8-methoxypsoralen (methoxsalen) plus ultra-violet
radiation, mustard gas and vinyl chloride), evidence of carcinogenicity in
experimental animals preceded evidence obtained from epidemiological studies or
case reports. Information compiled from the first 41 volumes of the IARC
Monographs(14) shows that, of the 44 agents and mixtures for which there is
sufficient or limited evidence of carcinogenicity to humans (see p. 26), all 37 that have
been tested adequately experimentally produce cancer in at least one animal
species. Although this association cannot establish that all agents and mixtures
that cause cancer in experimental animals also cause cancer in humans,
nevertheless, in the absence of adequate data on humans, it is biologically plausible
and prudent to regard agents and mixtures for which there is sufficient evidence (see
p. 27) of carcinogenicity in experimental animals as if they presented a carcinogenic risk
to humans.

The monographs are not intended to summarize all published studies. Those
that are inadequate (e.g., too short a duration, too few animals, poor survival; see
below) or are judged irrelevant to the evaluation are generally omitted. They may be
mentioned briefly, particularly when the information is considered to be a useful
supplement to that of other reports or when they provide the only data available.
Their inclusion does not, however, imply acceptance of the adequacy of the
experimental design or of the analysis and interpretation of their results.
Guidelines for adequate long-term carcinogenicity experiments have been outlined
(e.g., 15).

The nature and extent of impurities or contaminants present in the agent or
mixture being evaluated are given when available. Mention is made of all routes of
exposure that have been adequately studied and of all species in which relevant
experiments have been performed. Animal strain, sex, numbers per group, age at
start of treatment and survival are reported.

Experiments in which the agent or mixture was administered in conjunction
with known carcinogens or factors that modify carcinogenic effects are also
reported. Experiments on the carcinogenicity of known metabolites and derivatives may be included.

(a) Qualitative aspects

An assessment of carcinogenicity involves several considerations of qualitative importance, including (i) the experimental conditions under which the test was performed, including route and schedule of exposure, species, strain, sex, age, duration of follow-up; (ii) the consistency of the results, for example, across species and target organ(s); (iii) the spectrum of neoplastic response, from benign tumours to malignant neoplasms; and (iv) the possible role of modifying factors.

Considerations of importance to the Working Group in the interpretation and evaluation of a particular study include: (i) how clearly the agent was defined and, in the case of mixtures, how adequately the sample characterization was reported; (ii) whether the dose was adequately monitored, particularly in inhalation experiments; (iii) whether the doses used were appropriate and whether the survival of treated animals was similar to that of controls; (iv) whether there were adequate numbers of animals per group; (v) whether animals of both sexes were used; (vi) whether animals were allocated randomly to groups; (vii) whether the duration of observation was adequate; and (viii) whether the data were adequately reported. If available, recent data on the incidence of specific tumours in historical controls, as well as in concurrent controls, should be taken into account in the evaluation of tumour response.

When benign tumours occur together with and originate from the same cell type in an organ or tissue as malignant tumours in a particular study and appear to represent a stage in the progression to malignancy, it may be valid to combine them in assessing tumour incidence. The occurrence of lesions presumed to be preneoplastic may in certain instances aid in assessing the biological plausibility of any neoplastic response observed.

Of the many agents and mixtures that have been studied extensively, few induced only benign neoplasms. Benign tumours in experimental animals frequently represent a stage in the evolution of a malignant neoplasm, but they may be 'endpoints' that do not readily undergo transition to malignancy. However, if an agent or mixture is found to induce only benign neoplasms, it should be suspected of being a carcinogen and it requires further investigation.

(b) Quantitative aspects

The probability that tumours will occur may depend on the species and strain, the dose of the carcinogen and the route and period of exposure. Evidence of an increased incidence of neoplasms with increased level of exposure strengthens the inference of a causal association between the exposure and the development of neoplasms.
The form of the dose-response relationship can vary widely, depending on the particular agent under study and the target organ. Since many chemicals require metabolic activation before being converted into their reactive intermediates, both metabolic and pharmacokinetic aspects are important in determining the dose-response pattern. Saturation of steps such as absorption, activation, inactivation and elimination of the carcinogen may produce non-linearity in the dose-response relationship, as could saturation of processes such as DNA repair (16,17).

(c) Statistical analysis of long-term experiments in animals

Factors considered by the Working Group include the adequacy of the information given for each treatment group: (i) the number of animals studied and the number examined histologically, (ii) the number of animals with a given tumour type and (iii) length of survival. The statistical methods used should be clearly stated and should be the generally accepted techniques refined for this purpose (17,18). When there is no difference in survival between control and treatment groups, the Working Group usually compares the proportions of animals developing each tumour type in each of the groups. Otherwise, consideration is given as to whether or not appropriate adjustments have been made for differences in survival. These adjustments can include: comparisons of the proportions of tumour-bearing animals among the ‘effective number’ of animals alive at the time the first tumour is discovered, in the case where most differences in survival occur before tumours appear; life-table methods, when tumours are visible or when they may be considered ‘fatal’ because mortality rapidly follows tumour development; and the Mantel-Haenszel test or logistic regression, when occult tumours do not affect the animals’ risk of dying but are ‘incidental’ findings at autopsy.

In practice, classifying tumours as fatal or incidental may be difficult. Several survival-adjusted methods have been developed that do not require this distinction (17), although they have not been fully evaluated.

10. OTHER RELEVANT DATA IN EXPERIMENTAL SYSTEMS AND HUMANS

(a) Structure-activity considerations

This section describes structure-activity correlations that are relevant to an evaluation of the carcinogenicity of an agent.

(b) Absorption, distribution, excretion and metabolism

Concise information is given on absorption, distribution (including placental transfer) and excretion. Kinetic factors that may affect the dose-response relationship, such as saturation of uptake, protein binding, metabolic activation, detoxification and DNA repair processes, are mentioned. Studies that indicate the
metabolic fate of the agent in experimental animals and humans are summarized briefly, and comparisons of data from animals and humans are made when possible. Comparative information on the relationship between exposure and the dose that reaches the target site may be of particular importance for extrapolation between species.

(c) Toxicity

Data are given on acute and chronic toxic effects (other than cancer), such as organ toxicity, immunotoxicity, endocrine effects and preneoplastic lesions. Effects on reproduction, teratogenicity, feto- and embryotoxicity are also summarized briefly.

(d) Genetic and related effects

Tests of genetic and related effects may indicate possible carcinogenic activity. They can also be used in detecting active metabolites of known carcinogens in human or animal body fluids, in detecting active components in complex mixtures and in the elucidation of possible mechanisms of carcinogenesis.

The adequacy of the reporting of sample characterization is considered and, where necessary, commented upon. The available data are interpreted critically by phylogenetic group according to the endpoints detected, which may include DNA damage, gene mutation, sister chromatid exchange, micronuclei, chromosomal aberrations, aneuploidy and cell transformation. The concentrations (doses) employed are given and mention is made of whether an exogenous metabolic system was required. When appropriate, these data may be represented by bar graphs (activity profiles), with corresponding summary tables and listings of test systems, data and references. Detailed information on the preparation of these profiles is given in an appendix to those volumes in which they are used.

Positive results in tests using prokaryotes, lower eukaryotes, plants, insects and cultured mammalian cells suggest that genetic and related effects (and therefore possibly carcinogenic effects) could occur in mammals. Results from such tests may also give information about the types of genetic effect produced and about the involvement of metabolic activation. Some endpoints described are clearly genetic in nature (e.g., gene mutations and chromosomal aberrations), others are to a greater or lesser degree associated with genetic effects (e.g., unscheduled DNA synthesis). In-vitro tests for tumour-promoting activity and for cell transformation may detect changes that are not necessarily the result of genetic alterations but that may have specific relevance to the process of carcinogenesis. A critical appraisal of these tests has been published(15).

Genetic or other activity detected in the systems mentioned above is not always manifest in whole mammals. Positive indications of genetic effects in experimental mammals and in humans are regarded as being of greater relevance than those in
other organisms. The demonstration that an agent or mixture can induce gene and chromosomal mutations in whole mammals indicates that it may have the potential for carcinogenic activity, although this activity may not be detectably expressed in any or all species tested. Relative potency in tests for mutagenicity and related effects is not a reliable indicator of carcinogenic potency. Negative results in tests for mutagenicity in selected tissues from animals treated in vivo provide less weight, partly because they do not exclude the possibility of an effect in tissues other than those examined. Moreover, negative results in short-term tests with genetic endpoints cannot be considered to provide evidence to rule out carcinogenicity of agents or mixtures that act through other mechanisms. Factors may arise in many tests that could give misleading results; these have been discussed in detail elsewhere(15).

The adequacy of epidemiological studies of reproductive outcomes and genetic and related effects in humans is evaluated by the same criteria as are applied to epidemiological studies of cancer.

11. EVIDENCE FOR CARCINOGENICITY IN HUMANS

(a) Types of studies considered

Three types of epidemiological studies of cancer contribute data to the assessment of carcinogenicity in humans—cohort studies, case-control studies and correlation studies. Rarely, results from randomized trials may be available. Case reports of cancer in humans are also reviewed.

Cohort and case-control studies relate individual exposures under study to the occurrence of cancer in individuals and provide an estimate of relative risk (ratio of incidence in those exposed to incidence in those not exposed) as the main measure of association.

In correlation studies, the units of investigation are usually whole populations (e.g., in particular geographical areas or at particular times), and cancer frequency is related to a summary measure of the exposure of the population to the agent, mixture or exposure circumstance under study. Because individual exposure is not documented, however, a causal relationship is less easy to infer from correlation studies than from cohort and case-control studies.

Case reports generally arise from a suspicion, based on clinical experience, that the concurrence of two events—that is, a particular exposure and occurrence of a cancer—has happened rather more frequently than would be expected by chance. Case reports usually lack complete ascertainment of cases in any population, definition or enumeration of the population at risk and estimation of the expected number of cases in the absence of exposure.

The uncertainties surrounding interpretation of case reports and correlation studies make them inadequate, except in rare instances, to form the sole basis for
inferring a causal relationship. When taken together with case-control and cohort studies, however, relevant case reports or correlation studies may add materially to the judgement that a causal relationship is present.

Epidemiological studies of benign neoplasms and presumed preneoplastic lesions are also reviewed by working groups. They may, in some instances, strengthen inferences drawn from studies of cancer itself.

(b) Quality of studies considered

It is necessary to take into account the possible roles of bias, confounding and chance in the interpretation of epidemiological studies. By 'bias' is meant the operation of factors in study design or execution that lead erroneously to a stronger or weaker association than in fact exists between disease and an agent, mixture or exposure circumstance. By 'confounding' is meant a situation in which the relationship with disease is made to appear stronger or to appear weaker than it truly is as a result of an association between the apparent causal factor and another factor that is associated with either an increase or decrease in the incidence of the disease. In evaluating the extent to which these factors have been minimized in an individual study, working groups consider a number of aspects of design and analysis as described in the report of the study. Most of these considerations apply equally to case-control, cohort and correlation studies. Lack of clarity of any of these aspects in the reporting of a study can decrease its credibility and its consequent weighting in the final evaluation of the exposure.

Firstly, the study population, disease (or diseases) and exposure should have been well defined by the authors. Cases in the study population should have been identified in a way that was independent of the exposure of interest, and exposure should have been assessed in a way that was not related to disease status.

Secondly, the authors should have taken account in the study design and analysis of other variables that can influence the risk of disease and may have been related to the exposure of interest. Potential confounding by such variables should have been dealt with either in the design of the study, such as by matching, or in the analysis, by statistical adjustment. In cohort studies, comparisons with local rates of disease may be more appropriate than those with national rates. Internal comparisons of disease frequency among individuals at different levels of exposure should also have been made in the study.

Thirdly, the authors should have reported the basic data on which the conclusions are founded, even if sophisticated statistical analyses were employed. At the very least, they should have given the numbers of exposed and unexposed cases and controls in a case-control study and the numbers of cases observed and expected in a cohort study. Further tabulations by time since exposure began and other temporal factors are also important. In a cohort study, data on all cancer sites
and all causes of death should have been given, to avoid the possibility of reporting bias. In a case-control study, the effects of investigated factors other than the exposure of interest should have been reported.

Finally, the statistical methods used to obtain estimates of relative risk, absolute cancer rates, confidence intervals and significance tests, and to adjust for confounding should have been clearly stated by the authors. The methods used should preferably have been the generally accepted techniques that have been refined since the mid-1970s. These methods have been reviewed for case-control studies(19) and for cohort studies(20).

(c) Quantitative considerations
Detailed analyses of both relative and absolute risks in relation to age at first exposure and to temporal variables, such as time since first exposure, duration of exposure and time since exposure ceased, are reviewed and summarized when available. The analysis of temporal relationships can provide a useful guide in formulating models of carcinogenesis. In particular, such analyses may suggest whether a carcinogen acts early or late in the process of carcinogenesis(6), although such speculative inferences cannot be used to draw firm conclusions concerning the mechanism of action and hence the shape (linear or otherwise) of the dose-response relationship below the range of observation.

(d) Criteria for causality
After the quality of individual epidemiological studies has been summarized and assessed, a judgement is made concerning the strength of evidence that the agent, mixture or exposure circumstance in question is carcinogenic for humans. In making their judgement, the Working Group considers several criteria for causality. A strong association (i.e., a large relative risk) is more likely to indicate causality than a weak association, although it is recognized that relative risks of small magnitude do not imply lack of causality and may be important if the disease is common. Associations that are replicated in several studies of the same design or using different epidemiological approaches or under different circumstances of exposure are more likely to represent a causal relationship than isolated observations from single studies. If there are inconsistent results among investigations, possible reasons are sought (such as differences in amount of exposure), and results of studies judged to be of high quality are given more weight than those from studies judged to be methodologically less sound. When suspicion of carcinogenicity arises largely from a single study, these data are not combined with those from later studies in any subsequent reassessment of the strength of the evidence.

If the risk of the disease in question increases with the amount of exposure, this is considered to be a strong indication of causality, although absence of a graded
response is not necessarily evidence against a causal relationship. Demonstration of a decline in risk after cessation of or reduction in exposure in individuals or in whole populations also supports a causal interpretation of the findings.

Although a carcinogen may act upon more than one target, the specificity of an association (i.e., an increased occurrence of cancer at one anatomical site or of one morphological type) adds plausibility to a causal relationship, particularly when excess cancer occurrence is limited to one morphological type within the same organ.

Although rarely available, results from randomized trials showing different rates among exposed and unexposed individuals provide particularly strong evidence for causality.

When several epidemiological studies show little or no indication of an association between an exposure and cancer, the judgement may be made that, in the aggregate, they show evidence of lack of carcinogenicity. Such a judgement requires first of all that the studies giving rise to it meet, to a sufficient degree, the standards of design and analysis described above. Specifically, the possibility that bias, confounding or misclassification of exposure or outcome could explain the observed results should be considered and excluded with reasonable certainty. In addition, all studies that are judged to be methodologically sound should be consistent with a relative risk of unity for any observed level of exposure and, when considered together, should provide a pooled estimate of relative risk which is at or near unity and has a narrow confidence interval, due to sufficient population size. Moreover, no individual study nor the pooled results of all the studies should show any consistent tendency for relative risk of cancer to increase with increasing level of exposure. It is important to note that evidence of lack of carcinogenicity obtained in this way from several epidemiological studies can apply only to the type(s) of cancer studied and to dose levels and intervals between first exposure and observation of disease that are the same as or less than those observed in all the studies. Experience with human cancer indicates that, in some cases, the period from first exposure to the development of clinical cancer is seldom less than 20 years; latent periods substantially shorter than 30 years cannot provide evidence for lack of carcinogenicity.

12. SUMMARY OF DATA REPORTED

In this section, the relevant experimental and epidemiological data are summarized. Only reports, other than in abstract form, that meet the criteria outlined on p. 13 are considered for evaluating carcinogenicity. Inadequate studies are generally not summarized: such studies are usually identified by a square-bracketed comment in the text.
(a) **Exposures**

Human exposure is summarized on the basis of elements such as production, use, occurrence in the environment and determinations in human tissues and body fluids. Quantitative data are given when available.

(b) **Experimental carcinogenicity data**

Data relevant to the evaluation of carcinogenicity in animals are summarized. For each animal species and route of administration, it is stated whether an increased incidence of neoplasms was observed, and the tumour sites are indicated. If the agent or mixture produced tumours after prenatal exposure or in single-dose experiments, this is also indicated. Dose-response and other quantitative data may be given when available. Negative findings are also summarized.

(c) **Human carcinogenicity data**

Results of epidemiological studies that are considered to be pertinent to an assessment of human carcinogenicity are summarized. When relevant, case reports and correlation studies are also considered.

(d) **Other relevant data**

Structure-activity correlations are mentioned when relevant. Toxicological information and data on kinetics and metabolism in experimental animals are given when considered relevant. The results of tests for genetic and related effects are summarized for whole mammals, cultured mammalian cells and nonmammalian systems.

Data on other biological effects in humans of particular relevance are summarized. These may include kinetic and metabolic considerations and evidence of DNA binding, persistence of DNA lesions or genetic damage in exposed humans.

When available, comparisons of such data for humans and for animals, and particularly animals that have developed cancer, are described.

13. **EVALUATION**

Evaluations of the strength of the evidence for carcinogenicity arising from human and experimental animal data are made, using standard terms.

It is recognized that the criteria for these evaluations, described below, cannot encompass all of the factors that may be relevant to an evaluation of carcinogenicity. In considering all of the relevant data, the Working Group may assign the agent, mixture or exposure circumstance to a higher or lower category than a strict interpretation of these criteria would indicate.
(a) Degrees of evidence for carcinogenicity in humans and in experimental animals and supporting evidence

It should be noted that these categories refer only to the strength of the evidence that an exposure is carcinogenic and not to the extent of its carcinogenic activity (potency) nor to the mechanism involved. A classification may change as new information becomes available.

An evaluation of degree of evidence, whether for a single substance or a mixture, is limited to the materials tested, and these are chemically and physically defined. When the materials evaluated are considered by the Working Group to be sufficiently closely related, they may be grouped for the purpose of a single evaluation of degree of evidence.

(i) Human carcinogenicity data

The applicability of an evaluation of the carcinogenicity of a mixture, process, occupation or industry on the basis of evidence from epidemiological studies depends on the variability over time and place of the mixtures, processes, occupations and industries. The Working Group seeks to identify the specific exposure, process or activity which is considered most likely to be responsible for any excess risk. The evaluation is focused as narrowly as the available data on exposure and other aspects permit.

The evidence relevant to carcinogenicity from studies in humans is classified into one of the following categories:

Sufficient evidence of carcinogenicity: The Working Group considers that a causal relationship has been established between exposure to the agent, mixture or exposure circumstance and human cancer. That is, a positive relationship has been observed between the exposure and cancer in studies in which chance, bias and confounding could be ruled out with reasonable confidence.

Limited evidence of carcinogenicity: A positive association has been observed between exposure to the agent, mixture or exposure circumstance and cancer for which a causal interpretation is considered by the Working Group to be credible, but chance, bias or confounding could not be ruled out with reasonable confidence.

Inadequate evidence of carcinogenicity: The available studies are of insufficient quality, consistency or statistical power to permit a conclusion regarding the presence or absence of a causal association.

Evidence suggesting lack of carcinogenicity: There are several adequate studies covering the full range of levels of exposure that human beings are known to encounter, which are mutually consistent in not showing a positive association between exposure to the agent, mixture or exposure circumstance and any studied cancer at any observed level of exposure. A conclusion of 'evidence suggesting lack of carcinogenicity' is inevitably limited to the cancer sites, conditions and levels of
exposure and length of observation covered by the available studies. In addition, the possibility of a very small risk at the levels of exposure studied can never be excluded.

In some instances, the above categories may be used to classify the degree of evidence for carcinogenicity for specific organs or tissues.

(ii) Experimental carcinogenicity data

The evidence relevant to carcinogenicity in experimental animals is classified into one of the following categories:

*Sufficient evidence of carcinogenicity:* The Working Group considers that a causal relationship has been established between the agent or mixture and an increased incidence of malignant neoplasms or of an appropriate combination of benign and malignant neoplasms (as described on p. 18) in (a) two or more species of animals or (b) in two or more independent studies in one species carried out at different times or in different laboratories or under different protocols.

Exceptionally, a single study in one species might be considered to provide sufficient evidence of carcinogenicity when malignant neoplasms occur to an unusual degree with regard to incidence, site, type of tumour or age at onset.

In the absence of adequate data on humans, it is biologically plausible and prudent to regard agents and mixtures for which there is sufficient evidence of carcinogenicity in experimental animals as if they presented a carcinogenic risk to humans.

*Limited evidence of carcinogenicity:* The data suggest a carcinogenic effect but are limited for making a definitive evaluation because, e.g., (a) the evidence of carcinogenicity is restricted to a single experiment; or (b) there are unresolved questions regarding the adequacy of the design, conduct or interpretation of the study; or (c) the agent or mixture increases the incidence only of benign neoplasms or lesions of uncertain neoplastic potential, or of certain neoplasms which may occur spontaneously in high incidences in certain strains.

*Inadequate evidence of carcinogenicity:* The studies cannot be interpreted as showing either the presence or absence of a carcinogenic effect because of major qualitative or quantitative limitations.

*Evidence suggesting lack of carcinogenicity:* Adequate studies involving at least two species are available which show that, within the limits of the tests used, the agent or mixture is not carcinogenic. A conclusion of evidence suggesting lack of carcinogenicity is inevitably limited to the species, tumour sites and levels of exposure studied.

(iii) Supporting evidence of carcinogenicity

Other evidence judged to be relevant to an evaluation of carcinogenicity and of sufficient importance to affect the overall evaluation is then described. This may
include data on tumour pathology, genetic and related effects, structure-activity relationships, metabolism and pharmacokinetics, physicochemical parameters, chemical composition and possible mechanisms of action. For complex exposures, including occupational and industrial exposures, the potential contribution of carcinogens known to be present as well as the relevance of materials tested are considered by the Working Group in its overall evaluation of human carcinogenicity. The Working Group also determines to what extent the materials tested in experimental systems are relevant to those to which humans are exposed. The available experimental evidence may help to specify more precisely the causal factor(s).

(b) Overall evaluation

Finally, the body of evidence is considered as a whole, in order to reach an overall evaluation of the carcinogenicity to humans of an agent, mixture or circumstance of exposure.

An evaluation may be made for a group of chemical compounds that have been evaluated by the Working Group. In addition, when supporting data indicate that other, related compounds for which there is no direct evidence of capacity to induce cancer in animals or in humans may also be carcinogenic, a statement describing the rationale for this conclusion is added to the evaluation narrative; an additional evaluation may be made for this broader group of compounds if the strength of the evidence warrants it.

The agent, mixture or exposure circumstance is described according to the wording of one of the following categories, and the designated group is given. The categorization of an agent, mixture or exposure circumstance is a matter of scientific judgement, reflecting the strength of the evidence derived from studies in humans and in experimental animals and from other relevant data.

Group 1—The agent (mixture) is carcinogenic to humans. The exposure circumstance entails exposures that are carcinogenic to humans.

This category is used only when there is sufficient evidence of carcinogenicity in humans.

Group 2

This category includes agents, mixtures and exposure circumstances for which, at one extreme, the degree of evidence of carcinogenicity in humans is almost sufficient, as well as those for which, at the other extreme, there are no human data but for which there is experimental evidence of carcinogenicity. Agents, mixtures and exposure circumstances are assigned to either 2A (probably carcinogenic) or 2B (possibly carcinogenic) on the basis of epidemiological, experimental and other relevant data.
Group 2A—The agent (mixture) is probably carcinogenic to humans.  
The exposure circumstance entails exposures that are probably carcinogenic to humans. 
This category is used when there is limited evidence of carcinogenicity in humans and sufficient evidence of carcinogenicity in experimental animals. Exceptionally, an agent, mixture or exposure circumstance may be classified into this category solely on the basis of limited evidence of carcinogenicity in humans or of sufficient evidence of carcinogenicity in experimental animals strengthened by supporting evidence from other relevant data.

Group 2B—The agent (mixture) is possibly carcinogenic to humans.  
The exposure circumstance entails exposures that are possibly carcinogenic to humans. 
This category is generally used for agents, mixtures and exposure circumstances for which there is limited evidence of carcinogenicity in humans in the absence of sufficient evidence of carcinogenicity in experimental animals. It may also be used when there is inadequate evidence of carcinogenicity in humans or when human data are nonexistent but there is sufficient evidence of carcinogenicity in experimental animals. In some instances, an agent, mixture or exposure circumstance for which there is inadequate evidence of or no data on carcinogenicity in humans but limited evidence of carcinogenicity in experimental animals together with supporting evidence from other relevant data may be placed in this group.

Group 3—The agent (mixture, exposure circumstance) is not classifiable as to its carcinogenicity to humans. 
Agents, mixtures and exposure circumstances are placed in this category when they do not fall into any other group.

Group 4—The agent (mixture, exposure circumstance) is probably not carcinogenic to humans. 
This category is used for agents, mixtures and exposure circumstances for which there is evidence suggesting lack of carcinogenicity in humans together with evidence suggesting lack of carcinogenicity in experimental animals. In some instances, agents, mixtures or exposure circumstances for which there is inadequate evidence of or no data on carcinogenicity in humans but evidence suggesting lack of carcinogenicity in experimental animals, consistently and strongly supported by a broad range of other relevant data, may be classified in this group.

References


   Number 1 (1973) 52 pages  
   Number 2 (1973) 77 pages  
   Number 3 (1974) 67 pages  
   Number 4 (1974) 97 pages  
   Number 5 (1975) 88 pages  
   Number 6 (1976) 360 pages  
   Number 7 (1978) 460 pages  
   Number 8 (1979) 604 pages  
   Number 9 (1981) 294 pages  
   Number 10 (1983) 326 pages  
   Number 11 (1984) 370 pages  
   Number 12 (1986) 385 pages  
   Number 13 (1988) 404 pages


GENERAL REMARKS
ON THE SUBSTANCES CONSIDERED

This fiftieth volume of the *IARC Monographs* comprises monographs on five antineoplastic agents, four antimicrobial agents, two diuretics, ciclosporin (an immunosuppressant), cimetidine (used in the treatment of gastric and duodenal ulcers), paracetamol (a popular analgesic and antipyretic drug) and dantron (a laxative). Many pharmaceutical drugs were evaluated in previous *IARC Monographs* (see Table 1), including some of those covered in this volume. Azacitidine and trichlormethine—both antineoplastic agents—and nitrofuraz—an antibacterial drug—were re-evaluated because new data on carcinogenicity in experimental animals had been published since the earlier evaluations; thiotepa and chloramphenicol were re-evaluated largely because of new data on carcinogenicity in humans.

*Table 1. Pharmaceutical agents evaluated in the IARC Monographs*

<table>
<thead>
<tr>
<th>Agent</th>
<th>Vol. no.</th>
<th>Year</th>
<th>Evaluation*</th>
<th>Human</th>
<th>Animal</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaesthetics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaesthetics (unspecified mixtures)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>-</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Chloroform</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Cyclopropane</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>ND</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Diethyl ether</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>ND</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Divinyl ether</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>ND</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Enflurane</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Fluroxene</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>ND</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Halothane</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Isoflurane</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Methoxyflurane</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Nitrous oxide</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Trichloroethylene</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Analgesics and anti-inflammatory agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aurothiogluco</td>
<td>13</td>
<td>1977</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Oxyphenbutazone</td>
<td>13</td>
<td>1977</td>
<td>ND</td>
<td>ND</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Agent</td>
<td>Vol. no.</td>
<td>Year</td>
<td>Evaluation&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Human</td>
<td>Animal</td>
<td>Overall</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>----------</td>
<td>------</td>
<td>-------------------------</td>
<td>-------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Analgesics and anti-inflammatory agents (contd)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paracetamol (Acetaminophen)</td>
<td>50</td>
<td>1990</td>
<td>I</td>
<td>L</td>
<td>S</td>
<td>3</td>
</tr>
<tr>
<td>Phenacetin</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>L</td>
<td>S</td>
<td>L</td>
<td>2A</td>
</tr>
<tr>
<td>Analgesic mixtures containing phenacetin</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
<td>L</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Phenytoin hydrochloride</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td></td>
<td>2B</td>
</tr>
<tr>
<td>Phenylbutazone</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>ND</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td><strong>Antibacterial drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ampicillin</td>
<td>50</td>
<td>1990</td>
<td>I</td>
<td>L</td>
<td>S</td>
<td>3</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>50</td>
<td>1990</td>
<td>L</td>
<td>I</td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Chrysoidine</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Dapsone</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Dihydroxymethylfurazidine</td>
<td>24</td>
<td>1980</td>
<td>ND</td>
<td>I</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Ethionamide</td>
<td>13</td>
<td>1977</td>
<td>ND</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Isoniazid (Isonicotinic acid hydrazide)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Nitrofurazone</td>
<td>50</td>
<td>1990</td>
<td>I</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>50</td>
<td>1990</td>
<td>I</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>1-[[5-Nitrofurfurylidene]amino]-2-imidazolidinone (Nifuradene)</td>
<td>7</td>
<td>1974</td>
<td>ND</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide (Furothiazole)</td>
<td>7</td>
<td>1974</td>
<td>ND</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Panfuran S (a formulation with dihydroxymethylfurazidine and several other compounds)</td>
<td>24</td>
<td>1980</td>
<td>ND</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Penicillin</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>24</td>
<td>1980</td>
<td>ND</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Sulfadiazole (Sulphisoxazole)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Sulfamethoxazole</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td><strong>Antineoplastic drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actinomycin D (Dactinomycin)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Adriamycin (Doxorubicin)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Azacitidine (5-Azacytidine)</td>
<td>50</td>
<td>1990</td>
<td>ND</td>
<td>S</td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Azaserine</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
<td>S</td>
<td></td>
<td>2B</td>
</tr>
<tr>
<td>N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Bischloroethyl nitrosourea (BCNU)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>L</td>
<td>S</td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Bleomycins</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td></td>
<td>2B</td>
</tr>
<tr>
<td>1,4-Butanediol dimethanesulfonate (Myleran)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>
### Table 1 (contd)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Vol. no.</th>
<th>Year</th>
<th>Evaluation*</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antineoplastic drugs (contd)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td>2A</td>
</tr>
<tr>
<td>1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
<td>L</td>
<td>1</td>
</tr>
<tr>
<td>Chlorotrianisene (see Hormones)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorozotocin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cisplatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dacarbazine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daunomycin (Daunorubicin)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diethylstilboestrol (see Hormones)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethynodiol diacetate (see Hormones)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-Fluorouracil</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
</tr>
<tr>
<td>17α-Hydroxyprogesterone caproate (see Hormones)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isophosphamide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mannomustine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medphalan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Megestrol acetate (see Hormones)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melphalan</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
<td>S</td>
<td>1</td>
</tr>
<tr>
<td>6-Mercaptopurine</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
</tr>
<tr>
<td>Merphalan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitomycin C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MOPP and other combined chemotherapy including alkylating agents</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
<td>I</td>
<td>1</td>
</tr>
<tr>
<td>Nitrogen mustard</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>L</td>
<td>S</td>
<td>2A</td>
</tr>
<tr>
<td>Nitrogen mustard N-oxide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norethisterone (see Hormones)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednimustine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisone (see Hormones)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procabazine hydrochloride</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td>2A</td>
</tr>
<tr>
<td>Streptozotocin (Streptozocin)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treosulphan</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
<td>ND</td>
<td>1</td>
</tr>
<tr>
<td>Trichlormethine (Trimustine hydrochloride)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triethylene glycol diglycidyl ether (Ethoglucid)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tris(aziridinyl)-para-benzoquinone (Triaziquone)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td>3</td>
</tr>
</tbody>
</table>
Table 1 (contd)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Vol. no.</th>
<th>Year</th>
<th>Evaluationa</th>
<th>Human</th>
<th>Animal</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antineoplastic drugs (contd)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tris(1-aziridinyl)phosphine sulphide (Thiotepa)</td>
<td>50</td>
<td>1990</td>
<td>S</td>
<td>S</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>2,4,6-Tris(1-aziridinyl)-s-triazine</td>
<td>9</td>
<td>1975</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Uracil mustard (Uramustine)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Vinblastine sulphate</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Vincristine sulphate</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Antifungal, antiprotozoan and antiparasitic agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloroquine</td>
<td>13</td>
<td>1977</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>DDT (Clofenotane)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Furazolidone (also antibacterial)</td>
<td>31</td>
<td>1983</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Griseofulvin</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>ND</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>γ-Hexachlorocyclohexane (Lindane)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Hycanthone mesylate</td>
<td>13</td>
<td>1977</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Metronidazole (also antibacterial)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Niridazole</td>
<td>13</td>
<td>1977</td>
<td>ND</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Pyrimethamine</td>
<td>13</td>
<td>1977</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Trichlorfon (Metrifonate)</td>
<td>30</td>
<td>1983</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Antiseptic agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acridine orange</td>
<td>16</td>
<td>1978</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Acriflavinium chloride</td>
<td>13</td>
<td>1977</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Benzoyl peroxide (see Dermatological agents)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chrysoidine</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Eugenol (used in dentistry)</td>
<td>36</td>
<td>1985</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Hexachlorophene</td>
<td>20</td>
<td>1979</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Hydrogen peroxide</td>
<td>36</td>
<td>1985</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Phenol</td>
<td>47</td>
<td>1989</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Proflavine salts</td>
<td>24</td>
<td>1980</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>β-Propiolactone</td>
<td>4</td>
<td>1974</td>
<td>ND</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Scarlet Red</td>
<td>8</td>
<td>1975</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Tannic acid and tannins</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Dermatological agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>para-Aminobenzoic acid</td>
<td>16</td>
<td>1978</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Arsenic salts (Fowler’s solution) (also antineoplastic)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
<td>L</td>
<td>1e</td>
<td></td>
</tr>
<tr>
<td>Benzoyl peroxide (also antiseptic)</td>
<td>36</td>
<td>1985</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Cantharidin</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Coal-tars</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
<td>S</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>
Table 1 (contd)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Vol. no.</th>
<th>Year</th>
<th>Evaluationa</th>
<th>Human</th>
<th>Animal</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dermatological agents (contd)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diacetylaminoaztoluene</td>
<td>8</td>
<td>1975</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Dithranol (Anthralin)</td>
<td>13</td>
<td>1977</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Hydroquinone</td>
<td>15</td>
<td>1977</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>8-Hydroxyquinoline (<em>also antiseptic</em>)</td>
<td>13</td>
<td>1977</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>5-Methoxypsoralen</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td>2A</td>
<td></td>
</tr>
<tr>
<td>8-Methoxypsoralen (<em>Methoxsalen</em>) + UV</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
<td>S</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Resorcinol</td>
<td>15</td>
<td>1977</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Safrole (Oil of Sassafras)</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Selenium and selenium compounds</td>
<td>9</td>
<td>1975</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Tannic acid and tannins (<em>Antiseptic agents</em>)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4,5',8-Trimethylpsoralen</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Drugs for treating anaemia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iron-dextran complex</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Iron-dextrin complex</td>
<td>2</td>
<td>1973</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Iron-sorbitol-citric acid complex</td>
<td>2</td>
<td>1973</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Saccharated iron oxide</td>
<td>2</td>
<td>1973</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Drugs for treating cardiovascular disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clofibrate (<em>hypercholesterolaemia</em>)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Furosemide (<em>Frusemide</em>) (<em>hypertension</em>)</td>
<td>50</td>
<td>1990</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Hydralazine (<em>hypertension</em>)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide (<em>hypertension</em>)</td>
<td>50</td>
<td>1990</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Phenoxybenzamine hydrochloride (<em>hypertension</em>)</td>
<td>24</td>
<td>1980</td>
<td>ND</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Reserpine (<em>hypertension</em>)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Spironolactone (<em>hypertension</em>)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Drugs for treating central nervous disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diazepam (<em>anxiety</em>)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Oxazepam (<em>anxiety</em>)</td>
<td>13</td>
<td>1977</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Phenetazine sulphate (<em>depression</em>)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Phenobarbital (<em>epilepsy</em>)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Phenytoin (<em>epilepsy</em>)</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>L</td>
<td>L</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td><strong>Drugs for treating thyroid disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylthiouracil</td>
<td>7</td>
<td>1974</td>
<td>ND</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Propylthiouracil</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Thiouracil</td>
<td>7</td>
<td>1974</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Thiourea</td>
<td>7</td>
<td>1974</td>
<td>ND</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
</tbody>
</table>
Table 1 (contd)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Vol. no.</th>
<th>Year</th>
<th>Evaluationa</th>
<th>Human</th>
<th>Animal</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hormones</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Androgenic (anabolic) steroids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxymetholone</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>L</td>
<td>ND</td>
<td>2A</td>
<td></td>
</tr>
<tr>
<td>Testosterone</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>L</td>
<td>S</td>
<td>2A</td>
<td></td>
</tr>
<tr>
<td><strong>Oestrogens, progestins and combinations</strong></td>
<td>Suppl. 7</td>
<td>1987</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oestrogens</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsteroidal oestrogens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diethylstilboestrol</td>
<td>S</td>
<td></td>
<td></td>
<td>1c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dienoestrol</td>
<td>L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hexoestrol</td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorotrianisene</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steroidal oestrogens</td>
<td></td>
<td></td>
<td></td>
<td>1c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oestrogen replacement therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conjugated oestrogens</td>
<td></td>
<td>L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oestradiol-17β and esters</td>
<td></td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oestriol</td>
<td>L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oestrone</td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinyloestradiol</td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mestranol</td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Progestins</strong></td>
<td></td>
<td></td>
<td>2Bc</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medroxyprogesterone acetate</td>
<td>I</td>
<td>S</td>
<td>2B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlormadinone acetate</td>
<td>L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dimethisterone</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethynodiol diacetate</td>
<td>L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17α-Hydroxyprogesterone caproate</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lynoestrenol</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Megestrol acetate</td>
<td>L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norethisterone</td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norethynodrel</td>
<td>L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norgestrel</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Progesterone</td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oestrogen-progestin combinations</strong></td>
<td></td>
<td></td>
<td>1c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sequential oral contraceptives</td>
<td></td>
<td>S</td>
<td>1c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dimethisterone and oestrogens</td>
<td></td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined oral contraceptives</td>
<td></td>
<td>S</td>
<td>1d</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlormadinone acetate and oestrogens</td>
<td></td>
<td>L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethynodiol diacetate and oestrogens</td>
<td></td>
<td>L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lynoestrenol and oestrogens</td>
<td></td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 1 (contd)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Vol. no.</th>
<th>Year</th>
<th>Evaluation*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hormones (contd)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Megestrol acetate and oestrogens</td>
<td></td>
<td></td>
<td>L</td>
</tr>
<tr>
<td>Norethisterone and oestrogens</td>
<td></td>
<td></td>
<td>L</td>
</tr>
<tr>
<td>Norethynodrel and oestrogens</td>
<td></td>
<td></td>
<td>S</td>
</tr>
<tr>
<td>Norgestrel and oestrogens</td>
<td></td>
<td></td>
<td>I</td>
</tr>
<tr>
<td>Progesterone and oestrogens</td>
<td></td>
<td></td>
<td>L</td>
</tr>
<tr>
<td>Oestrogen-progestin replacement therapy</td>
<td></td>
<td></td>
<td>I</td>
</tr>
<tr>
<td>Anti-oestrogens</td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Clomiphene citrate</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
</tr>
<tr>
<td>Other hormones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisone</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>I</td>
</tr>
<tr>
<td><strong>Immunosuppressants</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azathioprine</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
</tr>
<tr>
<td>Ciclosporin (Cyclosporin A)</td>
<td>50</td>
<td>1990</td>
<td>L</td>
</tr>
<tr>
<td><strong>Traditional remedies of herbal origin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dantron (Chrysazin, 1,8-Dihydroxyanthraquinone) (Aloe sp., Cassia senna, Rhamnus purshianus or Cascara sagrada, and Rheum officinale)</td>
<td>50</td>
<td>1990</td>
<td>ND</td>
</tr>
<tr>
<td>Hydroxysenkirikine (Crotalaria sp.)</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
</tr>
<tr>
<td>Isatidine (Senecio sp.)</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
</tr>
<tr>
<td>Jacobine (Senecio sp.)</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
</tr>
<tr>
<td>Monocrotoline (Crotalaria sp.)</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
</tr>
<tr>
<td>Petasitenine (Petasites japonicus)</td>
<td>31</td>
<td>1983</td>
<td>ND</td>
</tr>
<tr>
<td>Retrorsine (Senecio sp.)</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
</tr>
<tr>
<td>Riddelliine (Crotalaria sp.)</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
</tr>
<tr>
<td>Seneciphylline (Senecio sp. and Crotalaria sp.)</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
</tr>
<tr>
<td>Senkirkine (Senecio kirkii)</td>
<td>31</td>
<td>1983</td>
<td>ND</td>
</tr>
<tr>
<td>Symphytine (Symphytum officinale)</td>
<td>31</td>
<td>1983</td>
<td>ND</td>
</tr>
<tr>
<td><strong>Miscellaneous drugs and experimental agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole (gastritis)</td>
<td>7</td>
<td>1974</td>
<td>ND</td>
</tr>
<tr>
<td>Angelicin + UVA (skin disorders)</td>
<td>40</td>
<td>1986</td>
<td>ND</td>
</tr>
<tr>
<td>Cimetidine (peptic ulcer)</td>
<td>50</td>
<td>1990</td>
<td>I</td>
</tr>
<tr>
<td>4,4'-Dimethylangelicin + UVA (skin disorders)</td>
<td>40</td>
<td>1986</td>
<td>ND</td>
</tr>
<tr>
<td>4,5'-Dimethylangelicin + UVA (skin disorders)</td>
<td>40</td>
<td>1986</td>
<td>ND</td>
</tr>
</tbody>
</table>
Table 1 (contd)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Vol. no.</th>
<th>Year</th>
<th>Evaluationa</th>
<th>Human</th>
<th>Animal</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Miscellaneous drugs and experimental agents (contd)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disulfiram (alcoholism)</td>
<td>12</td>
<td>1976</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Investigational oral contraceptives</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
<td>L</td>
<td>1&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Lasiocarpine (emetic)</td>
<td>10</td>
<td>1976</td>
<td>ND</td>
<td>S</td>
<td></td>
<td>2B</td>
</tr>
<tr>
<td>5-Methylangelenic + UVA (skin disorders)</td>
<td>40</td>
<td>1986</td>
<td>ND</td>
<td>S</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>N-Methyl-N-nitrosourea (antineoplastic)</td>
<td>17</td>
<td>1978</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>7-Methylpyrido[3,4-c]psoralsen (skin disorders)</td>
<td>40</td>
<td>1986</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Nafenopin (hypercholesterolaemia)</td>
<td>24</td>
<td>1980</td>
<td>ND</td>
<td>S</td>
<td></td>
<td>2B</td>
</tr>
<tr>
<td>Pyrido[3,4-c]psoralsen (skin disorders)</td>
<td>40</td>
<td>1986</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Sodium diethyldithiocarbamate (nickel poisoning)</td>
<td>12</td>
<td>1976</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>4,4',6-Trimethylangelenic + UVA (skin disorders)</td>
<td>40</td>
<td>1986</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td><strong>Veterinary drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acriflavinium chloride (see Antiseptic agents)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>para-Aminobenzoic acid (see Dermatological agents)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-Amino-2-nitrothiazole</td>
<td>31</td>
<td>1983</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Arsanilic acid</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
<td>L</td>
<td>1&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Diacetylaminoazotoluene (see Dermatological agents)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furazolidone (see Antifungal, antiprotozoan and antiparasitic agents)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hexachloroethane</td>
<td>20</td>
<td>1979</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Hexachlorophene (see Antisptic agents)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iron–dextran complex (see Drugs for treating anaemia)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lead arsenate</td>
<td>Suppl. 7</td>
<td>1987</td>
<td>S</td>
<td>L</td>
<td>1&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone (Furaltidone)</td>
<td>7</td>
<td>1974</td>
<td>ND</td>
<td>S</td>
<td>2B</td>
<td></td>
</tr>
<tr>
<td>Nithiazide</td>
<td>31</td>
<td>1983</td>
<td>ND</td>
<td>L</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>5-Nitro-2-furaldehyde semicarbazone</td>
<td>7</td>
<td>1974</td>
<td>ND</td>
<td>I</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>N-[4-(5-Nitro-2-furyl)-2-thiazolyl] acetamide (see Antibacterial drugs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1 (contd)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Vol. no</th>
<th>Year</th>
<th>Evaluation*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Human</td>
</tr>
<tr>
<td>Veterinary drugs (contd)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitrovin</td>
<td>31</td>
<td>1983</td>
<td>ND</td>
</tr>
<tr>
<td>Selenium (see Dermatological agents)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urethane</td>
<td>7</td>
<td>1974</td>
<td>ND</td>
</tr>
</tbody>
</table>

*1, inadequate; S, sufficient; L, limited. For definitions of the symbols used, see Preamble, pp. 26–29.
2Combined therapy with nitrogen mustard, vincristine, procarbazine and prednisone
3This evaluation applies to the group of chemicals as a whole and not necessarily to all individual chemicals within the group.
4There is also conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium.
5According to the overall evaluation of arsenic compounds

Derivatives of chloramphenicol without the NO₂ moiety have been developed; of these, thiamphenicol has been used extensively, but florfenicol is not used in man. Thiamphenicol and florfenicol were not considered in this volume, however, because there appear to be no published data with regard to their carcinogenicity. Similarly, ranitidine and famotidine are used therapeutically like cimetidine; but monographs on ranitidine and famotidine and their nitrosated derivatives were also not prepared due to a lack of relevant published studies.

In clinical use and in formulations, salts, esters and complexes of drugs are often designated by the name of the parent compound; this is the case with ampicillin and chloramphenicol. In the case of nitrofurantoin, products of different crystal size have been synthesized. While the Working Group attempted to distinguish these alternative forms, in some instances insufficient information was available to do so.

The primary source of human exposure to drugs is from their use in therapy. Other types of exposure may also occur, however: persons employed in the manufacture of drugs may be exposed, as well as nursing and other staff responsible for the preparation and administration of compounds and staff responsible for the care of treated patients. Veterinary use of drugs may result in their entry into the human food chain.

For the drugs considered here, as for many others, studies of human carcinogenicity present difficult problems. The symptoms of an undiagnosed cancer may prompt the use of drug, which is subsequently suspected as its cause. Alternatively, the condition for which the drug therapy is prescribed may itself be a risk factor for cancer. An additional problem is that patients commonly receive
more than one drug, and determination of the carcinogenicity of any single drug may not be feasible. Repeated reference is made in this volume to hypothesis-generating studies. These refer to sets of data containing information on many drugs and many outcomes, in which multiple comparisons are made. Statistically significant associations \((p < 0.05)\) are noted, but in terms of probability theory many such associations may be due to chance. For this reason, the \(p\) values given in the text must be interpreted with caution, and independent examination of associations identified in hypothesis-generating studies is particularly desirable. This situation is substantially different from that in which a prior hypothesis exists before the data are analysed.

An increasing number of agents, including pharmaceutical drugs, have been shown to inhibit cancer development in animal models. Such properties may lead to new possibilities for cancer treatment and prevention. The Working Group noted that in long-term experiments with paracetamol, nitrofurantoin and nitrofurural, reductions in tumour incidence were seen at some sites in some animal species, although such reductions may have other interpretations than an inhibition of tumour induction.

Exposure can generally be much more accurately measured for drugs than for other agents suspected or identified as human carcinogens, and therapeutic doses used in humans are often close to those tested in experimental animals. However, as is the policy in the IARC Monographs, no attempt was made to quantify cancer risk at specific dose levels. As stated in the Preamble, the Monographs represent the first stage in carcinogenic risk assessment. Subsequent stages, not attempted in the Monographs, may involve quantitative determinations. By extrapolation of available epidemiological data, and possibly experimental data, estimations of risk may be attempted for specific populations in respect of particular carcinogens. Such information may be a factor in regulatory or legislative processes, but no recommendation concerning these processes is given in the Monographs. However, the Working Group responsible for the present monographs observed that inference of carcinogenic hazard was likely to be a major factor in decision-making regarding the usage of many of the drugs considered.

Many (if not most) regulatory decisions concerning putative carcinogens necessitate consideration not only of perceived hazard but also of the benefit derived from particular chemicals. It is crucial, therefore, that decisions on the availability of drugs include assessment not only of potential carcinogenicity but also the health benefit derived from their usage.
THE MONOGRAPHS
ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE AGENTS
AZACITIDINE

This substance was considered by a previous Working Group, in October 1980, under the title 5-azacytidine (IARC, 1981). Since that time, new data have become available, and these have been incorporated into the monograph and taken into consideration in the present evaluation.

1. Chemical and Physical Data

1.1 Synonyms

Chem. Abstr. Name: 1,3,5-Triazin-2(1H)-one, 4-amino-1-ß-ribofuranosyl
Synonyms: Antibiotic U 18496; 5-azacytidine; ladakamycin; NSC 102816; U-18496; WR-183027

1.2 Structural and molecular formulae and molecular weight

![Chemical Structure](image)

C₈H₁₂N₄O₅  
Mol. wt: 244.2

1.3 Chemical and physical properties of the pure substance

From Winkley and Robins (1970), unless otherwise specified
(a) Description: White crystalline powder
(b) **Melting-point**: 235-237°C (decomposes)
(c) **Optical rotation**: $[\alpha]_D^{26} = +26.6$°C (c = 1.00; in water)
(d) **Solubility**: Soluble in warm water (40 mg/ml), cold water (14 mg/ml), 0.1 N hydrochloric acid (28 mg/ml) and 0.1 N sodium hydroxide (43 mg/ml); soluble in 35% ethanol (14.2-15.0 mg/l), acetone (1 mg/ml), chloroform (1 mg/ml), hexane (1 mg/ml) and dimethyl sulfoxide (52.7 mg/ml) (von Hoff et al., 1975)
(e) **Spectroscopy data**: Ultraviolet, infrared and nuclear magnetic resonance spectra have been reported (Beisler, 1978).
(f) **Stability**: Very unstable in aqueous media, rapid degradation to complex products occurring within hours of dissolution in intravenous solutions at room temperature (Reynolds, 1989)

1.4 Technical products and impurities

**Trade name**: Mylosar

Azacitidine is available as a lyophilized powder in vials containing 100 mg of the compound with 100 mg mannitol for reconstitution as injections of 5 mg/ml (von Hoff et al., 1975).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

(a) **Production**

Azacitidine, a pyrimidine analogue of cytidine with a nitrogen substituted for a 5-carbon, can be isolated from a culture of the bacterium *Streptoverticillium ladakanus*, but has also been prepared by synthetic methods. One reported method involved treatment of the trimethylsilyl derivative of 4-amino-1,3,5-triazin-2-one with 2,3,5-tri-O-acetyl-D-ribofuranosyl bromide, followed by deacetylation to give azacitidine (Winkley & Robins, 1970).

Azacitidine is synthesized in the Federal Republic of Germany (Chemical Information Services, 1989-90).

(b) **Occurrence**

Azacitidine is produced by the bacterium *Streptoverticillium ladakanus* (Winkley & Robins, 1970).

2.2 Use

Azacitidine is a cytostatic agent. It has been used mainly in the treatment of acute leukaemia, either as intravenous or intramuscular injections or as
intravenous infusions at a daily level of 40-750 mg/m² (Weiss et al., 1972; Skoda, 1975; von Hoff et al., 1975, 1976; von Hoff & Slavik, 1977; Wade, 1977; Glover et al., 1987; Reynolds, 1989). It is used alone, or in combination with vincristine, vinblastine, prednisone, cytarabine or amsacrine, at a daily dose of 50-150 mg/m² azacitidine. It has also been tested for use in the treatment of a variety of solid tumours (Glover et al., 1987).

2.3 Analysis

Azacitidine can be quantified in blood by microbiological assay (Pittillo & Woolley, 1969) and in plasma by high-performance liquid chromatography with ultraviolet detection (Rustum & Hoffman, 1987).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

(a) Intraperitoneal injection

*Mouse:* In a screening assay based on the accelerated induction of leukaemia in a strain highly susceptible to development of this neoplasm, 40 AKR female mice, two months of age, were given six intraperitoneal injections of azacitidine at 1.5 mg/kg bw [purity unspecified] over 20 days, and, because of toxicity, six injections of azacitidine at 0.8 mg/kg bw over the following 30 days. All treated mice had died of leukaemia by 60 days. A control group of 40 females survived free of disease for the observation time of 120 days (Vesely & Cihák, 1973).

In a screening assay based on the accelerated induction of lung tumours in a strain highly susceptible to development of this neoplasm, three groups of ten male and ten female A/He mice, six to eight weeks of age, received intraperitoneal injections of azacitidine [purity unspecified], in a vehicle composed of saline, polysorbate-80, carboxymethyl cellulose and benzyl alcohol, three times a week for eight weeks (total doses, 33, 62 and 90 mg/kg bw (which was the maximum tolerated dose)). Control groups received 24 intraperitoneal injections of 0.1 ml vehicle or were untreated. All animals were killed 24 weeks after the first injection. The numbers of mice with lung tumours, calculated on the basis of survivors of each sex, were 6/11 (54%), 5/15 (33%) and 8/19 (42%) in the groups receiving the high, mid and low doses, respectively. The results for untreated and vehicle-treated groups were expressed only as per cent tumour incidence; thus, 22% (males) and 17% (females) of untreated controls and 26% (males) and 23% (females) of
vehicle-treated controls developed lung tumours. The number of lung tumours per mouse (counted grossly) in animals of each sex treated with the highest dose was 0.73 ± 0.22 (SE), which was significantly higher ($p < 0.05$) than that in untreated (males, 0.22 ± 0.03; females, 0.17 ± 0.02) or vehicle-treated (males, 0.25 ± 0.05; females, 0.23 ± 0.04) control mice. With lower doses, the increase in the number of lung tumours per mouse was not statistically significant (Stoner et al., 1973).

Groups of 35 male and 35 female B6C3F1 mice, 38 days of age, received intraperitoneal injections of azacitidine at 2.2 or 4.4 mg/kg bw (>99% pure) in buffered saline three times a week for 52 weeks. Groups of 15 male and 15 female mice were untreated or received the vehicle only. Surviving mice were killed at 81 or 82 weeks. All high-dose females died before week 62, with no significant increase in the incidence of any tumour; of the low-dose females, 17/35 survived until termination of the experiment. Among males, 7/35 of the high-dose group and 13/35 of the low-dose group survived to the end of the study. The overall numbers of survivors in untreated and vehicle-treated groups were 25/30 and 20/30, respectively. In female mice of the low-dose group, lymphocytic and granulocytic neoplasms of the haematopoietic system were observed in 17/29 animals examined histologically, at a highly significant incidence ($p < 0.01$) compared with the vehicle-control group (0/14); 10 of the treated animals had granulocytic tumours (nine sarcomas, one leukaemia). A malignant lymphocytic lymphoma was observed in 1/15 untreated controls. No increase in the incidence of tumours was observed in male mice (National Cancer Institute, 1978).

Groups of 50 male and 50 female BALB/c/Cb/Se mice, eight weeks of age, were given intraperitoneal injections of azacitidine at 2.0 mg/kg bw in saline (99% pure) once a week for 50 weeks. Control groups received injections of saline. After 25 weeks, survival was reduced in exposed animals of each sex. The incidence of lymphoreticular neoplasms was increased, occurring in 12/50 ($p < 0.01$) males and 36/50 ($p < 0.001$) females, compared to 3/50 and 6/50 in control males and females, respectively. The incidence of lung adenomas was increased in treated males (27/50 versus 12/50 [$p < 0.01$]) but not in females. Mammary gland adenocarcinomas and adenoacanthomas were found in 7/50 treated females and in none of the controls. The incidence of skin tumours was increased in treated animals of each sex, occurring in 3/50 treated males compared to 0/50 controls [$p < 0.05$] and in 7/50 treated females compared to 1/50 controls [$p < 0.01$, log rank test] (Cavaliere et al., 1987). [The Working Group noted that adenoacanthomas are not described as mammary tumours in reference sources; see Turusov (1973, 1976).]

Rat: Two groups of 12 or 8 male Fischer rats, weighing 160-180 g, were given intraperitoneal injections of azacitidine at 2.5 or 10 mg/kg bw [purity unspecified] in saline twice a week for nine months. A control group of 12 male rats was maintained without treatment. All rats were killed at 18 months. Interstitial-cell testicular
tumours were found in 1/8 high-dose animals and 9/12 low-dose animals compared to 0/12 controls. In the high-dose group, two squamous-cell carcinomas of the skin and one skin appendage tumour at the site of injection were found, compared to none in controls (Carr et al., 1984). [The Working Group noted the small number of animals tested, and the absence in controls of testicular tumours, which occurred commonly in a second, shorter study by the same investigators (see below).]

Groups of 10, 10 or 100 young adult male Fischer rats, weighing 100-160 g, received intraperitoneal injections of azacitidine at 0.025, 0.25 or 2.5 mg/kg bw in saline [purity unspecified] three times a week for one year. A control group of 50 rats was injected with saline. At one year, when the study was terminated, 87/100 of animals at the high dose and 10/10 in each of the lower-dose groups were still alive. The highest dose increased the incidence of testicular interstitial-cell tumours to 56/87, compared to 10/49 in controls ($p < 0.001$). No other tumour was observed in controls. In the highest dose group, other tumours noted were four lymphomas, four renal tumours, one lung tumour, three skin tumours, two mesotheliomas and two sarcomas (Carr et al., 1988). [The Working Group noted the short duration of the experiment and the small numbers of animals in some groups.]

(b) Transplacental administration

Mouse: Groups of 32-37 pregnant NMRI mice received intraperitoneal injections of azacitidine at 1 or 2 mg/kg bw in saline [purity unspecified] on day 12, 14 or 16 of gestation. A group of 53 control dams was injected with saline. The number of stillbirths was increased at the high dose; survival of offspring was decreased in all exposed groups. In exposed progeny, increased percentages of tumour-bearing animals and increased incidences of leukaemias and lymphomas, lung tumours and liver tumours were seen in some groups (see Table 1). Some increases in the incidence of soft-tissue sarcomas were also seen (Schmahl et al., 1985).

c) Administration in combination with other compounds

Rat: In the experiment by Carr et al. (1984), described above, groups of 6-10 male Fischer rats were given N-nitrosodiethylamine at 50 mg/kg bw 18 h after partial hepatectomy, alone or with azacitidine at 2.5 or 10 mg/kg bw by intraperitoneal injection. Liver tumours were found in 2/10 and 8/10 animals given the low and the high dose of azacitidine, respectively, but not in the group given the nitroso compound alone.
Table 1. Incidences of tumours in the progeny of NMRI mice given azacitidine by intraperitoneal injection

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Sex</th>
<th>No. of animals</th>
<th>Leukaemias and lymphomas</th>
<th>Lung tumours</th>
<th>Liver tumours</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>No.</td>
<td>%</td>
<td>No.</td>
<td>%</td>
</tr>
<tr>
<td>mg/kg bw</td>
<td>day of gestation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>12</td>
<td>Males</td>
<td>165</td>
<td>81</td>
<td>49.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>158</td>
<td>80</td>
<td>50.6</td>
</tr>
<tr>
<td>2</td>
<td>12</td>
<td>Males</td>
<td>113</td>
<td>28</td>
<td>24.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>110</td>
<td>26</td>
<td>23.6</td>
</tr>
<tr>
<td>1</td>
<td>14</td>
<td>Males</td>
<td>178</td>
<td>42</td>
<td>23.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>171</td>
<td>26</td>
<td>15.2</td>
</tr>
<tr>
<td>2</td>
<td>14</td>
<td>Males</td>
<td>97</td>
<td>9</td>
<td>9.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>101</td>
<td>14</td>
<td>13.9</td>
</tr>
<tr>
<td>1</td>
<td>16</td>
<td>Males</td>
<td>153</td>
<td>97</td>
<td>63.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>160</td>
<td>98</td>
<td>61.3</td>
</tr>
<tr>
<td>2</td>
<td>16</td>
<td>Males</td>
<td>158</td>
<td>67</td>
<td>42.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>151</td>
<td>57</td>
<td>37.7</td>
</tr>
<tr>
<td>Controls</td>
<td></td>
<td>Males</td>
<td>293</td>
<td>84</td>
<td>28.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>279</td>
<td>82</td>
<td>29.4</td>
</tr>
</tbody>
</table>

*From Schmahl et al. (1985)*

3.2 Other relevant data

(a) Experimental systems

(i) Absorption, distribution, excretion and metabolism

Blood levels of azacitidine, determined by biological activity, in mice peaked within 0.5 h after intraperitoneal or oral administration. Maximal concentrations of azacitidine in blood after administration at 50 mg/kg bw were about 2 μg/ml after oral administration and 43 μg/ml after intraperitoneal injection (Neil et al., 1975).

In a study using a microbiological assay, maximal concentrations were found in blood 15 min after intraperitoneal injection of 9.5 and 4.75 mg/kg bw (LD<sub>10</sub> and 0.5 LD<sub>10</sub>) to mice. Elimination was rapid, and no azacitidine was detected in blood 1 h after injection of the high dose or 30 min after injection of the low dose. No drug was detected in liver, lung, brain, spleen or kidneys (Pittillo & Woolley, 1969).

In a further study, <sup>14</sup>C activity in blood diminished rapidly in mice after intraperitoneal administration of labelled azacitidine (Raska et al., 1965). The half-time for azacitidine and its radioactive metabolites was calculated by von Hoff and Slavic (1977) to be 3.8 h; radioactivity was retained in lymphatic organs.
As reported in an abstract, 50% of a dose [amount and route unspecified] administered to mice was excreted in the urine within 8 h; of the excreted radioactive material, 4% was associated with unchanged azacitidine. Six additional radioactive metabolites were found (Coles et al., 1975). In beagle dogs, azacitidine, 5-azacytosine, urea and guanidine were observed after intravenous administration of azacitidine at 0.5 mg/kg bw; 33% of the administered dose was excreted in urine by 4 h (Coles et al., 1974). In rabbits, most of the radioactivity (25-40%) was excreted in the urine after intravenous administration of labelled azacitidine at 15 mg/kg bw; only small amounts were excreted via the bile (Chan et al., 1977).

Azacitidine is phosphorylated and inhibits uridine kinase and orotidyllic acid hydroxylase (von Hoff et al., 1975, 1976). It is readily deaminated in biological systems to 5-azauridine, which is degraded further (Ciháč, 1974; Neil et al., 1975; Glover & Leyland-Jones, 1987).

(ii) Toxic effects

As reported in an abstract, the intraperitoneal LD50 for azacitidine in mice was 116 mg/kg bw and the oral LD50, 572 mg; five daily doses increased the toxicity considerably (Palm & Kensler, 1971).

After phosphorylation, azacitidine is incorporated into DNA and RNA in L1210 leukaemia cells in vitro (Li et al., 1970); it inhibits DNA synthesis in the liver of partially hepatectomized rats. Intraperitoneal injection of azacitidine at 10 μmol/100 g bw inhibited thymidine kinase and thymidylate kinase in rat liver (Ciháč & Vesely, 1972).

Azacitidine is cytotoxic to Friend erythroleukaemia cells (Hickey et al., 1986), L1210 leukaemia cells (Li et al., 1970) and normal rat hepatocytes (Carr et al., 1988) in vitro; after a dose of 1 × 10⁻⁴ M, 32% survival of rat hepatocytes was observed within 24 h.

(iii) Hypomethylation and effects on gene expression

After incorporation into DNA, azacitidine inhibits DNA methyl transferase noncompetitively, blocking cytosine methylation in newly replicated DNA. Since hypomethylation patterns in DNA are related to gene expression, this may be the mechanism by which azacitidine induces a range of biological effects (Glover et al., 1987). A number of in-vitro and in-vivo studies have shown that azacitidine treatment affects both differentiation (Constantinides et al., 1978; Taylor & Jones, 1979; Tsao et al., 1984; Csordas & Schauenstein, 1986; Liu et al., 1986; Sémat et al., 1986; Rothrock et al., 1988) and gene expression (Tennant et al., 1982; Harrison et al., 1983; Rothrock et al., 1983; Sugiyama et al., 1983; del Senno et al., 1984; Waalkes & Poirier, 1985; Castelazzi et al., 1986; Hickey et al., 1986; Hoshino et al., 1987; Ishikawa et al., 1987; Price-Haughey et al., 1987; Carr et al., 1988; Stephanopoulos et al., 1988; Wagner et al., 1988).
(iv) Effects on reproduction and prenatal toxicity

Intraperitoneal administration of azacitidine at 1.5-2.5 mg/kg bw to mice for various periods during pregnancy induced very high or total resorption of conceptuses when treatment was given in the preimplantation period up to day 6; after this time, the incidence of resorptions was only slightly greater than the control level (Svata et al., 1966; Seifertová et al., 1968). Other workers have shown that single intraperitoneal doses of 1-2 mg/kg to mice during the period of embryogenesis can cause a high resorption rate and malformations in the majority of surviving fetuses, including major central nervous system defects, facial clefts and limb defects (Schmahl et al., 1984; Takeuchi & Takeuchi, 1985).

Intraperitoneal injection of azacitidine at 1-4 mg/kg to mice at later stages of pregnancy, especially on day 15, can result in morphological changes in the brain (Langman & Shimada, 1971), and behavioural changes can be detected in offspring when tested as adults (Rodier et al., 1973; Langman et al., 1975; Rodier, 1979).

The primary mechanism by which azacitidine causes malformations in rats is thought to be induction of cell death, but inhibition of some but not all of the effects of azacitidine by administration of caffeine indicates that more than one mechanism may be involved (Kurishita & Ihara, 1987a,b).

(v) Genetic and related effects

In Escherichia coli, azacitidine caused DNA damage (Bhagwat & Roberts, 1987) and prophage induction (Barbe et al., 1986). It was mutagenic to E. coli (Fucik et al., 1965; Lal et al., 1988) and induced base-pair but not frameshift mutations in Salmonella typhimurium (Marquardt & Marquardt, 1977; Podger, 1983; Call et al., 1986; Levin & Ames, 1986; Schmuck et al., 1986).

Azacitidine induced mitotic recombinations, mitotic gene conversions and reverse mutations but not mitotic chromosome loss in Saccharomyces cerevisiae (Zimmermann & Scheel, 1984). It induced mitotic recombinations, deletions and gene mutations in the wing spot assay in Drosophila melanogaster (Katz, 1985) and chromosomal aberrations in root meristem cells of Vicia faba (Fucik et al., 1970).

Azacitidine inhibited DNA synthesis in Chinese hamster CHO cells (Tobey, 1972) and induced DNA strand breaks in HeLa cells (Snyder & Lachmann, 1989). It induced mutations at the hprt locus in Chinese hamster V79 cells in one study (at 5 μM; Marquardt & Marquardt, 1977) but not in another (at 40 μM; Landolph & Jones, 1982). It did not induce mutation at the hprt locus in Syrian hamster BHK cells (Bouck et al., 1984), primary rat tracheal epithelial cells (Walker & Nettesheim, 1986) or mouse lymphoma L5178Y cells (at 4 μM; McGregor et al., 1989). Azacitidine induced mutations at the hprt and tk loci in human fibroblasts (Call et al., 1986) and at the tk locus of mouse lymphoma L5178Y cells (Amacher & Turner, 1987; McGregor et al., 1989). It did not induce ouabain-resistant mutations in
AZACITIDINE

mouse C3H 10T½, Chinese hamster V79 (Landolph & Jones, 1982), Syrian hamster BHK (Bouck et al., 1984) or primary rat tracheal epithelial cells (Walker & Nettesheim, 1986).

Azacitidine induced sister chromatid exchange in a cloned hamster cell line (Banerjee & Benedict, 1979), in CHO cells (Hori, 1983) and in human peripheral lymphocytes in vitro [only one concentration, 8 μM, was tested] (Lavia et al., 1985). In another study, azacitidine did not induce sister chromatid exchange in human lymphocytes (up to 9 μM; Ioannidou et al., 1989). It induced chromosomal aberrations in Chinese hamster Don cells (Karon & Benedict, 1972) and in human peripheral lymphocytes in vitro [only one concentration, 8 μM, was tested] (Lavia et al., 1985) but not in human lymphoblasts (10 μM; Call et al., 1986).

Azacitidine induced transformation in mouse C3H/10T½ (Benedict et al., 1977), Syrian hamster BHK (Bouck et al., 1984), mouse BALB/3T3 (Yasutake et al., 1987) and primary rat tracheal epithelial cells (Walker & Nettesheim, 1986).

Azacitidine did not induce dominant lethal mutation in male mice after administration at 5 and 10 mg/kg bw intraperitoneally (Epstein et al., 1972).

(b) Humans

The toxicity, cytostatic activity and mechanism of action of azacitidine have been reviewed (Cihák, 1974; von Hoff & Slavik, 1977; Glover & Leyland-Jones, 1987).

(i) Pharmacokinetics

After an intravenous injection of radiolabelled azacitidine, the α-phase half-time of radioactivity was 16-33 min (Israeli et al., 1976), and the β-phase half-time was 3.4-6.2 h (Troetel et al., 1972; Israeli et al., 1976). After 30 min, less than 2% of the plasma radioactivity cochromatographed with azacitidine; at least two different metabolites or decomposition products were detected by thin-layer chromatography (Israeli et al., 1976), and 73-98% of the injected radioactivity was detected in the urine within three days (Israeli et al., 1976). Similar results were obtained by Troetel et al. (1972).

Less than 1% of radiolabelled azacitidine was bound to human serum albumin in vitro (Israeli et al., 1976).

(ii) Adverse effects

The major toxic effects of the clinical use of azacitidine have been gastrointestinal, haematological and hepatic (von Hoff et al., 1976; von Hoff & Slavik, 1977; Reynolds, 1989). Leukopenia is generally the dose-limiting toxicity; in a compilation of several studies with a total of 821 patients, the incidence of leukopenia (total leukocyte count, less than 1500/mm³) was 34% and was dose-related. Thrombocytopenia has been reported less frequently (von Hoff et al.,
Fatal hepatic damage was reported in four patients with previous hepatic dysfunction, who had been treated with azacitidine (Bellet et al., 1973).

(iii) Effects on reproduction and prenatal toxicity
No data were available to the Working Group.

(iv) Genetic and related effects
No adequate study was available to the Working Group.

3.3 Case reports and epidemiological studies of carcinogenicity to humans
No data were available to the Working Group.

4. Summary of Data Reported and Evaluation

4.1 Exposure data
Azacitidine is a cytostatic agent that has been used since the 1970s for the treatment of acute leukaemia.

4.2 Experimental carcinogenicity data
Azacitidine was tested for carcinogenicity by intraperitoneal injection in four studies in mice and in two studies in rats and by transplacental exposure in one study in mice. In one study in mice, it accelerated the development of leukaemias; in the two long-term studies and in the transplacental study, it increased the incidence of lymphoid neoplasms. In one of the long-term studies, the incidence of lung adenomas was increased in male mice and that of skin tumours in mice of each sex. In the transplacental study in mice, it also increased the incidences of lung and liver tumours. It accelerated the induction of lung tumours in mice. In rats, it increased the incidence of testicular tumours.

Intraperitoneal administration of azacitidine to rats enhanced the development of liver tumours induced by N-nitrosodiethylamine.

4.3 Human carcinogenicity data
No data were available to the Working Group.

4.4 Other relevant data
During the early stages of gestation, azacitidine induces embryomortality in mice; during the organogenesis period, multiple, gross structural malformations
can be induced; and during later stages of gestation, mainly central nervous system
defects have been induced in mice.

Azacitidine is readily deaminated to azauridine and further degraded. It is
incorporated into DNA and alters gene expression. In humans, it causes
leukopenia.

Azacitidine causes hypomethylation of DNA both in vivo and in vitro.

In one study, azacitidine did not induce dominant lethal mutations in mice.
Contradictory results have been reported with respect to the induction of
chromosomal aberrations and sister chromatid exchange in human cells. In single
studies, azacitidine induced gene mutations and DNA strand breaks in human
cells. It induced chromosomal aberrations in Chinese hamster cells, sister
chromatid exchange in cloned Chinese hamster cells, gene mutations in Chinese
hamster and mouse lymphoma cells and transformation in various cell lines. It
induced mitotic recombination and mutations in Drosophila. Azacitidine induced
chromosomal aberrations in Vicia faba. In Saccharomyces cerevisiae, it induced
gene mutations and mitotic recombination but not chromosomal loss. It induced
mutations and DNA damage in Salmonella typhimurium and Escherichia coli. (See
Appendix 1.)

4.5 Evaluation

There is sufficient evidence for the carcinogenicity of azacitidine in
experimental animals.

No data were available from studies in humans on the carcinogenicity of
azacitidine.

In making the overall evaluation, the Working Group also took note of the
following information. Azacitidine is active in a broad spectrum of assays for
genetic and related effects, including those involving mammalian cells.
Furthermore, azacitidine, a pyrimidine analogue, is incorporated into DNA,
causing hypomethylation.

Overall evaluation

Azacitidine is probably carcinogenic to humans (Group 2A).

---

1For description of the italicized terms, see Preamble, pp. 26–29.
5. References


Chemical Information Services (1989-90) Directory of World Chemical Producers, Oceanside, NY


AZACTIDINE


von Hoff, D.D., Handelsman, H. & Slavik, M. (1975) 5-Azacytidine (NSC 102816), Clinical Brochure, Bethesda, MD, National Cancer Institute, Division of Cancer Treatment


AZACITIDINE

National Cancer Institute (1978) Bioassay of 5-Azacytidine for Possible Carcinogenicity (NCI Publ. No. 279-526), Bethesda, MD


Turusov, V.S., ed. (1973) Pathology of Tumours in Laboratory Animals, Vol. 1, Tumours of the Rat, Part 1 (IARC Scientific Publications No. 5), Lyon, IARC

Turusov, V.S., ed. (1976) Pathology of Tumours in Laboratory Animals, Vol. 1, Tumours of the Rat, Part 2 (IARC Scientific Publications No. 6), Lyon, IARC


AZACITIDINE


1. Chemical and Physical Data

1.1 Synonyms


Chem. Abstr. Name: D-Glucose, 2-(((2-chloroethyl)nitrosoamino)carbonyl)amino)-2-deoxy-

Synonyms: D-Glucopyranose, 2-(((2-chloroethyl)nitrosoamino)carbonyl)amino)-2-deoxy-1-(2-chloroethyl)-1-nitroso-3-(D-glucos-2-yl)urea; 2-[3-(chboroethyl)-3-nitrosoureido]-2-deoxy-D-glucopyranose; DCNU; NSC-178248

1.2 Structural and molecular formulae and molecular weight

\[
\text{C}_9\text{H}_{16}\text{ClN}_3\text{O}_7 \quad \text{Mol. wt: 313.69}
\]

1.3 Chemical and physical properties of the pure substance

From Windholz (1983), unless otherwise specified

(a) Description: Ivory crystals

(b) Melting-point: 147-148°C (decomposes); 140-141°C (decomposes)

(c) Solubility: Soluble in water; decomposition in aqueous solution has been studied (Montgomery et al., 1975).

(d) Spectroscopy data: Infra-red and nuclear magnetic resonance spectra have been reported (Johnston et al., 1975).
(e) Stability: Stable (<5% decomposition by ultraviolet spectroscopy) in solution at room temperature (22-25°C) for 3 h and at 2-8°C for 24 h; powder is stable for 24 months under refrigeration

(f) Partition coefficient: \( P_c = 3 \) (octanol:water) (Johnston et al., 1975)

1.4 Technical products and impurities

Trade name: Dome

Chlorozotocin is available as a lyophilized powder in vials containing 50 mg of the compound with 48 mg citric acid and sodium hydroxide to adjust the pH (National Cancer Institute, 1988).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

Chlorozotocin is synthesized by nitrosation of the urea derivative prepared from D-glucosamine and 2-chloroethylisocyanate (Johnston et al., 1975). It is reported to be produced in the USA.

Chlorozotocin is not known to occur naturally.

2.2 Use

Chlorozotocin is a cytostatic agent. It can be used in the treatment of cancers of the stomach, large bowel, pancreas and lung, melanoma and multiple myeloma. It has been given intravenously, at doses of 100-225 mg/m² (Samson et al., 1982; Smith et al., 1982; Bukowski et al., 1983; Haas et al., 1983; Forman et al., 1984; Gastrointestinal Tumor Study Group, 1985). No indication for its use was given by Reynolds (1989).

2.3 Analysis

A colorimetric method for the analysis of chlorozotocin in plasma has been reported (Hoth et al., 1978; Kovach et al., 1979).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

(a) Intraperitoneal administration

Rat: Groups of 20 male and 20 female Sprague-Dawley rats, 100 days old, were given intraperitoneal injections of chlorozotocin (synthesized according to
standard methods) at 0.4 or 2.0 mg/kg bw once a week for up to 800 days. Control groups of 20 rats of each sex received injections of Cremophor EL: ethanol:saline in a ratio of 1:1:2 volume parts. The median survival times in days were as follows: control males, 724; low-dose males, 463; high-dose males, 307; control females, 750; low-dose females, 694; high-dose females, 346. Sarcomas and mesotheliomas of the peritoneal cavity occurred in 13/20 \( p < 0.001 \) and 14/20 \( p < 0.001 \), Fisher's exact test] high- and low-dose males, respectively, compared to 0/20 controls, and in 16/20 \( p < 0.001 \) and 10/20 \( p = 0.002 \), Fisher's exact test] high- and low-dose females, respectively, compared to 1/20 controls (Habs et al., 1979).

(b) Intravenous administration

Rat: Groups of 30 male Wistar rats [age unspecified] were given intravenous injections of chlorozotocin at 9.5, 19 or 38 mg/m\(^2\) every six weeks for 10 applications. A group of 120 controls received Cremophor EL:ethanol:water in a ratio of 1.5:1.5:20 volume parts. The median survival times in days were as follows: high dose, 474; median dose, 590; low dose, 583; controls, 621. Animals were observed for life. Malignant tumours of the nervous system, lung and forestomach were found in 4, 5 and 4\% of treated animals compared to 1, 0 and 1\% of controls, respectively (Eisenbrand & Habs, 1980; Eisenbrand et al., 1981; Zeller et al., 1982). [The Working Group noted the poor survival and limited reporting.]

3.2 Other relevant data

(a) Experimental systems

The toxicity of chlorozotocin has been reviewed (Schein et al., 1976; Macdonald et al., 1980; Wang et al., 1981; Eisenbrand, 1984; Eisenbrand et al., 1986; Johnston & Montgomery, 1986).

(i) Absorption, distribution, excretion and metabolism

No data were available to the Working Group.

(ii) Toxic effects

The LD\(_{50}\) of chlorozotocin within 60 days in Sprague-Dawley rats was 27.2 mg/kg bw after intraperitoneal injection and 22.5 mg/kg bw after intravenous injection (Fiebig et al., 1980).

In one study of acute toxicity, the LD\(_{50}\) after intravenous injection in BDF\(_1\) mice was 24.9 mg/kg bw for males and 30.3 mg/kg bw for females. In animals of each sex, tubular necrosis of the kidney and cast formation were observed, as well as splenic lymphoid atrophy. In the same study, a dose of 6 mg/kg bw was lethal to beagle dogs after five days, and 3 mg/kg bw after 19 days. Renal dysfunction with tubular necrosis also occurred in these animals. Elevated serum levels of alanine aminotransferase and alkaline phosphatase were observed in dogs injected
repeatedly with chlorozotocin. Nephrotoxicity was also seen in rhesus monkeys given 40 mg/kg intravenously (Gralla et al., 1979).

In Fischer rats, a lethal subcutaneous injection of chlorozotocin at 40 mg/kg bw caused renal necrosis in the cortex and, subsequently, necrosis of papillary collecting ducts. At sublethal doses, hypertrophy and karyomegaly were observed in collecting duct cells (Kramer et al., 1986). In Fischer rats given a subcutaneous injection of chlorozotocin at 25 or 40 mg/kg bw, no necrosis was observed in papillary collecting ducts, although karyomegaly was observed (Dees & Kramer, 1986).

Central nervous system vascular necrosis was observed in beagle dogs treated with chlorozotocin at 1.5-2.0 mg/kg bw once a week for two weeks or with a single intraventricular dose of 10 mg/kg bw (Levin et al., 1985).

Chlorozotocin affects cell cycle progression in Chinese hamster CHO cells. Non-cycling G1-arrested cells were the most sensitive; traverse from G1 to S was not affected, and chlorozotocin doubled the time for completion of DNA synthesis. Small quantities of polyploid cells were produced (Tobey et al., 1975). Chlorozotocin at a concentration of 200 μM induced differentiation and inhibited cell growth of mouse neuroblastoma N-18 cells (Yoda et al., 1982). DNA synthesis in L1210 leukaemia cells was almost completely inhibited (96%) within 24 h of an intraperitoneal administration to BD2F1 mice (Anderson et al., 1975). In vitro, DNA synthesis in L1210 leukaemia cells was inhibited by 68% (Fox et al., 1977).

Single intraperitoneal injections of chlorozotocin at 15 mg/kg bw (maximal nonlethal dose) to BDF1 mice slightly decreased peripheral white blood cell counts (Schein et al., 1976). Similar observations were made in CD2F1 mice (Fox et al., 1977; Macdonald et al., 1980). Intraperitoneal injections of chlorozotocin at 20 mg/kg bw to mice reduced peripheral lymphocyte counts by 50% in three days. Spleen weights were decreased by about 40%, and the response to mitogens was markedly reduced (Fisher et al., 1980).

In another study in mice, chlorozotocin was shown to have immunomodulating activity. The IgM plaque-forming cell response was suppressed when the drug was injected four days before immunization; furthermore, hypersensitivity to oxazolone treatment was increased by about 30% when animals were injected intraperitoneally with chlorozotocin four days before sensitization. Treatment with chlorozotocin in vivo inhibited the proliferative response of spleen cells to mitogens and stimulated the chemiluminescence of peritoneal macrophages (Florentin et al., 1983).

Chlorozotocin exerts its toxic and other adverse effects through the formation of mono- and bifunctional alkylating agents. It also carbamoylates proteins via an isocyanate intermediate formed upon decomposition (Eisenbrand, 1984).
Alkylation of nuclear chromatin in HeLa cells has been observed, and there was preferential alkylation of DNA associated with the nucleosome core particle (Tew et al., 1978).

(iii) Effects on reproduction and prenatal toxicity
No data were available to the Working Group.

(iv) Genetic and related effects
Chlorozotocin induced base-pair substitutions but not frameshift mutations in *Salmonella typhimurium* in the presence and absence of an exogenous metabolic system (Zimmer & Bhuyan, 1976; Franza et al., 1980; Suling et al., 1983). It induced mitotic gene conversion in *Saccharomyces cerevisiae* (Siebert & Eisenbrand, 1977) and sex-linked recessive mutations in *Drosophila melanogaster* (Kortselius, 1978).

Chlorozotocin alkylated DNA in mouse leukaemia L1210 cells (Panasci et al., 1979; Ahlgren et al., 1982). It induced DNA strand breaks in L1210 cells (Ewig & Kohn, 1977; Alexander et al., 1986) and in V79 Chinese hamster cells (Erickson et al., 1978), and interstrand cross-links in DNA of mouse leukaemia L1210 cells (Ewig & Kohn, 1977) and of human embryo cells (Erickson et al., 1980). It induced mutation at the *hpert* locus in V79 Chinese hamster cells (Bradley et al., 1980) and sister chromatid exchange in mouse leukaemia L1210 cells (Siddiqui et al., 1988) and in 9L rat brain tumour cells (Tofilon et al., 1983).

Chlorozotocin at a single intraperitoneal dose of 100 µmol/kg induced DNA strand breaks and interstrand cross-links in bone-marrow cells of Wistar rats treated in vivo (Bedford & Eisenbrand, 1984).

(b) Humans

(i) Pharmacokinetics
After an intravenous dose of chlorozotocin at 120 mg/m², the disappearance curve of the N-nitroso group from the circulation exhibited three successive exponential phases, with half-times of 3-4.5 min, 6-12 min and 18-30 min. Twenty-four hours after administration of either ethyl- or glucose-labelled chlorozotocin, 82-84% of the blood-borne radioactivity was bound to protein; after seven days, 2% of the peak radioactivity value was detected in the blood. By 48 h, 50% of the radioactivity from [ethyl-¹⁴C]chlorozotocin and 58% of that from [glucose-¹⁴C]chlorozotocin was excreted in the urine; only 5-8% was excreted as the intact drug (Hoth et al., 1978).

(ii) Adverse effects
Thrombocytopenia, leukopenia, elevated aminotransferase activity, nausea and vomiting were seen in patients after intravenous administration of chlorozotocin, generally at doses of 120 mg/m² or higher (Hoth et al., 1978;
Bukowski et al., 1983; Haas et al., 1983; Forman et al., 1984; Schutt et al., 1984; Gastrointestinal Tumor Study Group, 1985).

(iii) Effects on reproduction and prenatal toxicity
No data were available to the Working Group.

(iv) Genetic and related effects
No data were available to the Working Group.

3.3 Case reports and epidemiological studies of carcinogenicity to humans
No data were available to the Working Group.

4. Summary of Data Reported and Evaluation

4.1 Exposure data
Chlorozotocin has been used as a cytostatic drug for the treatment of cancers at a variety of sites.

4.2 Experimental carcinogenicity data
Chlorozotocin was tested for carcinogenicity in single experiments in rats by intraperitoneal and intravenous injection. Intraperitoneal administration induced a high incidence of sarcomas and mesotheliomas in the peritoneal cavity in rats of each sex. The study by intravenous administration was inadequate for evaluation.

4.3 Human carcinogenicity data
No data were available to the Working Group.

4.4 Other relevant data
Chlorozotocin alkylates DNA and protein and causes DNA interstrand cross-links. In humans, it induces leukopenia and thrombocytopenia; in animals, it suppresses the bone marrow and affects immune response.

It is hepatotoxic in both humans and experimental animals.

Chlorozotocin induced DNA damage in bone-marrow cells of rats in vivo. It induced DNA damage in human, mouse and Chinese hamster cells in vitro, sister chromatid exchange in mouse and rat cells and gene mutation in Chinese hamster cells. It induced sex-linked recessive lethal mutations in Drosophila and gene
conversion in *Saccharomyces cerevisiae*. Chlorozotocin induced mutations in *Salmonella typhimurium*. (See Appendix 1.)

4.5 Evaluation

There is *sufficient evidence* for the carcinogenicity of chlorozotocin in experimental animals.

No data were available from studies in humans on the carcinogenicity of chlorozotocin.

In making the overall evaluation, the Working Group also took note of the following information. Chlorozotocin is an alkylating agent and is structurally related to other chloroethyl nitrosoureas, one of which, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU), is carcinogenic to humans (Group 1) and two of which, bischloroethyl nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), are probably carcinogenic to humans (Group 2A) (IARC, 1987). Chlorozotocin has given consistently positive results in a broad spectrum of assays for genetic and related effects, including those involving mammalian cells.

**Overall evaluation**

Chlorozotocin is *probably carcinogenic to humans* (Group 2A).

5. References


---

1For description of the italicized terms, see Preamble, pp. 26–29.


CICLOSPORIN

1. Chemical and Physical Data

1.1 Synonyms

Chem. Abstr. Services Reg. No.: 59865-13-3 (cyclosporin A); 79217-60-0 (cyclosporine)


1.2 Structural and molecular formulae and molecular weight

\[C_{62}H_{111}N_{11}O_{12}\]  
Mol. wt: 1202.64
1.3 Chemical and physical properties of the pure substance

From Ruegger et al. (1976), Windholz (1983) and Hassan and Al Yahya (1987)

(a) Description: White prismatic crystals from acetone; neutral, hydrophobic, cyclic non-polar oligopeptide composed of 11 amino acid residues. The X-ray crystallographic structure is known.

(b) Melting-point: 148-151°C (natural); 149-150°C (synthetic)

(c) Optical rotation: \( [\alpha]_{D}^{20} = -244° \) (c = 0.6 in chloroform); \( [\alpha]_{D}^{20} = -189° \) (c = 0.5 in methanol)

(d) Solubility: Neutral; rich in hydrophobic amino acids; insoluble in water and n-hexane; very soluble in all other organic solvents

(e) Spectroscopy data: Ultraviolet, infrared, nuclear magnetic resonance and mass spectra have been reported.

(f) Stability: Stable in solution at temperatures below 30°C; sensitive to light, cold and oxidization (Reynolds, 1989)

1.4 Technical products and impurities

Trade names: Sandimmun; Sandimmune

Ciclosporin is available in bottles containing 100 mg/ml in an olive oil-based solution and 12.5% ethanol for oral administration, and in ampoules containing 50 mg/ml with 33% ethanol and 650 mg polyoxethylated castor oil for intravenous injection (Barnhart, 1989).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

The isolation of cyclosporins A and C from the fungus *Tolypocladium inflatum* Gams has been described (Rüegger et al., 1976), and the biosynthesis of ciclosporin has been reported (Kobel & Traber, 1982; Kobel et al., 1983; Billich & Zocher, 1987). It is also produced synthetically from N-methyl-9-amino acid with subsequent additions of appropriate peptides, followed by cyclization (Hassan & Al-Yahya, 1987).

Ciclosporin is manufactured commercially in Switzerland (Reynolds, 1989).

Cyclosporins (mostly A and C) are produced by the fungi *Tolypocladium inflatum* Gams and *T. cylindrosporum* and by other fungi isolated from soil.

2.2 Use

Ciclosporin is an immunosuppressive agent. It is used extensively in the prevention and treatment of graft-versus-host reactions in bone-marrow
transplantation, and for the prevention of rejection of kidney, heart and liver transplants. It has also been tested for the therapy of a large variety of other diseases in which immunological factors may have a pathogenetic role, including Graves' disease, uveitis, Crohn's disease, ulcerative colitis, chronic active hepatitis, primary biliary cirrhosis, diabetes mellitus, myasthenia gravis, sarcoidosis, dermatomyositis, systemic lupus erythematosus and psoriasis (Calne et al., 1978, 1979; Powles et al., 1980; Merion et al., 1984; Kahan et al., 1985; Reynolds, 1989).

The usual oral dose of ciclosporin is 18 mg/kg daily, beginning 12 h before transplantation and continuing for one to two weeks. Dosage may subsequently be reduced to 5-10 mg/kg or less. Ciclosporin may also be given intravenously, usually at one-third of the oral dose. This drug is often given for several months to transplant recipients (Reynolds, 1989).

2.3 Analysis

Ciclosporin has been measured in pharmaceutical preparations by high-performance liquid chromatography (HPLC; US Pharmacopeial Convention, Inc., 1989).

Ciclosporin and its metabolites have also been measured in biological fluids using HPLC (Awni & Maloney, 1988; Christians et al., 1988a,b; Birkel et al., 1988), and ciclosporin has been monitored in whole blood by radioimmunoassay (Donatsch et al., 1981; Vine & Bowers, 1987). Vine and Bowers (1987) provided a critical summary of HPLC methods used to measure ciclosporin in biological fluids, and Hassan and Al-Yahya (1987) reviewed the methods for analysing ciclosporin. Radioimmunoassay kits for the analysis of ciclosporin in plasma are available, and their performance has been compared to that of HPLC analyses (Vernilet et al., 1989; Wolf et al., 1989).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

(a) Oral administration

Mouse: Groups of 50 male and 50 female OF1 mice, weighing 26-39 and 19-28 g, respectively, were fed ciclosporin at 1, 4 or 16 mg/kg of diet for 78 weeks, at which time all survivors were killed. An untreated group of 50 males and 50 females served as controls. All mice were necropsied, and all macroscopic lesions were examined histologically. Mortality was higher in high-dose females (60%) than in
controls (40-50%) and in other treated groups (42-52%). No increase in the incidence of tumours was observed in treated mice (Ryffel et al., 1983).

In a screening assay based on the accelerated induction of leukaemia in a strain highly susceptible to development of this neoplasm, 30 male AKR mice, six weeks of age, were fed ciclosporin at 150 mg/kg of diet. The first thymic lymphoma in treated mice was noted at week 17; these tumours occurred in 13/18 animals killed between 20 and 29 weeks \( [p = 0.004] \) and in 9/9 killed between 30 and 34 weeks \( [p = 0.005, \text{ Fisher's exact test}] \). In 22 mice that received the basal diet only, the first thymic lymphoma was noted at week 23, and the incidences of these tumours in animals killed between 20 and 29 weeks and 30 and 34 weeks were 2/12 and 3/9, respectively (Hattori et al., 1986).

**Rat**: Groups of 50 male and 50 female OFA rats, weighing 242-326 and 169-244 g, respectively, were fed ciclosporin at 0.5, 2 or 8 mg/kg bw of diet for 95 weeks (males) and 105 weeks (females), at which time the experiment was terminated. An untreated group of 50 males and 50 females served as controls. All animals were necropsied, and all macroscopic lesions were examined histologically. Mortality rates were 68% in controls, 74% in low- and mid-dose groups, and 86% in the high-dose group. No increase in tumour incidence was observed in treated rats (Ryffel et al., 1983). [The Working Group noted the high incidence of tumours in the controls, which may have reduced the sensitivity of the assay.]

\((b)\) Administration with other treatments

**Mouse**: A group of 39 male Swiss Webster mice and 13 male C57Bl/6J mice, six to seven weeks of age, were given a single whole-body \( \gamma \)-irradiation of 350 rad and ten days later were fed ciclosporin [purity unspecified] at 150 mg/kg of diet for 35 weeks, at which time all survivors were killed and autopsied. A group of 26 male Swiss Webster and 14 male C57Bl/6J mice received the same irradiation and were maintained on basal diet. Two groups of 18 male Swiss Webster and 12 male C57Bl/6J mice received no irradiation and were maintained on control diet or were given ciclosporin at 150 mg/kg of diet. No tumour was observed in either of the strains of mice irradiated and maintained on basal diet alone or in either strain that received no radiation and were fed diets containing ciclosporin. Of the Swiss Webster mice that were irradiated and fed diets containing ciclosporin, 18/39 (46%) \( [p < 0.001, \text{ Fisher's exact test}] \) developed lymphoid tumours, primarily in the spleen and mesenteric lymph nodes, within an average latent period of 24 weeks. The tumours were interpreted as B-immunoblastic lymphomas with plasmacytoid features. Four of the 39 (10%) mice developed classical thymic lymphomas within an average latent period of 23.7 weeks. Of the C57Bl/6 mice irradiated and fed diets containing ciclosporin, 7/13 (54%) \( [p < 0.002, \text{ Fisher's exact test}] \) developed thymic
lymphomas within an average latent period of 27.4 weeks. No spleen or lymph node lymphoma developed in this strain (Hattori et al., 1988).

Two groups of 13 male Swiss Webster mice, six to seven weeks old, received a single intraperitoneal injection of 1 g/kg bw urethane. One week later, ciclosporin [purity unspecified] was administered at 150 mg/kg of diet. Two groups of 15 or 14 mice not receiving injections of urethane were fed the basal diet or ciclosporin at 150 mg/kg of diet. All animals were killed 22 weeks after the beginning of treatment. No significant difference in the number of lung adenomas was found between the groups receiving urethane and ciclosporin and those receiving urethane alone (Shinozuka et al., 1988). [The Working Group noted the small number of animals used and the short duration of the study.]

Groups of 28-41 male Swiss Webster mice, six to seven weeks of age, received a single intraperitoneal injection of N-methyl-N-nitrosourea (MNU) at 0, 12.5 or 25 mg/kg bw [vehicle unspecified] and one week later were fed either basal diet or ciclosporin [purity unspecified] at 150 mg/kg of diet for 35 weeks. Mice treated with MNU and ciclosporin had four- and eight-fold higher incidences of thymic lymphomas, respectively, than mice treated with either dose of MNU alone (< 2%) [figures not given]. Thymic lymphomas did not develop in mice treated with ciclosporin alone or maintained on basal diet (Shinozuka et al., 1988). [The Working Group noted the incomplete reporting of the study.]

*Rat:* Groups of 10-12 male Sprague-Dawley rats, weighing 100-120 g, received a single intraperitoneal injection of 0 or 25 mg/kg bw MNU in 10% ethanol and citrate buffer; one week later, they were fed basal diet or ciclosporin [purity unspecified] at 110 mg/kg of diet for 34 weeks, at which time the experiment was terminated. Autopsies were carried out on all rats killed during the course or at the end of the experiment, and tissues from the thymus, mesenteric lymph nodes, intestinal lymphoid plaques, spleen, lung, kidney and liver were examined histologically. Of the rats receiving MNU and ciclosporin, 6/10 developed intestinal adenocarcinomas in the region of intestinal lymphoid plaques: two in the lower portion of the ileum and four in the ascending and transverse colon; two of the latter had two tumours each in the colon. The first tumour appeared in week 23 of the study. Of the rats receiving MNU alone, 1/12 developed an intestinal adenocarcinoma in week 33 of the study (p < 0.05). No intestinal tumour was observed in rats receiving ciclosporin or basal diet alone, but in rats treated with ciclosporin alone, atypical epithelial proliferations of the intestinal mucosa associated with hyperplasia of gut-associated lymphoid structures was observed (Perera et al., 1986). [The Working Group noted the small number of animals used.]

*Rat:* Young male Wistar rats, weighing 62-80 g, were divided into six groups: group 1 (five animals) received daily subcutaneous injections of ciclosporin [purity unspecified] at 10 mg/kg bw in olive oil during week 1; group 2 (15 animals) received
daily subcutaneous injections of ciclosporin at 10 mg/kg bw in olive oil during week 1, followed by administration of \( N \)-methyl-\( N' \)-nitro-\( N \)-nitrosoguanidine (MNNG) at 83 \( \mu \)g/ml in the drinking-water ad libitum from week 3 to 28; group 3 (15 animals) received MNNG in the drinking-water from week 3 to 28; groups 4 and 5 (15 animals per group) received MNNG in the drinking-water in weeks 3-28 and daily subcutaneous injections of ciclosporin at 10 mg/kg bw during week 15 or during week 30; group 6 (ten animals) served as untreated controls. All surviving animals were sacrificed in week 39. No rat in group 1 or 6 died during the experiment, and no tumour was found in any animal in these groups. In group 2, 7/9 surviving rats had a total of 14 tumours (one intestinal carcinosarcoma, 13 adenocarcinomas of the stomach and small intestine; mean number of tumours per rat, 1.56). In group 3, 8/12 survivors had a total of 12 tumours (mostly adenocarcinomas of the stomach, small intestine or both; mean number of tumours per rat, 1.00). In group 4, 10/13 survivors had a total of 19 tumours (18 adenocarcinomas of the stomach, small intestine or both, and one large-cell lymphoma involving coeliac lymph nodes, liver and spleen; mean number of tumours per rat, 1.46). In group 5, 10/12 survivors had a total of 20 tumours (one carcinosarcoma, 19 adenocarcinomas of the stomach, small intestine or both; mean number of tumours per rat, 1.67). No statistical difference in the incidence of tumours was observed among groups 2-5 (Johnson et al., 1984).

**Monkey:** A group of 55 macaques [age and sex unspecified] that had received cardiac or heart-lung allografts and had survived the first two post-operative weeks received daily intramuscular injections of ciclosporin [purity unspecified] at 25 mg/kg bw in miglyol 812 (an oil base) for 14 days, after which they were treated either every other day or daily with intramuscular injections of 17 mg/kg bw ciclosporin continuously. Eight subgroups were formed: group 1 (16 animals) received no treatment other than ciclosporin; group 2 (nine animals) was treated concurrently with 2 mg/kg bw azathioprine; group 3 (six animals) had previously received daily injections of 10 mg/kg bw rabbit antithymocyte globulin on post-operative days 0-7; group 4 (13 animals) received concurrent weekly treatment with 14 mg/kg bw antithymocyte globulin, azathioprine and methylprednisolone; group 5 (11 animals) had received total lymphoid radiation at a dose of 100 rads per day (total dose, 600-1800 rads) prior to operation; group 6 (ten animals) received injections of azathioprine plus methylprednisolone; group 7 (23 animals) received azathioprine, methylprednisolone and antithymocyte globulin; and group 8 (nine animals) received azathioprine, antithymocyte globulin and total lymphoid irradiation. No lymphoma was observed among animals receiving treatment other than with ciclosporin (groups 6-8). Of the animals treated with ciclosporin alone or in combination with other immunosuppressive agents, B-cell lymphomas developed in 12/55 monkeys \([p < 0.001, \text{ Fisher's exact test}]: 2/16 \text{ treated with} \)
CICLOSPORIN

Ciclosporin alone (group 1), 4/9 with ciclosporin plus azathioprine (group 2), 1/6 with ciclosporin plus antithymocyte globulin (group 3), 2/13 with ciclosporin, antithymocyte globulin, azathioprine and methylprednisolone (group 4), and 3/11 with ciclosporin and total lymphoid radiation (group 5). Viral particles were noted within the endoplasmic reticulum of plasmacytoid cells in 6/8 tumours from animals treated with ciclosporin alone or in combination with other immuno-suppressive agents. The authors noted that the incidence of spontaneous haematopoietic neoplasms in nonhuman primates is generally considered to be low, although outbreaks of lymphomas have been reported among macaques (Bieber et al., 1982).

3.2 Other relevant data

(a) Experimental systems

The experimental toxicology of ciclosporin has been widely reviewed (e.g., Feutren & Bach, 1987; Aszalos, 1988; Grace, 1988; de Groen, 1988; Humes & Jackson, 1988; Kahan et al., 1988a,b; Mihatsch et al., 1988a,b).

(i) Absorption, distribution, excretion and metabolism

The toxicokinetics and toxicodynamics of ciclosporin have been reviewed (Wood et al., 1983; Maurer, 1985; Wood & Lemaire, 1985; Grevel, 1986a,b; Lemaire et al., 1986).

Orally administered ciclosporin (in olive oil) was rapidly absorbed in dogs and rats. About 50% of a single dose reached the circulation (plasma levels determined by radioimmunoassay) in both species; there was no tendency for accumulation in beagle dogs after repeated daily administration for a year (Ryffel et al., 1983).

A single oral administration of 82 mg/kg bw to WAG/Rij rats resulted in levels of 80 μg/g in liver, kidney and brain 3 and 7 h after administration. Slow elimination occurred thereafter: even after five days, significant amounts (10 μg/g) were detected. A short time after oral administration, 3.5 μg/ml of ciclosporin were detected in blood, and the levels remained almost the same for about two days; 2% of the administered dose was eliminated unchanged in bile and 2% in urine (Nooter et al., 1984a). About 2% of an oral dose of ciclosporin was absorbed into the intestinal lymphatic system in rats (Ueda et al., 1983).

Pharmacokinetic studies were also performed after intravenous administration of 20, 40 or 80 mg/kg bw to WAG/Rij rats (Nooter et al., 1984b). Elimination of ciclosporin at the lowest dose was best described by a two-compartment model (t½: 6 min and 16.5 h); at the higher dose levels, a three-compartment model best described the observed data. Urine and bile excretion was 10 and 20% of the total administered dose. The bioavailability of ciclosporin in Wistar rats increased with increasing oral dose. Daily oral administration of 4 mg/kg bw was necessary to
maintain plasma levels at about 130 ng/ml in very young rats, while 7.5 mg/kg bw per
day were needed in one-month-old animals (Levy-Marchal et al., 1988).

Absorption of orally administered tritium-labelled ciclosporin by Sprague-
Dawley and Wistar rats was slow and was not affected by the vehicle. The degree of
absorption was about 30%. Labelled ciclosporin was widely distributed throughout
the body. The terminal elimination half-time of the radiolabel was 46 h after dosing
with 10 mg/kg bw daily in olive oil for 21 days; elimination from kidney and liver
had a half-time of 70-100 h. Accumulation of the parent compound was evident
after repeated treatments, with high levels in kidney, liver, blood and lymph nodes
and particularly in skin and adipose tissue (Wagner et al., 1987).

In male CD-COBS rats treated intravenously, blood concentrations during
elimination were best described by a three-compartment model, with half-times of
0.11 h, 1.8 h and 23.8 h. The apparent distribution volume ranged from 4.88 to 6.84
l/kg. Elimination was almost entirely by hepatic metabolism (Sangalli et al., 1988).
Total body clearance was lower in obese rats than in lean Zucker rats (Brunner et al.,
1988).

A non-linear pharmacokinetic behaviour was seen in New Zealand white
rabbits injected intravenously. The volume of distribution at steady state increased
with increasing dose (Awni & Sawchuk, 1985). The mean half-time after intra-
venous administration of 15 mg/kg bw to male New Zealand rabbits was 229.7 min
(D’Souza et al., 1988).

In rabbits, the concentrations of ciclosporin in blood were about 100 ng/ml
from day 43 to 120 after repeated subcutaneous injections; the calculated
absorption half-time was 33 days following injection with 20 mg/kg twice a week
during days 7-29 of the experiment (Shah et al., 1988). In BALB/c mice injected
subcutaneously with 12.5, 50 or 200 mg/kg bw, ciclosporin was detected (by
radioimmunoassay) in every organ investigated (Boland et al., 1984). The organs in
mice that are susceptible to toxicity (e.g., brain, kidney, liver) retained ciclosporin
after intraperitoneal injection (Belitsky et al., 1986).

Following oral, intraperitoneal, subcutaneous or intravenous administration
of radiolabelled ciclosporin to C57Bl mice, a high initial concentration of radiolabel
was observed in liver, pancreas, salivary glands, spleen and fat tissue by whole-body
autoradiography. Relatively high levels were retained in liver, bone marrow, thymus
and lymph nodes. In kidney, the radiolabel was confined to the outer zone and outer
medulla. No radioactivity was seen in the central nervous system or in fetuses
(Bäckman et al., 1987, 1988).

When ciclosporin was mixed with human or rat blood in vitro, 50% was found
in erythrocytes, 15% in leukocytes and 30-40% in plasma. At concentrations of
25-100 ng/ml in human plasma, 65-80% of tritiated ciclosporin was associated with lipoproteins (Lemaire & Tillement, 1982; Niederberger et al., 1983).

Ciclosporin is extensively metabolized by cytochrome P450-mediated oxidation, hydroxylation and N-demethylation (Maurer et al., 1984; Maurer, 1985; Burke & Whiting, 1986; Maurer & Lemaire, 1986; Bertault-Peres et al., 1987; Wagner et al., 1987). Figure 1 shows some characteristics of the metabolites that have been isolated. The numbers in the following text refer to the amino acids and metabolites identified in the figure.

Fig. 1. Structures and molecular weights of metabolites of ciclosporin that have been isolated"
All ciclosporin metabolites from dog urine and from rat bile and faeces retained the intact cyclic oligopeptide structure of ciclosporin. Conjugations with sulfuric or glucuronic acid were not detected (Maurer et al., 1984). Using perfused rabbit liver, 27 metabolites were characterized, including three dihydrodiol metabolites probably derived from epoxide intermediates (Wallemacq et al., 1989a).

An $\alpha,\beta$-unsaturated carboxylic acid metabolite of amino acid 9 (AA9) was isolated in rabbit urine after intravenous administration of ciclosporin (Hartman et al., 1985). In a study on ciclosporin metabolism in rats, parent ciclosporin predominated over metabolites in blood. Metabolite 1 was found to be the major one in this species. Intraperitoneal injections of phenobarbital and methyl prednisolone to Wistar rats receiving daily subcutaneous treatments with ciclosporin decreased ciclosporin levels in blood (Pell et al., 1988). In rats injected intravenously, covalently bound ciclosporin was detected in protein fractions of liver and kidney homogenates, and phenobarbital treatment enhanced adduct formation.

---

**Fig. 1 (contd)**

<table>
<thead>
<tr>
<th>Metabolite no.</th>
<th>R</th>
<th>$R_1$</th>
<th>$R_2$</th>
<th>$R_3$</th>
<th>$R_4$</th>
<th>Other modification</th>
<th>Molecular weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciclosporin</td>
<td>H</td>
<td>CH$_3$</td>
<td>CH$_3$</td>
<td>H</td>
<td>H</td>
<td></td>
<td>1202.64</td>
</tr>
<tr>
<td>1</td>
<td>OH</td>
<td>CH$_3$</td>
<td>CH$_3$</td>
<td>H</td>
<td>H</td>
<td></td>
<td>1218.64</td>
</tr>
<tr>
<td>8</td>
<td>OH</td>
<td>CH$_2$OH</td>
<td>CH$_3$</td>
<td>H</td>
<td>H</td>
<td></td>
<td>1234.64</td>
</tr>
<tr>
<td>9</td>
<td>OH</td>
<td>CH$_3$</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td></td>
<td>1220.64</td>
</tr>
<tr>
<td>10</td>
<td>OH</td>
<td>CH$_3$</td>
<td>CH$_3$</td>
<td>OH</td>
<td>H</td>
<td></td>
<td>1234.64</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hydroxylated and $N$-demethylated derivative of ciclosporin</td>
<td>1204.62</td>
</tr>
<tr>
<td>16</td>
<td>OH</td>
<td>CH$_3$</td>
<td>CH$_3$</td>
<td>H</td>
<td>OH</td>
<td></td>
<td>1234.64</td>
</tr>
<tr>
<td>17</td>
<td>H</td>
<td>CH$_2$OH</td>
<td>CH$_3$</td>
<td>H</td>
<td>H</td>
<td></td>
<td>1218.64</td>
</tr>
<tr>
<td>18</td>
<td>H</td>
<td>CH$_2$OH</td>
<td>CH$_3$</td>
<td>H</td>
<td>H</td>
<td>O (\beta , e , \xi) CH CH-CH$_2$ of AA1</td>
<td>1218.64</td>
</tr>
<tr>
<td>22</td>
<td>H</td>
<td>CH$_3$</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td></td>
<td>1188.62</td>
</tr>
<tr>
<td>25</td>
<td>H</td>
<td>CH$_2$OH</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td></td>
<td>1202.64</td>
</tr>
<tr>
<td>26</td>
<td>OH</td>
<td>CH$_2$OH</td>
<td>CH$_3$</td>
<td>H</td>
<td>H</td>
<td>O (\beta , e , \xi) CH CH-CH$_2$ of AA1</td>
<td>1204.62</td>
</tr>
<tr>
<td>203–218</td>
<td>H</td>
<td>COOH</td>
<td>CH$_3$</td>
<td>H</td>
<td>H</td>
<td></td>
<td>1234.64</td>
</tr>
</tbody>
</table>

*From Maurer & Lemaire (1986)*
Covalent binding to protein was found \textit{in vitro} after incubation of labelled ciclosporin with a rat liver microsomal fraction in the presence of NADPH. Binding also occurred in isolated hepatocytes. SKF-525A inhibited the covalent binding, and glutathione depletion increased ciclosporin binding to protein (Nagelkerke \textit{et al.}, 1987).

No association of radioactivity was observed with cellular proteins or with DNA in liver homogenates from mice administered the drug parenterally (Bäckman \textit{et al.}, 1987, 1988).

(ii) \textit{Toxic effects}

The LD$_{50}$s for ciclosporin after a single oral administration to mice, rats and rabbits were 2.3, 1.5 and $> 1.0$ g/kg bw, respectively. The corresponding figures after a single intravenous administration were 107, 25 and $> 10$ mg/kg bw. Toxic signs were hyperventilation, drowsiness and muscular spasms. After oral administration, weight loss and diarrhoea were noted (Ryffel \textit{et al.}, 1983, 1986).

Daily subcutaneous injections of ciclosporin into BALB/c mice at a dose of 200 mg/kg bw per day resulted in a median survival time of about 13 days. Nephrotoxicity, hypocellularity of the thymus, lymph nodes and spleen and fatty changes in the liver were observed; no abnormality of femoral bone marrow was found (Boland \textit{et al.}, 1984).

Histological findings in OFA rats fed a diet containing ciclosporin for 13 weeks included leukocytosis, lymphopenia, hypochromic anaemia, monocytosis and eosinopenia without myelotoxic effects. Lymphoid tissues were atrophied. Doses of 45 mg/kg bw per day and more produced nephrotoxicity and hepatotoxicity. A chronic nonspecific gingivitis with atrophy of periodontal tissue was observed in treated rats. Nephrotoxicity and hepatotoxicity were also observed among rats administered ciclosporin orally for 104 weeks (Ryffel \textit{et al.}, 1983).

OF1 mice were given ciclosporin in the diet at 1.4 and 16 mg/kg per day for 78 weeks. Females given the high dose had higher mortality rates than other mice and had haematological changes without myelotoxic signs (Ryffel \textit{et al.}, 1983).

NZW and RB rabbits treated subcutaneously with ciclosporin at 15 mg/kg bw daily had weight loss and reduced food and water intake. High mortality was observed within 60 days of treatment, and animals had distended stomachs and intestines (Gratwohl \textit{et al.}, 1986).

After intravenous treatment at 45 mg/kg bw day for four weeks, cynomolgus monkeys showed blood chemistry changes, marked neurological side-effects, and degenerative changes in kidney and liver. Rhesus monkeys tolerated high oral doses of ciclosporin (200-300 mg/kg bw) for 13 weeks, with small functional and histopathological changes (Ryffel \textit{et al.}, 1983).
The renal effects of ciclosporin in experimental systems have been studied extensively and reviewed (Sullivan \textit{et al.}, 1985; Ryffel & Mihatsch, 1986; Humes & Jackson, 1988).

The severity of histological changes in the kidneys of rats receiving subcutaneous injections daily for up to 30 days were directly correlated with tissue levels of ciclosporin (Kumar \textit{et al.}, 1988).

Ciclosporin induced marked renal vasoconstriction in rats (Kaskel \textit{et al.}, 1988; Monaco \textit{et al.}, 1988; Stanley Nahman \textit{et al.}, 1988) and sheep (Friedman \textit{et al.}, 1988). Various defects in renal function accompanied the vasoconstriction, including decreased glomerular filtration rate (Whiting \textit{et al.}, 1982; Sabbatini \textit{et al.}, 1988; Tejani \textit{et al.}, 1988), decreased sodium reabsorption (Whiting & Simpson, 1988), impairment of the diluting capacity of the thick ascending limb of the loop of Henle (Gnutzmann \textit{et al.}, 1986) and release of cellular enzymes into the urine (Whiting \textit{et al.}, 1986).

Sprague-Dawley rats given ciclosporin at 50 or 100 mg/kg bw per 48 h over 21 days by gastric intubation had elevated serum urea and creatinine levels, and urinary \textit{N}-acetyl-\textit{\beta}-D-glucosaminidase activity was increased (Thomson \textit{et al.}, 1981; Whiting \textit{et al.}, 1982). The renal and hepatic functional disturbances were reversible (Thomson \textit{et al.}, 1981). There was cytoplasmic vacuolization of the proximal tubule, swollen cells and cell necrosis—the latter at the higher dose. Vacuolization was due to dilatation of smooth and rough endoplasmic reticulum. The number of lysosomes was increased, and myeloid bodies were present (Whiting \textit{et al.}, 1982).

Rats given ciclosporin at 20 or 40 mg/kg bw in the diet showed augmentation of autolplagic vacuoles, lipid drops and loss of microvilli in the proximal nephron as well as prenecrotic damage of proximal tubular S2 and S3 cells (Pfaller \textit{et al.}, 1986). Similar observations were made by Verani (1986), Jackson \textit{et al.} (1987), Dieperink \textit{et al.} (1988), Gillum \textit{et al.} (1988), Jackson \textit{et al.} (1988) and Starklint \textit{et al.} (1988a,b), although strain differences have been reported (Duncan \textit{et al.}, 1986).

When ciclosporin was given by gavage at 30 mg/kg bw per day to Sprague-Dawley rats for four weeks, serum testosterone levels were decreased by 50%; this change was reversible (Sikka \textit{et al.}, 1988).

Rats injected intraperitoneally with ciclosporin at 5, 10 or 15 mg/kg bw for one or three weeks had significantly raised levels of serum bile acids. Both bile salt-dependent and independent-flow were decreased (Stone \textit{et al.}, 1988).

Ciclosporin markedly decreased pancreatic insulin content and insulin release in rats administered the drug by intramuscular injection for two weeks (Hahn \textit{et al.}, 1986). Electron microscopy demonstrated cytoplasmic degranulation, nuclear
inclusions and cisternal dilatation of endoplasmic reticulum and of the Golgi apparatus in pancreatic \( \beta \) cells (Hamaguchi et al., 1988).

When Sprague-Dawley rats were fed ciclosporin at 150 mg/kg of diet, their thymuses and lymph nodes were smaller after eight weeks. Proliferative changes were observed in gut-associated lymphoid tissue, with mitotically active lymphocytes that displayed local tissue invasion and destruction (Demetris et al., 1984).

Oral administration of immunosuppressive doses of ciclosporin reduced the trabecular bone volume of Sprague-Dawley rats. Osteoclast number and bone resorption were significantly increased at low (7.5 mg/kg bw per day) and high (15 mg/kg bw per day) doses of ciclosporin (Movsowitz et al., 1988).

Thromboxane synthesis in rats and its excretion in urine were increased by ciclosporin treatment (Perico et al., 1986a,b; Coffman et al., 1987; Benigni et al., 1988; Rogers et al., 1988). Prostaglandin production was stimulated by ciclosporin (Coffman et al., 1987), and administration of prostaglandin E\(_2\) (Ryffel et al., 1986) or its analogues (Paller, 1988a,b) reduced the nephrotoxicity of ciclosporin. A thromboxane synthetase inhibitor (CGS 12970) also prevented nephrotoxicity in rats (Smeesters et al., 1988a,b).

Ciclosporin affected protein synthesis in vivo and in vitro (Bäckman et al., 1988; Buss et al., 1988), altered hepatic glycogen metabolism (Betschart et al., 1988) and inhibited P450-dependent metabolism in vivo (Augustine & Zemaitis, 1986; Moochhala & Renton, 1986).

It induced dose-dependent malonaldehyde production in rat renal microsomes (Insellmann et al., 1988). It bound with high affinity to cyclophilin, a low-molecular-weight cytosolic protein that occurs ubiquitously in eukaryotic cells and is thought to be a regulator of T- and B-cell activation (Harding & Handschumacher, 1988; Quesniaux et al., 1988).

Ciclosporin inhibited \( T \)-lymphocyte proliferation (Borel et al., 1977) but did not affect protein kinase \( C \). It inhibited the augmentation of ornithine decarboxylase levels in mouse skin induced by phorbol ester (Elder et al., 1988) and interfered with intracellular calcium metabolism (for reviews, see Aszalos, 1988; Bijsterbosch et al., 1988).

(iii) Effects on reproduction and prenatal toxicity

In routine studies to evaluate the safety of ciclosporin, oral administration at 1.5, 5 or 15 mg/kg bw to male and female rats daily from before mating (males, 12 weeks; females, two weeks) until weaning had no adverse effect on reproduction. In rats administered ciclosporin at 10-300 mg/kg bw orally from day 6 to 15 of gestation, there was no embryotoxic effect at doses up to 17 mg/kg bw. At 30 mg/kg bw, which was clearly toxic to the mother, high rates of embryolethality (90%)
occurred, average fetal weights were lower than those of controls and skeletal retardations were seen frequently, but there was no increase in the frequency of minor or major anomalies. At higher doses, embryolethality was 100%. In a similarly designed study in rabbits, using doses of 10-300 mg/kg bw, no adverse effect was observed up to 30 mg/kg. At 100 mg/kg and above, maternal toxicity was seen, with an increased frequency of resorptions; however, no major or minor anomaly was found. In a peri-/postnatal study in rats at three dose levels (5, 15, and 45 mg/kg bw), a distinct increase in pre-/perinatal and early postnatal mortality of offspring was observed at the highest dose level (Ryffel et al., 1983).

Two further studies confirm the toxic effects of ciclosporin on rat fetuses after daily exposure during late gestational stages at a maternally toxic dose (25 mg/kg). Fetal kidneys that could be examined showed evidence of ciclosporin-induced proximal tubular-cell damage (Brown et al., 1985; Mason et al., 1985).

When ciclosporin was administered subcutaneously for 14 days at daily doses of 10, 20 and 40 mg/kg bw to sexually mature male rats, dose-dependent changes in body and reproductive organ weights were noted. Histological examination of the testis showed degenerative changes, and sperm counts and motility were decreased in all three treated groups. Rats treated with the two highest doses were infertile (Seethalakshmi et al., 1987). This effect was reversible after withdrawal of the drug (Seethalakshmi et al., 1988).

(iv) Genetic and related effects

Ciclosporin did not induce mutation in Salmonella typhimurium in either the presence or absence of an exogenous metabolic system (Matter et al., 1982). It did not induce mutations at the hprt locus of Chinese hamster V79 cells in the presence or absence of an exogenous metabolic system (Zwanenburg et al., 1988). It induced sister chromatid exchange in human peripheral lymphocytes in vitro (Yuzawa et al., 1986, 1987).

At doses up to 1000-3000 mg/kg, ciclosporin did not induce chromosomal aberrations or micronuclei in bone-marrow cells of CD-1 mice or Chinese hamsters in vivo, or unscheduled DNA synthesis [dose unspecified] or dominant lethal mutations in CD-1 mice (Matter et al., 1982).

(b) Humans

(i) Pharmacokinetics

The kinetics of ciclosporin has been reviewed (Bowers et al., 1986; Grevel, 1986a,b; Lemaire et al., 1986; Vine & Bowers, 1987; Grevel, 1988; McMillan, 1989). In studies on the kinetics of ciclosporin, radioimmunoassay and liquid chromatography have generally been used. If not indicated otherwise, the data
given below are from studies in which high-performance liquid chromatography analysis was used, which is the most specific for ciclosporin.

Absorption of orally administered ciclosporin is variable and low: the oral bioavailability was 35 ± 11% in heart transplant patients (Venkataramanan et al., 1986), 36 ± 17% in adult uremic patients (Grevel et al., 1989) and 27 ± 20% in 41 renal transplant recipients; it was < 10% in 17% of these subjects (Ptachcinski et al., 1985). Peak blood ciclosporin concentrations were reached between 1 and 8 h after oral dosing (Beveridge et al., 1981; Ptachcinski et al., 1985; Venkataramanan et al., 1986).

Ciclosporin is rapidly and widely distributed; distribution half-times after intravenous administration have been reported to be 0.1 ± 0.03 h (Follath et al., 1983) and 0.3-0.5 h (Yee et al., 1984). The steady-state apparent volume of distribution is large, and means of 2.7-5.1 l/kg have been calculated (Follath et al., 1983; Yee et al., 1984; Ptachcinski et al., 1985; Venkataramanan et al., 1986; Clardy et al., 1988). Concentrations of ciclosporin in rejected kidney were higher than preoperative values in the blood of three patients (Kahn et al., 1986; Rosano et al., 1986). High concentrations of ciclosporin and its metabolites are found in, e.g., fat, gall-bladder, liver, gastrointestinal tract and pancreas (Atkinson et al., 1983a; Kahan et al., 1983a; Ried et al., 1983).

After the distribution phase, two further first-order disappearance phases may be discerned, with half-times of approximately 1 and 16 h, respectively (Follath et al., 1983). Even in a case of acute overdose of ciclosporin (5000 mg), saturation of clearance was not observed (Schroeder et al., 1986). Clearance of ciclosporin from the blood is rapid: in bone-marrow transplant recipients with normal liver and kidney function, clearance of 12.8 ± 1.6 ml/min per kg was reported; in those with elevated serum bilirubin but normal renal function, it was 9.8 ± 2.1 ml/min per kg. In another study, however, no relationship was noted between the disappearance of ciclosporin from the blood and the degree of impairment of hepatic function in patients with primary biliary cirrhosis (Robson et al., 1984). In renal and heart transplant recipients, average clearance values of 6.5 and 5.7 ml/min per kg were reported (Ptachcinski et al., 1985; Venkataramanan et al., 1986), while in patients with renal failure clearance was 369 ml/kg per h [6.15 ml/min per kg] (Follath et al., 1983). In healthy subjects, a value of 51 ml/h per kg [8.5 ml/min per kg] was reported (Grevel et al., 1986); in this study, however, the radioimmunological assay method was used, which provides an underestimate of clearance (Grevel et al., 1989).

After administration of tritiated ciclosporin to two patients, 6% of the dose was recovered in the urine (Maurer et al., 1984; Maurer, 1985; Lemaire et al., 1986). In healthy volunteers, approximately 0.1-0.2% of a dose was excreted in the urine as unchanged ciclosporin (Beveridge et al., 1981; Maurer & Lemaire, 1986).
More ciclosporin and ciclosporin metabolites were detected in the bile than in urine after intravenous and oral administrations (Kahan et al., 1983b; Venkataramanan et al., 1985). Unchanged ciclosporin is a minor component in the bile (mean, 0.29% of an oral dose) (Venkataramanan et al., 1985).

The concentration of ciclosporin in blood cells is approximately double that in the plasma (Follath et al., 1983). The majority of ciclosporin and/or its metabolites in serum is bound to different lipoprotein fractions (Mraz et al., 1983; Gurecki et al., 1985). After treatment of pregnant women with ciclosporin, it was detected in cord blood at concentrations somewhat lower than those in maternal blood (Lewis et al., 1983; Venkataramanan et al., 1988; Rose et al., 1989). Ciclosporin has also been detected in breast milk (Lewis et al., 1983).

The first study of the metabolism of ciclosporin in humans was performed by Maurer et al. (1984), who isolated and identified nine ether-extractable metabolites from the urine of two patients who had received a single oral dose of 300 mg $^3$H-ciclosporin. All identified metabolites retained the intact cyclic peptide structure; the sites on the molecule that are changed by metabolism are indicated in Figure 1. The primary metabolites were products of hydroxylation; the secondary metabolites identified were products of oxidation or demethylation of oxidized primary metabolites or of a cyclization reaction. Similar oxidized ciclosporin metabolites have been identified in the blood and bile of patients treated with ciclosporin (Hartman et al., 1985; Rosano et al., 1986; Lensmayer et al., 1987a,b; Wallemacq et al., 1989a,b; Wang et al., 1989). Twenty-seven ciclosporin metabolites were identified in human bile; these included a vicinal dihydrodiol and a demethylated vicinal dihydrodiol, suggesting that an epoxide is the intermediate (Wallemacq et al., 1989a).

In addition to metabolites generated by oxidation, demethylation and cyclization reactions, three further metabolites have been isolated in which the double bond in amino acid 1 (AA1 in Fig. 1) is probably saturated (Wang et al., 1989). This metabolite and metabolites 1, 8, 17 and 203-218 (Fig. 1) were reported to be the major metabolites of ciclosporin in human bile (Hartman et al., 1985; Maurer, 1985; Wang et al., 1989; Maurer & Lemaire, 1986). A sulfate conjugate of ciclosporin was also identified in human bile and plasma (Henricsson et al., 1989). Metabolite 17 was the main metabolite in human blood, and metabolites 1, 8 and 21 were the other major ones (Maurer, 1985; Maurer & Lemaire, 1986; Rosano et al., 1986). Metabolite 17 was the main metabolite detected in kidney (Rosano et al., 1986).

A cytochrome P450 isolated from human liver catalysed the formation of mono- and dihydroxylated and demethylated metabolites from ciclosporin (Combalbert et al., 1989). This cytochrome is encoded by the gene P450IIIA3, as is
nifedipine oxidase; it is induced by treatment with rifampicin (Kronbach et al., 1988; Combalbert et al., 1989).

(ii) Immunosuppressive action

The pharmacological effects of ciclosporin on the human immune system have been reviewed (Thomson, 1983; Shevach, 1985; Drugge & Handschumacher, 1988; Kerman, 1988; Kahan, 1989; Lorber, 1989). The ratio of T-helper cells to T-suppressor cells was decreased in renal transplant recipients during treatment with ciclosporin and prednisolone (Kerman et al., 1987). Production of \(\alpha\)-interferon, \(\gamma\)-interferon and interleukin-2 by isolated leukocytes was decreased in renal and heart transplant patients receiving ciclosporin and prednisolone, as compared to healthy volunteers (Dupont et al., 1985).

Many studies have been published on the immunosuppressive effects of ciclosporin since the detection (Borel et al., 1977) of its biological and clinical significance in the early 1970s (for review, see Feutren & Bach, 1987). Its immunosuppressive effects have been demonstrated experimentally to lead to tolerance of tissue grafts (Morris et al., 1980; Pennock et al., 1981; Bain et al., 1988; Chisholm & Bevan, 1988; Finsen et al., 1988; Kimura et al., 1988; Lear et al., 1988; White & Lim, 1988; for reviews, see Lorber, 1986; Tutschka, 1986; Hopt et al., 1988; Kahan et al., 1988a,b) and to affect a variety of experimental autoimmune diseases, such as uveitis (Nordmann et al., 1986; Dinning et al., 1987; Mahlberg et al., 1987; Caspi et al., 1988a,b; Kaswan et al., 1988), myasthenia gravis (for review see Feutren & Bach, 1987; for a tabular summary, see Gunn et al., 1988), mercuric chloride-induced glomerulonephritis (Aten et al., 1988), allergic encephalomyelitis (Polman et al., 1988) and serum sickness nephritis (Shigematsu & Koyama, 1988).

Ciclosporin is preferentially active on proliferating T cells (White et al., 1979) and selectively inhibits T-helper cell function (Caspi et al., 1988a,b) while sparing T-suppressor cell activities (Kupiec-Weglinski et al., 1984; Bucy, 1988). It inhibits the production of interleukin-2 (Larsson, 1980; Bunjes et al., 1981; Caspi et al., 1988b; Tracey et al., 1988) from T-helper cells and of interleukin-1 from splenic adherent cells (Bunjes et al., 1981). Ciclosporin metabolites also suppressed concanavalin A-stimulated human peripheral blood mononuclear cell proliferation (Cheung et al., 1988).

Ciclosporin was bound to a low-affinity site \((K_D = 3.6 \times 10^{-7} \text{ M})\) on human splenic T-lymphocytes in vitro, while B-lymphocytes showed both a high-affinity \((K_D = 2 \times 10^{-9} \text{ M})\) and a low-affinity binding site (LeGrue et al., 1983).

Ciclosporin depressed the synthesis of \(\gamma\)-interferon by human thymocytes and T-lymphocytes in vitro (Reem et al., 1983; McKenna et al., 1989), as well as the synthesis of lymphotoxin and tumour necrosis factor by lymphocytes activated in mixed-lymphocyte culture or by concanavalin A (McKenna et al., 1989; Szturm et
Ciclosporin reduced T-cell growth factor (interleukin-2) gene transcription in a cloned human leukaemic T-cell line (Krönke et al., 1984) and binding of radiolabelled human recombinant interleukin-2 to high-affinity receptors in human T-lymphocytes (Povlsen et al., 1989). Ciclosporin also inhibited the release of γ-interferon from alloactivated human peripheral blood mononuclear cells (Bishop & Hall, 1988).

(iii) Adverse effects

The adverse effects of ciclosporin therapy have been reviewed (Kahan et al., 1985; Bennett & Norman, 1986; Myers, 1986; Keown et al., 1987; Mihatsch et al., 1988a,b; Racusen & Solez, 1988; Schachter, 1988; Weidle & Vlasses, 1988; Dieperink, 1989; Mihatsch et al., 1989; Reynolds, 1989; Steinmuller, 1989).

The first report on the use of ciclosporin in the treatment of renal allograft rejection (Calne et al., 1978) documented nephrotoxicity, hepatotoxicity and hirsutism as side-effects of the therapy. Nephrotoxicity has since been amply documented as the most prevalent and serious complication of ciclosporin therapy, in recipients of kidney transplants (Calne et al., 1979; Klintmalm et al., 1981a,b; Merion et al., 1984) and in other transplant recipients (Powles et al., 1980; Klintmalm et al., 1981b; Shulman et al., 1981; Atkinson et al., 1983b; Hows et al., 1983; Myers et al., 1984). Morphological changes related to ciclosporin administration include diffuse interstitial fibrosis (associated with oligo- or anuria), tubular toxicity, peritubular capillary congestion and a combination of the last two. These two changes have been associated with acute renal damage; acutely impaired renal function was not, however, necessarily accompanied by microscopic changes. Arteriolopathy and interstitial fibrosis with tubular atrophy, or a combination of the two, have been attributed to chronic ciclosporin toxicity (Mihatsch et al., 1988a,b, 1989). Mechanisms of the renal toxicity of ciclosporin have been reviewed (Bennett et al., 1988; Dieperink et al., 1988; Grace, 1988; Neild, 1988; Benigni et al., 1989).

Mild functional disturbances of the liver have been reported in 20-40% of treated patients (Klintmalm et al., 1981a; Kahan et al., 1985).

Other side-effects reported include gastrointestinal disturbances, hirsutism, acne, gingival hyperplasia, neurotoxicity, altered blood coagulability, hypertension, electrolyte changes and gout. Anaphylactoid reactions have occurred following intravenous administration of preparations containing ciclosporin (Kahan et al., 1985; Bennett & Norman, 1986; Weidle & Vlasses, 1988; Lin et al., 1989; Reynolds, 1989).

(iii) Effects on reproduction and prenatal toxicity

In two of three published reports of babies born to mothers treated throughout pregnancy with ciclosporin (Lewis et al., 1983; Klintmalm et al., 1984; Endler et al.,
1987), growth was retarded. However, whether this effect was due to the drug or to
the general condition of the mother is uncertain.

(iv) Genetic and related effects

A group of 25 kidney transplant patients received daily oral treatment with
ciclosporin at 12-14 mg/kg bw (reduced to 4 mg/kg) combined with variable doses of
prednisolone for over one year (Fukuda et al., 1987). In an extension of this study
(Fukuda et al., 1988), the number of patients was increased to 40. More patients
receiving ciclosporin had chromosomal aberrations in their peripheral lymphocytes
(68% and 48% in the two studies, respectively) than did 50 healthy individuals (0%)
or 50 haemodialysis patients (2%). [The Working Group noted the poor reporting
of the studies and that cells were cultured for 72 h.]

Unscheduled DNA synthesis was reported to be elevated in the lymphocytes of
kidney transplant patients treated with ciclosporin [dose and length of treatment
unspecified] in comparison with those from healthy individuals (Petitjean et al.,
1986). [The Working Group noted the incomplete reporting of the study.]

3.3 Case reports and epidemiological studies of carcinogenicity to humans

(a) Case reports

Numerous case reports have been published of neoplasms occurring in organ
transplant recipients who received only ciclosporin, without azathioprine or
cytotoxic agents. The majority of these neoplasms were lymphomas, commonly of
the gastrointestinal tract (Thiru et al., 1981; Beveridge et al., 1984; Bencini et al.,
1985; Bloom et al., 1985; Castro et al., 1985; Thompson et al., 1985; Walker et al.,
1989), but Kaposi’s sarcoma and skin cancers have also been reported (Thompson
et al., 1985; Gorg et al., 1986; Arico et al., 1987; Cockburn, 1987; Bencini et al., 1988;
Civati et al., 1988). Malignancies at other sites have also been seen (Maung et al.,
1985; Thompson et al., 1985). Regression of lymphomas when the drug was dis-
continued has sometimes been reported (Bencini et al., 1988).

In the most recent report from a registry of organ transplant recipients who
developed tumours (Penn & Brunson, 1988), 412 tumours had been recorded in
ciclosporin-treated patients. Of these, the most frequently reported were
lymphoma (29%), skin cancer (22%) and Kaposi’s sarcoma (11%). [The Working
Group noted that the size of the underlying population was unknown; but, given the
low incidence of Kaposi’s sarcoma in the general population, the number of cases in
this registry is strikingly large.]

Cockburn and Krupp (1989) described the occurrence of 186 neoplasms in
organ transplant recipients treated with ciclosporin and reported to the drug
manufacturer. The most frequent malignancies were lymphomas and leukaemias
(55 cases) and Kaposi's sarcoma (26 cases). The lymphomas were found predominantly in the gastrointestinal tract.

(b) Cohort studies

Anderson et al. (1978) reported that among 143 cardiac transplant recipients treated with ciclosporin and other immunosuppressive agents, six developed lymphomas.

Calne et al. (1979) followed up 34 organ transplant recipients treated with ciclosporin, six of whom had also received a cyclophosphamide derivative; three lymphomas developed—two in patients treated with ciclosporin only and one in a patient treated with both drugs.

Starzl et al. (1984) reported lymphoproliferative lesions (15 lymphomas, two other lesions) that occurred during follow-up in eight of 315 renal transplant, four of 129 heart transplant, three of 48 liver transplant and two of six heart-lung transplant patients treated, in general, with ciclosporin alone. In seven renal transplant patients with these lesions who were operated on for bowel perforation, discontinuation of ciclosporin treatment resulted in tumour regression, as determined by a second laparotomy.

Bencini et al. (1986) followed 67 renal transplant recipients treated with ciclosporin for 1-17 months (mean, 3.2 months); one developed a squamous epithelioma and one, skin nodules thought to be a lymphoma.

Sheil et al. (1987) reported three-year results of a trial of ciclosporin in renal transplant patients. One malignant melanoma and one adenocarcinoma of the remaining kidney were observed among 140 renal transplant patients receiving long-term treatment with ciclosporin alone, while no tumour was reported among a further 140 patients who received treatment with ciclosporin alone for three months followed by treatment with azathioprine.

Smith et al. (1989) reported that lymphomas developed in two of 712 organ transplant patients who received azathioprine, none of 160 treated with ciclosporin and seven of 132 who received both.

Cockburn and Krupp (1989) followed up 4040 organ transplant recipients treated with ciclosporin and compared observed with expected numbers based on population rates. Increased risks were noted for lymphoma (relative risk, 27.5; 11 cases observed), skin cancers (6.8; 11) and urinary-tract cancers (5.9; 11). [The Working Group noted that it was not clear that the only immunosuppressive treatment received was ciclosporin.]

Table 1 summarizes the studies in which lymphomas were reported in transplant patients who had received ciclosporin but not azathioprine or cytotoxic drugs. The Working Group estimated upper limits for the expected values (not
Table 1. Non–Hodgkin’s lymphomas in organ transplant patients treated with ciclosporin (without azathioprine or cytotoxic drugs)

<table>
<thead>
<tr>
<th>No. of patients</th>
<th>Maximal follow-up (years)</th>
<th>Non–Hodgkin’s lymphomas</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Expected&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Observed</td>
</tr>
<tr>
<td>28</td>
<td>1.5</td>
<td>0.02</td>
<td>2</td>
</tr>
<tr>
<td>498</td>
<td>4</td>
<td>1.0</td>
<td>11</td>
</tr>
<tr>
<td>67</td>
<td>1.5</td>
<td>0.05</td>
<td>0</td>
</tr>
<tr>
<td>120</td>
<td>5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.3</td>
<td>0</td>
</tr>
<tr>
<td>160</td>
<td>5</td>
<td>0.4</td>
<td>0</td>
</tr>
<tr>
<td>873 (total)</td>
<td>1.8</td>
<td>13</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>As estimated by the Working Group

<sup>b</sup>Mean, as given in paper

provided in the original papers), on the basis of assumptions adverse to a causal relationship, as follows:

(i) When the total period of follow-up was not given, the time of observation of every patient was equivalent to the maximal observation time of the relevant study.

(ii) The incidence rate for any age group below 70 years was the highest published in the Connecticut Tumor Registry (higher than in any UK or Australian registry), i.e., 50/100 000 per year (Muir et al., 1987).

(iii) All patients followed up received only ciclosporin. In fact, it is known that some had received other agents, but only patients with lymphomas who had not received other agents were included in the count of observed cases.

Even with the above assumptions, the occurrence of lymphomas was remarkably high.

[The Working Group noted that in many studies no information on dose, survival or follow-up time was given for any group, and it was difficult to compare rates. As is clear from estimates of expected numbers made by the Working Group, however, the incidence of lymphoma in the cohort studies is remarkably high. In addition, Kaposi’s sarcoma has figured prominently in case reports. It is also noteworthy that lymphomas regressed following discontinuation of ciclosporin in two studies. A higher incidence of lymphomas was noted when ciclosporin was
used in combination with other immunosuppressive agents, as was a frequent practice soon after its introduction (Anderson et al., 1978; Calne et al., 1979; Kinlen, 1982; Beveridge et al., 1984). This is consistent with other evidence that the intensity of immunosuppression has an important influence on lymphoma incidence.

4. Summary of Data Reported and Evaluation

4.1 Exposure data

Ciclosporin has been used as an immunosuppressive agent since the mid-1980s.

4.2 Experimental carcinogenicity data

Ciclosporin was tested for carcinogenicity by oral administration in two studies in mice and in one study in rats. In one study in mice, it accelerated the development of leukaemias; tumours were not induced in a chronic bioassay. In rats, negative results were obtained in a study with limited sensitivity.

Ciclosporin enhanced the development of lymphomas induced in two strains of male mice by single whole-body irradiation or N-methyl-N-nitrosourea. In grafted macaques, ciclosporin increased the incidence of lymphomas, a neoplasm that occurs extremely infrequently in this species of monkeys. When given in combination with various other immunosuppressive regimens, ciclosporin induced a substantial increase in the incidence of lymphomas when compared to immunosuppressive regimens excluding ciclosporin. This drug also enhanced the incidence of intestinal adenocarcinomas induced in male rats by N-methyl-N-nitrosourea.

4.3 Human carcinogenicity data

In case reports, both lymphomas and Kaposi’s sarcoma have been associated frequently with exposure to ciclosporin. Four cohort studies recorded a high incidence of lymphoma in organ transplant recipients; in two of these, ciclosporin was given without azathioprine or cytotoxic drugs. In several cases, there has been well-documented regression of lymphoma following withdrawal of the drug.

4.4 Other relevant data

Ciclosporin induced dose-dependent changes in reproductive organ weights in male rats and caused sterility at high doses. Fetal mortality was observed in rats and rabbits when the drug was administered during the second half of gestation at maternally toxic doses. No other sign of embryo- or fetotoxicity was noted.
Ciclosporin is rapidly absorbed and widely distributed in humans and in experimental animals. It is extensively metabolized by the cytochrome P450 system. Adverse effects include nephro- and hepatotoxicity. The compound is immunosuppressive, resulting in tolerance to tissue grafts; its main effect is on the early proliferation of T-cells.

In a single study, ciclosporin was reported to increase the incidence of chromosomal aberrations in the lymphocytes of kidney transplant patients. Ciclosporin did not induce dominant lethal mutations in mice, chromosomal aberrations in the bone marrow of Chinese hamsters or micronuclei in the bone marrow of Chinese hamsters or mice in vivo. It induced sister chromatid exchange in human peripheral lymphocytes in vitro but did not induce gene mutations in Chinese hamster cells. Ciclosporin did not induce mutations in Salmonella typhimurium. (See Appendix 1.)

4.5 Evaluation

There is sufficient evidence for the carcinogenicity of ciclosporin in humans. There is limited evidence for the carcinogenicity of ciclosporin in experimental animals.

Overall evaluation

Ciclosporin is carcinogenic to humans (Group 1).

5. References


1For description of the italicized terms, see Preamble, pp. 26-29.


Bijsterbosch, M.K., McLaughlin, J.B., Holman, M. & Klaus, G.G.B. (1988) Activation and proliferation signals in mouse B cells. IX. Protein kinase C activators synergize with non-mitogenic anti-immunoglobulin antibodies to drive B cells into G1. Immunology, 64, 163-168


McKenna, R.M., Szturm, K., Jeffrey, J.R. & Rush, D.N. (1989) Inhibition of cytokine production by cyclosporine A and G. Transplantation, 47, 343-348


Morris, P.J., Finch, D.R., Garvey, J.F., Poole, M.D. & Millard, P.R. (1980) Suppression of rejection of allogeneic islet tissue in the rat. Diabetes, 29 (Suppl. 1), 107-112


Paller, M.S. (1988b) Effects of the prostaglandin E1 analog misoprostol on cyclosporine nephrotoxicity. Transplantation, 45, 1126-1131


Smeesters, C., Chaland, P., Giroux, L., Moutquin, J.M., Etienne, P., Douglas, F., Corman, J.,
a thromboxane synthetase inhibitor. Transplant. Proc., 20 (Suppl. 3), 658-664

Smeesters, C., Chaland, P., Giroux, L., Moutquin, J.M., Etienne, P., Douglas, F., Corman, J.,
a thromboxane synthetase inhibitor. Transplant. Proc., 20 (Suppl. 2), 663-669

Smith, J.L., Wilkison, A.H., Hunsicker, L.G., Tobacman, J., Kapelanski, D.P., Johnson, M.,
Wright, F.H., Behrendt, D.M. & Corry, R.J. (1989) Increased frequency of
posttransplant lymphomas in patients treated with cyclosporin, azathioprine and prednisone. Transplant. Proc., 21,

Cyclosporine nephrotoxicity in spontaneously hypertensive rats. Transplantation, 45, 768-772

Starzl, T.E., Nalesnik, M.A., Porter, K.A., Ho, M., Iwatsuki, S., Griffith, B.P., Rosenthal,
Reversibility of lymphomas and lymphoproliferative lesions developing under
cyclosporin-steroid therapy. Lancet, i, 583-587


cyclosporine-induced cholestasis in the rat. Transplant. Proc., 20 (Suppl. 3), 841-844

laboratory animals. Transplant. Proc., 17 (Suppl. 1), 145-154

inhibition of cytokine production. Transplant. Proc., 21, 857

cyclosporine A and cyclosporine G in a rat model. Transplantation, 45, 184-187

with cyclosporin-A as one of the immunsuppressive agents. Transplant. Proc., 13,
359-364

patients treated with cyclosporin. Lancet, i, 158-159

61, 147-172

Pathological changes developing in the rat during a 3-week course of high dosage
cyclosporin A and their reversal following drug withdrawal. Transplantation, 32, 271-277


1. Chemical and Physical Data

1.1 Synonyms


*Synonyms:* Prednisolone, 21-({parabis(2-chloroethyl)-αβ-amino]phenyl}-butyrate); 11β,17,21-trihydroxypregna-1,4-diene-3,20-dione-21-({parabis-(2-chloroethyl)amino]phenyl}butyrate); Leo 1031; NSC 134087

1.2 Structural and molecular formulae and molecular weight

\[
\begin{align*}
\text{C}_{35}\text{H}_{45}\text{Cl}_{2}\text{N}0_{6} & \quad \text{Mol. wt: 646.66} \\
\end{align*}
\]

1.3 Chemical and physical properties of the pure substance

From Windholz (1983), unless otherwise specified

(a) *Description:* Crystals from methanol-water

(b) *Melting-point:* 163–164°C

(c) *Optical rotation:* \([\alpha]^{24}_D = +92.9^\circ\) \((c = 1.06\text{ in chloroform})\)
1.4 Technical products and impurities

*Trade names:* Mostarine; Sterecyt; Stéréocyt

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

Prednimustine can be produced by the esterification of chlorambucil with prednisolone (*Fex et al.,* 1970). It is synthesized in Sweden.

Prednimustine is not known to occur naturally.

2.2 Use

Prednimustine is a cytostatic agent. It has been used in the treatment of various malignancies, including chronic lymphatic leukaemia and non-Hodgkin’s lymphomas, at daily oral doses of 140-200 mg for three to five days or continuously at 20-30 mg per day (*Reynolds, 1989; Szanto et al., 1989*). It has also been tested for use in the treatment of breast cancer (*Loeber et al.,* 1983; *Rankin et al.,* 1987).

2.3 Analysis

Prednimustine has been quantified in plasma by high-performance liquid chromatography (*Newell et al.,* 1979). It has also been quantified after hydrolysis to chlorambucil, by gas chromatography-mass spectrometry (*Jakhammer et al.,* 1977) and high-performance liquid chromatography (*Workman et al.,* 1987).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

(a) *Oral administration*

*Rat:* Four groups of 30 female Sprague-Dawley rats, 100 days of age, received prednimustine [purity unspecified] at 12 mg/kg bw in a vehicle consisting of
carboxymethylcellulose, Tween 80 and glucose in water by gavage once, twice, 4.5 or nine times per month for 18 months. The last group had significantly reduced survival. A group of 120 female rats received the vehicle alone by gavage nine times per month for 18 months. A significant increase \((p < 0.01; \text{Peto test: Peto et al., 1980})\) in the incidence of squamous-cell carcinomas of the external auditory canal was observed (controls, 0/30; once per month, 0/30; twice per month, 1/30; 4.5 times per month, 2/30; nine times per month, 2/30). No increase in the incidence of other tumours was observed (Berger et al., 1985, 1986).

(b) Carcinogenicity of metabolites

Chlorambucil has been evaluated in the IARC Monographs (IARC, 1975, 1981, 1987).

3.2 Other relevant data

(a) Experimental systems

(i) Absorption, distribution, excretion and metabolism

Following a subcutaneous injection of radiolabelled prednimustine at 20 mg/kg bw to female Wistar rats, radioactivity appeared gradually in blood plasma over 48 h. The levels of chlorambucil and phenylacetic mustard in plasma were below 5 \(\mu\)M. Radioactivity levels in all tissues studied were lower than those in plasma; in the small intestine, activity peaked at 2-4 h after administration. No or little radioactivity was detected in bone marrow (Newell et al., 1981).

When radiolabelled prednimustine was injected intravenously to baboons, low urinary and biliary excretion was observed. The radioactivity in blood and kidney decreased with time, but it was stable in the liver over the observation period of 6 h. In muscle, prostate, lung, spleen and seminal vesicles, however, radioactivity levels rose after 4 and 6 h (Kirdani et al., 1978).

Prednimustine is hydrolysed completely in vitro by rat plasma esterases to chlorambucil and prednisolone (Wilkinson et al., 1978). A cholesterol ester of chlorambucil, originating from prednimustine by acyltransferase-catalysed trans-esterification, was detected when prednimustine was incubated with human, rat or dog plasma in vivo. The same ester was identified in plasma of dogs after intravenous injection in vivo (Gunnarsson et al., 1984).

(ii) Toxic effects

In an acute lethality study, survival of Wistar rats given prednimustine at 128 mg/kg bw subcutaneously was 70% after 21 days. The drug was less toxic than chlorambucil and less toxic than chlorambucil and prednisolone given in combination (Harrap et al., 1977).

In subacute toxicity experiments, the mortality caused by daily oral administrations of prednimustine for four weeks to Sprague-Dawley rats was low
compared to that induced by chlorambucil and prednisolone given together. Mortality in prednimustine-treated animals was about 10% at dose levels of 32 and 64 mg/kg bw. Dose-related lymphopenia was observed, and spleen and adrenal weights were reduced (Fredholm et al., 1978).

No symptom of toxicity was observed during a life-time carcinogenicity study with prednimustine given to Sprague-Dawley rats at 12 mg/kg bw one to nine times per month for 18 months (Berger et al., 1986).

Prednimustine caused a dose-dependent decrease in survival in Chinese hamster V79-4 cells; it was at least three times as toxic as chlorambucil throughout the dose range (Hartley-Asp et al., 1986). Dose-dependent cell death was also observed in the hormone-sensitive S49 mouse lymphoma cell line after incubation for 24 h with prednimustine at $10^{-8}$ M up to $5 \times 10^{-7}$ M prednimustine (Harrap et al., 1977).

(iii) **Effects on reproduction and prenatal toxicity**

No data were available to the Working Group.

(iv) **Genetic and related effects**

No data were available to the Working Group.

(b) **Humans**

(i) **Pharmacokinetics**

When prednimustine was given orally at doses up to 200 mg, no unchanged drug could be detected in blood (Newell et al., 1979; Ehrsson et al., 1983; Gaver et al., 1983; Newell et al., 1983; Oppitz et al., 1989) or in urine (Kirdani et al., 1978). When prednimustine was given orally at 20 mg, no chlorambucil or phenylacetic mustard was detected in the circulation (Newell et al., 1979, 1983); however, when a higher dose (100 or 200 mg) was given, chlorambucil was detected in blood (Ehrsson et al., 1983; Oppitz et al., 1989). After a dose of 200 mg, phenylacetic mustard was also identified in the circulation (Oppitz et al., 1989), and, after an oral dose of 100 mg, free prednisolone was detected (Sayed et al., 1981). The concentrations of chlorambucil and its metabolites and of prednisolone detected in the circulation after an oral dose of prednimustine were lower than those after equimolar doses of chlorambucil and prednisolone given separately (Sayed et al., 1981; Ehrsson et al., 1983; Oppitz et al., 1989). After a single oral dose of prednimustine, the peak values of chlorambucil and phenylacetic acid mustard in the serum were reached later and the disappearance half-time was longer than after administration of chlorambucil and prednisolone separately (Ehrsson et al., 1983; Oppitz et al., 1989). Three to six hours after a single oral dose of 40 mg/m$^2$ radiolabelled prednimustine, 50% of the plasma radioactivity could be extracted into organic solvents; the extractable proportion decreased with time and was <10% after 12-18 h. The terminal
half-time of ten days for prednimustine-derived radioactivity in plasma could be attributed to these covalently bound metabolites (Gaver et al., 1983).

When a trace amount of double-labelled prednimustine ($^{14}$C in the bischloroethyl group, $^{3}$H at positions 6 and 7 of the steroid part) was administered intravenously, $^{14}$C and $^{3}$H in the urine cochromatographed partially during the first hour after the injection but were fully separated thereafter, indicating that intact prednimustine is excreted in the urine only immediately after injection (Kirdani et al., 1978).

(ii) **Adverse effects**

Leukopenia and thrombocytopenia seem to be dose-dependent and may limit the dose that can be used. Nausea and vomiting are frequent (Könyves et al., 1975; Loeber et al., 1983; Rankin et al., 1987; Szanto et al., 1989).

(iii) **Effects on reproduction and prenatal toxicity**

No data were available to the Working Group.

(iv) **Genetic and related effects**

No adequate studies were available to the Working Group.

3.3 Case reports and epidemiological studies of carcinogenicity to humans

No data were available to the Working Group.

4. **Summary of Data Reported and Evaluation**

4.1 Exposure data

Prednimustine has been used as a cytostatic drug, mainly for the treatment of malignancies of lymphatic tissue.

4.2 Experimental carcinogenicity data

Prednimustine given by oral administration to rats induced a low but significant increase in the incidence of squamous-cell carcinomas of the external auditory canal.

4.3 Human carcinogenicity data

No data were available to the Working Group.

4.4 Other relevant data

In humans, prednimustine causes leukopenia and thrombocytopenia; in experimental animals, it causes lymphopenia. It is hydrolysed to chlorambucil and prednisolone *in vivo*. (See Appendix 1.)
4.5 Evaluation

There is inadequate evidence for the carcinogenicity of prednimustine in experimental animals.

No data were available from studies in humans on the carcinogenicity of prednimustine.

Overall evaluation

Prednimustine is not classifiable as to its carcinogenicity to humans (Group 3).

5. References


---

1For description of the italicized terms, see Preamble, pp. 26–29.
PREDNIMUSTINE


THIOTEPA

This substance was considered by previous working groups, in April 1975 and March 1987, under the title tris(1-aziridinyl)phosphine sulphide (IARC, 1975, 1987). Since that time, new data have become available, and these have been incorporated into the monograph and taken into consideration in the present evaluation.

1. Chemical and Physical Data

1.1 Synonyms

Chem. Abstr. Services Reg. No.: 52-24-4
Chem. Abstr. Name: Aziridine, 1,1',1"-phosphinothiodylidenetris
Synonyms: NSC-6396; phosphoric tri(ethyleneamide); TESP; thiophosphamide; thiotriethylene phosphoramide; triaziridinylphosphine sulphide; \(N,N',N"\)-tri-1,2-ethanediylphosphorothioic triamide; \(N,N',N"\)-tri-1,2-ethanediylthiophosphoramide; tri(ethyleneimino)thiophosphoramide; meta-triethylenethio-phosphoramide; \(N,N',N"\)-triethylenethiophosphoramide; meta-tris(aziridin-1-yl)phosphine sulphide; triethylenethiophosphorotriamide; tris-(1-aziridinyl)-phosphine sulphide; tris-(ethyleneimino)-thiophosphate; TSPA; WR-45312

1.2 Structural and molecular formulae and molecular weight

\[
\begin{align*}
\text{C}_6\text{H}_{12}\text{N}_3\text{PS} & \quad \text{Mol. wt: 189.23} \\
\end{align*}
\]
1.3 Chemical and physical properties of the pure substance

From Windholz (1983) and Barnhart (1989), unless otherwise indicated

(a) Description: White, crystalline solid; fine white crystalline flakes from pentane or ether

(b) Melting-point: 51.5°C; 52-57°C (Reynolds, 1989)

(c) Solubility: 1:8 in water; 19 g/100 ml water at 25°C; soluble in ethanol, diethyl ether, benzene and chloroform

(d) Stability: At temperatures above 2-8°C, thiotepa polymerizes and becomes inactive. The bulk drug is stable (up to two years) at 2-8°C, is unstable in acid and is sensitive to light. Aqueous solutions of 10 mg/ml are stable for five days at 2-8°C. Thiotepa is stable in alkaline solution.

1.4 Technical products and impurities

Trade names: Ledertepa, Onco Thiotepa, Tespamin; Thio-TEPA; Tifosyl

Thiotepa is available in vials containing 15 mg thiotepa, 80 mg sodium chloride and 50 mg sodium bicarbonate; when reconstituted, the pH is 7.6 (Barnhart, 1989).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

Thiotepa has been prepared by the addition of trichlorophosphine sulfide to aziridine and triethylamine (Kuh & Seeger, 1954) and by the addition of aziridine to phosphorus oxychloride (Bestian, 1950). Thiotepa is synthesized in Japan.

Thiotepa is not known to occur naturally.

2.2 Use

Thiotepa is a cytostatic agent. It has been used in the treatment of lymphomas and a variety of solid tumours, such as those of breast and ovary; it has also been used in cases of urinary bladder malignancies, meningeal carcinomatosis and various soft-tissue tumours (Wright et al., 1958; Hollister & Coleman, 1980; Hagen et al., 1987; Reynolds, 1989). Thiotepa is administered intramuscularly, intravenously and intrathecally; other parenteral routes (e.g., intratumoral injections) have also been used. It has been used as instillations in cases of urinary bladder carcinoma (Hollister & Coleman, 1980). Thiotepa has been used recently at high doses in combination chemotherapy with cyclophosphamide in patients with
refractory malignancies treated with autologous bone transplantation (Henner et al., 1987; Lazarus et al., 1987; Williams et al., 1987; Ackland et al., 1988; Eder et al., 1988; Williams et al., 1989).

The initial dosage of thiotepa has generally been 5-40 mg [3-23 mg/m²] at one-to four-weekly intervals (Wright et al., 1958; Cohen et al., 1986; Hagen et al., 1987); doses up to 75 mg/m² have been used in children (Heideman et al., 1989). The dosage is generally adjusted on the basis of changes in leukocyte counts. High-dose therapy has involved daily doses in excess of 1100 mg/m² (Lazarus et al., 1987).

2.3 Analysis

Thiotepa has been determined in pharmaceutical preparations by colorimetric titration (US Pharmacopeial Convention, Inc., 1989) and in biological fluids by chromatography (Egorin et al., 1985; Hagen et al., 1985; McDermott et al., 1985) and high-performance liquid chromatography (Sano et al., 1988).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

The carcinogenicity of antineoplastic drugs, including thiotepa, in animals has been reviewed (Berger, 1986).

(a) Intraperitoneal administration

Mouse: In a screening assay based on the accelerated induction of lung tumours in a strain highly susceptible to development of this neoplasm, three groups of ten male and ten female strain A/He mice, six to eight weeks of age, received intraperitoneal injections of thiotepa (purity, 95-99%) in 0.1 ml of purified tricaprylin three times per week for four weeks (total doses, 19, 47 and 94 mg/kg bw). A group of 80 males and 80 females received 24 injections of 0.1 ml of tricaprylin alone. All mice were killed 24 weeks after the first injection. The incidences of lung tumours in treated mice were 16/20, 10/20 and 11/20 in the groups receiving the high, mid and low doses, respectively, compared to 28% and 20% in male and female controls. The numbers of lung adenomas per mouse were significantly higher in the high-dose (1.50; p < 0.001) and mid-dose (0.74; p < 0.05) groups in comparison to male (0.24) and female (0.20) controls (Stoner et al., 1973).

Groups of 35 male and 35 female B6C3F1 mice, six weeks of age, received intraperitoneal injections of thiotepa (purity, 98.0 ± 1.0%) at 1.15 or 2.3 mg/kg bw
three times a week for up to 52 weeks and were observed for an additional 34 weeks. Two groups of 15 males and 15 females were untreated or received injections of phosphate-buffered saline vehicle only and served as matched controls. Pooled vehicle controls were also used, by adding 15 animals of each sex taken from a bioassay on another chemical. By 43 weeks, all high-dose females had died, and, by 56 weeks, all high-dose males had died. At weeks 86-87, 15/35 low-dose males, 17/35 low-dose females, 7/15 vehicle-control males and 12/15 vehicle-control females were still alive, at which time the study was terminated. Because of early deaths, statistical analyses were based only on time-adjusted incidences of tumours, eliminating those mice that had died before week 52. The incidences of malignant lymphoma and lymphocytic leukaemia combined were significantly greater in high-dose animals (32/32 females, 26/28 males; \( p < 0.001 \), Cochran-Armitage test, Fisher’s exact test) in comparison with vehicle and pooled controls (0/14 and 0/29 females; 1/8 and 1/18 males) (National Cancer Institute, 1978). [The Working Group noted the poor survival among the high-dose animals and that the study design involved controls pooled from different studies.]

Rat: Groups of 35-39 male and 31-35 female Sprague-Dawley rats, aged 35, 42 or 58 days, received intraperitoneal injections of thiotepa (purity, 98.0 ± 1.0%) at 0.7, 1.4 or 2.8 mg/kg bw three times a week for up to 52 weeks and were observed for additional periods of time. Two groups of ten males and ten females were untreated or received injections of buffered saline alone at 2.5 ml/kg bw and served as controls. A lower-dose group was started 69 weeks after the beginning of the original study, together with two additional control groups. Pooled vehicle controls were also used, by adding ten rats of each sex from bioassays on other chemicals. All high-dose males had died by week 19 and all high-dose females by week 21. Treatment of mid-dose groups was terminated at week 34, and animals were observed until weeks 78-81, at which time all of them had died. All other groups were observed until weeks 82-87. Because of early deaths, statistical analyses were based only on time-adjusted incidences of tumours, eliminating those rats that had died before week 52. Malignant lymphomas, lymphocytic leukaemia and granulocytic leukaemia were observed in 6/34 low-dose (pooled controls, 0/29; \( p = 0.020 \) and 6/16 mid-dose (pooled controls, 0/30; \( p < 0.001 \) males. Uterine adenocarcinomas were found in 7/21 mid-dose females (pooled controls, 0/28; \( p = 0.001 \) and 2/29 low-dose females but not in corresponding lower-dose controls. The incidence of adenocarcinomas of the mammary gland was significantly increased in mid-dose females (8/24; pooled controls, 1/28; \( p = 0.006 \), but this tumour was also observed in one lower-dose pooled control and in 3/10 lower-dose untreated controls. The incidences of neuroepitheliomas or nasal carcinomas (three in low-dose males, two in low-dose females, two in mid-dose females) were not statistically significantly increased, although they did not occur among
corresponding controls or among the 388 pooled vehicle controls (National Cancer Institute, 1978). [The Working Group noted the high mortality among high- and mid-dose groups, which necessitated the later inclusion of the lower dose-treated group, and that the study design included controls pooled from different studies.]

(b) Intravenous administration

Rat: A group of 48 male BR46 rats, 100 days of age, received weekly intravenous injections of thiotepa [purity and vehicle unspecified] at 1 mg/kg bw for 52 weeks. A group of 89 untreated males served as controls. Of the treated animals, 30 were still alive when the first tumour appeared, compared to 65 controls. Malignant tumours developed in 9/30 treated animals (two sarcomas of the abdominal cavity, one lymphosarcoma, one 'myelosis', one seminoma, one fibrosarcoma and one haemangioendothelioma of the salivary gland, one mammary sarcoma, one phaeochromocytoma) and in 4/65 controls (three mammary sarcomas, one phaeochromocytoma) \( (p < 0.01) \). Benign tumours occurred in 5/30 treated and 3/65 control animals (Schmäh & Osswald, 1970; Schmähl, 1975). [The Working Group noted the short latency of tumour induction.]

3.2 Other relevant data

(a) Experimental systems

(i) Absorption, distribution, excretion and metabolism

One hour after intraperitoneal injection of thiotepa at 9.3 mg/kg bw into Sprague-Dawley rats, radioactivity was found in plasma (5.4%), peritoneal fluid (26%), urine (1.9%), kidney (0.7%), liver (3.8%), lung (0.6%) and muscle (25.9%) (Litterst et al., 1982). In another study, 5 min after intravenous or intraarterial injection of labelled thiotepa in Sprague-Dawley rats, slightly higher levels of radioactivity were found in plasma, heart, kidneys and lungs, compared to other organs; 94-98% of radioactivity administered intravenously was excreted in urine within 8.5 h. Most of the urinary radioactivity was associated with unchanged thiotepa; tris(l-aziridinyl)phosphine oxide (tepa) was responsible for about 30% of the radioactivity (Boone et al., 1962).

In female mongrel dogs, 75-85% of an intravenous dose of labelled thiotepa was recovered in the urine; only 0.2-0.3% unchanged thiotepa was found (Mellett et al., 1962). Following intravenous (at 3 mg/kg bw) or oral (at 6 mg/kg bw) administration of thiotepa to dogs, about 13% of the dose was excreted as tepa. The plasma level of tepa was about 1.2 \( \mu g/ml \) 2 h after intravenous injection of thiotepa. The authors concluded that 50% of the administered thiotepa was absorbed (Mellett & Woods, 1960).

A biexponential decline in thiotepa concentration in plasma was seen during the first hours after intravenous injection of thiotepa at 5 mg/kg bw in
Swiss-Webster mice. The half-time was 0.21 min for the first phase and 9.62 min for the second (Egorin et al., 1984).

After an intravenous dose of thiotepa to rhesus monkeys, equilibrium with plasma levels in lumbar and ventricular cerebrospinal fluid was obtained rapidly. After intravenous administration, the total body clearance of thiotepa was about 35 ml/min (Strong et al., 1986).

The major urinary metabolite in rats, rabbits and dogs following a single intravenous injection of $^{32}$P-thiotepa was tepa, which is also an alkylating agent. Most of the radioactivity in mouse urine, however, was recovered as inorganic phosphate. In mice and rats, a small proportion of radioactivity was detected in most tissues nine days after an intravenous injection of thiotepa; higher levels were detected in blood of rats (Craig et al., 1959).

After addition of thiotepa to sera from patients and healthy individuals, about 10% was bound to protein (Hagen & Nilsen, 1987).

(ii) Toxic effects

The LD$_{50}$ of thiotepa in rats was about 9.5 mg/kg bw by intravenous injection and about 8.8 mg after intraarterial injection (Boone et al., 1962). The LD$_{50}$ in mice was 400 mg/kg bw 24 h after an intraperitoneal injection. The acute lethality after 1 h and 24 h was markedly increased by intraperitoneal injection of 60 mg/kg bw pentobarbital shortly after the thiotepa injection (Munson et al., 1974). Pretreatment of mice with 40 mg/kg bw SKF525A also enhanced the acute lethality of thiotepa (Mellett & Woods, 1960).

Thiotepa caused a dose-dependent inhibition of the growth of P388 murine leukaemia cells in culture (Miller et al., 1988).

(iii) Effects on reproduction and prenatal toxicity

When rats were given thiotepa at 4 mg/kg bw by intraperitoneal injection on gestation day 12, teratogenic effects occurred in the offspring (Murphy et al., 1958). [The Working Group noted that the details given in the paper were insufficient to assess the significance of the effect.]

In an extensive study of the effects of thiotepa in pregnant mice, Tanimura (1968) demonstrated both dose-related and time-related effects. Prenatal mortality was most pronounced following intraperitoneal injection of 5-10 mg/kg bw on days 7.5 and 8.5 of gestation, and fetal growth was suppressed after injection on days 10.5-12.5 of gestation. The lowest single teratogenic dose was shown to be 1.0 mg/kg bw; the dose that caused 100% incidence of malformed fetuses was 10.0 mg/kg. The malformations observed were exencephaly, spina bifida, cleft palate, kinky tail and digit alterations.
(iv) Genetic and related effects

Thiotepa was mutagenic to *Salmonella typhimurium* TA1535 (Benedict et al., 1977a) and TA100 (Pak et al., 1979) but gave contradictory results in TA98 (Bruce & Heddle, 1979; Pak et al., 1979) in the absence of an exogenous metabolic system. Rats perfused with thiotepa produced urine that was mutagenic to *S. typhimurium* (Pak et al., 1979). In the host-mediated assay in mice, thiotepa was mutagenic to *S. typhimurium* TA1535 (Arni et al., 1977) and G46 (Devi & Reddy, 1980).

Thiotepa induced forward mutations to 8-azaguanine resistance in *Aspergillus nidulans* (Bignami et al., 1982) and chromosomal aberrations (Kihlman, 1975; Sturelid & Kihlman, 1975; Popa et al., 1976) and sister chromatid exchange (Kihlman, 1975) in root meristem cells of *Vicia faba*. It induced sex-linked recessive lethal mutations in *Drosophila melanogaster* (Lüers & Röhrborn, 1965; Fahmy & Fahmy, 1970) and dominant lethal mutations in *Aedes aegypti* (Rodriguez & Rodriguez, 1985).

Thiotepa induced unscheduled DNA synthesis in unstimulated human peripheral lymphocytes (Titenko, 1983). It induced mutations at the *hprt* locus in Chinese hamster V79 cells (Paschin & Kozachenko, 1982), and, in a host-mediated assay with mice and mouse lymphoma L5178Y cells, it induced resistance to thymidine and methotrexate (Lee, 1973).

Thiotepa induced sister chromatid exchange in mouse cells (Andersen, 1983), a cloned hamster cell line (Banerjee & Benedict, 1979), Chinese hamster cells (Chebotarev & Seleznova, 1979; Chebotarev et al., 1980; Seleznova et al., 1982) and peripheral lymphocytes of rhesus monkeys (Kuzin et al., 1987) and humans (Littlefield et al., 1979; Mourelatos, 1979; Chebotarev & Listopad, 1980; Listopad & Chebotarev, 1982; Shcheglova & Chebotarev, 1983a). It induced chromosomal aberrations in a cloned hamster cell line (Benedict et al., 1977b), in Chinese hamster CHO cells (Maier & Schmid, 1976; Sturelid, 1976), in peripheral lymphocytes of rabbits (Bochkov et al., 1982) and in human peripheral lymphocytes in *vitro* (Hampel et al., 1966; Bochkov & Kuleshov, 1972; Bochkov et al., 1972; Chebotarev, 1974; Kirichenko, 1974; Kirichenko & Chebotarev, 1976; Yakovenko & Nazarenko, 1977; Bochkov et al., 1979; Wolff & Arutyunyan, 1979; Yakovenko & Kagramanyan, 1982; Shcheglova & Chebotarev, 1983a). Thiotepa induced morphological transformation of C3H/10T½ cells (Benedict et al., 1977b).

Thiotepa induced DNA cross-links in chick embryos (McCann et al., 1971). It induced sister chromatid exchange (Shcheglova & Chebotarev, 1983b) and chromosomal aberrations (Malashenko & Surkova, 1974a,b, 1975; Sram, 1976; Leonard et al., 1979; Malashenko & Surkova, 1979; Shcheglova & Chebotarev, 1983b) in bone marrow of mice treated *in vivo*. It induced micronuclei in the bone marrow of rats (Setnikar et al., 1976) and mice (Maier & Schmid, 1976; Ioan et al., 1977; Bruce & Heddle, 1979; Leonard et al., 1979) and chromosomal aberrations in
peripheral lymphocytes of rabbits (Bochkov et al., 1982) and rhesus monkeys (Kuzin et al., 1987) in vivo. Treatment of pregnant mice with thiotepa led to chromosomal aberrations in embryonic liver cells (Korogodina et al., 1979; Korogodina & S’yakste, 1981).

Thiotepa induced dominant lethal mutations (Machemer & Hess, 1971; Epstein et al., 1972; Setnikar et al., 1976; Sram, 1976; Semenov & Malashenko, 1981) and chromosomal aberrations in spermatogonia (Malashenko & Beskova, 1988) and spermatocytes [one dose] (Devi & Reddy, 1980; Meistrich et al., 1982) in mice in vivo. Treatment of male mice with thiotepa led to chromosomal aberrations in preimplantation embryos [one dose] (Malashenko et al., 1978a; Semenov & Malashenko, 1979). Thiotepa also induced sperm abnormalities (Bruce & Heddle, 1979) and heritable translocations [one dose] (Malashenko & Surkova, 1974b; Semenov & Malashenko, 1977; Malashenko et al., 1978b; Malashenko & Goetz, 1981) in mice in vivo. Thiotepa produced liver protein variants in F1 fetuses derived from treated male mice [one dose] (Paschin & Ambrossieva, 1984).

(b) Humans

(i) Pharmacokinetics

Because of acid instability, absorption of thiotepa after oral administration is erratic and incomplete (Mellet et al., 1962). After an intravenous bolus injection of thiotepa at 12 mg/m², a biexponential disappearance from the plasma was observed; the second-phase half-time was 73.7 min (Egorin et al., 1985). Disappearance half-times of 1.3-2.1 h were reported in further studies (McDermott et al., 1985; Cohen et al., 1986; Hagen et al., 1987; Henner et al., 1987; Hagen et al., 1988; Heideman et al., 1989) after intravenous or intramuscular administration. At dose levels in excess of 25 mg/m² (Heidemann et al., 1989), 180 mg/m² (Henner et al., 1987) and 4.8 mg/kg (Ackland et al., 1988), the plasma clearance of thiotepa was reported to decline with increasing dose. However, in one study with high doses (45-1215 mg/m²), no dose-dependence of kinetics was reported (Lazarus et al., 1987). The volume of distribution of thiotepa has been reported to be approximately 50 l (Cohen et al., 1986; Henner et al., 1987; Hagen et al., 1988; Heidemann et al., 1989).

After an intravenous injection of thiotepa in paediatric patients, the cerebrospinal fluid:plasma ratio of thiotepa was 0.92 (Heideman et al., 1989). After intraventricular administration of thiotepa, the ratio of thiotepa concentrations in cerebral ventricular fluid:plasma was almost 1000 (Strong et al., 1986); in another, similar study, it was approximately 200 (Grochow et al., 1982). The urinary excretion of unchanged thiotepa is complete usually within 8 h of the injection, and less than 1.5% of the dose is excreted in the urine unchanged (Egorin et al., 1985; Hagen et al., 1985; Cohen et al., 1986; Hagen et al., 1987). Five minutes after an intravenous
injection of thiotepa, tepa was observed in the blood; after 120 min, the concentration of tepa in the blood was higher than that of thiotepa. The proportion of thiotepa in urine was 1.5%, and that of tepa was 4.2%; other alkylating metabolites represented another 23.5% of the dose administered (Cohen et al., 1986).

(ii) Adverse effects

The toxic effect of thiotepa that limits the dose that can be given is myelosuppression, characterized by granulocytopenia and thrombocytopenia; disturbances in hepatic and renal function, neurotoxicity, nausea and vomiting were uncommon at dose levels of approximately 75 mg/m² or less (Wright et al., 1958; Heideman et al., 1989). In high-dose therapy with autologous bone-marrow transplantation, central nervous system disturbances, hepatic damage, infections, nausea, vomiting, diarrhoea, mucositis, skin rashes, haemorrhagic cystitis and cardiomyopathy may be severe (Lazarus et al., 1987; Williams et al., 1987, 1989). Severe myelosuppression has also been described after intravesicular instillations of thiotepa (Bruce & Edgcomb, 1967; Watkins et al., 1967; Hollister & Coleman, 1980).

(iii) Effects on reproduction and prenatal toxicity

Use of thiotepa in the third trimester of pregnancy had no adverse effect on the progeny (Nicholson, 1968; Sweet & Kinzie, 1976). In a report of the effects of treatment of women with stage-II and stage-III Hodgkin’s disease with radiotherapy and chemotherapy with TVPP (thiotepa, vinblastine, vincristine, procarbazine and prednisone), menstrual function ceased in two of four women aged 35-44 years but continued in all 30 women under 35 years of age. Ten of the women had a total of 12 babies, all with normal development (Lacher & Toner, 1986).

As reported in an abstract, transient azoospermia occurred in a man treated with thiotepa; the effect was reversed when the dose interval was increased from monthly to three-monthly dosing (Bayar et al., 1978).

(iv) Genetic and related effects

Five patients who received a total dose of thiotepa at 40-100 mg had 9.5 ± 1.07% aberrant cells in peripheral lymphocytes 24 h after the last treatment, compared with 1.4 ± 0.1% in a control group (Selezneva & Korman, 1973).

3.3 Case reports and epidemiological studies of carcinogenicity to humans

Many case reports have been made of cancer occurring following treatment with thiotepa (IARC, 1975; Nakanuma et al., 1976; Anon., 1977; Hollister & Coleman, 1980; Sheibani et al., 1980; Easton & Poon, 1983; Silberberg & Zarrabi,
1987). All report the occurrence of nonlymphocytic leukaemia, and usually thiotepa was the only chemotherapeutic agent administered.

No increased risk of second malignancies was found among 470 patients with colorectal cancer randomized to low-dose (four doses of 0.2 mg/kg bw) adjuvant therapy with thiotepa, followed for 3102 person-years (30 second noncolorectal malignancies observed, 31.4 expected; Boice et al., 1980). No increased risk of second malignancies was found among 90 patients with breast cancer randomized to adjuvant therapy with thiotepa for one year (at 0.8 mg/kg bw in divided doses followed by 0.2 mg/kg bw weekly maintenance); after an average follow-up of approximately five years, five nonskin, nonbreast cancers had occurred in 5819 person-years among 90 treated subjects compared with six in 4746 person-years among the 77 nonexposed patients (Kardinal & Donegan, 1980). [The Working Group considered these two studies to be too small to provide useful information.]

Kaldor et al. (1990) compared 114 cases of leukaemia that developed in patients previously diagnosed with ovarian cancer, with 342 controls with ovarian cancer who had survived as long as the cases and who were matched by age and year of diagnosis of ovarian cancer. Chemotherapy (without radiotherapy) was associated with a relative risk of 12 (95% confidence interval, 4.4-32) compared to treatment by surgery only. For nine cases and 11 controls, the only chemotherapy was thiotepa; 21 cases and 187 controls had had no chemotherapy. The matched relative risks were 8.3 and 9.7 in a lower- and a higher-dose group, and these were significantly different from 1.0 ($p < 0.01$). In the same study, four other alkylating agents known to be carcinogenic (melphalan, chlorambucil, cyclophosphamide and treosulphan; see IARC, 1987) were independently associated with significantly increased risks for leukaemia.

4. Summary of Data Reported and Evaluation

4.1 Exposure data

Thiotepa is a cytostatic agent that has been used in the treatment of malignant lymphomas and solid tumours, in a wide range of doses.

4.2 Experimental carcinogenicity data

Thiotepa was tested for carcinogenicity by intraperitoneal administration in mice and rats and by intravenous administration in male rats. In mice, it induced an increased incidence of lung tumours and lymphoproliferative malignancies in mice of each sex. In rats, intraperitoneal administration induced an increased incidence of lymphoproliferative malignancies in males and of uterine adenocarcinomas and
mammary carcinomas in females. Intravenous administration to male rats induced tumours at a variety of sites.

4.3 Human carcinogenicity data

Several cases of leukaemia following treatment with thiotepa alone have been reported. One case-control study has shown a strong association between risk for leukaemia and treatment with thiotepa.

4.4 Other relevant data

In one study, there was no evidence that thiotepa therapy adversely affected subsequent fertility in women. Thiotepa is embryotoxic to mice and rats, and embryo- and fetolethality and gross structural abnormalities were induced during organogenesis after single intraperitoneal injections.

Thiotepa is converted to alkylating metabolites in vivo. It suppresses the bone marrow in humans.

In one study, increased frequencies of chromosomal aberrations were observed in peripheral lymphocytes of patients receiving thiotepa.

Thiotepa induced chromosomal aberrations in germ cells, sperm abnormalities and dominant lethal mutation in mice in vivo. It induced micronuclei in the bone marrow of rats and mice, chromosomal aberrations in bone-marrow cells and liver cells of mice and in peripheral lymphocytes of rabbits and rhesus monkeys and sister chromatid exchange in bone-marrow cells of mice in vivo. Thiotepa induced DNA damage in chick embryos. It induced chromosomal aberrations in cloned hamster cells, in Chinese hamster cells and in human cells, sister chromatid exchange in human, mouse, Chinese hamster and rabbit cells, gene mutations in Chinese hamster cells and unscheduled DNA synthesis in human peripheral lymphocytes in vitro. It induced cell transformation in mouse cells. Thiotepa induced sex-linked recessive lethal mutations in Drosophila and sister chromatid exchange and chromosomal aberrations in Vicia faba. It induced gene mutations in Aspergillus nidulans and Salmonella typhimurium. (See Appendix 1.)

4.5 Evaluation

There is sufficient evidence for the carcinogenicity of thiotepa in humans.

There is sufficient evidence for the carcinogenicity of thiotepa in experimental animals.

---

1For description of the italicized terms, see Preamble, pp. 26-29.
Overall evaluation

Thiotepa is carcinogenic to humans (Group 1).

5. References


Andersen, O. (1983) Effects of coal combustion products and metal compounds on sister chromatid exchange (SCE) in a macrophagelike cell line. Environ. Health Perspect., 47, 239-253


THIOTEPA


Kihlman, B.A. (1975) Sister chromatid exchanges in Vicia faba. II. Effects of thiopeta, caffeine and 8-ethoxycaffeine on the frequency of SCE’s. Chromosoma, 51, 11-18


Lacher, M.J. & Toner, K. (1986) Pregnancies and menstrual function before and after combined radiation (RT) and chemotherapy (TVPP) for Hodgkin’s disease. Cancer Invest., 4, 93-100


TRICHLORMETHINE (TRIMUSTINE HYDROCHLORIDE)

This substance was considered by a previous Working Group, in April 1975, under the title trichlorotriethylamine hydrochloride (IARC, 1975). Since that time, new data have become available, and these have been incorporated into the monograph and taken into consideration in the present evaluation.

1. Chemical and Physical Data

1.1 Synonyms

*Chem. Abstr. Services Reg. No.: 817-09-4*

*Chem. Abstr. Name:* Ethanamine-2-Chloro-N,N-bis(2-chloroethyl) hydrochloride

*Synonyms:* HN3; HN3 hydrochloride NSC-3021; R-47; SK-100; tri(β-chloroethyl)amine hydrochloride; trichlorotriethylamine hydrochloride; 2,2',2''-trichlorotriethylamine hydrochloride; trimustine; tris(2-chloroethyl)amine hydrochloride; tris(β-chloroethyl)amine hydrochloride; tris(2-chloroethyl)amine monohydrochloride; tris(β-chloroethyl)amine monohydrochloride; tris-N-lost; TS-160

1.2 Structural and molecular formulae and molecular weight

\[
\text{C}_6\text{H}_{12}\text{Cl}_3\text{N.HCl} \quad \text{Mol. wt: 241.0}
\]

\[
\begin{align*}
\text{ClCH}_2\text{CH}_2\text{N} & \quad \cdot \text{HCl} \\
\text{CH}_2\text{CH}_2\text{Cl} & \\
\text{CH}_2\text{CH}_2\text{Cl} & 
\end{align*}
\]

1This name is also used for the free base, trichlorotriethylamine.
1.3 Chemical and physical properties of the pure substance

From Reynolds (1982) and Windholz (1983)

(a) **Description:** Crystals
(b) **Melting-point:** 130-131°C
(c) **Solubility:** Very soluble in water; soluble in ethanol
(d) **Stability:** Aqueous solutions deteriorate rapidly.

1.4 Technical products and impurities

*Trade names:* Lekamin; Sinalost; Trilekamin; Trimitan

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

Trichlormethine can be prepared by treating triethanolamine with thionyl chloride (Ward, 1935). No current manufacturer is known.

Trichlormethine is not known to occur naturally.

2.2 Use and therapy


2.3 Analysis

A colorimetric method in which 4-(4'-nitrobenzyl)pyridine is used as the analytical reagent has been used to analyse for various alkylating agents. Trichlormethine may also be determined by thin-layer chromatography (Epstein *et al.*, 1955; Petering & Van Giessen, 1963; Sawicki & Sawicki, 1969).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

The Working Group was aware of a short letter (Griffin *et al.*, 1950) in which experiments were described with mice and rats injected subcutaneously with trichlormethine.
Subcutaneous administration

**Mouse:** A group of 20 mice [age, strain and sex unspecified] received weekly subcutaneous injections of trichlormethine [purity unspecified] at 1 mg/kg bw in aqueous solution for ten weeks, after which time only four mice were alive and treatment was terminated. At survival times of 548-567 days, one of the four mice had a lung adenoma, one had a lung carcinoma and one had a lung carcinoma and a spindle-cell sarcoma at the site of injection. In a control group of 40 untreated mice killed between 14 and 18 months of age, six animals had lung adenomas, two had hepatomas and three had enlarged lymph nodes (Boyland & Horning, 1949). [The Working Group noted the very small number of surviving animals.]

**Rat:** Groups of ten male and ten female random-bred SPF Wistar rats, two months of age, received daily subcutaneous injections of trichlormethine [purity unspecified] at 0.1 or 0.25 mg/kg bw or weekly subcutaneous injections of 1 mg/kg bw in water for six months and were observed for one year after termination of treatment. Total doses were approximately 16.5, 40-42 and 24 mg/kg bw in the three treated groups, respectively. A control group of ten male and ten female rats received injections of 0.3 ml water only for six months. Survival was decreased in males receiving daily injections of trichlormethine. The incidences of sarcomas (mostly spindle-cell type) at the injection site were: males — low daily, 7/10 \( [p < 0.0015] \); high daily, 8/10 \( [p = 0.0004] \); weekly, 5/10 \( [p = 0.016] \); females — low daily, 7/10 \( [p < 0.0015] \); high daily, 7/9 \( [p = 0.0007] \); weekly, 4/10 \( [p = 0.04] \). In the group receiving 0.25 mg/kg bw daily, three males and one female had a mucus-secreting intestinal adenocarcinoma. Tumours were not seen in controls (Sýkora et al., 1981).

### 3.2 Other relevant data

(a) **Experimental systems**

(i) *Absorption, distribution, excretion and metabolism*

No data were available to the Working Group.

(ii) *Toxic effects*

The LD\(_{50}\)s for mice, rats, rabbits and dogs after dermal application of trichlormethine were 7, 4.9, 19 and 1 mg/kg bw, respectively. After subcutaneous injections in saline, the LD\(_{50}\) for mice was 2.0 mg/kg bw. The LD\(_{50}\)s after intravenous injections were 0.7 mg/kg for rats and 2.5 mg/kg bw for rabbits (Anslow et al., 1947).

Trichlormethine caused vomiting, anorexia and blood-containing faeces in dogs a few hours after a single intravenous injection of 1 mg/kg bw. Coma preceded death caused by anoxia as a consequence of peripheral circulatory failure (Houck et al., 1947).
Decreased peripheral lymphocyte counts were observed in rabbits injected intravenously (Friederici, 1955) and in mice injected subcutaneously (Boyland & Horning, 1949) with trichlormethine.

This compound caused cross-links in membrane proteins and haemoglobin in human erythrocytes \textit{in vitro} (Wildenauer & Weger, 1979; Ankel \textit{et al.}, 1986); it alkylated nucleic acids \textit{in vitro} (Szinicz \textit{et al.}, 1981).

(iii) Effects on reproduction and prenatal toxicity

No data were available to the Working Group.

(iv) Genetic and related effects

Trichlormethine inhibited DNA synthesis and induced mutations at the \textit{hprt} locus of Chinese hamster V79 cells (Slamenova \textit{et al.}, 1983). It induced chromosomal aberrations in transplanted Walker rat carcinoma cells (Boyland \textit{et al.}, 1948) and transplanted Ehrlich and Krebs tumour cells (Koller, 1969) following intraperitoneal injection into animals carrying these cells. [The Working Group noted that these early papers on transplanted tumour cells did not permit detailed evaluation.] A single intraperitoneal treatment with trichlormethine at 5 mg/kg induced dominant lethal mutations in mice (Sýkora & Gandalovicova, 1978).

(b) Humans

(i) Pharmacokinetics

No data were available to the Working Group.

(ii) Adverse effects

Lymphopenia, granulocytopenia, thrombocytopenia, anaemia, nausea and vomiting and thrombophlebitis in the vein receiving the infusion were reported after use of trichlormethine (Goodman \textit{et al.}, 1946).

(iii) Effects on reproduction and prenatal toxicity

No data were available to the Working Group.

(iv) Genetic and related effects

No data were available to the Working Group.

3.3 Case reports and epidemiological studies of carcinogenicity to humans

No data were available to the Working Group.

4. Summary of Data Reported and Evaluation

4.1 Exposure data

Trichlormethine is a cytostatic agent that has been used since 1946 for the treatment of leukaemia and lymphoma.
4.2 Experimental carcinogenicity data

Trichlormethine was tested for carcinogenicity by subcutaneous injection in mice and rats. The study in mice was inadequate for evaluation. In rats, trichlormethine induced a high incidence of sarcomas (mostly spindle-cell type) in animals of each sex at the site of subcutaneous injection, as well as a few intestinal adenocarcinomas; neither tumour type was seen in controls.

4.3 Human carcinogenicity data

No data were available to the Working Group.

4.4 Other relevant data

In single studies, trichlormethine induced dominant lethal mutations in mice and gene mutations in Chinese hamster cells. (See Appendix 1.)

4.5 Evaluation

There is sufficient evidence for the carcinogenicity of trichlormethine in experimental animals.

No data were available from studies in humans on the carcinogenicity of trichlormethine.

Overall evaluation

Trichlormethine is possibly carcinogenic to humans (Group 2B).

5. References


For description of the italicized terms, see Preamble, pp. 26-29.

Bundesverband der pharmazeutischen Industrie (1969) Rote Liste [Red List], Frankfurt


Friederici, L. (1955) Der Einfluss von Sulfonamiden, Stickstoff-Lost, TEM und Aminopterin auf das Blut und die blutbildenden Organe des Kaninchens. [The influence of sulfonamides, nitrogen mustard, triethanomelamine and aminopterin on the blood and haematopoietic tissues of rabbits (Ger.)] Folia haematol., 73, 49-74


ANTIMICROBIAL AGENTS
AMPICILLIN

1. Chemical and Physical Data

1.1 Synonyms

Chem. Abstr. Services Reg. No.: 69-53-4; 7177-48-2 (trihydrate); 69-52-3 (sodium salt)
Chem. Abstr. Name: 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-, \{25-[2\alpha, 5\alpha, 6\beta(S^*)]\}-
Synonyms: Anhydrous: (2S,5R,6R)-6-[(R)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; ampicillinum; ampicillinum anhydricum; amhydrous ampicillin; (6R)-6-(\alpha-D-phenylglycylamino)penicillanic acid. Trihydrate: aminobenzylpenicillin (3H2O); \alpha-aminobenzyl-penicillin (3H2O); ampicillinum trihydricum; (sodium salt) ampicillinnatrium; ampicillinum natricum

1.2 Structural and molecular formulae and molecular weight

\[
\begin{align*}
CHCONH & \\
\text{CH}_3 & \\
\text{NH}_2 & \\
\text{H} & \\
\text{H} & \\
\text{COOH} & \\
\text{S} & \\
\text{CH}_3 & \\
\text{CH}_3 & \\
\end{align*}
\]

\[C_{16}H_9N_3O_4S \quad \text{Mol. wt: } 349.40; 403.46 (3H_2O); 371.4 \text{ (sodium salt)}\]

1.3 Chemical and physical properties of the pure substance

From Ivashkiv (1973), unless otherwise specified
(a) Description: White, crystalline powder; practically odourless; also occurs as trihydrate; pH of 10 g/ml aqueous solution, 3.5-6.0
(b) Melting-point: Ampicillin monohydrate melts with decomposition at 202°C; sodium ampicillin melts with decomposition at 205°C; sesqui-hydrate and anhydrous ampicillin decompose at 199-202°C. The melting range for ampicillin trihydrate with decomposition has been reported as 214.5-215°C and 202-204°C.

(c) Optical rotation: Ampicillin monohydrate, [α]_D^{21} + 281° (c = 1 in H_2O); ampicillin sesquihydrate, [α]_D^{20} + 283.1° (c in H_2O); sodium ampicillin [α]_D^{20} + 209° (c = 0.2 in H_2O); anhydrous ampicillin [α]_D^{20} + 287.9° (c = 1 in H_2O)

(d) Solubility: The solubilities of anhydrous ampicillin, ampicillin trihydrate and sodium ampicillin in various solvents are given in detail by Ivashkiv (1973).

(e) Spectroscopy data: Ultraviolet, infrared, nuclear magnetic resonance and mass spectra have been reported.

(f) Stability: Ampicillin powders are stable when stored in a closed system at 43% and 81% relative humidity at room temperature for six weeks. Ampicillin is also stable at 35°C in such closed systems for nine weeks. Stability decreases significantly in the presence of sugars (Reynolds, 1989).

(g) Dissociation constant: pK_a = 2.5, 7.3 (23°C)

1.4 Technical products and impurities

Trade names: A-Cillin; Adobacillin; Aletmicina; Alpen; Alpen-N; Amblosin; Amcill; Amcill-S; Amfipen; Ampen; Amperil; Ampibel; Ampi-Biopharma; Ampibiopic; Amphirone Capsules; Ampicil; Ampicillat; Ampicilline; Ampicimian; Ampicin; Ampicur; Ampifen; Ampi-Framan; Ampidal; Ampikel; Ampilag; Ampilan; Ampiland; Ampilar; Ampilean; Ampilisa; Ampilux; Ampinebiot; Ampinova; Ampinoxi; Ampi-Oral; Ampiourus; Ampinex; Amp-rol; Ampisint; Ampi-Tablinen; Ampitex; Ampivax; Ampi-Vial; Ampixillon; Ampi-Zoja; Amplibios; Amplicid; Amplimedix; Amplipen; Amplipenyl; Ampliscocil; Amplital; Amplizer; Anhypen; Anidropen; Antibipen; Anticyl; Apo-Ampi; Argocillin; Austrapan; Bemicina; Benuset Oral; Binotal; Bio-ampi; Biocellina; Bionacillin; Biosan; Bonapicillin; Bristin; Britapen; Britcin; Cileral; Cimexillin; Citicil; Cuxacillin; Cymbi; D-Amp; Deripen; Diancina; Doktacillin; Domicillin; DuraAmpicillin; Espectrosira; Espimin-Cilina; Eurocillin; Famicillin; Farmampil; Fidesbiotic; Fortapen; Fuerpen; Germicillina; Geycillina; Globipen Balsamico; Gobemicina; Gramcillina; Grampenil; Guicitrina; Helvecillin; Hostes; Iwacillin; Lampocillina; Lifeampil; Marisiolan; Maxicilina; Medicillin-D; Morepen; Napicil; NC Cilin; Negmapen; Novoexpectro; Nuvapen; Omnipen; Omnipen-N; Overcillina; Panbiotic; Panestes; Pen-A; Pen Ampil; Penampil; Pen A/N; Penberin; Pen-Bristol;
AMPICILLIN

Penbristol; Penbritin; Penbritine; Penbrock; Péniciline; Penimaster; Penimic; Penimul; Peninovel; Penisint B.G.; Penisintex; Penorsin; Penrite; Pensyn; Pentrex; Pentrexil; Pentrexyl; Pentrexyl-K; Petercillin; Pharcillin; Platocillina; Plumericin; Poenbiotico; Polycillin; Prestacilina; Principen; Principen/N; Quimetam; Racenacillin; Radiocillina; Resan; Rivocillin; Rosampline; Roscillin; Saicil; Semicillin; Sernabiotic; Servicillina; Sesquicillina; Sintopenyl; SK-Ampicillin; SK-Ampicillin-N; Spectracil; Sumipanto; Supen; Suractin; Synpenin; Synthecillin; Tauglicolcinna; Togram; Tokiocillin; Tolimal; Totaciclina; Totacillin; Totacillin N; Totalcilina; Totapen; Trafarbiot; Trifacilina; Ukapen; Ultrabion; Urebion Ampicillina; Valmingina; Viacilina-A; Vidopen

The following names have been used for multi-ingredient preparations containing ampicillin, ampicillin salts and ampicillin trihydrate: Ampicin-PRB; Ampiclox; Ampicyn; Flu-Amp; Magnapen; Nuwapen Reard; Orbecilina; Penbritin KS; Pentrex-F; Polycillin-PRB; Principen with Probenecid; Pro-Biosan; Unasyn

USP anhydrous ampicillin contains 900-1050 μg/mg ampicillin (calculated as the anhydrous base), and the trihydrate contains 845-988 μg/mg. Ampicillin is available in 125-, 200-, 250- and 500-mg tablets that contain 90-120% labelled active ingredient, in 125-, 250- and 500-mg capsules containing 90-120% labelled active ingredient, and as oral suspensions of 100, 125 and 250 mg/5 ml containing 90-120% of the labelled active ingredient and probenecid. The sodium salt of ampicillin is available for injection in vials of 0.125, 0.25, 0.5, 1, 2 and 10 g.

Impurities of ampicillin that occur during preparation of the product are D-(−)-α-phenylglycine and 6-aminopenicillanic acid. It has been reported that sodium ampicillin in aqueous solution undergoes a reaction to form oligomeric products (Van der Bijl et al., 1988).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

Ampicillin is produced by the acylation of 6-aminopenicillanic acid with D-(−)-α-phenylglycine by either microbiological or chemical synthesis (Ivashkiv, 1973). It was first marketed in 1961 in the UK. It is synthesized in Austria, Brazil, Hungary, India, Italy, Japan, the Republic of Korea, Mexico, the Netherlands, Romania, Spain, Sweden, Turkey, the USA and Yugoslavia (Chemical Information Services, 1989-90).

In Sweden, ampicillin sales in 1988 were 0.05 defined daily doses per 1000 inhabitants (Apoteksbolaget, 1988, 1989). In 1988, over six million new prescriptions of ampicillin were issued in the USA (La Piana Simonsen, 1989).
Ampicillin is not known to occur naturally.

2.2 Use

Ampicillin is bactericidal and has a similar mode of action to that of benzylpenicillin, although it has a broader spectrum of activity, covering several additional gram-positive and gram-negative organisms. Ampicillin may have a synergistic action with aminoglycosides and with the β-lactamase inhibitors clavulanic acid and sulbactam (Foulds, 1986; Barnhart, 1989).

The clinical indications for ampicillin cover a variety of infections, including those of the respiratory and urinary tracts, gonorrhoea, meningitis, septicaemia and enteric infections.

Expressed in various formulations as ampicillin equivalents, the usual oral dosing is 0.25-1 g every 6 h. The disposition of ampicillin is altered in pregnancy, and therefore higher doses may be required for severe infections in pregnancy (Assael et al., 1979). Children may be given half the adult dose. The usual doses of ampicillin given by injection are 500 mg every 4 or 6 h intramuscularly (painful), by slow (5 min) intravenous injection or by intravenous infusion. Intrapleural, intraperitoneal and intrathecal injections of ampicillin are used occasionally (Reynolds, 1989).

2.3 Analysis

Ampicillin can be analysed in pharmaceutical preparations by microbiological, iodometric, colorimetric, high-performance liquid chromatographic (US Food and Drug Administration, 1988) and fluorometric assays (Barbhaiya & Turner, 1976) and by gas chromatography-mass spectrometry (Wu et al., 1977). Ampicillin can be analysed in biological fluids by high-performance liquid chromatography (Miyazaki et al., 1983; Haginaka & Wakai, 1987; Abuirjeie & Abdel-Hamid, 1988).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

Oral administration

Mouse: Groups of 50 male and 50 female B6C3F1 mice, seven to eight weeks of age, were administered ampicillin trihydrate (purity, 97%) by gavage at 0, 1500 or
AMPICILLIN

3000 mg/kg bw in corn oil on five days per week for 103 weeks. The animals were maintained for a further one to two weeks, after which time they were killed. Weight gain was similar in all groups, and no significant difference in survival was observed in mice of either sex: at the end of the study period, 32/50, 21/50 and 20/50 males in the control, low-dose and high-dose groups, respectively, and 34/50, 27/50 and 28/50 females in the control, low-dose and high-dose groups, respectively, were still alive. In female mice, a slight increase in the incidence of benign lung tumours was observed (control, 1/50; low-dose, 0/50; high-dose, 4/50; \( p = 0.049 \), incidental tumour test). No increase in the incidence of any other neoplasm was recorded (National Toxicology Program, 1987; Dunnick et al., 1989).

**Rat:** Groups of 50 male and 50 female Fischer 344/N rats, seven to eight weeks old, were administered ampicillin trihydrate (purity, 97%) by gavage at 0, 750 or 1500 mg/kg bw in corn oil on five days per week for 103 weeks. Animals were observed for a further one to two weeks, after which time they were killed. Mean body weights of treated males and females were similar to those of controls. At the end of the study, 31/50, 27/50 and 26/50 control, low-dose and high-dose males, respectively, and 32/50, 31/50 and 31/50 control, low-dose and high-dose females, respectively, were still alive. An increase in the incidence of mononuclear-cell leukaemia was observed in treated males: control, 5/50; low-dose, 14/50 (\( p = 0.019 \), life-table test); high-dose, 13/50 (\( p = 0.029 \), life-table test; \( p = 0.024 \), life-table test for trend). A dose-related increase in the incidence of combined benign and malignant phaeochromocytomas of the adrenal medulla was also observed in males: control, 13/50; low-dose, 16/50; high-dose, 23/49 (\( p = 0.007 \), incidental tumour test; \( p = 0.007 \), trend test for incidental tumours). The incidences of mammary gland fibroadenomas in females were: control, 16/50; low-dose, 25/50 (\( p = 0.019 \), incidental tumour test); high-dose, 19/50. No increase in the incidence of tumours at other sites was observed (National Toxicology Program, 1987; Dunnick et al., 1989). [The Working Group noted the high frequency of spontaneous tumours and that the increase in the incidence of mammary gland fibroadenomas was not dose-related.]

### 3.2 Other relevant data

**(a)** *Experimental systems*

**(i)** *Absorption, distribution, excretion and metabolism*

Following intraperitoneal injection to rats, ampicillin was distributed throughout the major organ systems; the serum half-life was estimated to be 27 min (Fabre, 1977). Assay of serum collected after a single subcutaneous dose of sodium ampicillin at 10 mg/kg bw to guinea-pigs yielded ampicillin levels of approximately
10 µg/ml at 5 min, which fell rapidly to less than 0.2 µg/ml at 60 min (Young et al., 1987).

(ii) Toxic effects

The intraperitoneal LD$_{50}$ for ampicillin was 3300 mg/kg bw for one-day-old rats and 4500 mg/kg bw for 83-day-old rats (Goldenthal, 1971). The oral LD$_{50}$ in rats was 10 g/kg bw and that in mice, 15.2 g/kg bw (Khosid et al., 1975). Deaths occurred in 63, 45 and 100% of rabbits that received oral doses of ampicillin at 5, 15 and 50 mg/kg bw, respectively, for three consecutive days (Milhaud et al., 1976).

Ampicillin administered as a single oral or subcutaneous dose of up to 5000 mg/kg bw had no noticeable toxic effect in mice or rats. Intravenous administration of 2000 mg/kg bw to mice caused muscle tremors, slowed respiration and mild convulsions. No biochemical, haematological or histological abnormality was seen in rats administered ampicillin at 100 or 500 mg/kg bw for 12 weeks (Brown & Acred, 1961). Administration of 25 mg/l in the drinking-water to four-week-old rats for up to eight weeks resulted in an increase in body weight gain; no toxic effect was noted (King, 1975).

Nabata et al. (1988) reported that intravenous exposures of rats to ampicillin at 1200 mg/kg bw per day for 28 days were well tolerated. Intravenous administration of sulbactam:ampicillin (1:2) at 90-1800 mg/kg bw for 28 days caused caecal enlargement; deposition of glycogen-like droplets in the liver occurred at the higher dose levels.

The toxicity of ampicillin trihydrate has been studied in Fischer 344/N rats and B6C3F1 mice (National Toxicology Program, 1987). In 14-day studies of rats and mice administered ampicillin at 200-2400 mg/kg bw by gavage, dose-related clinical signs included diarrhoea and excessive salivation in the high-dose rats immediately after dosing. Diarrhoea of minimal severity was observed in high-dose mice given 2400 mg/kg. No dose-related gross pathology or histopathology was observed in either species.

In 13-week studies, doses of 180-3000 mg/kg bw were administered by gavage on five days per week to rats and mice. All rats given 300 mg/kg bw and one of ten male mice at either 2000 mg/kg or 3000 mg/kg had diarrhoea. No compound-related pathology or histopathology was observed grossly in either species.

In the two-year studies (see section 3.1), ampicillin at doses of 750 or 1500 mg/kg bw (rats) and 1500 or 3000 mg/kg bw (mice) was administered by gavage on five days per week for 103 weeks. Clinical signs observed in treated rats included diarrhoea, excessive urination and chromodacryorrhea; those in treated mice included increased salivation and decreased activity. The incidence of C-cell hyperplasia of the thyroid gland was increased in low-dose male and high-dose female rats. High-dose male rats showed increased incidences of hyperkeratosis
and acanthosis of the forestomach. In male and female mice, an increased incidence of forestomach lesions, including ulcers, inflammation, hyperkeratosis, acanthosis and evidence of fungal infection, was observed in exposed animals.

(iii) **Effects on reproduction and prenatal toxicity**

The absence of experimental details precluded assessment of the only study of prenatal toxicity (Korzhova et al., 1981).

(iv) **Genetic and related effects**

Ampicillin induced lysogenic phage in *Staphylococcus aureus* (Manthey et al., 1975). It did not induce a SOS response in *Escherichia coli* PQ37 (Venier et al., 1989), and no differential toxicity was observed in *E. coli* in the absence (Green & Tweats, 1981) or presence of an exogenous metabolic system (Tweats et al., 1981; De Flora et al., 1984). In *Salmonella typhimurium* plate incorporation tests, ampicillin was not mutagenic in the presence or absence of an exogenous metabolic system (De Flora et al., 1984; Mortelmans et al., 1986; National Toxicology Program, 1987).

Treatment of *Vicia faba* seeds with a 0.5% solution of ampicillin led to chromosomal aberrations in root-tip meristem cells (Prasad, 1977).

Ampicillin did not induce mutation at the *tk* locus in L5178Y mouse lymphoma cells in the presence or absence of an exogenous metabolic system at concentrations up to 5000 μg/ml (National Toxicology Program, 1987). No increase in the frequency of sister chromatid exchange was observed in Chinese hamster CHO cells with concentrations of ampicillin up to 1500 μg/ml in the presence or absence of an exogenous metabolic system (National Toxicology Program, 1987). Ampicillin did not induce sister chromatid exchange in human lymphocytes *in vitro* (Jaju et al., 1984). No chromosomal aberration was observed in Chinese hamster CHO cells treated with ampicillin at 0-1500 μg/ml in the presence or absence of an exogenous metabolic system (National Toxicology Program, 1987). Ampicillin did not induce chromosomal aberrations in human fibroblasts after 50 h of treatment with a concentration of 4000 μg/ml (Byarugaba et al., 1975), but a dose of 28 μg/ml induced chromosomal aberrations in human peripheral lymphocytes *in vitro* (Jaju et al., 1984). [The Working Group noted the low concentration used in this test, as compared to those of other reports.] It was reported in an abstract that ampicillin did not induce chromosomal aberrations in human lymphocytes *in vitro* at concentrations up to 10 mg/ml (Stemp et al., 1988).

It was reported in an abstract that ampicillin at single- or double-dose oral regimens of 5 mg/kg did not induce micronuclei in rats treated *in vivo* (Stemp et al., 1988).
(b) **Humans**

(i) **Pharmacokinetics**

The pharmacokinetics of ampicillin have been reviewed (Barza & Weinstein, 1976).

Ampicillin is relatively stable in the acid contents of the stomach; anhydrous or trihydrated ampicillin is absorbed incompletely from the gut after oral administration. Peak concentrations in plasma (2-6 mg/l after an oral dose of 500 mg) occur within 1-2 h. Ester prodrugs (pivampicillin, bacampicillin) and the condensation prodrug (hetacillin) of ampicillin are absorbed more readily than ampicillin (Jusko & Lewis, 1973; Loo et al., 1974; Magni et al., 1978; Pennington & Crooks, 1983). Ampicillin at 500 mg given by intramuscular injection as the sodium salt produced plasma peaks of 7-14 mg/l within about 1 h (Doluisio et al., 1971).

Ampicillin is distributed widely, and therapeutic concentrations can be achieved in soft tissues, including ascitic, pleural and joint fluids (Lewis & Jusko, 1975). Bacampicillin produces higher tissue concentrations than ampicillin (Bronsveld et al., 1978). Only 20% of ampicillin is bound to plasma proteins (Barza & Weinstein, 1976). It crosses the placenta (Hirsch et al., 1974; Kraybill et al., 1980), and detectable concentrations of ampicillin occur in the milk of nursing mothers (Chow & Jewesson, 1985).

Ampicillin is excreted via renal glomerular and tubular routes in the urine; its plasma half-time is usually 1-2 h (Sjövall, 1985) but is longer in elderly people (Triggs et al., 1980). In patients with renal failure, the half-time was as long as 20 h (Hori et al., 1983).

Healthy subjects metabolize about 20% of a given dose (250-500 mg) of ampicillin. Within 12 h, 7% of the total dose is excreted as metabolites in urine (Cole et al., 1973; Haginaka & Wakai, 1987). Ampicillin is metabolized to 5R,6R-penicilloic acid and 5S,6R-penicilloic acid (Bird et al., 1983) and to piperazine-2,5-dione after oral intake (Haginaka & Wakai, 1987). Other, unidentified metabolites have been reported (Masada et al., 1979).

(ii) **Adverse effects**

Skin rashes (Almeyda & Levantine, 1972) are the most common side-effects of ampicillin treatment and are either urticarial or maculopapular. The allergic nature of the maculopapular rash is uncertain (Bierman et al., 1972; Campbell & Soyka, 1977; Sokoloff, 1977; van Ketel, 1984). Non-allergic fever due to ampicillin occurs rarely (Mackowiak & LeMaistre, 1987). The overall incidence of skin reactions among a group of patients who received the drug between 1975 and 1982 was 59/1775 (3.3%) (Bigby et al., 1986), although higher incidences have been reported. Unusually high incidences of skin rashes occur during treatment with
ampicillin of glandular fever and lymphatic leukaemia (Cameron & Richmond, 1971; Lambert et al., 1972).

Ampicillin commonly affects the gastrointestinal tract, at least in children (25-35%) (Feder, 1982). It has been reported to be one of the drugs most frequently associated with pseudomembranous colitis (Gorbach, 1987). Seizures have been reported after use of ampicillin in cases of underlying cerebral dysfunction (Serdaru et al., 1982) or concomitant renal insufficiency resulting in high serum concentrations of ampicillin (Hodgman et al., 1984).

(iii) Effects on reproduction and prenatal toxicity

In a study of 280,000 women belonging to a prepaid health plan in Seattle, WA (USA), all drug prescriptions and all pregnancy outcomes were monitored between July 1977 and December 1979. Among the liveborn babies of 6837 women, 80 (1.2%) had major congenital malformations. Four infants born to 309 women for whom ampicillin had been prescribed in the first trimester had major malformations [types not specified], giving a prevalence of 13 per 1000, which was not significantly different from the overall prevalence in the total population studied (12 per 1000) (Jick et al., 1981).

In a second study of the same population covering January 1980 to June 1982, 6509 women had pregnancies ending in livebirths, and 105 (1.5%) of these had major congenital malformations. Three infants born to 409 women for whom ampicillin had been prescribed in the first trimester had major malformations [types not specified], giving a prevalence of seven per 1000, compared with an overall prevalence in the entire group of 15 per 1000 (Aselton et al., 1985).

In a hospital study of Australian women, 7371 mothers had singleton pregnancies in 1978-81; 1060 of them had used amoxycillin or ampicillin [not recorded separately] at some time during pregnancy: 211 had been treated in the first trimester only and 73 in the first trimester and later. It was stated that there was no evidence of any association between use of these drugs and the incidence or type of congenital malformations, which were observed in 12 of the 284 (4.2%) exposed babies, compared with the nonexposed (297/6311, 4.7%). There was no association with use of these drugs and intrauterine growth retardation or perinatal death, but there was a significant ($p < 0.01$) difference in the rate of prematurity in the users (8.9%) compared with nonusers (6.5%), which was not due to age or differences in use of alcohol. There was also a significant ($p < 0.0001$) increase in the prevalence of low-birth-weight (<2.5 kg) babies among users (9.6%) compared with nonusers (6.6%), which was still significant ($p < 0.05$) when controlled for length of gestation (Colley et al. 1983). [The Working Group noted that the effects might have been due to underlying infection in the mothers.]
(iv) Genetic and related effects

No adequate study was available to the Working Group.

3.3 Case reports and epidemiological studies of carcinogenicity to humans

One case each of lymphoproliferative disease and Kaposi's sarcoma has been reported in association with use of ampicillin (Gordon & Luk, 1982; Brenner et al., 1984).

Ampicillin was included in a hypothesis-generating cohort study designed to screen a large number (215) of drugs for possible carcinogenicity, which covered more than 140,000 subscribers enrolled in July 1969 to August 1973 in a prepaid medical care programme in northern California (USA). Computer records of persons to whom at least one drug prescription was dispensed were linked to cancer records from hospitals and the local cancer registry. Observed numbers of cancers were compared with expected numbers, standardized for age and sex, derived from the entire cohort. Three publications have summarized the screening findings for follow-up periods of up to seven years (Friedman & Ury, 1980), nine years (Friedman & Ury, 1983) and 15 years (Selby et al., 1989). [The Working Group chose to omit mention of associations based on fewer than three cases.] Among 6706 persons who received ampicillin, an association was noted with subsequent skin cancer (four cases observed, 0.9 expected; \( p < 0.05 \)) in the seven-year report. In the 15-year report, an association was noted with lung cancer (48 cases observed, 27.3 expected; \( p < 0.002 \)). The latter association, although apparently not explained by cigarette smoking in an analysis of smoking habits carried out specifically for people taking ampicillin, was also seen for several other antibiotics. [The Working Group noted, as did the authors, that, since some 12,000 comparisons were made in this hypothesis-generating study, the associations should be verified independently. Data on duration of use were not provided.]

4. Summary of Data Reported and Evaluation

4.1 Exposure data

Ampicillin is a broad-spectrum antibiotic and has been used extensively to treat bacterial infections since 1961.

4.2 Experimental carcinogenicity data

Ampicillin was tested for carcinogenicity by oral administration in mice and rats. It increased the incidences of mononuclear-cell leukaemia and of
phaeochromocytomas of the adrenal medulla in male rats. A slight increase in the incidence of benign lung tumours was observed in female mice.

4.3 Human carcinogenicity data

In a hypothesis-generating cohort study, use of ampicillin was associated with the occurrence of lung and skin cancers, but these findings could have been due to chance.

4.4 Other relevant data

Use of ampicillin during the first trimester of pregnancy has not been associated with an increase in the incidence of major congenital malformations. Ampicillin increased the frequency of chromosomal aberrations in human lymphocytes but not in human fibroblasts in vitro. It did not induce chromosomal aberrations in Chinese hamster cells, mutations in mouse lymphoma cells or sister chromatid exchange in human lymphocytes or in Chinese hamster cells. Ampicillin induced chromosomal aberrations in Vicia faba. It was not mutagenic to Salmonella typhimurium and did not induce differential toxicity in Escherichia coli strains. (See Appendix 1.)

4.5 Evaluation

There is inadequate evidence for the carcinogenicity of ampicillin in humans. There is limited evidence for the carcinogenicity of ampicillin in experimental animals.

Overall evaluation

Ampicillin is not classifiable as to its carcinogenicity to humans (Group 3).

5. References


\footnote{For description of the italicized terms, see Preamble, pp. 26-29.}


Chemical Information Services (1989-90) Directory of World Chemical Producers, Oceanside, NY


Fabre, J. (1977) Pharmacocinetique tissulaire de la doxycycline compared à celle d'autres antibiotiques chez le rat. [Tissue pharmacokinetics of doxycycline compared to those of other antibiotics in rats (Fr.).] *Nouv. Presse méd.*, 9, 71-76


King, J. (1975) The response of growing rats to a diet supplemented with the antibiotic ampicillin. Lab. Anim., 9, 211-214


Mortelmans, K., Haworth, S.S., Lawlor, T., Speck, W., Tainer, B. & Zeiger, E. (1986) Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. Environ. Mutagenesis, 8 (Suppl. 7), 1-119

National Toxicology Program (1987) *Toxicology and Carcinogenesis Studies of Ampicillin Trihydrate (CAS No. 7177-48-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies)* (NTP Technical Report 318), Research Triangle Park, NC, pp. 17-18, 139-143


This substance was considered by previous working groups, in October 1975 and March 1987 (IARC, 1976, 1987a,b). Since that time, new data have become available, and these have been incorporated into the monograph and taken into consideration in the present evaluation.

1. Chemical and Physical Data

1.1 Synonyms

*Chem. Abstr. Services Reg. No.: 56-75-7*

*Chem. Abstr. Name:* Acetamide, 2,2-dichloro-N-[2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-[R-(R*,R*)]-

*Synonyms:* 2,2-Dichloro-N-[(αR,βR)-β-hydroxy-α-hydroxymethyl-4-nitrophene-nethyl]acetamide; D-(-)-threo-2-dichloroacetamido-1-para-nitrophenyl-1,3-propanediol; D-threo-N-dichloroacetyl-1-para-nitrophenyl-2-amino-1,3-propanediol; D-threo-(-)-2,2-dichloro-N-[β-hydroxy-α-(hydroxymethyl)-para-nitrophenethyl]acetamide; D-threo-N-(1,1'-dihydroxy-1-para-nitrophenyliso-propyl)dichloroacetamide; D-(−)-threo-para-nitrophenyl-1-dichloroacetamido-2-propanediol-(1,3)

1.2 Structural and molecular formulae and molecular weight

\[
\begin{align*}
N\text{O}_2 \\
HOC\text{H} \\
\text{HCNHCOCHCl}_2 \\
\text{CH}_2\text{OH}
\end{align*}
\]

\[
C_{11}H_{12}Cl_2N_2O_5 \quad \text{Mol. wt: 323.14}
\]
1.3 Chemical and physical properties of the pure substance

Data from Szulczewski and Eng (1975) and Al-Badr and El-Obeid (1986), unless otherwise specified.

(a) **Description:** White to greyish-white or yellowish-white fine crystalline powder or fine crystals, needles or elongated plates. Of the four possible stereoisomers, only the αR,βR (or D-threo) form is active (Anon., 1979).

(b) **Melting-point:** 149-153°C (sublimes in high vacuum)

(c) **Optical rotation:** \([\alpha]^{27}_D = + 18.6^\circ (4.86\% \text{ in ethanol})\)

(d) **Solubility:** 1:400 in water at 25°C; aqueous solutions are neutral; 1:6 in propylene glycol at 25°C; very soluble in methanol, ethanol, butanol, ethyl acetate, acetone; fairly soluble in diethyl ether (Windholz, 1983)

(e) **Spectroscopy data:** Ultraviolet, infrared, nuclear magnetic resonance and mass spectra have been reported.

(f) **Stability:** Stable in the solid state as a bulk drug and when present in solid dosage forms. Reasonable precautions taken to prevent excessive exposure to light or moisture are adequate to prevent significant decomposition over an extended period. In solution, chloramphenicol undergoes a number of degradative changes related to pH, temperature, photolysis and microbiological effects.

(g) **Reactivity:** The nitro group is readily reduced to the amine.

1.4 Technical products and impurities

**Trade names:** Ak-Chlor; Alcon Opules Chloramphenicol; Amphicol; Antibiopto; Aquamycetin; Arcomicetina; Biomicin; Bioticaps; Cafenolo; Cébénicol; Chemicetina; Chemyzin; Chlomin; Chloramex; Chloramol; Chloratets; Chlorcol; Chlorfair; Chloromycetin; Chloroptic; Chlorsig; Cloramffen; Cloramplast; Clorbiotina; Clorfenicol Wolner; Cloromicetin; Cloromisol; Cloromoin; Cloroptic; Cutispray No. 4; Doctamicina; Econochlor; Espectro Medical; Farmicetina; Fenicol; Globenicol; Hortfenicol; I-Chlor; Iprobiot; Isopto Fenicol; Kamaver; Kemicetina; Kemicetine; Kloramfenikol Minims; Labamicol; Lennacol; Leukomycin; Levomicetina; Micolorina; Micodry; Minims Chloramphenicol; Mycetin; Mychel; Nevimycin; Normofenicol; Novochlorocap; Ocu-Chlor; Oftalent; Oleomycetin; Opclor; Ophtaphénicol; Ophthochlor; Paidomicetina; Pantofenicol; Pantovernil; Paraxin; Paraxin Succinat A; Pentamycetin; Plastodermo; Quemicetina; Ranphenicol; Rivomycine; Septicol; Sificetina; Sintomicetina; Sno Phenicol; Solnicol Ercé; Solu-Paraxin; Sopamycetin; Spersanicol; Succicaf; Synthomycetine; Thilocanfol; Tifomycine; Tramina; Troymycetin; Vernacetin
Many fixed combinations also contain chloramphenicol. Chloramphenicol is often formulated as the cinnamate, palmitate (1.7 g equivalent to 1.0 g chloramphenicol) or sodium succinate salt (US Pharmacopeial Convention, 1975; Reynolds, 1989). Preparations are available as capsules (50, 100 and 250 mg; USP grade contains 90-120% of the labelled amount of active ingredient), ear drops (solution in propylene glycol), eye drops (0.5% solution or sterile, dry mixture of chloramphenicol and suitable buffers containing 90-130% of the labelled amount of chloramphenicol; US Pharmacopeial Convention, Inc., 1975) and eye ointment (1% chloramphenicol; USP grade contains 90-130% of the labelled amount of active ingredient); and as the palmitate in a suspension for oral administration (USP 5 ml, 30 mg/ml, containing 90-120% of the labelled amount of active ingredient) and the succinate in vials of 1 g for injection (USP grade containing 90-115% of the labelled amount of active ingredient).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

Chloramphenicol is an antibiotic produced by *Streptomyces venezuelae* (Ehrlich et al., 1947). The crystalline antibiotic substance was isolated by Bartz in 1948 (Goodman & Gilman, 1970), and, in 1949, its structural determination (Rebstock et al., 1949) and chemical synthesis (Controulis et al., 1949) were reported. Chloramphenicol can be synthesized by condensation of para-nitrobenzoyl chloride with ethyl malonate to give para-nitroacetophenone, followed by bromination in acetic acid to form para-nitro-α-bromoacetophenone, and reaction of this with hexamethylene tetramine, followed by hydrolysis to give para-nitro-α-aminoacetophenone; subsequent acetylation of the amine group and condensation with formaldehyde give a hydroxymethyl group alpha to the amine group. Treatment with aluminium isopropylate reduces the keto group to a secondary alcohol, and, after deacetylation, condensation of the amine group with methyl dichloroacetate gives chloramphenicol (Anon., 1969). Chemical syntheses of chloramphenicol usually include a resolution step to separate stereoisomers.

In Japan, production by a fermentation process has also been described. The process resulted from the discovery and isolation of a new strain of microbe and does not require separation of stereoisomers (Anon., 1972).

Chloramphenicol is synthesized in Brazil, China, Czechoslovakia, the Federal Republic of Germany, Hungary, Italy, India, Israel, Japan, Mexico, Romania, South Africa, Spain and the USSR and has also been produced in France, Switzerland, the UK and the USA. Commercial production of chloramphenicol in the USA was first
reported in 1948 (US Tarff Commission, 1949; Chemical Information Services, 1989-90).

In Sweden, 584 780 packages of chloramphenicol were sold in 1988 (Apoteksbolaget, 1988, 1989). In Finland, sales of chloramphenicol in 1987 were 0.01 defined daily doses per 1000 inhabitants (Finnish Committee on Drug Information and Statistics, 1988).

Chloramphenicol can be isolated from *Streptomyces venezuelae* in soil.

### 2.2 Use

Chloramphenicol is an antimicrobial agent recommended for serious infections in which the location of the infection, susceptibility of the pathogen or poor response to other therapy indicate restricted antimicrobial options. It has been used since the 1950s for a wide range of microbial infections, including typhoid fever and other forms of salmonellosis, and central nervous system, anaerobic and ocular infections (Bartlett, 1982; Sande & Mandell, 1985).

The usual dosage of chloramphenicol is 50 mg/kg daily in divided doses up to two to four weeks (Bartlett, 1982; Sande & Mandell, 1985). In certain indications, e.g. cystic fibrosis, treatment has been continued for years (Harley et al., 1970).


Chloramphenicol is believed to have been widely used as a veterinary antibiotic, despite legal controls in many countries, and there have been a few reports of residual amounts in various animal products (Allen, 1985). In countries in which its veterinary use is permitted, food regulations require withdrawal periods so as to avoid residues in the final product (FAO/WHO, 1969; FAO/WHO Expert Committee on Food Additives, 1988).

### 2.3 Analysis

Methods for the analysis of chloramphenicol have been reviewed (Wenk et al., 1984; Al-Badr & El-Obeid, 1986). The compound has been determined in serum by high-performance liquid chromatography (Ryan et al., 1984; Sood et al., 1987; Meatherall & Ford, 1988) and enzyme immunoassay (Schwartz et al., 1988).

Chloramphenicol has been analysed in pharmaceutical preparations using microbiological turbidimetric and spectrophotometric assays (US Food and Drug Administration, 1988; US Pharmacopeial Convention, Inc., 1989).

Analytical methods for chloramphenicol residues in meat, milk and eggs have been reviewed (Allen, 1985). The methods include high-performance liquid chromatography (Schmidt et al., 1985) and radioimmunoassay (Arnold et al., 1984; Arnold & Somogyi, 1985; Hock & Liemann, 1985).
3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

(a) Oral administration

Mouse: In a study reported in an abstract, groups of 50 male and 50 female BALB/c mice, six weeks of age, were administered chloramphenicol [purity unspecified] at 0, 500 or 2000 mg/l in drinking-water for 104 weeks, at which time all survivors were killed. The incidences of lymphomas in mice of each sex (combined) were 3% in controls, 6% in low-dose animals and 12% in high-dose animals ($p < 0.05$). The incidences of other types of tumour were similar in treated and control animals (Sanguineti et al., 1983). [The Working Group noted the incomplete reporting of the study.]

As reported in the same abstract, groups of 50 male and 50 female C57Bl/6N mice, six weeks of age, were administered chloramphenicol [purity unspecified] at 0, 500 or 2000 mg/l in drinking-water for 104 weeks, at which time all survivors were killed. The incidences of lymphomas in mice of each sex (combined) were 8% in controls, 22% in low-dose animals ($p < 0.05$) and 23% in high-dose animals ($p < 0.01$). The incidences of malignant liver-cell tumours in mice of each sex (combined) were: control, 0; low-dose, 2/90; and high-dose, 11/91 ($p < 0.01$) (Sanguineti et al., 1983). [The Working Group noted the incomplete reporting of the study.]

(b) Intraperitoneal administration

Mouse: Two groups of 45 male BALB/c x AF1 mice, six to eight weeks of age, received four intraperitoneal injections of 0.25 ml acetone in distilled water. After a 20-week rest period, one group received daily intraperitoneal injections of chloramphenicol [purity unspecified] at 0.25 ml (2.5 mg) in 0.9% saline solution on five days per week for five weeks. The mice were killed on day 350. Controls received injections of saline solution only. No increase in the incidence of tumours was observed (Robin et al., 1981). [The Working Group noted the short duration of treatment and observation.]

(c) Administration with known carcinogens

Mouse: Two groups of 45 male BALB/c x AF1 mice, six to eight weeks of age, received intraperitoneal injections every two weeks of four doses of 0.5 mg busulphan (1,4-butanediol dimethanesulfonate) in 0.25 ml acetone. After a 20-week rest period (on day 183 of the experiment), one group received chloramphenicol [purity unspecified] at 2.5 mg on five days per week for five weeks. On day 350 of the experiment, all surviving mice were killed. The incidence of lymphomas was 13/37
in the combined treatment group compared with 4/35 in a group treated with busulphan alone ($p = 0.02$, Fisher's exact test) (Robin et al., 1981). [The Working Group noted the short duration of the experiment.]

3.2 Other relevant data

(a) Experimental systems

(i) Absorption, distribution, excretion and metabolism

In dogs, chloramphenicol was readily absorbed after oral administration of 50 mg/kg bw, giving plasma levels of 16.5 $\mu$g/ml 2 h after dosing (Watson, 1972, 1977a). Similar findings were made in rabbits (Cid et al., 1983).

Five minutes after intravenous administration of $^{14}$C-chloramphenicol to newborn pigs at 0.52 mg/kg bw, most tissues had higher levels of $^{14}$C label than the blood; however, levels of chloramphenicol in bone marrow did not reach those noted in serum (Appelgren et al., 1982).

Chloramphenicol and its metabolites were excreted in the urine of rats after oral dosing; up to 70% of an oral dose may be excreted in this way (Glazko et al., 1949). About 0.4% of an intramuscular dose of 40 mg/kg to rats was detected in the bile within 4 h (Kunii et al., 1983). In newborn pigs, most of an intravenous dose of chloramphenicol was excreted in the urine (Appelgren et al., 1982). Following intravenous administration to goats, 69% of the dose was excreted in the urine within 12 h (Javed et al., 1984).

Chloramphenicol was detected in the milk of goats and cattle after parenteral administration (Roy et al., 1986); however, after oral administration [dose unspecified] to cattle, no chloramphenicol was detected in milk (De Corte-Baeten & Debackere, 1976).

In addition to free chloramphenicol and the glucuronide, the oxamic acid, alcohol, base, acetylatedlamine and arylamine metabolites have been found in the urine of rats given intramuscular doses of $^{3}$H-chloramphenicol (the 1R,2R-isomer). On the basis of recovered radioactivity, the major metabolites were assumed to be chloramphenicol base (~26%) and the acetylatedlamine derivative (~20%) (Bories et al., 1983).

In dogs, chloramphenicol base and chloramphenicol glucuronide conjugate were reported to be the major metabolites (Glazko et al., 1950). Chloramphenicol, the glucuronide conjugate and the oxamic acid, acetylatedlamine, arylamine and base derivatives were found in the urine of goats given intramuscular injections of chloramphenicol (Bories et al., 1983).

The glucuronide is the main metabolic product in isolated rat hepatocytes exposed to chloramphenicol (Siliciano et al., 1978). A study using perfused rat liver
and rat liver microsomes indicated that the arylamine derivative may undergo N-oxidation to form nitrosochloramphenicol (Ascherl et al., 1985).

(ii) Toxic effects

The intravenous and intraperitoneal LD₅₀s for single doses of chloramphenicol in albino mice were 200 and 1320 mg/kg bw, respectively. The intravenous LD₅₀ in rats was 170 mg/kg bw. Lethal amounts of chloramphenicol given orally or parenterally produced respiratory failure (Gruhzit et al., 1949). In rats treated with chloramphenicol at 50 and 100 mg/kg bw, the lipid content of the liver increased and the activities of aspartate and alanine aminotransferases in serum were elevated (Mandal et al., 1982).

After three groups of ten three-month-old Swiss mice were given daily intraperitoneal injections of chloramphenicol at 20, 40 or 100 mg/kg bw for three months, splenomegaly, hepatomegaly, lymph adenopathy and hypertrophy of the thymus occurred in a dose-dependent fashion (German & Loc, 1962).

Chloramphenicol caused decreased entry into S-phase in dividing bone-marrow cells of mice treated in vivo (Benes et al., 1980). The drug had a deleterious effect on bone-marrow recovery in mice after X-irradiation (Benes et al., 1980; Vacha et al., 1981) and after busulfan treatment in one study (Morley et al., 1976) but not another (Pazdernik & Corbett, 1980). Bone-marrow damage has been described in cats and dogs after 14-21 days’ treatment with chloramphenicol (Penny et al., 1967; Watson, 1977b; Watson & Middleton, 1978; Watson, 1980). Effects included vacuolation of the myeloid and erythroid precursors and bone-marrow hypoplasia in cats, and suppression of erythropoiesis and a reduced rate of granulocyte formation but not bone-marrow vacuolation in dogs.

Chloramphenicol caused dose-related inhibition of erythroid and granulocytic colony forming units obtained from LAF₁ mice (Yunis, 1977).

Chloramphenicol and nitrosochloramphenicol inhibited DNA synthesis in rat bone-marrow cells in vitro. This effect was reversible with chloramphenicol but not with the nitroso compound. Similarly, the nitroso compound but not chloramphenicol bound irreversibly to bone-marrow cells (Gross et al., 1982). In another study in vitro, chloramphenicol and nitrosochloramphenicol had no effect on mouse haematopoietic precursor cells (Pazdernik & Corbett, 1979).

Several studies have demonstrated an effect of chloramphenicol on mitochondrial protein synthesis. In vitro, chloramphenicol inhibited mitochondrial protein synthesis in rat liver and rabbit bone marrow (Summ et al., 1976; Abou-Khalil et al., 1980). Nitrosochloramphenicol inhibited rat mitochondrial DNA polymerase in vitro, whereas the arylamine derivative and chloramphenicol itself did not (Lim et al., 1984).
176

(iii) Effects on reproduction and prenatal toxicity

High oral doses of chloramphenicol of 500-2000 mg/kg to rats and mice and of 500 and 1000 mg/kg to rabbits produced high incidences of embryonic and fetal deaths and fetal growth retardation in all three species. Teratogenic effects—predominantly umbilical hernia—were observed only in rats. The pregnant animals showed no toxic sign, except that those given the highest dose gained significantly less weight than controls (Fritz & Hess, 1971).

Groups of eight pregnant albino mice were given chloramphenicol orally at 25, 50, 100, or 200 mg/kg bw in 10 ml distilled water over the third stage of pregnancy for seven days. Animals were allowed to give birth, and the young were tested for conditioned avoidance response, electroshock seizure threshold and performance in open-field tests. Dose-related effects were seen in all three elements of the test: progeny of chloramphenicol-treated dams had reduced learning ability, higher brain seizure threshold and poorer performance in the open-field test (Al-Hachim & Al-Baker, 1974).

Chloramphenicol was also investigated for its effects on avoidance learning in rats. Four groups of 15 pregnant Wistar rats each were treated as follows: chloramphenicol was given subcutaneously at 50 mg/kg bw on days 7-21 of gestation; chloramphenicol was given subcutaneously at 50 and 100 mg/kg bw to pups for the first three days after birth; and the fourth group served as controls. No adverse effect on pregnancy or postnatal weight gain was seen, but when the animals were 60 days old, they had significant impairment of avoidance learning (Bertolini & Poggioli, 1981).

(iv) Genetic and related effects

The genetic toxicology of chloramphenicol has been reviewed (Rosenkranz, 1988).

Chloramphenicol did not induce lysogenic phage in Staphylococcus aureus (Manthey et al., 1975). It did not induce differential toxicity in Escherichia coli (Slater et al., 1971; Shimizu & Rosenberg, 1973; Longnecker et al., 1974; Venturini & Monti-Bragadin, 1978; Mitchell et al., 1980; Leifer et al., 1981), Salmonella typhimurium (Nader et al., 1981; Pall & Hunter, 1985), Proteus mirabilis (Adler et al., 1976) or Bacillus subtilis (Kada et al., 1972; Suter & Jaeger, 1982), although a contradictory positive result was obtained in the rec assay with E. coli (Suter & Jaeger, 1982). Chloramphenicol gave negative results in the SOS chromotest in E. coli (Mamber et al., 1986). It induced breaks in DNA of E. coli B/r and S. typhimurium TA1976 (Jackson et al., 1977). It did not induce mutations in E. coli (Hemmerly & Demerec, 1955) and was not mutagenic in plate incorporation assays with S. typhimurium in the presence or absence of an exogenous metabolic system (Brem et al., 1974; McCann et al., 1975; Mortelmans et al., 1986).
pre-incubation assay, chloramphenicol did not induce reversions in *E. coli*; it did, however, induce forward mutations to azetidine-2-carboxylic acid resistance in the same bacterial strain. In the same assay system, chloramphenicol was weakly mutagenic to *S. typhimurium* TA98 in the presence or absence of an exogenous metabolic system (Mitchell *et al*., 1980).

Chloramphenicol induced petite mutations in haploid strains of *Saccharomyces cerevisiae* (Weislogel & Butow, 1970; Williamson *et al*., 1971) but not in diploid strains (Carnevali *et al*., 1971).


Chloramphenicol did not induce sex-linked recessive lethal mutations in *Drosophila melanogaster* treated either by injection (Clark, 1963) or by feeding (Nasrat *et al*., 1977).

It inhibited DNA synthesis in human lymphoblastoid cell lines (Yunis *et al*., 1973), in rat bone-marrow cells (Gross *et al*., 1982) and in mouse Ehrlich ascites cells (Freeman *et al*., 1977). DNA strand breaks were induced in human lymphocytes by chloramphenicol at 2.0 mM (Yunis *et al*., 1987) but not at 0.8 mM in a human lymphoblastoid cell line, in human lymphocytes or in human bone-marrow cells (Isildar *et al*., 1988). Chloramphenicol did not induce unscheduled DNA synthesis in Syrian hamster embryo cells in the presence or absence of an exogenous metabolic system (Suzuki, 1987).

The drug induced mutations at the *tk* locus of L5178Y mouse lymphoma cells in the presence and absence of an exogenous metabolic system (Mitchell *et al*., 1988; Myhr & Caspary, 1988). It induced sister chromatid exchange in Syrian hamster embryo cells (Suzuki, 1987) but not in human leukocytes (Pant *et al*., 1976). When human white blood cells were treated with low concentrations (10-40 µg/ml) of chloramphenicol, a concentration-dependent increase in the number of cells with chromosomal aberrations was observed (Mitus & Coleman, 1970). Chloramphenicol did not induce chromosomal aberrations in human lymphocytes (Jensen, 1972; Sasaki & Tonomura, 1973; Goh, 1979) or in human fibroblasts (Byarugaba *et al*., 1975).

No morphological transformation was observed in Syrian hamster embryo cells after treatment with chloramphenicol at 100-1000 µg/ml (Suzuki, 1987). Chloramphenicol did not reproducibly enhance the transformation of Syrian hamster embryo cells by simian adenovirus SA7 (Hatch *et al*., 1986).
Subcutaneous injections to C57Bl/10 mice of chloramphenicol at 320 mg/kg bw three times daily for three days led to inhibition of thymidine incorporation in bone-marrow cells (Benes et al., 1980). Intramuscular injections of chloramphenicol (three times 1000 mg/kg bw) to Wistar rats did not induce chromosomal aberrations in bone-marrow cells (Jensen, 1972). At 50 mg/kg bw, the drug induced chromosomal aberrations in bone-marrow cells of mice [site of injection and number of animals tested unspecified] (Manna & Bardhan, 1972, 1977). Intramuscular injection of chloramphenicol at 50 mg/kg to Swiss albino mice [number of animals unspecified] induced chromosomal aberrations in mitotic and meiotic germ line cells (Roy & Manna, 1981).

Chloramphenicol did not induce dominant lethal mutations in mice when given twice at up to 15 000 mg/kg intraperitoneally (Epstein & Shafner, 1968; Ehling, 1971; Epstein et al., 1972) but did when given at 500 mg/kg bw (Sram, 1972).

(b) Humans

(i) Pharmacokinetics

Chloramphenicol is readily absorbed from the gastrointestinal tract after oral administration of a crystalline powder of the active drug itself or a palmitate ester; the latter is hydrolysed in the small intestine to active chloramphenicol before absorption (Kauffman et al., 1981). Esters of chloramphenicol—for example, the succinate—are converted to chloramphenicol in vivo (Salem et al., 1981). Peak levels of 10-20 µg/ml appear 2-3 h after administration of chloramphenicol orally at 15 mg/kg bw (see Bartlett, 1982).

Chloramphenicol is also well absorbed by infants and neonates after oral administration. Serum (peak) concentrations of 20-24 µg/ml were noted after oral doses of 40 mg/kg bw to neonates. Infants given 26 mg/kg bw were found to have peak concentrations of 14 µg/ml (Mulhall et al., 1983).

Chloramphenicol is distributed extensively in humans, regardless of its route of administration. The compound has been found in heart, lung, kidney, liver, spleen, pleural fluid, seminal fluid, ascitic fluid and saliva (Gray, 1955; Ambrose, 1984). It penetrates the blood-brain barrier, and its concentrations in cerebrospinal fluid can reach about 60% of that in plasma (Friedman et al., 1979). The concentrations in brain tissue equal or even exceed those in plasma (Kramer et al., 1969). Chloramphenicol easily crosses the placenta, and it is also excreted in breast milk (Havelka et al., 1968).

Chloramphenicol has a half-time ranging from 1.6 to 4.6 h; using different techniques and in different adult patients, apparent volumes of distribution ranging from 0.2 to 3.1 l/kg have been measured (see Ambrose, 1984). The half-time is considerably longer in neonates (Rajchgot et al., 1983): in one- to eight-day-old
infants the half-life ranged from 10 to over 48 h, and in 11-day- to eight-week-old infants the range was 5-16 h (Glazer et al., 1980).

Six hours after an intravenous dose of 500 mg chloramphenicol succinate, the blood level was 4.5 μg/ml (2.8-6.9 μg/ml) in patients with chloramphenicol-induced bone-marrow depression, while in the control group the mean level was 1.2 μg/ml (0.2-3 μg/ml). Such findings suggest that patients susceptible to the effects of chloramphenicol on bone marrow may clear the drug from the blood more slowly than those who are not susceptible (Suhrland & Weisberger, 1969).

Chloramphenicol is excreted primarily in the urine (90%); up to 15% is excreted as the parent compound and the remainder as metabolites, including conjugated derivatives (Yunis, 1973; Burke et al., 1980; Ambrose, 1984). Glomerular excretion is thought to be the major mechanism of excretion (Glazko et al., 1949).

Approximately 48% of the chloramphenicol excreted in urine within 8 h of an oral dosing was the glucuronide conjugate; only 6% was excreted as the parent compound and 4% as the base derivative (Nagakawa et al., 1975; Baselt, 1982; Bories et al., 1983). The alcohol derivative has been detected in the urine of neonates (Dill et al., 1960).

Human liver microsomes have been shown to reduce the nitro group of chloramphenicol (Salem et al., 1981).

Chloramphenicol arylamide is formed by intestinal bacterial reduction of the NO₂ group to NH₂, which is acetylated and excreted in urine (Meissner & Smith, 1979). Oxamic acid (formed by oxidative dechlorination of the side chain) was identified as a major metabolite in one human volunteer (Corpet & Bories, 1987).

(ii) Adverse effects

The most important adverse effects of chloramphenicol involve the haematopoietic system (as reviewed by the FAO/WHO Expert Committee on Food Additives, 1988). Potentially fatal toxicity may develop in neonates exposed to excessive doses of chloramphenicol (Sande & Mandell, 1985). This so-called ‘grey baby syndrome’ may also occur in older children and in adults receiving doses resulting in serum concentrations of 40-200 μg/ml (see Bartlett, 1982). Other adverse effects include hypersensitivity reactions, gastrointestinal complaints and neurological complications after long-term treatment. Chloramphenicol can also precipitate haemolytic anaemia in subjects with glucose-6-phosphate dehydrogenase deficiency (Robertson et al., 1968).

Dose-dependent, reversible bone-marrow suppression affects primarily the erythroid series and occurs regularly when plasma concentrations of chloramphenicol are 25 μg/ml or higher (Scott et al., 1965; Yunis & Adamson, 1977). Another haematological side-effect is rare, unpredictable, non-dose-related
aplastic anaemia, which often appears after the drug has been discontinued (Best, 1967).

The metabolite (or metabolites) responsible for the induction of aplastic anaemia in human beings is unknown, but nitrosochloramphenicol has been implicated (Nagai & Kanamuru, 1978; Yunis, 1988); it is known to be toxic to human bone-marrow cells in vitro and, moreover, is more toxic than chloramphenicol itself (Yunis et al., 1980a,b). Metabolites of chloramphenicol, such as dehydrochloramphenicol, produced by intestinal bacteria, are more than 20-fold more cytotoxic than the parent drug (Yunis, 1988).

There have been many case reports of the occurrence of aplastic anaemia following administration of chloramphenicol by various routes (Rosenthal & Blackman, 1965; Nagao & Mauer, 1969; Carpenter, 1975; Yunis, 1978; Abrams et al., 1980; Silver & Zuckerman, 1980; Flach, 1982; Fraunfelder et al., 1982; Plaut & Best, 1982; Issaragrisil & Piankijagum, 1985; Korting & Kifle, 1985; Elberg & Hansen, 1986; von Muhlendahl, 1987). In many of these cases, large doses had been taken repeatedly over periods of many years before the onset of symptoms of aplastic anaemia. Case-control studies have also suggested an association between chloramphenicol use and aplastic anaemia (for review, see FAO/WHO Expert Committee on Food Additives, 1988). A widely discussed causal association between topical application of chloramphenicol eye-drops and aplastic anaemia (Wade, 1972; Carpenter, 1975; Fraunfelder et al., 1982) has not been established.

(iii) Effects on reproduction and prenatal toxicity

In the Collaborative Perinatal Project, in which drug intake and pregnancy outcome were studied in a series of 50 282 women in 1959-65, 98 women had been exposed to choramphenicol during the first trimester of pregnancy. There were eight malformed children in the exposed group, giving a nonsignificant standardized relative risk (RR) of 1.17. A total of 348 women had had exposure at any time during pregnancy with no evidence of an increase in the incidence of congenital malformations (Heinonen et al., 1977).

No adverse effect was reported in the children of 22 patients treated at various stages of pregnancy with chloramphenicol (Cunningham et al., 1973).

(iv) Genetic and related effects

No adequate study was available to the Working Group.

3.3 Case reports and epidemiological studies

Numerous case reports have been published of leukaemia occurring following chloramphenicol-induced aplastic anaemia (Edwards, 1969; Seaman, 1969; Goh, 1971; Cohen & Huang, 1973; Meyer & Boxer, 1973; Hellriegel & Gross, 1974; Modan et al., 1975; IARC, 1976; Ellims et al., 1979; Witschel, 1986; IARC, 1987a); three case
reports have been published of leukaemia following chloramphenicol therapy in the absence of interceding aplastic anaemia (Humphries, 1968; Popa & Iordacheanu, 1975; Aboul-Enein et al., 1977).

Shu et al. (1987) reported a case-control study of 309 childhood leukaemia cases (under 15 years) notified to a population-based cancer registry in Shanghai, China, during 1974-86, and 618 age- and sex-matched population controls. Information was obtained from parents or guardians for lifetime use of selected drugs, including prescribed chloramphenicol and syntomycin (a racemic mixture of D- and L-chloramphenicol). The risk for all types of leukaemia combined showed a marked increase with accumulated use of chloramphenicol, yielding RR of 1.7 (95% confidence interval, 1.2-2.5), 2.8 (1.5-5.1) and 9.7 (3.9-24.1) for one to five days', six to ten days' and more than ten days' treatment, respectively. The association was present in a subgroup in which first use occurred more than five years prior to diagnosis and in one in which last use had been more than two years before diagnosis. Significant trends in risk with dose were observed both for acute lymphocytic leukaemia (56% of cases) and for acute nonlymphocytic leukaemia (30%). An association with leukaemia was also seen for use of syntomycin (RR, 1.9; 1.1-3.2). [The Working Group noted that interview was undertaken up to ten years after diagnosis, which adds to the possibility of differential recall between the parents of cases and controls. Little information was available with regard to use of other antibiotics, making it difficult to evaluate the possibility of bias.]

4. Summary of Data Reported and Evaluation

4.1 Exposure data

Chloramphenicol has been used widely as an antibiotic since the 1950s. Veterinary use of chloramphenicol has resulted in the occurrence of residues in animal-derived food.

4.2 Experimental carcinogenicity data

No adequate study was available to evaluate the carcinogenicity of chloramphenicol to experimental animals.

Intraperitoneal administration of chloramphenicol to mice enhanced the incidence of lymphomas induced by 1,4-butanediol dimethanesulfonate.

4.3 Human carcinogenicity data

Many case reports have described an unusual succession of leukaemia following chloramphenicol-induced aplastic anaemia and bone-marrow
depression. Additional evidence for the association between use of chloramphenicol and leukaemia has come from a single large case-control study in China, which demonstrated a relationship with duration of exposure.

4.4 Other relevant data

Use of chloramphenicol during the first trimester of pregnancy has not been associated with an increase in the incidence of congenital malformations. Chloramphenicol caused embryo- and fetolethality in mice, rats and rabbits.

In humans, chloramphenicol causes aplastic anaemia. In both humans and animals administered chloramphenicol, reversible suppression of the bone marrow is frequent whenever the drug reaches relatively high plasma concentrations.

Chloramphenicol induced chromosomal aberrations in bone-marrow cells of mice but not of rats treated in vivo. It induced chromosomal aberrations in meiotic cells of male mice. Contradictory results were obtained in dominant lethal tests in mice. In human cells, chloramphenicol did not induce sister chromatid exchange or chromosomal aberrations but gave contradictory results for DNA damage. It induced sister chromatid exchange in Syrian hamster cells. Chloramphenicol induced gene mutations in mouse lymphoma cells but did not induce DNA damage in hamster cells. Chloramphenicol did not induce sex-linked recessive lethal mutations in Drosophila. It induced chromosomal aberrations in plants. In haploid yeast, chloramphenicol induced petite mutations. In most studies, chloramphenicol was not mutagenic to and did not cause DNA damage in Salmonella typhimurium or Escherichia coli and did not induce DNA damage in Proteus mirabilis or Bacillus subtilis. (See Appendix 1.)

4.5 Evaluation

There is limited evidence for the carcinogenicity of chloramphenicol in humans.

There is inadequate evidence for the carcinogenicity of chloramphenicol in experimental animals.

In making the overall evaluation, the Working Group also took note of the following information. Chloramphenicol induces aplastic anaemia, and this condition is related to the occurrence of leukaemia.

Overall evaluation

Chloramphenicol is probably carcinogenic to humans (Group 2A).

---

1For description of the italicized terms, see Preamble, pp. 26–29.
5. References


Apoteksbolaget (1988) *Svensk Läkemedelsstatistiek* [Swedish Drugs Statistics], Stockholm, Pharmaceutical Association of Sweden


Chemical Information Services (1989-90) Directory of World Chemical Producers, 1989/90, Oceanside, NY


Clark, A.M. (1963) The effects of chloramphenicol, streptomycin and penicillin on the induction of mutations by X-rays in Drosophila melanogaster. Z. Vererbungsl., 94, 121-125


CHLORAMPHENICOL


Müller, A.J. (1965) A survey of agents tested with regard to their ability to induce recessive lethals in *Arabidopsis*. *Arabidopsis Inf. Serv.*, 2, 22-24


Quéinnec, G., Babilé, R., Darré, R., Berland, H.M. & Espinasse, J. (1975) Induction d'anomalies chromosomiques par le furoxone ou le chloramphénicol. [Induction of chromosomal anomalies by furoxone or chloramphenicol (Fr.).] *Rev. Méd. vét.*, 126, 1611-1626


CHLORAMPHENICOL


Shimizu, M. & Rosenberg, B. (1973) A similar action to UV-irradiation and a preferential inhibition of DNA synthesis in E. coli by antitumor platinum compounds. J. Antibioto., 26, 243-245


Sram, R.J. (1972) Effect of chloramphenicol and puromycin on the dominant lethals induced by TEPA in mice. Folia biol., 18, 367-373


NITROFURAL (NITROFURAZONE)

This substance was considered by a previous Working Group, in June 1974, under the title 5-nitro-2-furaldehyde semicarbazone (IARC, 1974). Since that time, new data have become available, and these have been incorporated into the monograph and taken into consideration in the present evaluation.

1. Chemical and Physical Data

1.1 Synonyms

Chem. Abstr. Services Reg. No.: 59-87-0
Chem. Abstr. Name: Hydrazinecarboxamide, 2-[(5-nitro-2-furanyl)methylene] -
Synonyms: 2-Furancarboxaldehyde; 5-nitrofuraldehyde semicarbazide; nitrofuraldehyde semicarbazone; 5-nitro-2-furaldehyde semicarbazone; 5-nitrofuran-2-aldehyde semicarbazone; 5-nitro-2-furancarboxaldehyde semicarbazone; 5-nitro-2-furfuraldehyde semicarbazone; 5-nitrofurfural semicarbazone; 5-nitro-2-furfural semicarbazone; (5-nitro-2-furfurylideneamino)urea; 1-(5-nitro-2-furfurylidene)semicarbazide

1.2 Structural and molecular formula and molecular weight

\[
C_8H_6N_4O_4 \quad \text{Mol. wt: 198.14}
\]

1.3 Chemical and physical properties of the pure substance

From Windholz (1983) and Reynolds (1989)
(a) Description: Pale-yellow needles
(b) Melting-point: 236-240°C (decomposition)
(c) **Solubility**: Very slightly soluble (1:4200) in water at pH 6.0-6.5, soluble in alkaline solutions; slightly soluble in ethanol (1:590), propylene glycol (1:350), acetone (1:415), dimethylformamide (1:15) and polyethylene glycol (1:86); almost insoluble in chloroform (1:27000) and benzene (1:43500).

(d) **Spectroscopy data**: Infrared and ultraviolet spectra have been reported.

(e) **Stability**: Stable in solid state at less than 40°C when protected from light; darkens with prolonged exposure; discolours on contact with alkali.

### 1.4 Technical products and impurities

**Trade names**: Acutol; Aldomycin; Alfucin; Amifur; Babrocid; Becafurazona; Becafurazone; Biofuracina; Biofurea; Chemofuran; Chixin; Cocafurin; Coxistat; Dermofural; Dymazone; Eldezo F-6; Fedacin; Flavazone; Fracine; Furacillin; Furacilinum; Furacillin; Furacin; Furacin-E; Furaccine; Furacinetten; Furacin-HC; Furacoccid; Furacort; Furacycline; Furalcin; Furaldon; Furalone; Furametral; Furan-ofteno; Furaplast; Furaseptyl; Furaskin; Furazilina; Furazin; Furazina; Furazol W; Furazone; Furesol; Furfurin; Furosem; Fuvacillin; Germex; Hemofuran; Ibiofural; Mammex; Mastofuran; Monafuracin; Nefco; NF-7; NFS; Nfz mix; Nifucin; Nifurid; Nifuzon; Nitrazone; Nitreofural; Nitrofurastan; Nitrofurazan; NSC-2100; Nitrozone; Otofural; Otofurazn; Rivafurazon; Rivopon-S; Sanfuran; Spray-Dermis; Spray-foral; Vabrocid; Veterinary nitrofurazne; Yatrocin

Nitrofural has been reported to contain 3% 5-nitro-2-furaldehyde azine as an impurity (Morris et al., 1969). It is available in the USA as creams, ointments, powders, solutions, sprays, suppositories and surgical dressings (Barnhart, 1989).

### 2. Production, Occurrence, Use and Analysis

#### 2.1 Production and occurrence

The action of nitrofural as a topical antibacterial agent was first reported in the USA in 1944 (Dodd & Stillman, 1944), and the product was available for general use in 1945 (Miura & Reckendorf, 1967). Commercial production in the USA was first reported in 1955 (US Tariff Commission, 1956).

Nitrofural can be prepared by the reaction of 5-nitrofurfural with an aqueous solution of a mixture of semicarbazide hydrochloride (see IARC, 1987) and sodium acetate (Stillman & Scott, 1947). It can also be synthesized from the reaction of acetone semicarbazone or other semicarbazones with 5-nitrofurfuraldoxime (Gever & O'Keefe, 1960). It is synthesized in China, Hungary, India, Mexico and Spain (Chemical Information Services, 1989-90).
Nitrofural is not known to occur naturally.

2.2 Use

Nitrofural is a broad-spectrum bactericidal (Chamberlain, 1976). It also has antiprotozoal and antiparasitic activities (Reynolds, 1982).

Nitrofural is used locally for the treatment of wounds, burns, ulcers and skin infections; it has also been applied locally to the ear, eye and bladder. Nitrofural is used as a coccidiostatic and antibacterial agent in farm animals, administered in water or feed (Anon., 1979; Reynolds, 1989).

Oral administration has been restricted to the treatment of late-stage African trypanosomiasis that is refractory to melarsoprol. The dosage for adults is 500 mg three or four times daily for five to seven days. In addition, it has been given orally in doses of 100 mg four times daily for five to six days in the treatment of acute bacillary dysentery (Reynolds, 1982).

2.3 Analysis

Nitrofural has been analysed in pharmaceutical preparations by spectrophotometry (US Pharmacopieal Convention, Inc., 1980) and polarography (Mishra & Gode, 1985). The separation and identification of nitrofural in medicated feeds have been reviewed by Fishbein (1972). High-performance liquid chromatography methods for analysing nitrofural in medicated feeds have also been reported (Cieri, 1979; Thorpe, 1980).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

(a) Oral administration

*Mouse:* Groups of 50 male and 50 female B6C3F1 mice, seven to eight weeks of age, were administered nitrofural (99% pure) at 0, 150 or 310 mg/kg of diet for 103 weeks; all surviving animals were killed at 112 weeks. The average amount of nitrofural consumed per day was 14-16 mg/kg bw for low-dose male and female mice and 29-33 mg/kg bw for high-dose animals. Survival of high-dose males was lower than that of controls after week 88. At the end of the experiment, survival was: 39/50, 31/50 and 27/50 control, low-dose and high-dose males, and 39/50, 40/50 and 35/50 control, low-dose and high-dose females. Ovarian atrophy was found in 7/47
controls, 44/50 low-dose and 38/50 high-dose mice. Granulosa-cell tumours of the ovary developed in 4/50 low-dose and 9/50 high-dose females ($p = 0.03$, incidental tumour test for trend) compared with 1/47 controls. The incidence of benign mixed tumours of the ovary was 17/50 low-dose and 20/50 high-dose animals ($p < 0.001$, incidental tumour test for trend); no such tumour occurred among controls. No significant difference in the incidence of other types of tumour was observed among treated or control mice (National Toxicology Program, 1988; Kari et al., 1989).

**Rat:** A group of 30 female weanling Sprague-Dawley rats were administered nitrofural (pharmaceutical grade) at 1000 mg/kg of diet for 46 weeks (daily intake, 8-13 mg/rat), after which they were maintained on control diet for 20 weeks. A control group of 30 rats received control diet for 66 weeks. Of the treated females that lived 22 weeks or more, 22/29 developed mammary fibroadenomas, compared with 2/29 controls (Ertürk et al., 1970). (The Working Group noted that data on survival were not given.)

Groups of 50 male and 50 female Fischer 344/N rats, six to seven weeks of age, were administered nitrofural (99% pure) at 0, 310 or 620 mg/kg of diet for 103 weeks. The average amount of nitrofural consumed per day was 11-12 mg/kg bw for low-dose male and female rats and 24-26 mg/kg bw for high-dose animals. All surviving animals were killed at 111 weeks. Survival in high-dose males was lower than that in controls after week 92. At the end of the experiment, survival was: 33/50, 30/50 and 20/50 controls, low-dose and high-dose males, and 28/50, 37/50 and 31/50 controls, low-dose and high-dose females, respectively. Adenomas of the sebaceous glands of the skin were observed in high-dose males only (4/50 high-dose versus 0/50 control; $p = 0.067$, incidental tumour test). Mammary fibroadenomas occurred in 8/49 control, 36/50 low-dose ($p < 0.001$, incidental tumour test) and 36/50 high-dose females ($p < 0.001$, incidental tumour test; $p < 0.001$, incidental tumour test for trend); adenocarcinomas were also observed in one control and two high-dose females. Mononuclear-cell leukaemias occurred in 21/50 control males, 23/50 low-dose males and 6/50 high-dose males ($p = 0.04$, life-table test); 15/49 control females, 2/25 low-dose females ($p < 0.001$) and 2/50 high-dose females ($p < 0.001$, life-table test). Testicular interstitial-cell tumours occurred in 45/50 controls, 30/50 low-dose males ($p < 0.001$, incidental tumour test) and 28/50 high-dose males ($p < 0.001$, incidental tumour test; $p < 0.001$, incidental tumour test for trend) (National Toxicology Program, 1988; Kari et al., 1989).

**(b) Transplacental administration**

**Mouse:** A group of 20 pregnant ICR/Jcl mice, 10-12 weeks of age, received three subcutaneous injections of nitrofural [purity unspecified] at 75 μg/g bw suspended in 1% gelatin solution on days 13, 15 and 17 of gestation. Offspring were foster-nursed by untreated dams and were killed 32 weeks after birth. Treatment
with nitrofural resulted in a marked reduction in the number of live births. At 32 weeks, 67/145 treated animals and 548/844 controls were still alive. The incidence of lung tumours was not significantly increased in nitrofural-treated mice as compared with gelatin-treated controls. All tumours reported were papillary adenomas of the lung (Nomura et al., 1984). [The Working Group noted the short duration and limited reporting of the experiment; interlitter variation was not recorded.]

A group of newborn ICR/Jcl mice, exposed transplacentally as described above, received a subcutaneous injection of nitrofural [purity unspecified] at 75 μg/g bw suspended in 1% gelatin solution within 12 h of birth; three further injections were given on days 7, 14 and 21 after birth. A further group of mice received treatment with gelatin only, and another received no treatment. At 32 weeks, 61/176 treated animals and 548/844 controls were still alive. The number of tumour-bearing mice was 12/61 (19.7%; \( p < 0.001, \chi^2 \) test with Yates’ correction against gelatin controls) compared to 5/203 (2.5%) untreated controls. All tumours reported were papillary adenomas of the lung (Nomura et al., 1984). [The Working Group noted the short duration and limited reporting of the experiment; interlitter variation was not recorded.]

3.2 Other relevant data

(a) Experimental systems

(i) Absorption, distribution, excretion and metabolism

Within 24 h after a single oral administration of 100 mg/kg bw \(^{14}\)C-nitrofural to rats, about two-thirds of the radioactivity appeared in the urine, 26% in the faeces and approximately 1% in expired carbon dioxide; complete recovery of the administered dose was observed after 96 h, less than 15% of the label being recovered as unchanged parent compound (Tatsumi et al., 1971). Major metabolites of nitrofural detected and identified in the urine of dosed rats included hydroxylaminofuraldehyde semicarbazone, aminofuraldehyde semicarbazone and 4-cyano-2-oxobutyraldehyde semicarbazone (Paul et al., 1960). The reduced nitrofural metabolite, 4-cyano-2-oxobutyraldehyde semicarbazone, was detected in the urine of germ-free rats treated with the drug (Yeung et al., 1983). Binding of \(^{14}\)C label to liver protein, DNA, ribosomal RNA and kidney protein was demonstrated in rats after oral administration of \(^{14}\)C-nitrofural (Tatsumi et al., 1977).

Nitrofural is reduced by mouse liver homogenate and by several mammalian cell lines, most efficiently under gas mixtures containing 5% O\(_2\) or less (Paul et al., 1960; Olive & McCalla, 1975).
(ii) Toxic effects

Oral LD$_{50}$ values of 590 mg/kg bw in rats and 460 mg/kg bw in mice have been reported (Miyaji, 1971). Mice and rats receiving 300 mg/kg bw or more orally showed hyperirritability, tremors and seizures and died from respiratory arrest (Krantz & Evans, 1945). In mice and rats, subcutaneous injection of large doses (3 g/kg bw) produced marked changes in the structure of the liver and kidney, but only slight hepatic changes were seen after lethal oral doses (45 mg/kg bw for four to six days) (Dodd, 1946).

Toxicity was studied by feeding diets containing nitrofural (99% pure) to groups of F344/N rats and B6C3F$_1$ mice for 14 days, 13 weeks or two years. In the 14-day studies, in which the doses ranged from 630 to 10 000 mg/kg of diet, nitrofural was more toxic to mice than to rats. In the 13-week studies, doses for rats ranged from 150 to 2500 mg/kg of diet and for mice from 70 to 1250 mg/kg of diet. At the higher doses, convulsive seizures and gonadal hypoplasia were observed in both species. Evidence of toxicity in rats also included degenerative arthropathy. In the two-year studies (see section 3.1), nitrofural caused testicular degeneration (atrophy of germinal epithelium and aspermatogenesis) in rats and degeneration of vertebral and knee articular cartilage in rats of each sex. In mice of each sex, nitrofural administration induced stimulus-sensitive convulsive seizures, primarily during the first year of study (National Toxicology Program, 1988; Kari et al., 1989).

(iii) Effects on reproduction and prenatal toxicity

The gonadotoxicity of nitrofural in male mice has been recognized for more than three decades. Nissim (1957) showed that administration to mice in the diet at a dose equivalent to 375 mg/kg bw caused testicular atrophy. Similar degeneration was observed in rat testis following daily doses of 100 mg/kg bw by gastric intubation for seven days (Miyaji et al., 1964).

In male Sprague-Dawley rats given nitrofural in the diet at a dosage equivalent to 64 mg/kg bw per day for 28 days, the mean weight of the testes was only 28% that of the controls. All stages of spermatogenesis were affected, but Sertoli cells and Leydig cells were not damaged (Hagenäs et al., 1978).

After a single subcutaneous injection to ICR/Jcl mice of nitrofural at 300 mg/kg bw on day 10 of gestation, increased embryo- and fetomortality and decreased fetal weight were observed compared with controls. A significant ($p < 0.001$) increase in the incidence of malformations was observed, predominantly affecting the limbs, digits and tail. After administration of nitrofural at 100 mg/kg bw subcutaneously on days 9-11, the only significant effect observed was a reduction in fetal weight (Nomura et al., 1984).

Pregnant CD1 mice were given nitrofural in the diet at doses equivalent to 6.3-82 mg/kg bw from days 6-15 of gestation. No teratogenic effect was observed,
but there was increased fetal death and reduced fetal weight at the highest dose (National Toxicology Program, 1988).

(iv) Genetic and related effects

The genetic toxicology of nitrofurans has been reviewed (Klemencic & Wang, 1978; McCalla, 1983).


Nitrofural induced mutations in *E. coli* (Zampieri & Greenberg, 1964; McCalla & Voutsinos, 1974; Yahagi *et al*., 1974; McCalla *et al*., 1975; Tanooka, 1977; Haveland-Smith *et al*., 1979; Lu *et al*., 1979; Ebringer & Bencova, 1980; Clarke & Shankel, 1989) in the absence of an exogenous metabolic system, but not in strains lacking nitroreductase activity (McCalla & Voutsinos, 1974; McCalla *et al*., 1975). In the presence of a microsomal preparation from *Drosophila melanogaster*, nitrofural induced mutations in *E. coli* (Baars *et al*., 1980). It was not mutagenic to *S. typhimurium* strains TA1535, TA1536, TA1537 or TA1538 (Yahagi *et al*., 1974; McCalla *et al*., 1975) but induced mutations in TA1535 in a fluctuation test (Green *et al*., 1977) and in plate incorporation tests, only in the presence of an exogenous metabolic system (Zeiger *et al*., 1987; National Toxicology Program, 1988). Nitrofural induced mutations in *S. typhimurium* TA100 and in TA98 in the presence and absence of an exogenous metabolic system (Yahagi *et al*., 1976; Goodman *et al*., 1977; Green *et al*., 1977; Chin *et al*., 1978; Rosin & Stich, 1978; Bruce & Heddle, 1979; Haveland-Smith *et al*., 1979; Imamura *et al*., 1983; Obaseki-Ebor & Akerele, 1986; Ni *et al*., 1987; Zeiger *et al*., 1987; National Toxicology Program, 1988).

Nitrofural was mutagenic to *Neurospora crassa* (Ong, 1977) but not to *Aspergillus nidulans* (Bignami *et al*., 1982).

Feeding of *Drosophila melanogaster* for three days with nitrofural at 5 mM did not induce sex-linked recessive lethal mutations (Kramers, 1982).

Nitrofural inhibited DNA synthesis in mouse L-929 cells (Olive, 1979a,b). It induced DNA strand breaks in human KB, Syrian hamster BHK-21 and mouse L-929 cells (Olive & McCalla, 1975; Olive, 1978). No unscheduled DNA synthesis was induced by nitrofural in either rat or mouse primary hepatocytes (Mori *et al*., 1987) or in human fibroblasts (Tonomura & Sasaki, 1973).

Nitrofural induced mutations to 6-thioguanine resistance in Chinese hamster lung (V79) cells (Olive, 1981) but not in Chinese hamster ovary (CHO) cells.
(Anderson & Phillips, 1985), either in the presence or absence of an exogenous metabolic system. It induced mutations at the tk locus of mouse L5178Y lymphoma cells (National Toxicology Program, 1988). Nitrofural induced sister chromatid exchange in CHO cells in the presence and absence of an exogenous metabolic system (National Toxicology Program, 1988). It induced chromosomal aberrations in Chinese hamster lung cells in the presence and absence of an exogenous metabolic system (Matsuoka et al., 1979; Ishidate, 1988). In CHO cells, however, nitrofural induced chromosomal aberrations in the absence, but not in the presence, of an exogenous metabolic system (National Toxicology Program, 1988). Nitrofural did not induce chromosomal aberrations in human lymphocytes in vitro (Tonomura & Sasaki, 1973).

It was not active in micronucleus tests either in rats treated twice with 7.5-30 mg/kg bw intraperitoneally at 30 h and 6 h before they were killed (Goodman et al., 1977) or in mice treated with 150 mg/kg bw intraperitoneally on five consecutive days (Bruce & Heddle, 1979). Nitrofural did not induce chromosomal aberrations in bone-marrow cells of rats either after a single intraperitoneal injection of 60 mg/kg bw (Goodman et al., 1977) or after single oral doses of 40-400 mg/kg bw or five daily oral doses of 15-150 mg/kg bw (Anderson & Phillips, 1985).

Nitrofural did not induce sperm abnormalities in mice treated intraperitoneally with 15-150 mg/kg bw on five consecutive days (Bruce & Heddle, 1979).

(b) Humans

(i) Pharmacokinetics

Nitrofural is not significantly absorbed from skin or mucous membranes after local administration (Marion-Landais et al., 1975; Harvey, 1985).

(ii) Adverse effects

Sensitization and generalized allergic skin reactions are known adverse effects of topically administered nitrofural. In a literature review of studies published in 1945-65, 176 (1.2%) cases of skin reactions were reported among 15,162 treated patients (Glascock et al., 1969; Reynolds, 1989).

Nausea, vomiting, joint pains, headaches and polyneuritis are typical toxic effects after oral administration (Reynolds, 1989). Polyneuropathy is common among trypanosomiasis patients treated with nitrofural (Cancado et al., 1964; Robertson & Knight, 1964; Spencer et al., 1975).

Nitrofural has been reported to cause haemolytic anaemia in individuals with glucose-6-phosphate dehydrogenase deficiency (see Prankerd, 1962).

(iii) Effects on reproduction and prenatal toxicity

In the Collaborative Perinatal Project, in which drug intake and pregnancy outcome were studied in a series of 50,282 women in 1959-65, 234 women had been
exposed to nitrofural administered topically during the first trimester of pregnancy. Fifteen malformed children were born in the exposed group, giving a standardized relative risk of 0.99 (Heinonen et al., 1977).

(iv) Genetic and related effects
No data were available to the Working Group.

3.3 Case reports and epidemiological studies of carcinogenicity to humans

In a hypothesis-generating cohort study designed to screen a large number of drugs for possible carcinogenicity (described in detail in the monograph on ampicillin), 317 persons to whom at least one prescription for nitrofural had been dispensed during 1969-73 were followed up for up to 15 years (Selby et al., 1989). No statistically significant association was noted with cancer at any site or at all sites combined. [The Working Group noted that the number of users was small and therefore the power of the study to detect carcinogenic effects was probably low. Data on duration of use were not provided.]

4. Summary of Data Reported and Evaluation

4.1 Exposure data
Nitrofural is an antibacterial agent used since 1945 mainly for the local treatment of skin infections. It has been used orally in the treatment of refractory African trypanosomiasis.

4.2 Experimental carcinogenicity data
Nitrofural was tested by oral administration in one study in mice and in two studies in rats, and by transplacental administration to mice. Oral administration to mice increased the incidence of granulosa-cell and benign mixed tumours of the ovary. In rats, an increased incidence of mammary fibroadenomas was observed in females in both studies. Two studies of transplacental administration of nitrofural to mice were inadequate for evaluation.

4.3 Human carcinogenicity data
In a hypothesis-generating cohort study, use of nitrofural was not associated with an increase in cancer incidence, but the power of the study was low.

4.4 Other relevant data
One study did not provide evidence that topical use of nitrofural during pregnancy is associated with birth defects. Nitrofural is gonadotoxic in male and female mice and in male rats and is teratogenic in mice.
In humans, nitrofural is poorly absorbed from skin and mucous membranes after local administration. The drug binds to liver protein and DNA as well as to kidney protein in rats treated in vivo.

Nitrofural did not induce chromosomal aberrations in rats, micronuclei in mice or rats or sperm abnormalities in mice. It induced sister chromatid exchange in Chinese hamster cells in vitro; contradictory results were obtained on the induction of chromosomal aberrations in mammalian cells. Nitrofural induced DNA strand breaks in human, hamster and mouse cells but did not induce unscheduled DNA synthesis in human, rat or mouse cells. Both positive and negative results were obtained in gene mutation assays in rodent cells. Nitrofural did not induce sex-linked recessive lethal mutations in Drosophila. It was mutagenic to Neurospora but not to Aspergillus and induced differential toxicity in Escherichia coli and Bacillus subtilis and mutations in E. coli and Salmonella typhimurium. (See Appendix 1.)

4.5 Evaluation

There is inadequate evidence for the carcinogenicity of nitrofural in humans.

There is limited evidence for the carcinogenicity of nitrofural in experimental animals.

Overall evaluation

Nitrofural is not classifiable as to its carcinogenicity to humans (Group 3).

5. References


---

1For description of the italicized terms, see Preamble, pp. 26–29.


Chemical Information Services (1989-90) *Directory of World Chemical Producers 1989/90*, Oceanside, NY


Miyaji, T., Miyamoto, M. & Ueda, Y. (1964) Inhibition of spermatogenesis and atrophy of the testis caused by nitrofuran compounds. *Acta pathol. jap.*, 14, 261-273


National Toxicology Program (1988) *Toxicology and Carcinogenesis Studies of Nitrofurazone (CAS No. 59-87-0) in F344/N Rats and B6C3F1 Mice (Feed Studies)* (NTP Technical Report 337), Research Triangle Park, NC, pp. 18-19, 160-164


1. Chemical and Physical Data

1.1 Synonyms

Chem. Abstr. Services Reg. No.: 67-20-9; 17140-81-7 (monohydrate); 54-87-5 (sodium salt)
Chem. Abstr. Name: 2,4-Imidazolidinedione, 1-\{[(5-nitro-2-furanyl)methylene]amino}\-
Synonyms: 1-[(5-Nitrofurfurylidene)amino]imidazolidine-2,4-dione; 1-[(5-
nitrofurfurylidene)amino]hydantoin

1.2 Structural and molecular formulae and molecular weight

\[ \text{C}_8\text{H}_6\text{N}_4\text{O}_5 \quad \text{Mol. wt: 238.16} \]

1.3 Chemical and physical properties of the pure substance

From Cadwallader and Jun (1976) and Windholz (1983)
(a) Description: Pale orange-yellow needles from dilute acetic acid
(b) Melting-point: 270-272°C (decomposes)
(c) Solubility: Solubilities of nitrofurantoin in many aqueous media and organic solvents have been reported.
(d) Spectroscopy data: Ultraviolet, infrared and nuclear magnetic resonance spectra have been reported.
(e) Stability: Tablets and suspension stable for five years at room temperature in regular glass containers; crystals and solutions discoloured by alkali and by exposure to light
1.4 Technical products and impurities

Trade names: Berkfurin; Chemiofuran; Chemiofurin; Cistofuran; Cyantin; Cystit; Dantafur; Fua-Med; Furadantin; Furadantina; Furadantine; Furadöine; Furadonine; Furandoninium; Furalan; Furantoin; Furantonia; Furatin; Furedan; Furil; Furobactina; Furophen; Gurachel; Ituran; Ivadantin; Microdoin; Micturol Simple; Nephronex; Nierofu; Nifuran; Nitrex; Nitrofor-50; Nitrofor-100; Nitrofurantoinum; Nitrofurin; Novofuran; N-Toin; Orafuran; Parfuran; Phenurin; Sarodant; Trantoin; Trocurine; Uranto; Urefuran; Uretoin; Uriston; Urizept; Urodil; Urodin; Urolisa; Urolong; Urosagen; UroTablinen; Urotoin; Uvamine; Welfurin; Zofurin

Macrocrystalline products: Furadantin MC; Macrodantin; Uvamin retard

Nitrofurantoin is available as tablets (50 mg and 100 mg) and as a suspension (Barnhart, 1989; Reynolds, 1989). Impurities in the tablets include calcium pyrophosphate, magnesium stearate, starch and sucrose; and those in the suspension include carboxymethyl cellulose, sodium citric acid, glycerine, magnesium aluminium silicate, methylparaben, propylparaben, saccharin (see IARC, 1987a), sodium citrate and sorbitol. Nitrofurantoin is available from at least one manufacturer in macrocrystalline form (Cunha, 1988).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

Nitrofurantoin can be prepared from 1-aminohydantoin sulfate or hydrochloride and 5-nitro-2-furaldehyde diacetate in isopropyl alcohol (sec IARC, 1987b) media (Cadwallader & Jun, 1976). It is synthesized in China, India, Italy, the Netherlands and Spain (Chemical Information Services, 1989-90). In Sweden, sales of nitrofurantoin in 1988 were 0.09 defined daily doses per 1000 inhabitants (Apoteksbolaget, 1988, 1989).

Nitrofurantoin is not known to occur naturally.

2.2 Use

Nitrofurantoin is used extensively in the treatment and prophylaxis of uncomplicated lower urinary-tract infections. The usual oral dose for adults is 50-100 mg four times daily, with meals and at bedtime. Treatment is usually continued for 14 days. The daily dose for children is 5-7 mg/kg given in four divided
oral doses. The dosage is reduced if continued beyond 14 days or if used for prophylaxis (Reynolds, 1989). In long-term treatment, a dose as low as 1 mg/kg may be used (Lohr et al., 1977). A single dose of 50-100 mg at bedtime may be sufficient to prevent recurrences (Stamey et al., 1977).

2.3 Analysis

Analytical methods have been described for nitrofurantoin in pharmaceutical formulations using thin-layer chromatography (Cadwallader & Jun, 1976), high-performance liquid chromatography (US Pharmacopeial Convention, Inc., 1989), polarography (Surmann & Aswakun, 1985; Morales et al., 1987) and electrochemical methods (Fogg & Ghawji, 1988). Methods for analysing the compound in plasma and urine include high-performance liquid chromatography (Vree et al., 1979), polarography (Morales et al., 1987) and electrochemical analysis (Mason & Sandmann, 1976).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

(a) Oral administration

Mouse: Groups of 52-53 male and 54 female (C57Bl/6N x DBA/2N)F1 (BDF1) mice, nine weeks of age, were administered nitrofurantoin [purity and crystalline form unspecified] at 0, 750 or 3000 mg/kg of diet for 104 weeks, when the experiment was terminated. At that time, survival in males and females combined was 50.5%, 42.5% and 46.2% in control, low-dose and high-dose groups, respectively. Administration of the high dose significantly lowered body weights in mice of each sex in comparison with controls. In males, a reduced incidence of hepatic adenomas was observed: 6/53 controls, 1/52 low-dose and 0/52 high-dose mice (p = 0.014, Fisher’s exact test). No increase in the incidence of tumours at any site was observed (Ito et al., 1983).

Groups of 50 male and 50 female Swiss (Crl:CDR-1(ICR)BR) mice, about 50 days of age, received nitrofurantoin (pharmaceutical grade macrocrystals) at 0, 50, 100 or 200 mg/kg of diet for 22 months. Increased mortality was observed in males treated with the high-dose. In males, the incidences of malignant lymphomas at all sites were: controls, 2/50; low-dose, 6/50; mid-dose, 4/49; and high-dose, 10/50 [p = 0.014, Fisher’s exact test; p = 0.012, Cochran-Armitage trend test] (Butler et al., 1990).
Groups of 50 male and 50 female B6C3F1 mice, eight to nine weeks of age, were fed nitrofurantoin (pharmaceutical grade) at 0, 1300 or 2500 mg/kg of diet for 103 weeks. Survival at termination of the experiment was reduced in control females: controls, 19/50; low-dose, 37/50; and high-dose, 37/50. Mean body weights of male and female high-dose mice were 12% lower than those of controls. In females, ovarian atrophy was seen in 0/50 control, 48/50 low-dose and 49/50 high-dose animals. Controls had ovarian abscesses (18/50) and suppurative inflammation of the uterus (11/50). There was no significant increase in the incidence of any individual type of tumour; however, when tubular adenomas and benign mixed tumours of the ovary are combined, the incidence is significant: 0/50 controls, 0/50 low-dose and 9/50 high-dose (p = 0.01, incidental tumour test) (National Toxicology Program, 1989). [The Working Group noted the poor survival and the high incidence of ovarian abscesses in the controls.]

In a study of ovarian atrophy, three groups of female B6C3F1 mice, five to six weeks of age, were given nitrofurantoin (pharmaceutical grade) at 0, 350 or 500 mg/kg bw daily in the diet for 64 weeks. Intermittent sacrifices were made at 4, 8, 13, 17 and 47 weeks; the numbers of mice still alive at 65 weeks were 20 controls, 19 low-dose and 18 high-dose animals. Treated animals gained significantly less weight than the controls. There was no increase in the incidence of neoplasms of the reproductive system [the only tissues reported]. By week 43, there was evidence of ovarian atrophy in treated females; by the end of the study, the incidences were: control, 0/20; low-dose, 18/19; and high-dose, 18/18 (Stitzel et al., 1989). [The Working Group noted the short duration of the study and the small number of animals used.]

**Rat:** A group of weanling female Sprague-Dawley rats (36 animals alive at ten weeks), weighing 40-72 g, was administered nitrofurantoin ("pure"; identity and purity checked by infrared and ultraviolet absorption spectrophotometry, melting-point and paper chromatography) at 1870 mg/kg of diet for 16 weeks, after which time the dose was reduced to 1000 mg/kg of diet in weeks 16-75 due to impaired growth and premature mortality. The experiment was terminated at week 80. A group of untreated rats served as controls (30 alive at ten weeks). No increase in tumour incidence was observed (Cohen et al., 1973). [The Working Group noted the short duration of the experiment and the small number of effective animals.]

Two groups of 11-12 weanling, germ-free female Sprague-Dawley rats, weighing 85-100 g, were fed nitrofurantoin (extracted from pharmaceutical grade, macrocrystalline nitrofurantoin) at 0 or 1880 mg/kg of diet for 104 weeks. The growth rate in treated rats was slightly retarded as compared with that in controls. The median survival time was 96 weeks for controls and 90 weeks for treated animals. The incidences of mammary fibroadenomas were 2/11 controls and 9/12 treated rats (p < 0.01, Fisher's exact test). No increase in the incidence of tumours
at other sites was observed (Wang et al., 1984). [The Working Group noted the small number of animals used.]

Groups of 50 male and 50 female Fischer 344 rats, six to seven weeks of age, were given nitrofurantoin (pharmaceutical grade) at 0, 600 or 1300 mg/kg bw (females) and 0, 1300 or 2500 mg/kg (males) of diet for 103 weeks. Mean body weights were similar in control and treated animals. Survival at termination of the experiment was: males—control, 24/50; low-dose, 27/50; and high-dose, 26/50; females—control, 25/50; low-dose, 26/50; and high-dose, 31/50. Chronic tubular nephropathy was observed in all treated rats. In males, the incidence of mainly microscopic renal tubular adenomas was 3/50 controls, 11/50 low-dose [p = 0.02, Fisher’s exact test] and 19/50 [p < 0.001; Fisher’s exact test] high-dose animals [p < 0.001, Cochran-Armitage test for trend]. Renal tubular carcinomas were seen in two high-dose males. Osteosarcomas were seen in one low-dose and two high-dose males. Reductions in the incidences of a number of neoplasias were observed in males: preputial gland adenomas—control, 6/48; low-dose, 5/50; and high-dose, 0/47 (p = 0.018, incidental tumour test); preputial gland carcinomas—control, 6/48; low-dose, 6/50; and high-dose, 0/47 (p = 0.028, incidental tumour test); and interstitial-cell adenomas of the testis—control, 47/50; low-dose, 45/50; and high-dose, 21/50 (p < 0.001, incidental tumour test). No change in tumour incidence was observed in females (National Toxicology Program, 1989). [The Working Group was not convinced of the neoplastic nature of the microscopic kidney lesions.]

(b) Transplacental administration

Mouse: A group of 10 pregnant ICR/Jcl mice, 10-12 weeks of age, received three subcutaneous injections of nitrofurantoin [purity unspecified] at 75 μg/g bw suspended in a 1% gelatin solution on days 13, 15 and 17 of gestation. Groups of 22 gelatin-treated and 76 untreated dams served as controls. Offspring were foster-nursed by untreated dams and were sacrificed 32 weeks after birth. Survival was comparable in treated and untreated mice at 32 weeks. The incidence of papillary adenomas of the lung in the offspring of nitrofurantoin-treated dams was 10/78, that in gelatine controls, 5/203, and that in untreated controls, 29/478 (Nomura et al., 1984). [The Working Group noted that the distribution of tumours among litters was not given, that the sex of the offspring was not given and that the experiment was short.]

3.2 Other relevant data

(a) Experimental systems

(i) Absorption, distribution, excretion and metabolism

The pharmacokinetics of nitrofurantoin have been reviewed (Conklin, 1978).
After oral or parenteral administration, nitrofurantoin is rapidly absorbed and is excreted primarily unchanged in the urine and bile of rats (Paul et al., 1960; Buzard et al., 1961; Veronese et al., 1974; Wierzba et al., 1982) and mice (Maiti & Banerjee, 1978). After intravenous administration of nitrofurantoin to dogs at 1.5-24 mg/kg bw, up to 23% was recovered from the bile, while urinary excretion accounted for up to 36% (Conklin & Wagner, 1971). In male Sprague-Dawley rats, 16-30% of a total dose of nitrofurantoin was recovered in the urine (Olivard et al., 1976). After a single administration of nitrofurantoin at 25 mg/kg bw by gavage to female albino rats, 52% and 2.0% of the total dose were recovered in the urine and faeces, respectively (Paul et al., 1960). Excretion of nitrofurantoin in the urine of rats has been reported to be age-dependent (Braunlich et al., 1978; Wierzba et al., 1982).

Intravenous administration of nitrofurantoin at 1.5-24 mg/kg bw to adult male beagle dogs weighing 10-16 kg stimulated bile excretion, and nitrofurantoin was found in bile (at 6 mg/kg bw, 22.6 ± 4.7% total dose) and urine (24.1 ± 4.7%) (Conklin & Wagner, 1971). Nitrofurantoin is excreted in bile, reabsorbed and recirculated enterohepatically (Conklin et al., 1973). After intravenous administration of nitrofurantoin to rats, the plasma half-time was 25 min, and 50% was recovered in the urine as unchanged compound (Buzard et al., 1961). The small intestine was considered to be the main site of absorption (Maiti & Banerjee, 1978).

4-Hydroxyfurantoin has been isolated from the urine of rats treated with nitrofurantoin (Olivard et al., 1976; Streeter et al., 1988). Reductive metabolism of nitrofurantoin under anaerobic conditions has been described in both rodent tissue and bacteria. In the absence of oxygen, nitrofurantoin appears to be reduced irreversibly via nitroso and/or hydroxylamine forms (Mason & Holtzman, 1975a; Biaglow et al., 1977; Leskovac & Popovic, 1980).

Under aerobic conditions in vitro, reduction of nitrofurantoin stimulates consumption of oxygen and production of superoxide anion, free radicals and hydrogen peroxide in avian liver and in mammalian liver, lung, small intestine, kidney and gastrointestinal contents (Mason & Holtzman, 1975b; Biaglow et al., 1977; Aufrere et al., 1978; Sasame & Boyd, 1979; Leskovac & Popovic, 1980; Peterson et al., 1982).

Under anaerobic conditions, microsomal and soluble fractions from rat lung and liver mediated the covalent binding of 14C-nitrofurantoin-derived radioactivity to macromolecules. Covalent binding of 14C-nitrofurantoin activity was greatest in the kidney, liver, ileum, lung and heart of rats (Boyd et al., 1979).

(ii) Toxic effects

The LD₅₀ of nitrofurantoin in mice was 150 mg/kg bw by intraperitoneal injection and 306 mg/kg bw by gavage (Åkerblom & Campbell, 1973).
Subcutaneous administration of nitrofurantoin to male rats caused severe pulmonary damage characterized by oedema, congestion and haemorrhage (Boyd et al., 1979). Male and female rats administered nitrofurantoin orally at 20, 50 or 100 mg/kg bw twice a day were reported to develop structural and functional changes in the sciatic nerve (Behar et al., 1965).

When nitrofurantoin was administered to female mice in the diet at 350 and 500 mg/kg bw and animals were examined after 4-64 weeks of treatment, a dose-related effect on body weight gain was seen as well as a reduction in uterus:brain and ovary:brain weight ratios. Histological examination revealed a dose-related decrease in the occurrence of old corpora lutea and an increase in the occurrence of intermediate and atretic follicles. The effects were more pronounced with higher dose and longer treatments. Oestrous cycles were lengthened in a dose-dependent fashion. Ovaries were atrophic and non-functioning at 43 weeks (Stitzel et al., 1989).

In a 90-day toxicity study involving the administration of nitrofurantoin in the diets of rats and mice, necrosis of ovarian follicular epithelial cells was the principal pathological finding (Maronpot, 1987).

Four of five male and four of five female mice fed nitrofurantoin at 10 000 mg/kg of diet died within 14 days. No rats receiving up to 20 000 mg/kg of diet for 14 days died; treatment-related signs included inactivity, rough coats, sunken eyes, bright yellow urine and/or yellow fur. Feeding of nitrofurantoin at 10 000 mg/kg of diet to female rats for 13 weeks caused normal-to-mild necrosis of ovarian follicles; the effect was seen in a smaller proportion of animals receiving lower doses. Minimal-to-mild degeneration of the germinal epithelium of the testis was observed in male mice fed nitrofurantoin at up to 5000 mg/kg of diet for 13 weeks. Similar treatment of male mice caused minimal-to-mild necrosis of the kidney epithelium (National Toxicology Program, 1989).

In two-year studies (see section 3.1), ovarian atrophy was observed in low- and high-dose female mice, and testicular aspermatogenesis, degeneration of the germinal epithelium and atypical cells and depletion of the epididymis were observed at increased incidences in high-dose male mice. Spindle-cell hyperplasia of the adrenal cortex occurred in treated female mice, and mineralization of the renal medulla and dilatation of the renal tubules were observed in high-dose mice. Ovarian abscesses were observed in control but not in treated mice. In the two-year study in rats, fibrous osteodystrophy and mineralization of the glandular stomach occurred in treated animals. Atypical cells of the epididymis and degeneration of the testis were observed in high-dose animals; and fibrinoid necrosis of arterioles and perivascular infiltration of mononuclear cells were observed in the testis (National Toxicology Program, 1989).
(iii) **Effects on reproduction and prenatal toxicity**

Nitrofurantoin has similar toxic effects on the testis as other nitrofurans (Cohen, 1978). Rats treated with nitrofurantoin at 10 or 85 mg/kg bw by gastric intubation daily for one month showed depression of spermatogenesis, mainly at the stage of primary spermatocytes; some effect on spermatogonia was also observed. Partial regeneration had occurred by 48 days after cessation of treatment. The gonadotoxic effects could be prevented by simultaneous administration of ‘cystine’ (Yunda et al., 1974). [The Working Group assumed that cysteine was meant.]

Testicular and ovarian degeneration was observed in F344/N rats given nitrofurantoin in the diet at a dose equivalent to 110 mg/kg bw (males) and 60 mg/kg bw (females) for 13 weeks. Testicular degeneration was observed in B6C3F1 mice given nitrofurantoin in the diet at a dose equivalent to 285 mg/kg bw for 13 weeks (National Toxicology Program, 1989).

In routine safety evaluations of nitrofurantoin macrocrystals, including studies of fertility and perinatal-postnatal effects in rats and teratogenicity in rats and rabbits, no adverse effect was observed with daily doses of 10, 20 and 30 mg/kg bw administered orally. In the fertility test, however, male rats were treated with only 10 mg/kg bw; at this dose, no adverse effect on fertility or testicular histology was observed (Pryherch et al., 1984).

After subcutaneous injection of nitrofurantoin to ICR/Jcl mice at 100 or 250 mg/kg bw on days 9-11 of gestation, no increase in embryo- or fetomortality was observed, but a decrease in fetal weight occurred in the high-dose group only. A significant ($p < 0.001$) increase in the incidence of malformations (cleft palate and syndactyly) was observed in the high-dose group only (Nomura et al., 1984).

(iv) **Genetic and related effects**

The mutagenicity of nitrofurans has been reviewed (Klemencic & Wang, 1978; McCalla, 1983).

Nitrofurantoin inhibited DNA synthesis in *Escherichia coli* (Lu & McCalla, 1978). It induced DNA single-strand breaks in a nitroreductase-proficient but not in a nitroreductase-deficient strain of *E. coli* (McCalla et al., 1971). It induced differential toxicity in *E. coli*, *Salmonella typhimurium* and *Bacillus subtilis* in the presence and absence of an exogenous metabolic system (McCalla & Voutsinos, 1974; Yahagi et al., 1974; Ebringer & Bencova, 1980; McCarroll et al., 1981a,b; Suter & Jaeger, 1982; De Flora et al., 1984).

Nitrofurantoin was weakly mutagenic to *E. coli* in the presence and absence of an exogenous metabolic system (McCalla & Voutsinos, 1974; Yahagi et al., 1974; Setnikar et al., 1976; Lu et al., 1979; Ebringer & Bencova, 1980; Obaseiki-Ebor & Akerele, 1986). It was mutagenic to *S. typhimurium* TA100 and TA98, in the

Urine of rats fed a diet containing 0.5% nitrofurantoin was mutagenic to S. typhimurium (Wang & Lee, 1976).

The urine of rats treated orally with nitrofurantoin at 500 or 1000 mg/kg bw induced mitotic gene conversion in S. cerevisiae D4-RDII (Siebert et al., 1979). In a host-mediated assay with mice treated orally with nitrofurantoin at 0.3 mM/kg [72 mg/kg], no increase in the frequency of gene conversion was found in S. cerevisiae D4 (Setnikar et al., 1976). Oral treatment of rats with nitrofurantoin at 500 mg/kg bw led to an increase in the frequency of gene conversion in S. cerevisiae D4-RDII (Siebert et al., 1979).

Nitrofurantoin did not induce gene conversion in Saccharomyces cerevisiae D4 (Setnikar et al., 1976). In strains D4-RDII and D7, it induced mitotic gene conversion (Siebert et al., 1979; Callen, 1981). It induced non-disjunction and mitotic crossing-over in spot tests with diploid strains of Aspergillus nidulans (Bignami et al., 1974).

Nitrofurantoin fed or injected to adult Drosophila melanogaster gave ambiguous results in the sex-linked recessive lethal test (Kramers, 1982; Zimmering et al., 1985). It gave positive results in the wing spot test in Drosophila, producing large single spots (Graf et al., 1989).

Nitrofurantoin inhibited DNA synthesis in mouse L-929 cells (Olive, 1979) and in diploid human fibroblasts (Hirsch-Kauffmann et al., 1978). In Chinese hamster ovary (CHO K1-BH4 and CHO UV-5) cells, it induced mutations to 6-thioguanine resistance in the presence, but not in the absence, of an exogenous metabolic system (Gao et al., 1989). Nitrofurantoin induced DNA strand breaks in mouse L cells (Olive & McCalla, 1977), in purified rat liver nuclei and in the human cell line HuF22 (Parodi et al., 1983). It did not induce unscheduled DNA synthesis in human fibroblasts (Tonomura & Sasaki, 1973) or in rat primary hepatocytes (Williams et al., 1989).

Nitrofurantoin induced sister chromatid exchange in Chinese hamster CHO cells (Shirai & Wang, 1980) but not in the human fibroblastic cell line HE 2144 (Sasaki et al., 1980). It did not induce chromosomal aberrations in human lymphocytes in vitro (Tonomura & Sasaki, 1973) or in the human cell line HE 2144
(Sasaki et al., 1980). It induced chromosomal aberrations in Chinese hamster lung (CHL) cells (Ishidate, 1988).

Intraperitoneal injection of nitrofurantoin at up to 112 mg/kg bw induced DNA strand breaks in liver (Russo et al., 1982), kidney, lung and spleen cells of rats and in mouse bone-marrow cells (Parodi et al., 1983). Intraperitoneal treatment at up to 64 mg/kg bw induced sister chromatid exchange in mouse bone-marrow cells in vivo (Parodi et al., 1983).

Nitrofurantoin at 80 mg/kg bw intraperitoneally gave negative results in the mouse spot test (Gocke et al., 1983) and, at up to 200 mg/kg intraperitoneally or 400 mg/kg orally, in the rat micronucleus test (Setnikar et al., 1976; Goodman et al., 1977). At five daily intraperitoneal doses of 8 or 40 mg/kg bw, nitrofurantoin did not induce chromosomal aberrations in spermatocytes of mice (Fonatsch, 1977). It also gave negative results in the dominant lethal test in mice after intraperitoneal administration of 16 and 80 mg/kg bw (Epstein et al., 1972) and equivocal results after five daily oral doses of 17.5 mg/kg bw (Setnikar et al., 1976).

(b) Humans

(i) Pharmacokinetics

Nitrofurantoin is readily absorbed from the gastrointestinal tract (Reynolds, 1989). The macrocrystalline form is dissolved and absorbed more slowly and produces lower serum concentrations than the microcrystalline form, and peak concentrations in the urine are achieved more slowly (Cunha, 1988; Reynolds, 1989).

After oral administration of nitrofurantoin at 50 mg to six healthy men, the bioavailability was 94 ± 13% on a full stomach and 87 ± 13% on a fasting stomach (Hoener & Patterson, 1981). About 60% of the nitrofurantoin was bound to plasma proteins. After a 45-min intravenous infusion, the plasma distribution followed an open two-compartment model, with a terminal half-time of approximately 1 h. After oral and intravenous infusion, 34 and 47% of the dose was excreted unchanged in the urine, respectively, and 1.2-1.4% was recovered as the reduced metabolite aminofurantoin.

Nitrofurantoin is reduced to aminofurantoin, thus following pathways similar to those known for other nitrofurans (Hoener & Patterson, 1981). Hydroxylation of the furan ring of nitrofurantoin has also been shown (Olivard et al., 1976).

Recovery of the drug in the urine is related linearly to creatinine clearance (Sachs et al., 1968).

After parenteral administration, nitrofurantoin crosses the human placenta (Perry & Leblanc, 1967; Kobyletzki, 1968).
(ii) Adverse effects

In a study of 757 courses of nitrofurantoin in hospitalized patients, the overall frequency of adverse reactions was 9.2%. Toxic reactions constituted 5.1% of adverse effects; the remainder were allergic (Koch-Weser et al., 1971).

The most common gastrointestinal side-effects of nitrofurantoin are nausea, vomiting and anorexia. These symptoms usually occur during the first week of treatment and are dose-related. Abdominal pain, gastrointestinal bleeding and diarrhoea occur less frequently and without a clear dose-response (Koch-Weser et al., 1971; Gleckman et al., 1979).

Pulmonary infiltration may be caused by sensitivity to nitrofurantoin (Israel & Diamond, 1962). Acute pulmonary sensitivity reactions are manifested by fever, chills, cough, dyspnoea, and possible bronchospasm and chest pain associated with eosinophilia (Glueck & Janower, 1969). Subacute pulmonary reactions have been considered to be a separate syndrome (Gleckman et al., 1979; D'Arcy, 1985), developing after one month of treatment with nitrofurantoin, and are characterized by persistent and progressive cough, dyspnoea and fever, together with interstitial pneumonitis (Sollaccio et al., 1966; Sovijärvi et al., 1977). The chronic nitrofurantoin pulmonary reaction is characterized histologically by nonspecific, diffuse interstitial pneumonitis and fibrosis (Rosenow et al., 1968; Ruikka et al., 1971; Castleman, 1974; Holmberg et al., 1980).

Nitrofurantoin has been associated with adverse effects on the liver, including acute hepatocellular and cholestatic injury (Goldstein et al., 1974), as well as rare cases resembling chronic active hepatitis (Klemola et al., 1975; Black et al., 1980; Sharp et al., 1980).

Peripheral polyneuropathy is the most common neurological side-effect, although dizziness, vertigo, diplopia and cerebellar disturbance have also been reported (Graebner et al., 1973).

Haemolytic anaemia is a well-documented complication of nitrofurantoin therapy in patients with glucose-6-phosphate dehydrogenase deficiency (Swanson & Cook, 1977). Haemolysis has also been reported in patients deficient in enolase and glutathione peroxidases (Steinberg et al., 1970; Stefanini, 1972). In addition, there have been case reports of megaloblastic anaemia (Bass, 1963), agranulocytosis (Palva & Lehmola, 1973; Böttiger & Westerholm, 1977) and aplastic anaemia (Böttiger & Westerholm, 1977).

(iii) Effects on reproduction and prenatal toxicity

In the Collaborative Perinatal Project, in which drug intake and pregnancy outcome were studied in a series of 50,282 women in 1959-65, 83 women had been exposed to nitrofurantoin during the first trimester of pregnancy. Six malformed
children were born in the exposed group, giving a standardized nonsignificant relative risk of 1.07 (Heinonen et al. 1977).

Hailey et al. (1983) reported on the use of nitrofurantoin during 91 pregnancies in 81 women in one practice in 1972-80. In 36% of women, treatment was given during the first trimester. In the 91 pregnancies, one fetal death and two malformed babies (all with exposure during the second or third trimester) were observed. There was no significant difference in the incidence of mortality, malformation, prematurity or low birth weight compared with the general population.

In a brief review of the management of urinary-tract infections in pregnancy, it was stated that, in over 5000 pregnancies treated with nitrofurantoin macrocrystals at 100 mg daily for ten days, the treatment did not produce adverse fetal or neonatal effects and there was no recorded case of neonatal haemolytic anaemia (Whalley, 1985).

(iv) Genetic and related effects

Urine of 12 patients was collected before and after treatment with nitrofurantoin at 100 mg. Increased mutagenic activity in S. typhimurium TA100 was found in samples taken after treatment (Wang et al., 1977).

3.3 Case reports and epidemiological studies of carcinogenicity to humans

A single case report has been published of focal nodular hyperplasia of the liver in association with nitrofurantoin treatment in a six-year-old girl who had been treated for seven months (Anttinen et al., 1982).

In a hypothesis-generating cohort study designed to screen a large number of drugs for possible carcinogenicity (described in detail in the monograph on ampicillin), 1305 persons to whom at least one prescription for nitrofurantoin had been dispensed during 1969-73 were followed for up to 15 years (Selby et al., 1989). Increased risks were noted for cancer of the uterine corpus (six cases observed, 2.1 expected; \( p < 0.05 \)) and for cancer of other female genital organs (three cases observed, 0.3 expected; \( p < 0.05 \)) during follow-up of up to nine years (Friedman & Ury, 1980, 1983), and for cancers of the nervous system [other than brain] (three cases observed, 0.6 expected; \( p < 0.05 \)) during follow-up of up to 15 years (Selby et al., 1989). [The Working Group noted, as did the authors, that, since some 12 000 comparisons were made in this study, the associations should be verified independently. Data on duration of use were not provided.]
4. Summary of Data Reported and Evaluation

4.1 Exposure data

Nitrofurantoin has been used since 1972 in the treatment of urinary-tract infections.

4.2 Experimental carcinogenicity data

Nitrofurantoin was tested by oral administration to mice in four studies and to rats in three studies and by transplacental administration to mice in one study. Two of the studies in mice, including the transplacental study, were inadequate for evaluation. In one study in mice, an increase in the incidence of ovarian tubular adenomas and benign mixed tumours was observed. In two studies in other strains of mice, no such increase was observed, although in one study there was an increase in the incidence of malignant lymphomas in males. One study in rats was inadequate for evaluation. A further study in female rats demonstrated an increase in the incidence of mammary fibroadenomas. In the third study in rats, although a few rare tumours were observed, there was no significant increase in the incidence of malignant neoplasms.

4.3 Human carcinogenicity data

In a hypothesis-generating cohort study, use of nitrofurantoin was associated with the occurrence of cancers of the female genital tract and nervous system, but these findings could have been due to chance.

4.4 Other relevant data

Use of nitrofurantoin during pregnancy has not been associated with birth defects. The drug has gonadotoxic effects in male and female rats and mice and teratogenic effects in mice at high doses.

In humans, use of nitrofurantoin has been associated with pulmonary fibrosis, hepatocellular injury, aplastic anaemia and other blood dyscrasias.

Nitrofurantoin gave negative results in the mouse spot test and in the rat micronucleus test. It did not induce chromosomal aberrations in male germ cells or dominant lethal effects in mice. It induced DNA strand breaks in rats and mice and sister chromatid exchange and unscheduled DNA synthesis in bone-marrow cells of mice. Nitrofurantoin induced DNA strand breaks in mouse, rat and human cells in
vitro and increased the frequency of sister chromatid exchange in Chinese hamster cells but not in human cells in vitro. Nitrofurantoin induced chromosomal aberrations in Chinese hamster cells but not in human cells in vitro. It did not induce unscheduled DNA synthesis in human fibroblasts or rat hepatocytes in vitro. It induced gene mutations in Chinese hamster cells. Nitrofurantoin gave ambiguous results in Drosophila in the sex-linked recessive lethal test but positive results in the wing spot test. It gave contradictory results in tests for mitotic gene conversion in Saccharomyces cerevisiae. Nitrofurantoin induced differential toxicity in Escherichia coli, Salmonella typhimurium and Bacillus subtilis and mutations in E. coli and S. typhimurium. (See Appendix 1.)

4.5 Evaluation

There is inadequate evidence for the carcinogenicity of nitrofurantoin in humans. There is limited evidence for the carcinogenicity of nitrofurantoin in experimental animals.

Overall evaluation

Nitrofurantoin is not classifiable as to its carcinogenicity to humans (Group 3).

5. References


1For description of the italicized terms, see Preamble, pp. 26-29.
NITROFURANTOIN 225


Chemical Information Services (1989-90) *Directory of World Chemical Producers 1989/90*, Oceanside, NY


NITROFURANTOIN


National Toxicology Program (1989) *Toxicology and Carcinogenesis Studies of Nitrofurantoin (CAS No. 67-20-9) in F344/N Rats and B6C3Fl Mice (Feed Studies)* (NTP Technical Report No. 341), Research Triangle Park, NC


OTHER DRUGS
CIMETIDINE

1. Chemical and Physical Data

Cimetidine

1.1 Synonyms

Chem. Abstr. Services Reg. No.: 51481-61-9
Chem. Abstr. Name: Guanidine N-cyano-N'-methyl-N''-(2-[(5-methyl-1H-imidazol-4-yl)methyl]thio)ethyl)-
Synonym: 2-Cyano-1-methyl-3-[2-(5-methylimidazo-4-ylmethylthio)ethyl]guanidine

1.2 Structural and molecular formula and molecular weight

\[
\begin{align*}
\text{C}_{10}\text{H}_{16}\text{N}_{6}\text{S} & \quad \text{Mol. wt: 252.34}
\end{align*}
\]

1.3 Chemical and physical properties of the pure substance

From Windholz (1983) and Bavin et al. (1984)
(a) Description: White to off-white crystalline powder
(b) Melting point: 141-143°C (base), 193°C dec (hydrochloride)
(c) Solubility: Soluble (1.14%) in water at 37°C; soluble in ethanol; very slightly soluble in chloroform; insoluble in diethyl ether. The hydrochloride is freely soluble in water; soluble in ethanol; very slightly soluble in chloroform; and practically insoluble in diethyl ether.
(d) **Spectroscopy data:** Ultraviolet, infrared, nuclear magnetic resonance and mass spectral data have been reported.

(e) **Stability:** Dry compound, stored in a closed container at room temperature, showed no decomposition after five years. Cimetidine hydrochloride is stable for 48 h at normal room temperature when diluted with most commonly used solutions for intravenous injection.

1.4 Technical products and impurities

**Trade names:** Acibilin; Aciloc; Acinil; Altramet; Cianosel; ‘Cim’; Cimal; Cimegan; Cimet; Citimid; Cimetidina; Cimetin; Cimetum; Cinamet; Cinulceus; Citimid; Citius; Climatidine; Dina; Duncamet; Duogastril; Duractin; Dyspamet; Edalene; Etidine; Eureceptor; Evicer; Fisiol; Fremet; Gasmetin; Gastrobitan; Gastro H2; Gastromet; Himetin; Itacem; Lucimet; Lucomet; Mansal; Nimus (Udine) Gadol; Notul; Novocimetine; Peptol; Prometidine; Regastric; SKF 92334; Stomakon; Tagacid; Tagama; Tagagel; Tagamet; Tametin; Temic; Tratul; Tratul Retard (SR); Ulcedine; Ulcenon; Ulcerdine; Ulcerfen; Ulcestop; Ulcidin; Ulcimet; Ulcodina; Ulcomedina; Ulhys; Vagolisal; Valmagen

**Hydrochloride:** Biomag; Brumetidina; Cimet; Notul

Cimetidine is available for oral administration as 200- or 300-mg tablets. The hydrochloride is available for oral administration as a 300 mg/5 ml solution and for parenteral administration as a 150 mg/ml liquid.

Impurities in tablets available in the USA include cellulose, D&C yellow #0, FD&C Blue #2, FD&C Red #40, FD&C yellow #6, hydroxypropyl methylcellulose, iron oxides (see IARC, 1987a), magnesium stearate, povidone, propylene glycol, sodium lauryl sulfate, sodium starch glycolate, starch and titanium dioxide (see IARC, 1989a). Impurities in the liquid (oral) preparation are ethanol (2.8%), FD&C Yellow #6, methylparaben, polyoxyethylene polyoxypropylene glycol, propylene glycol, propylparaben, saccharin sodium (see IARC, 1987b), sodium chloride, sodium phosphate, sorbitol and water. Solutions for intramuscular or intravenous injections contain phenol (0.5%; see IARC, 1989b) (Barnhart, 1989).

Single-dose, premixed plastic containers for intravenous administration are available (300 mg cimetidine, 0.45 g sodium chloride and no preservative) (Barnhart, 1989).

**N-Nitrosocimetidine**

1.1 Synonyms

*Chem. Abstr. Services Reg. No.: 73785-50-7*
Chem. Abstr. Name: Guanidine, N-cyano-N'-methyl-N'-nitroso-N"-(2-[[5-methyl-1H-imidazol-4-yl]methyl][thio]ethyl)-

1.2 Structural and molecular formulae and molecular weight

\[
\begin{align*}
\text{C}_{10}\text{H}_{15}\text{N}_{7}\text{OS} & \quad \text{Mol wt: 281.33} \\
\end{align*}
\]

1.3 Chemical and physical properties of the pure substance

From Bavin et al. (1980) and Foster et al. (1980)

(a) Description: Pale-yellow crystals
(b) Melting-point: 112-113°C
(c) Solubility: Soluble in dimethylsulfoxide
(d) Spectroscopy data: Ultraviolet, nuclear magnetic resonance and field desorption mass spectra have been recorded.
(e) Stability: Unstable in alkaline solution

1.4 Technical products and impurities

N-Nitrosocimetidine has been synthesized for research purposes (Bavin et al., 1980; Foster et al., 1980). The N-methyl-N'-cyanoguanidine moiety of cimetidine can be converted to the corresponding N-nitroso derivative (N-nitrosocimetidine) by the action of acidic solutions of nitrite (Bavin et al., 1980).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

Cimetidine is prepared from 2-methyl-3-hydroxymethyl-1H-imidazole via a multistep synthesis involving sequential additions of 2-mercaptoethylamine, dimethylcyanodithioimidocarbonate and methylamine and variations of this method (Durant et al., 1974; Bavin et al., 1984). The hydrochloride is prepared by addition of hydrochloric acid and ethyl acetate as an ethanolic suspension of cimetidine (Bavin et al., 1984).

Cimetidine is synthesized in Brazil, Hungary, India, Italy, Mexico, the Republic of Korea, Spain, Taiwan and Yugoslavia (Chemical Information Services, 1989-90).
In Sweden, cimetidine sales in 1988 were 2.32 defined daily doses (1 g) per 1000 inhabitants (Apoteksbolaget, 1988, 1989). In Finland, cimetidine sales in 1987 were 0.15 defined daily doses per 1000 inhabitants (Finnish Committee on Drug Information and Statistics, 1987). In the USA, cimetidine was the sixth ranking prescription drug in 1988 (La Piana Simonsen, 1989).

Cimetidine is not known to occur as a natural product.

The intragastric formation of N-nitrosocimetidine has been proposed via reaction of cimetidine with nitrous acid (Elder et al., 1979a,b).

2.2 Use

As a histamine H2-receptor antagonist, cimetidine inhibits gastric acid secretion and reduces pepsin output; it may also inhibit other actions of histamine that are mediated via H2-receptors. Its clinical indications include duodenal and gastric ulcers, oesophageal reflux, selected cases of persistent dyspepsia and pathological hypersecretory states such as the Zollinger-Ellison syndrome. Due to its capacity to inhibit acid secretion, it is also indicated for the prophylaxis of gastrointestinal haemorrhage in stress ulceration and in patients at risk of acid aspiration during general anaesthesia. Cimetidine may also be used to reduce malabsorption and fluid loss in patients with the short-bowel syndrome and to reduce the degradation of enzyme supplements given to patients with pancreatic insufficiency (Reynolds, 1989). Treatment of damage to the gastric mucosa by non-steroidal anti-inflammatory drugs (Friedman et al., 1989) is a minor indication.

Cimetidine may be given orally (400 mg two to four times daily), by the nasogastric route or parenterally by intramuscular or slow intravenous injections (200 mg) as well as by intravenous infusion (400 mg in 1 h repeated every 4-6 h) (Reynolds, 1989). In maintenance therapy of duodenal ulcer, cimetidine has been administered daily for up to five years (Barnhart, 1989).

The use of cimetidine in children, in particular in neonates, is limited. In full-term neonates, the dosage adjustments are based on renal function, and the dose of 15-20 mg/kg daily is reduced in premature infants (Ziemniak et al. 1984). The dosage regimen in children aged 4-13 years is 30 mg/kg bw daily, divided into three or more doses (see Reynolds, 1989).

In elderly people, the standard dose of cimetidine can be reduced by about 30-50% without loss of effectiveness (see p. 248) (Redolfi et al., 1979).

2.3 Analysis

Analysis of cimetidine and its metabolites in biological fluids by high-performance liquid chromatography has been described (Randolph et al., 1977; Kunitani et al., 1981; Ziemniak et al., 1981; Lloyd & Martin, 1985; Chiou et al.,
Cimetidine can be analysed in pharmaceutical preparations by high-performance liquid chromatography, thin-layer chromatography and spectrophotometric methods (Bavin et al., 1984; Lovering & Curran, 1985).

A method for the analysis of N-nitrosocimetidine in human gastric juice samples using reverse-phase high-performance liquid chromatography with an N-nitroso compound specific detector has been reported (Shuker & Tannenbaum, 1983).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

Cimetidine

(a) Oral administration

Mouse: In a two-generation carcinogenicity study, groups of male BALB/c and female C57Bl/6 mice [numbers unspecified], seven to eight weeks of age, were given pharmaceutical-grade cimetidine at either what was stated to be a common human dose—0.113 mg/ml—or at 1.13 mg/ml in their drinking-water for two weeks. Treated mice were mated, and F₀ females were treated throughout gestation, lactation and the remainder of their lives. The hybrid progeny (F₁) were weaned at four weeks and were also dosed throughout their life. A group of 20 untreated female C57Bl/6 mice served as controls for the treated dams and were mated with untreated BALB/c males. A group of 51 male and 66 female untreated hybrid progeny served as controls for the F₁ generation. The average daily doses of cimetidine were 18.8 mg/kg bw and 190 mg/kg bw, and the average total doses were 15.5 g/kg bw and 155 g/kg bw in the low-dose and high-dose groups, respectively. All moribund mice were killed and subjected to complete necropsy, and all major organs, tissues and lesions were examined histologically. Among the treated C57Bl/6 dams, the effective numbers of animals were 15 at the low dose and 16 at the high dose, with mean survival times of 21-24 months; no significant difference in either survival rates or tumour incidence was observed in comparison with the control group. Among the progeny, the effective numbers of females ranged from 39 to 66 among the different groups, with mean survival times of 28.0-30.8 months; the effective numbers of males ranged from 50 to 79 among the different groups, with mean survival times of 23.5-27 months. In the cimetidine-treated progeny, a significant dose-related increase in the incidence of lymphoid neoplasms [site and
histology unspecified) was observed in females (31/66, 30/65 and 41/59 in the control, low- and high-dose groups, respectively; \( p = 0.008 \), Fisher’s exact test) (Anderson et al., 1985). [The Working Group noted the high incidence of this neoplasm in control animals.]

**Rat:** Groups of 65, 70 and 100 male and 65, 70 and 99 female SPF Wistar rats, 5.5 weeks of age, received clinical-grade cimetidine at 150, 378 or 950 mg/kg bw (which represent 30, 75 and 190 times the dose required for 50% inhibition of basal gastric acid secretion in the rat and are equivalent to 9, 22.6 and 57 times the recommended daily dose for a 60-kg human) in distilled water by gavage daily for two years. One control group of 84 males and 85 females received distilled water by gavage daily, and another group of 107 males and 108 females served as untreated controls. Interim kills were carried out at 6, 10 and 12 months after the start of the experiment, during which a total of 54/235 and 55/234 treated males and females and 32/191 and 32/193 control males and females were killed. The experiment was terminated at 105-106 weeks, at which time survival was: males—untreated controls, 58/107; water controls, 34/84; low-dose, 24/65; mid-dose, 14/70; and high-dose, 34/100; females—untreated controls, 71/108; water controls, 32/85; low-dose, 26/65; mid-dose, 18/70; and high-dose, 34/99. During the first year of the experiment, those rats that died did so mainly as a result of either reflux or direct administration of the dose into the trachea. All rats were necropsied, and major organs and tissues were examined histologically. An increased incidence of benign Leydig-cell tumours of the testis was observed among treated animals (low-dose, 15/65; mid-dose, 14/68; high-dose, 23/98) as compared to combined controls (35/191). The increase was significant in the low- and high-dose groups (\( p < 0.025 \) for both groups; Peto test: Peto et al., 1980). A slightly greater incidence of follicular-cell tumours (benign and malignant) of the thyroid gland was observed in high-dose males (4/98) as compared to control males (2/191) (\( p = 0.049 \), Peto exact test) (Leslie et al., 1981).

**Dog:** Eight male and four female beagle dogs, 7-9.5 months of age, received a daily oral administration of cimetidine in film-coated tablets at 144 mg/kg bw for 385 weeks. Four male and two female controls received placebo tablets. Multiple biopsies of gastric mucosa were taken at intervals of about six months from week 177 to week 363. Two cimetidine-treated and three control dogs died during the experiment. All animals were necropsied, and numerous samples from the stomach and other major organs and tissues were examined histologically. No increase in the incidence of either neoplasms or preneoplastic lesions was observed among the treated animals (Walker et al., 1987a). [The Working Group noted the small number of animals used and the high mortality].
(b) **Administration with other compounds**

**Mouse:** In the study described on p. 239, groups of male BALB/c and female C57Bl/6 mice were given sodium nitrite at either 0.184 or 1.84 mg/ml or cimetidine at 0.113 or 1.13 mg/ml with sodium nitrite at either 0.184 or 1.84 mg/ml in the drinking-water for two weeks. Treated mice were mated, and females were treated throughout gestation, lactation and for the remainder of their lives. The hybrid progeny were weaned at four weeks of age and dosed from that time throughout their lives. No increase in tumour incidence was seen in the dams. Among the progeny, there was a dose-related increase in the incidence of lung tumours in males: 30/52, 36/50 and 71/79 in the untreated control, low- and high-dose groups, respectively ($p < 0.01$, Cox exact test for trend) (Anderson et al., 1985).

**Rat:** Two groups of 20 male Sprague-Dawley rats, weighing 250 g, were wounded surgically in the antro-fundic gastric mucosa. Seven days later, the groups received 1-1.4 ml of either sodium nitrate at 3.75 mg/ml and sodium nitrite at 0.75 mg/ml in deionized water (nitrate-nitrite solution) or commercial-grade cimetidine at 25 mg/kg bw in nitrate-nitrite solution, by gavage daily on six days per week for six months. A group of 50 males served as untreated controls. An interim kill of five rats from each group was carried out at six months, and all surviving rats were killed at 14-15 months. Including the five animals per group from the interim kill, 19 and 20 animals from the nitrate-nitrite and treated groups were necropsied, but samples for histological examination were taken only from the stomach and grossly visible lesions. No neoplasm was found (Elder et al., 1982). [The Working Group noted the small number of animals used, the short duration of the study and the limited histological examination.]

Two groups of 25 Sprague-Dawley rats received weekly subcutaneous injections of either 1,2-dimethylhydrazine alone at 20 mg/kg bw for 16 weeks or concurrently with cimetidine at 100 mg/kg bw daily in the drinking-water for 26 weeks, at which time the experiment was terminated. One group of ten rats received cimetidine treatment only. No increase in the incidence of colonic tumours was observed in the combined cimetidine plus 1,2-dimethylhydrazine-treated group (15/22) over that in the group receiving 1,2-dimethylhydrazine alone (14/22); no such tumour occurred in rats given cimetidine alone (Nee et al., 1984). [The Working Group noted the small number of animals used and the short duration of treatment.]

Two groups of 15 weanling male Sprague-Dawley rats received 1,2-dimethylhydrazine at 30 mg/kg bw in saline by gavage once a week for five weeks. Four days after the last treatment, the groups received either cimetidine at 500 mg/ml in the drinking-water or drinking-water alone, until the animals were killed, seven months after the beginning of the experiment. All animals were necropsied, and samples from the gastrointestinal tract and lymph nodes from the peritoneal cavity and...
lungs were examined histologically. The incidence of colonic carcinomas among survivors was significantly different ($p < 0.05$; Mann-Whitney non-parametric test) for the group receiving 1,2-dimethylhydrazine (4/13) compared with that receiving 1,2-dimethylhydrazine and cimetidine together (10/14) (Caignard et al., 1984). [The Working Group noted the absence of a group treated with cimetidine only.]

**N-Nitrosocimetidine**

Because of the suspicion that N-nitrosocimetidine might be a carcinogenic derivative of cimetidine, it was tested in a number of studies. N-Nitroso compounds are often potent carcinogens, and so, in these studies, small numbers of animals were used. Since the studies would have detected a potent carcinogen, they are included to support the interpretation that N-nitrosocimetidine is, at least, not a strong carcinogen.

(a) *Oral administration*

**Mouse:** In the study described on p. 239, groups of male BALB/c and female C57Bl/6 mice were given N-nitrosocimetidine (purity, 98%) at either 0.113 or 1.13 mg/ml in the drinking-water for two weeks. Treated mice were mated, and females were treated throughout gestation, lactation and for the remainder of their lives. The hybrid progeny were weaned at four weeks of age and dosed from that time throughout their life. The average daily doses of N-nitrosocimetidine were 18.8 mg/kg bw and 190.0 mg/kg bw, and the average total doses were 15.5 g/kg bw and 155 g/kg bw in the low-dose and high-dose groups, respectively. No significant difference in either survival rates or the incidence of tumours was observed between treated and control groups (Anderson et al., 1985).

Two groups of 20 female hybrid B6D2F1 mice, eight weeks of age, were given four weekly intragastric administrations of olive oil, which was used as the vehicle for other compounds; one week after the last dose, they received either N-nitrosocimetidine at 1.13 mg/ml in the drinking-water or deionized water alone. All survivors were killed 14 months after the beginning of treatment. Papillomas of the forestomach occurred in 2/20 mice receiving N-nitrosocimetidine and in 0/19 controls (Anderson et al., 1988). [The Working Group noted the small number of animals used.]

Groups of male BALB/CANCr mice, six weeks of age, received intraperitoneal injections of saline solution once a week for ten weeks, after which time they were given N-nitrosocimetidine at 0, 1.0 or 1.8 mg/ml in the drinking-water. All survivors were killed at 14 months. The effective numbers of animals were 13 in the group receiving N-nitrosocimetidine and 15 in the control group. Lung neoplasms [type unspecified] were observed in 3/13 animals in each treated group and in 6/15
control mice (Anderson et al., 1988). [The Working Group noted the small number of animals used and the short duration of the study.]

**Rat:** Groups of 20 male and 20 female outbred Sprague-Dawley rats, approximately 100 days old, received N-nitrosocimetidine at 50 or 500 mg/kg bw by gavage twice a week for one year. A group of 50 male and 50 female rats served as untreated controls. All animals were observed for life or were killed when moribund, and were necropsied. Samples from the forestomach, glandular stomach, duodenum and all other organs with gross lesions were examined histologically. Mean survival was 393 days in high-dose animals, 400 days in low-dose animals and 630 days in controls. No increase in the incidence of tumours and no gastric neoplasm were found in treated animals (Habs et al., 1982a,b). [The Working Group noted the small number of animals used and the poor survival of treated animals.]

Two groups of 20 male Sprague-Dawley rats, weighing 250 g, were wounded surgically in the antro-fundic gastric mucosa. Seven days later, the groups received 1-1.4 ml of either sodium nitrate at 3.75 mg/ml and sodium nitrite at 0.75 mg/ml in deionized water (nitrate-nitrite solution) or N-nitrosocimetidine at 2.80 mg/ml in nitrate-nitrite solution, by gavage daily on six days per week for six months. A group of 50 males served as untreated controls. An interim kill of five rats from each group was carried out at six months, and all surviving rats were killed at 14-15 months. Including the five animals per group from the interim kill, 19, 16 and 9 animals from the respective groups were necropsied, but samples for histological examination were taken only from the stomach and grossly visible lesions. A gastric carcinoma at the site of wounding was found in one rat treated with N-nitrosocimetidine. No other neoplasm was found (Elder et al., 1982). [The Working Group noted the small number of animals used.]

Groups of 20 male and 20 female Fischer 344 rats [age unspecified] received N-nitrosocimetidine at 20 ml (0.15 mg/ml) in deionized water daily as drinking fluid on five days per week for 106 weeks (total dose, 1.6 g/rat). Groups of 20 males and 20 females were untreated and served as controls. All survivors were killed at week 131, and all animals were necropsied and major organs and lesions examined histologically. At 90 weeks, survival was 19/20 males and 20/20 females in the treated group and 15/20 males and 17/20 females in controls. No increase in the incidence of tumours was observed (Lijinksy & Reuber, 1984). [The Working Group noted the small number of animals used.]

**Skin application**

**Mouse:** Groups of 20 female Swiss mice [age unspecified] received twice-weekly 25-μl skin applications on the shaved interscapular skin of either N-nitrosocimetidine (reagent grade) at 2.2 or 5.6 mg/ml in acetone (total doses, 12 or
31 mg/mouse), or acetone alone for 110 weeks or were left untreated. Skin was the only tissue examined grossly and histologically. At week 100, survival among treated animals was 18/20 at the low dose and 13/20 at the high dose. A malignant lymphoma of the skin [site unspecified] was observed in one high-dose mouse (Lijinsky, 1982). [The Working Group noted that the tumour incidence among control groups was not specified and that survival was poor in the group given the high dose.]

3.2 Other relevant data

(a) Experimental systems

(i) Absorption, distribution, excretion and metabolism

The kinetics, absorption, distribution, metabolism and elimination of cimetidine in humans and experimental animals have been reviewed (Griffiths et al., 1977).

In rats and dogs, cimetidine is rapidly absorbed; the concentration of unchanged cimetidine in plasma is greater than that of any metabolite, and the plasma half-time is about 1 h. The drug is excreted mainly unchanged in the urine. The principal metabolite in both rats and dogs is formed by oxidation of the side-chain sulfur to give the sulfoxide (Taylor, D.C. et al., 1978).

In rats, detoxication of N-nitrosocimetidine involves denitrosation, primarily (but not exclusively) by haemoglobin sulfhydryl residues. The rates of degradation of N-nitrosocimetidine by isolated whole blood decreased in the order: rat > mouse ≈ guinea-pig > hamster ≈ human; the half-time of N-nitrosocimetidine at 37°C was ~2 min in hamster blood and 27 min in human blood. After intravenous administration to hamsters in vivo, the half-time of N-nitrosocimetidine was ≤5 min and degradation via denitrosation reached 100%. Additional denitrosating activity was found in the cytosol of several organs from rats and hamsters; this activity required reduced glutathione (Jensen, 1983; Jensen et al., 1987).

The metabolic fate of N-nitrosocimetidine has been investigated, although it has not been shown to be formed in animals in vivo.

Radiolabelled N-nitrosocimetidine, but not cimetidine, methylated DNA in a variety of tissues in rats after oral administration (Gombar & Magee, 1982). In studies in which cimetidine was administered with an excess of nitrite by stomach tube to rats, no evidence could be obtained for the presence of \( O^6 \)-methylguanine in DNA isolated from stomach, liver or intestine (large and small pooled) (Kyrtopoulos et al., 1982). \( N \)-Nitrosocimetidine produced a low level of DNA alkylation (determined as 7-methylguanine) in the liver and other organs of hamsters after intravenous administration (Jensen et al., 1987).
(ii) Toxic effects

The oral LD$_{50}$s of cimetidine were approximately 2.6 g/kg bw in mice, 5 g/kg bw in rats, 4 g/kg bw in hamsters and 2.60 g/kg bw in dogs. The intraperitoneal LD$_{50}$s were 470 mg/kg bw in mice, 650 mg/kg bw in rats and 880 mg/kg bw in hamsters (Crean et al., 1981).

Daily oral administration of 160 mg/kg bw cimetidine to female Sprague-Dawley rats for two months increased total gastrin-cell numbers, gastrin-cell density of antral mucosa and parietal-cell density of fundic mucosa, as compared with controls (Del Tacca et al., 1987). In contrast, in male Wistar/Lewis rats receiving cimetidine orally at 150-200 mg/kg bw daily for up to 12 months, it was not possible to demonstrate by autoradiography epithelial proliferation in either fundus or antrum as a consequence of treatment (Eastwood & Quimby, 1983).

In studies of up to 24 months’ duration, rats receiving repeated doses of cimetidine at up to 950 mg/kg bw per day showed few adverse effects. Liver weight was consistently increased at the highest dose, and testis, prostate and seminal vesicle weights were reduced in a dose- and time-related manner (Brimblecombe et al., 1985).

In a study of up to 12 months’ duration, two dogs receiving cimetidine at 504 mg/kg bw per day orally exhibited degenerative changes in the liver, renal tubular nephrosis and elevated levels of serum transaminases. No such change was seen with doses of 366 mg/kg bw per day or less. Prostate weights were reduced in a dose- and time-related manner. In beagle dogs administered cimetidine at 144 mg/kg bw per day orally, no treatment-related effect was seen after four years, on the basis of haematology, clinical biochemistry, urinalysis, electrocardiography or clinical condition, and no treatment-associated change was observed in biopsies of gastric mucosa. After seven years of follow-up, no change of the stomach mucosa was seen during regular biopsy (Crean et al., 1981; Brimblecombe et al., 1985).

In-vivo and in-vitro studies suggest that cimetidine inhibits gastric acid secretion in rats and dogs by blocking histamine H$_2$-receptors in the gastric mucosa (Brimblecombe et al., 1978). Cimetidine administered intraperitoneally to male Wistar rats at 20 mg/kg bw twice daily for seven days reduced the gastric mucosal concentrations of prostaglandin E$_2$ and 6-keto-prostaglandin F$_{1a}$, both 30 min and 24 h after the last injection (Arakawa et al., 1988).

In rats, the oral LD$_{50}$ of N-nitrosocimetidine did not differ from that of cimetidine itself. No tissue-specific toxic lesion could be attributed to the nitroso derivative (Ogiu et al., 1986).

(iii) Effects on reproduction and prenatal toxicity

In routine safety evaluation studies on cimetidine, including fertility and peri- and postnatal studies in rats and teratology studies in mice, rats and rabbits, no
adverse effect was reported with oral doses of up to 950 mg/kg bw (Brimblecombe et al., 1978). [The Working Group noted the lack of detailed reporting.]

Cimetidine has been shown to possess weak antiandrogenic activity in rats, as shown by reduced weights of testis, prostate and seminal vesicles (Brimblecombe et al., 1978; Pereira, 1987). Inhibition of dihydrotestosterone binding to the prostatic androgen receptor has been demonstrated (Sivelle et al., 1982).

Differentiation of the genital organs of male fetuses is influenced by endogenous testosterone produced during prenatal development, and gonadal and sexual dysfunction have been reported in adult male rats after prenatal and neonatal exposure to cimetidine at daily doses of 17.1 and 137 mg/kg bw in drinking-water from day 12 of pregnancy until weaning on postnatal day 21 (Anand & Van Thiel, 1982; Parker et al., 1984a,b). These results were not confirmed in other studies. Rats were administered cimetidine at 180 mg/kg bw daily in the drinking-water from day 12 of pregnancy until the end of lactation or during late lactation only, or a combination of drinking-water during pregnancy and early lactation and gavage treatment during late lactation. Several end-points, such as anogenital distance, serum testosterone, mating performance and sexual organ weights, were evaluated soon after littering or up to 148 days postnatally. Maternally administered cimetidine had no effect in male offspring on any parameter measured (Walker et al., 1987b).

In another study, cimetidine was administered to rats in drinking-water from day 17 of gestation through day 7 of lactation. With the highest drug concentration tested (4 mg/ml), the daily dose ingested ranged from about 400 mg/kg bw before parturition to approximately 850 mg/kg bw afterwards. The developmental profile of serum dehydroepiandrosterone, androstenedione, testosterone and 5-α-dihydrotestosterone, when measured at 1, 4 and 18 weeks of age, was unaffected by perinatal exposure to cimetidine (Shapiro et al., 1988).

The effects of maternally administered cimetidine during lactation on the development of drug metabolizing enzymes in BALB/c mouse pups have been investigated. When dams were administered cimetidine at 50 mg/kg bw per day intraperitoneally for six weeks after delivery, microsomal enzyme activity was inhibited in pups. Dams were less affected than pups (Kwanashie, 1989).

(iv) Genetic and related effects

Cimetidine did not induce differential toxicity in Escherichia coli (Pool et al., 1979; De Flora, 1981).

Cimetidine was reported not to be mutagenic to Salmonella typhimurium (De Flora & Picciotto, 1980; O'Connor et al., 1987). Cimetidine alone or in combination with sodium nitrite gave negative results in S. typhimurium in a host-mediated assay in mice (Baumeister, 1982).
No single-strand breakage, measured by the alkaline elution assay, was found in the DNA of a transformed mouse epithelial cell line after treatment with cimetidine at concentrations of up to 5 mM (Schwarz et al., 1980). In an alkaline elution assay with rat primary hepatocytes, the highest concentration of cimetidine hydrochloride (3 mM) induced a significant increase in the frequency of DNA strand breaks (Martelli et al., 1983). No such effect was observed in human hepatocytes (Martelli et al., 1986).

Cimetidine hydrochloride induced unscheduled DNA synthesis in cultures of rat primary hepatocytes (Martelli et al., 1983; Lefevre & Ashby, 1985), while the base was inactive (Lefevre & Ashby, 1985). In another study, cimetidine [form not specified] did not induce unscheduled DNA synthesis in rat hepatocytes (Williams et al., 1989). Human hepatocytes from four donors did not exhibit unscheduled DNA synthesis after treatment with cimetidine hydrochloride (Martelli et al., 1986). In an abstract, it was reported that cimetidine did not induce mutation to 6-thioguanine resistance, to trifluorothymidine resistance or to ouabain resistance in a human lymphoblastoid cell line (TK6) after 1-h treatment with concentrations of up to 1.2 mM, with a cell survival of 6% (Tatsumi et al., 1987).

Cimetidine did not induce sister chromatid exchange in human lymphocytes in vitro (Inoue et al., 1985).

When rats were given cimetidine orally at 250 mg/kg bw, no DNA damage was detected in cells of the gastric mucosa (Pino & Robbiano, 1983) or in liver cells (Brambilla et al., 1982); combination treatment with sodium nitrite also gave negative results.

N-Nitrosocimetidine and cimetidine treated with sodium nitrite in an acid environment like that of human gastric juice have consistently been shown to be directly mutagenic in vitro: either treatment induced differential toxicity and mutation in bacteria, inhibited DNA synthesis in human cells and induced DNA single-strand breaks, mutation, sister chromatid exchange, chromosomal damage and morphological transformation in mammalian cells. For a comprehensive tabulation of these data and their references, see Appendix 2.

(b) Humans

(i) Pharmacokinetics

The pharmacokinetics of cimetidine have been reviewed (Reynolds, 1989).

Cimetidine is readily absorbed from the gastrointestinal tract, and peak plasma concentrations are obtained about 1 h after administration on an empty stomach and about 2 h after administration with food (Somogyi & Gugler, 1983). The bioavailability of cimetidine is 60-70%, as a result of moderate first-pass metabolism. Twenty percent of cimetidine is bound to plasma proteins, and its elimination half-time from plasma is about 2 h; it is partially metabolized in the liver...
to the sulfoxide and to hydroxymethylcimetidine. After intravenous administration, 50-80% of the dose was excreted unchanged in the urine. After an oral dose, the corresponding figure was 40%. Cimetidine penetrates the blood-brain barrier with difficulty but easily crosses the placental barrier and is excreted into milk, where the concentrations may be higher than those in plasma. Dose-dependent kinetics of cimetidine have been observed in neonates (Lloyd et al., 1985).

A markedly reduced plasma clearance of cimetidine has been reported in elderly patients (Gugler & Somogyi, 1979; Redolfi et al., 1979). A decrease in non-renal clearance of cimetidine was reported in patients with liver cirrhosis (Gugler et al., 1982; Cello & Oie, 1983); in one study, this effect was limited to cirrhosis patients with a history of hepatic encephalopathy (Ziemniak et al., 1983). Renal failure may lead to elevated plasma levels of cimetidine (Larsson et al., 1982).

(ii) Adverse effects

The toxicity of cimetidine has been reviewed (Penston & Wormsley, 1986). Adverse effects are infrequent and are usually reversible following reduction of dosage or withdrawal of therapy. Diarrhoea, rashes and other allergic phenomena have been reported. Various symptoms of the central nervous system have been reported frequently, particularly at greater than therapeutic doses (Nelson, 1977; Illingworth & Jarvie, 1979; Schentag et al., 1979). Adverse haematological effects possibly associated with cimetidine are rare and include granulocytopenia or agranulocytosis, thrombocytopenia and pancytopenia (Penston & Wormsley, 1986).

Strongly reduced gastric acid secretion favours colonization of the stomach by bacteria, some of which can reduce nitrate to nitrite and catalyse nitrosation of amino precursors at neutral pH (Hill, 1986; Leaf et al., 1989). Since these conditions could lead to intragastric formation of nitroso compounds, gastric juice samples from patients before and after treatment with cimetidine have been analysed for total nitroso compounds or nitrite in several studies. Fasting gastric juice from 140 patients taking cimetidine for a variety of gastric or duodenal disorders (daily doses of 0.2-1.6 g for periods of one week to 45 months) and 267 subjects who had not taken the drug were analysed. Significantly higher mean levels of total nitroso compounds were found in the former group (Reed et al., 1981).

In a study of a group of 23 peptic ulcer patients after a six-week course of 1 g cimetidine per day, a statistically significant increase in nitrite and nitroso compound concentrations was found (Stockbrugger et al., 1982). In six volunteers who took 200 mg cimetidine three times a day and 400 mg a night for at least three weeks, increases in the level of gastric juice nitrite were found only rarely (Muscroft et al., 1981). In eight healthy subjects studied half-hourly or hourly for 24-h periods before, during and after cimetidine treatment (two weeks with 1 g per day), no
significant difference in the level of intragastric nitrite or total nitroso compounds was found following cimetidine treatment (Milton-Thompson et al., 1982).

Gastric juice and urine collected from 17 duodenal ulcer patients receiving 0.8 g cimetidine per day for four to six weeks were analysed for nitrosation capacity before, during and after treatment using the N-nitrosoproline test (Ohshima & Bartsch, 1981). Cimetidine treatment did not lead to a uniform or pronounced rise in gastric levels of total nitroso compounds or urinary N-nitrosoproline levels (Bartsch et al., 1984).

The methods used for determining total nitroso compounds in gastric juice in all these studies have been criticized because of their lack of specificity (Pignatelli et al., 1987); moreover, in none of the studies was N-nitrosocimetidine itself measured in the gastric juice samples.

Cimetidine inhibits cytochrome P450-dependent microsomal mixed-function oxidase (Pelkonen & Puuronen, 1980), elevating the plasma levels of other drugs, such as lignocaine, phenytoin, theophylline, warfarin and ciclosporin (Somogyi & Muirhead, 1987; Rodighiero, 1989).

(iii) Effects on reproduction and prenatal toxicity

A number of case reports have been published of cimetidine use in pregnancy, indicating no adverse effect (Coraza et al., 1982; Meggs et al., 1984) or abnormal outcome (Glade et al., 1980; Say et al., 1985); the significance of these reports cannot be assessed.

In a UK postmarketing surveillance study, 9928 patients given cimetidine in general practices were compared with 9351 age- and sex-matched unexposed people from the same practices; 98.8% of takers and 97.7% of controls were successfully followed up for at least one year (Colin-Jones et al., 1983, 1985a,b). In the 20 exposed women and the 22 controls who became pregnant during the study year, there was no evidence of an adverse effect of cimetidine treatment.

Impotence, reduced sperm count and gynaecomastia have been reported in men treated with cimetidine. In one study, gynaecomastia was reported in 20/6240 men (3.2/1000), but in only 13 of these was cimetidine thought to be the likely cause. Impotence was reported in 12/6240 men (2/1000) taking cimetidine and in 3/5868 controls (0.5/1000); however, impotence and gynaecomastia were not reported in the same individuals (Colin-Jones et al., 1985a,b). [The Working Group considered that, because of the method of ascertainment, underreporting was likely.] In other studies in which cimetidine was administered at doses larger than those normally used in ulcer therapy, these adverse effects were more common. In a study by Jensen et al. (1983), of patients with gastric hypersecretion (mostly Zollinger-Ellison syndrome) who were treated with high doses of cimetidine, 11/22 subjects developed one or more signs or symptoms of impotence, breast tenderness or
gynaecomastia. The 11 affected subjects had received a mean daily dose of 5.3 g, compared with 3.0 g in the unaffected group. Spence and Celestin (1979), however, reported gynaecomastia in 5/25 (20%) male patients treated with 1.6 g cimetidine daily. In all the reported cases, the condition reversed rapidly after cessation of and sometimes during treatment.

Several well-controlled studies have shown no effect of cimetidine on sperm count (Wang et al., 1982; Paulsen et al., 1983; Bianchi Porro et al., 1985), but one showed a small but significant reduction (Van Thiel et al., 1979). No consistent effect on plasma levels of gonadotrophins or sex hormones was demonstrated in these studies.

(iv) Genetic and related effects

When gastric juice from patients who had received cimetidine at 200 mg 2 h earlier was incubated with sodium nitrite at 10 μg/ml, a significant increase in the number of revertants was seen in S. typhimurium TA100 in the absence of an exogenous metabolic system (DeFlora & Picciotto, 1980).

Gastric juice taken from 49 patients 1-3 h after intake of cimetidine at 400 mg was mutagenic when tested in S. typhimurium TA100; no mutagenic activity was seen in samples taken 12 h later (Morris et al., 1984). When the mutagenicity of gastric juice from eight fasting patients under cimetidine treatment (400 mg twice daily) was tested before and after administration of the drug, using S. typhimurium TA98 and TA100, considerable variation in mutagenicity was seen between subjects, all samples being mutagenic even before therapy. No significant change in mutagenic activity was detected after therapy and there was no relation to duration of therapy, changes in gastric pH or ulcer healing (O'Connor et al., 1987).

3.3 Case reports and epidemiological studies in humans

(a) Case reports

Numerous case reports of neoplasms following cimetidine use have been published (Welsh et al., 1977; Murray et al., 1978; Taylor, TV. et al., 1978; Buck et al., 1979; Elder et al., 1979a,b; Reed et al., 1979; Taylor et al., 1979; Hawker et al., 1980; Kjærgaard et al., 1980; Knigge et al., 1980; Stoddard et al., 1980; Scotcher et al., 1981; Taylor et al., 1981; Kaplinsky et al., 1982; Eschar et al., 1983; Porter et al., 1984; Stockley & Kiff, 1987). The stomach has been the most frequently reported cancer site, followed by lymphomas of the gastrointestinal tract; less commonly, benign and malignant tumours at other sites have been reported (Kaplinsky et al., 1982; Eschar et al., 1983). Most of the cases were diagnosed within one year; the longest interval was five years (Stockley & Kiff, 1987). In certain of the reports, gastric carcinoma had arisen after oesophagitis or duodenal ulcer—conditions not thought to be associated with gastric carcinoma. In other reports, gastric ulcers diagnosed
as benign on the basis of biopsy samples and appearance on gastroscopy have been followed by malignant changes.

(b) **Cohort studies**

A cohort of (initially) 9940 individuals who received cimetidine during 1977-79 in the UK and who were followed up for four years has been the subject of four papers (Colin-Jones *et al.*, 1982, 1983, 1985a,b). Also studied were (initially) 9366 controls matched for age, sex and general practice, who did not receive cimetidine, but these were followed up for only one year. For this reason, national rates were used as the standard for evaluation of mortality (incident cancers were evaluated only in the first year). A total of 330 deaths were due to neoplasms in cimetidine users (compared to 65.6 expected), most of the excess being gastric and lung cancers. The relative risks (RRs) declined markedly over the study period: for gastric cancer, the approximative RRs for men and women combined (and observed numbers) were 12.9 (45 deaths), 3.4 (12), 1.8 (6) and 2.3 (8) after one, two, three and four years follow-up, respectively. Some of the patients were known to have had cancer before cimetidine use was started, and, even among deaths after the first year, there were three such deaths from gastric cancer. For lung cancer, the RRs in the four periods were 2.8 (35 deaths), 2.0 (25), 1.4 (17) and 1.8 (22). In an approximately 5% sample of study participants, 45% of the exposed and 28% of unexposed subjects had smoked > 15 cigarettes per day five years previously. [The Working Group noted that cigarette smoking is associated with peptic ulcer as well as lung cancer and that smoking habits were not accounted for in the evaluation of lung cancer risk.]

A second cohort study concerned cancer incidence among 16 739 patients treated with cimetidine in Denmark in the period 1977-81 who were followed for up to eight years by linkage procedures with the central population and national cancer registers (Møller *et al.*, 1989). A total of 105 cases of gastric cancer were recorded, compared with 39.5 expected (RR, 2.6). The RR was greatest early in the follow-up period, declining markedly later. For sites with positive associations and for all other sites combined, the RRs and observed numbers of cases during the first year, during the second and third years and for more than three years of follow-up are shown in Table 1. The increased risks for gastric cancer were greater in persons with a diagnosis of gastric ulcer (19.3 (45 observed cases), 3.5 (16) and 3.2 (13) for the three time periods) than in those with duodenal ulcer (2.2, 1.1 and 1.1, with seven observed cases each). Increased incidences of gastric and certain other gastrointestinal malignancies were noted particularly in the first year of follow-up. The increased incidences of lymphatic and haematopoietic malignancies were due mainly to non-Hodgkin's lymphoma of the stomach and small intestine. The risk
Table 1. Relative risks (RRs) and numbers of cases observed after different periods in patients treated with cimetidine

<table>
<thead>
<tr>
<th>Site</th>
<th>&lt; 1 year</th>
<th></th>
<th>1–3 years</th>
<th></th>
<th>&gt;3 years</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RR</td>
<td>Obs</td>
<td>RR</td>
<td>Obs</td>
<td>RR</td>
<td>Obs</td>
</tr>
<tr>
<td>Stomach</td>
<td>9.4</td>
<td>57</td>
<td>2.3</td>
<td>27</td>
<td>1.7</td>
<td>21</td>
</tr>
<tr>
<td>Pancreas</td>
<td>4.7</td>
<td>21</td>
<td>1.5</td>
<td>15</td>
<td>1.7</td>
<td>14</td>
</tr>
<tr>
<td>Colon</td>
<td>2.1</td>
<td>23</td>
<td>1.8</td>
<td>38</td>
<td>1.3</td>
<td>26</td>
</tr>
<tr>
<td>Small intestine</td>
<td>10.5</td>
<td>4</td>
<td>3.9</td>
<td>3</td>
<td>3.4</td>
<td>2</td>
</tr>
<tr>
<td>Lymphatic and haematopoietic</td>
<td>3.0</td>
<td>22</td>
<td>0.9</td>
<td>13</td>
<td>1.5</td>
<td>20</td>
</tr>
<tr>
<td>tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>1.4</td>
<td>34</td>
<td>1.7</td>
<td>83</td>
<td>1.6</td>
<td>73</td>
</tr>
<tr>
<td>Other sites</td>
<td>1.1</td>
<td>91</td>
<td>1.4</td>
<td>218</td>
<td>1.1</td>
<td>169</td>
</tr>
</tbody>
</table>

*From Møller et al. (1989). RRs calculated by the Working Group for the two sexes combined*

for lung cancer did not change appreciably over time. [The Working Group noted that no data on smoking status were provided.]

By record linkage, 3802 cimetidine users and an equal number of non-users matched by age, sex and general practitioner in Tayside, Scotland, were followed up for mortality during a period of four years (Beardon et al., 1988). Mortality due to neoplasms of the digestive organs and peritoneum was markedly increased in the cimetidine takers, with a RR of 2.7 (95% confidence interval, 1.6-4.7) based on 49 deaths. The largest excesses were seen for neoplasms of the oesophagus, stomach and pancreas. Mortality from all causes among cimetidine users was increased only during the first two years of follow-up [corresponding data by duration of follow-up were not presented for cancer]. There was no significant increase in mortality due to neoplasms of respiratory and intrathoracic organs (32 deaths; RR, 1.1; 95% confidence interval, 0.67-1.8) or other neoplasms.

[The Working Group noted, as did the authors of the relevant studies, that in the case reports and studies undiagnosed gastric and intra-abdominal neoplasms could have been responsible for the symptoms that led to use of cimetidine. This possibility is supported by the short interval between exposure and observation of increased RRs and by the decreasing risks for intra-abdominal cancer, particularly gastric cancer, with time. The maximal interval that follow-up studies have so far covered is only eight years.]
4. Summary of Data Reported and Evaluation

4.1 Exposure data

Cimetidine is a histamine H₂-receptor antagonist which inhibits gastric acid secretion. Since its introduction in the mid-1970s, it has been used widely by oral administration for the treatment of duodenal and gastric ulcers.

Although cimetidine can be nitrosated in vitro in the presence of nitrite under acidic conditions to form N-nitrosocimetidine, no study in experimental animals or in humans has demonstrated that this reaction occurs in vivo.

4.2 Experimental carcinogenicity data

Cimetidine was tested for carcinogenicity by oral administration in single studies in mice, rats and dogs. In the experiment in mice, dams were treated throughout life beginning two weeks prior to pregnancy, with no increase in tumour incidence. In female progeny that were exposed throughout life from conception, there was an increase in the incidence of lymphomas, although these tumours also occurred at relatively high rates in control animals. In rats, an increase in the incidence of benign Leydig-cell tumours of the testis was observed in the low- and high-dose groups but not in the mid-dose group. The study in dogs was inadequate for evaluation.

In a study in which mice were exposed from conception throughout life to a combination of cimetidine and sodium nitrite, males had an increased incidence of lung neoplasms, although these tumours also occurred at a high frequency in control animals.

N-Nitrosocimetidine was tested for carcinogenicity by oral administration in mice and rats and by skin application in mice. The experiments in rats and three of the studies in mice were inadequate for evaluation. In one study by oral administration in mice, there was no increase in the incidence of tumours.

4.3 Human carcinogenicity data

In a large number of case reports, cancer, particularly gastric cancer, was diagnosed at various intervals after the start of cimetidine therapy. These reports are difficult to interpret because gastric cancer is a common malignancy and cimetidine is a commonly used drug, and coincidence cannot be ruled out.

Three cohort studies showed increased incidences of gastric cancer but also of other gastrointestinal cancers among cimetidine users; however, as for the case reports, the association could well have been due to the drug being given for symptoms of pre-existing cancers. This interpretation is supported by a diminution
of the association with increasing duration of follow-up. Two of the studies also showed an association between cimetidine use and lung cancer, but confounding with cigarette smoking could well have been the explanation.

4.4 Other relevant data

Cimetidine has been associated with reversible impotence and other anti-androgenic effects in men.

*N-Nitrosocimetidine is rapidly converted to cimetidine* *in vivo* in experimental animals.

Cimetidine did not induce single-strand breaks in DNA from rats treated *in vivo*, nor did it methylate DNA in a variety of tissues of rats *in vivo*. It did not induce single-strand breaks in the DNA of rat cells treated *in vitro*. Cimetidine was not mutagenic to and did not cause DNA damage in *Salmonella typhimurium* or *Escherichia coli*. Cimetidine hydrochloride induced single-strand breaks and unscheduled DNA synthesis in rat but not human cells *in vitro*. It did not cause sister chromatid exchange in human cells *in vitro*.

Cimetidine in combination with sodium nitrite did not induce DNA damage *in vivo* or methylate DNA in a variety of tissues of rats *in vivo*. Gastric juice from cimetidine-treated patients was mutagenic to bacteria when enriched with nitrite.

*N-Nitrosocimetidine has not been demonstrated* in gastric juice of humans; however, increased gastric concentrations of nitrite and total *N*-nitroso compounds have been reported in some studies of patients taking cimetidine. *N*-Nitrosocimetidine induced DNA damage, sister chromatid exchange, chromosomal aberrations and morphological transformation in mammalian cells *in vitro* and caused DNA damage and mutation in bacteria. Radiolabelled *N*-nitrosocimetidine methylated DNA in a variety of tissues of rats *in vivo*. (See Appendix 1.)

4.5 Evaluation\(^1\)

There is *inadequate evidence* for the carcinogenicity of cimetidine in humans.

There is *inadequate evidence* for the carcinogenicity of cimetidine in experimental animals.

**Overall evaluation**

Cimetidine is not classifiable as to its carcinogenicity to humans (Group 3).

---

\(^1\)For description of the italicized terms, see Preamble, pp. 26–29.
5. References


gonadal and sexual dysfunction in adult males. *Science*, 218, 493-494

cimetidine, nitrite, cimetidine plus nitrite and nitrosocimetidine on tumors in mice
following transplacental plus lifetime exposure. *Cancer Res.*, 45, 3561-3566

Rice, J.M. (1988) N-Nitrosocimetidine as a modifier of chemically-initiated tumours in
mice. *Cancer Lett.*, 42, 159-167

Apoteksbolaget (1988) *Svensk Läkemedelsstatistic* [Swedish Drugs Statistics], Stockholm,
Pharmaceutical Association of Sweden

Pharmaceutical Association of Sweden

Gastric mucosal resistance and prosanoid levels after cimetidine treatment in rats.
*Digestion*, 41, 1-8

chromosome aberrations in cultured mammalian cells by N-nitrosocimetidine. *Cancer
Lett.*, 14, 71-75

307

Barrows, L.R., Gombar, C.T. & Magee, P.N. (1982) Mutation, DNA labeling, and

Bartsch, H., Ohshima, H., Muñoz, N., Crespi, M., Cassale, V., Ramazotti, V., Lambert, R.,
lesions and cancers of the gastrointestinal tract. On-going studies and preliminary
*N-Nitroso Compounds: Occurrence, Biological Effects and Relevance to Human Cancer*
(IARC Scientific Publications No. 57), Lyon, IARC, pp. 955-962

compounds formed from amines and nitrite. *Toxicol. Lett.*, 12, 281-288

Bavin, P.M.G., Durant, G.J., Miles, P.D., Mitchell, R.C. & Pepper, E.S. (1980) Nitrosation of
cimetidine — \(N''-\text{cyano-N-methyl-N''-}(2-[(5\text{-methylimidazol-4-yl})\text{methylthio})\text{ethyl-}
guanidine}\). *Chem. Res.*, 5, 212-213

127-182

prescribed non-steroidal anti-inflammatory drugs: a controlled study using record


Chemical Information Services Ltd (1989-90) Directory of World Chemical Producers, Oceanside, NY


CIMETIDINE


La Piana Simonsen, L. (1989) Top 20 drugs of 1988. Branded new Rx rise 4.0% and total Rx move up 1.2%. Pharm. Times, 55, 40-48


Reed, P.I., Cassell, P.G. & Walters, C.L. (1979) Gastric cancer in patients who have taken cimetidine. *Lancet*, i, 1234-1235


DANTRON (CHRYSAZIN; 1,8-DIHYDROXYANTHRQUINONE)

1. Chemical and Physical Data

1.1 Synonyms

Chem. Abstr. Name: 9,10-Anthracenedione, 1,8-dihydroxy-
Synonyms: Antrapurol; danthron; dianthon; dihydroxyanthraquinone; 1,8-dihydroxy-9,10-anthraquinone; dioxyanthrachinonum; 1,8-dioxyanthraquinone

1.2 Structural and molecular formulae and molecular weight

\[ \text{HO} \quad \text{O} \quad \text{OH} \]

\[ \text{C}_{14}\text{H}_{8}\text{O}_{4} \quad \text{Mol. wt: 240.23} \]

1.3 Chemical and physical properties of the pure substance

(a) Description: Red or reddish-yellow needles or leaves (from ethanol) (Weast, 1985); orange crystalline powder (Anon., 1981)

(b) Melting-point: 193°C (Weast, 1985); 195°C (Anon., 1981)

(c) Spectroscopy data\(^1\): Infrared (Coblenz [5147]; Aldrich, prism [900D]; Aldrich, prism-FT [87D]), ultraviolet (Sadtler [4318]), proton nuclear

\(^1\)Bracketed numbers are spectrum numbers in the relevant compilation.
magnetic resonance (Aldrich [91B]) and mass (Aldermaston [195]) spectral data have been reported (Sadtler Research Laboratories, 1980; Pouchert, 1981, 1983, 1985; Weast & Astle, 1985).

(d) Solubility. Very soluble in aqueous alkali hydroxides; soluble in acetone, chloroform, diethyl ether and ethanol; almost insoluble in water (Enviro Control, 1981; Weast, 1985)

1.4 Technical products and impurities

Trade Names: Altan; Antrapurol; Bancon; Benno; DanSunate D; Danthron; Diaquone; Dionone; Dorban; Dorbane; Duolax; Fructines-Vichy; Istin; Istizin; Julax; Laxanorm; Laxans; Laxanthreen; Laxenta; Laxipur; Laxipurin; Modane; Neokutin S; Pastomin; Prugol; Roydan; Scatron D; Solven; Unilax; Zwitsalax

The following trade names are those of multi-ingredient preparations containing dantron: Agarol Capsules; Coloxyl; Dorbanate; Dorbanex; Dorbantyl; Doss; Doxidan; Normax (Reynolds, 1989).

Dantron is available commercially at a purity of 95-99% (Aldrich Chemical Co., 1988; Lancaster Synthesis Ltd, 1988; Sigma Chemical Co., 1988).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

(a) Production

Dantron has been prepared by several processes, including the alkaline hydrolysis of 1,8-dinitroanthraquinone, the caustic fusion of 1,8-anthraquinone-disulfonic acid, the diazotization of 1,8-diaminoanthraquinone followed by hydrolysis of the bisdiazo compound, the acid hydrolysis of 1,8-dimethoxyanthraquinone in glacial acetic acid-sulfuric acid, the alkaline hydrolysis of 1,8-anthraquinone-disulfonic acid using calcium oxide, and the reaction of 1,8-dinitroanthraquinone with sodium formate or potassium formate (Michalowicz, 1981).


Dantron is synthesized in the Federal Republic of Germany, India, Japan, Poland, the UK and the USA (Chemical Information Services Ltd, 1989-90).

(b) Natural occurrence

Dantron has been isolated from dried leaves and stems of Xyris semifuscata harvested in Madagascar (Fournier et al., 1975). Dantron is the basic structure of
the aglycones of naturally occurring laxative glycosides, in, e.g., Cassia (senna), Aloe, Rheum and Rhamnus (cascara) species (Baars et al., 1976; Reynolds, 1989).

Dantron has been identified in larvae of the elm-leaf beetle, Pyrrhalta luteola. The presence of a mixture of anthraquinones and anthrones was suggested to be a means of protection from predators, and these compounds appear to be biosynthesized by the insect (Howard et al., 1982).

2.2 Use

Dantron has been widely used since the beginning of this century as a laxative and as an intermediate for dyes (Enviro Control, 1981; Michalowicz, 1981).

2.3 Analysis

Dantron can be determined in pharmaceutical preparations by high-performance liquid chromatography with ultraviolet detection (Wurster & Upadrashta, 1986) and by fluorimetry (Miller & Danielson, 1987). It has been determined in urine and faeces by gas chromatography with flame ionization detection (Baars et al., 1976) and in urine by gas chromatography with mass spectrometry (Kok & Faber, 1981) and high-performance liquid chromatography with fluorimetry (Miller & Danielson, 1987).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

(a) Oral administration

Mouse: A group of 20 male C3H/HeN mice, eight weeks of age, was fed dantron (commercial grade; no impurity detected on thin-layer chromatography) at 200 mg/kg diet for 540 days, at which time the experiment was terminated. A group of 20 untreated male mice served as controls. Hepatocellular adenomas were found in 9/17 treated and 5/19 control mice. Hepatocellular carcinomas were found in 4/17 treated mice (all also had adenomas), an incidence that was significantly different ($p < 0.05$; Fisher exact test) from that in controls (0/19). Adenomatous [polypoid] hyperplasia, occasionally associated with dysplastic changes, was observed in the caecum of 17/17 treated mice and in the remainder of the colon of 5/17 treated mice, but not in controls (Mori et al., 1986).

Rat: A group of 18 male ACI rats, eight weeks of age, was fed dantron [purity unspecified] at 10 000 mg/kg diet for 16 months. A group of 15 untreated males
served as controls. Twelve treated and 14 untreated rats survived more than one year. Nine tumours of the large intestine were found in 7/12 treated rats (three adenomas and four adenocarcinomas ($p < 0.02$) of the colon and two adenomas of the caecum). In addition, focal epithelial hyperplasia was observed frequently in the mucosa of the colon and caecum of treated rats with and without intestinal tumours. No intestinal tumour or hyperplastic lesion was found in the 14 controls (Mori et al., 1985).

(b) Administration with known carcinogens

Mouse: In a two-stage carcinogenesis experiment, a group of 20 female ICR/Ha Swiss mice, seven weeks of age, received a single skin application of 7,12-dimethylbenz[a]anthracene at 20 µg in 0.1 ml acetone, followed two weeks later by applications three times a week of commercial-grade dantron at 170 µg in 0.1 ml acetone. A control group of 20 female mice received only skin applications of dantron at 170 µg in 0.1 ml acetone three times a week. Median survival time of animals in both groups was greater than 490 days, when the experiment was terminated. No skin tumour was found in either group (Segal et al., 1971).

Rat: In a two-stage carcinogenicity study, groups of 30 male Sprague-Dawley rats, 50 days of age, received a single subcutaneous injection of 1,2-dimethylhydrazine (DMH) at 150 mg/kg bw. After one week they were fed dantron (purity, > 97%) at 0, 600 or 2400 mg/kg diet; the average daily intakes were approximately 30 and 60 mg/kg bw. After 26 weeks, all animals were killed. Two additional groups of 30 male rats received either no treatment or were given the diet with the higher concentration of dantron alone. There was no significant difference in mean body weight gain between treated and control animals. In the rats treated with DMH plus dantron, the combined incidences of intestinal adenomas and adenocarcinomas were 4/30 in the low-dose and 2/30 in the high-dose group. The incidences of intestinal adenocarcinomas were 0/30 in untreated controls, 0/30 in the group treated with dantron alone and 2/30 in the group treated with DMH alone. The difference in tumour incidence between animals treated with DMH alone and DMH plus dantron was not significant (Sjöberg et al., 1988).

3.2 Other relevant data

(a) Experimental systems

(i) Absorption, distribution, excretion and metabolism

Male Wistar rats were given the sodium salt of dantron intravenously at 4.8, 22 or 58 µmol/kg [1.2, 5.3 or 14 mg/kg] bw or at 120 µmol/kg [28.8 mg/kg] bw by gastric tube. Metabolites identified in the bile and urine following administration by either
route included the monosulfate, β-glucuronide and other unidentified metabolites. Following intravenous administration, about 80% of the dantron conjugates in bile were excreted after 1 h; the dose fractions found after 5 h represented about 20%, 30% and 40% of the low-, intermediate- and high-dose levels, respectively. The corresponding fractions in urine were 16%, 12% and 10%, giving rise to bile:urine excretion ratios of 1.3, 2.7 and 4.0, respectively. Only 30-50% of the dose could be accounted for by conjugates (Sund, 1987). Earlier studies also showed that after oral administration of dantron only 30-40% of the total dose administered could be recovered in faeces and urine, mostly during the first 24 h (Breimer & Baars, 1976).

In vitro, rat jejunum and colon transformed dantron into its monoglucuronide and monosulfate, the monoglucuronide being the major metabolite (Sund & Elvegård, 1988).

(ii) Toxic effects

The oral LD₅₀ for dantron in male ARS/ICR mice was > 7 g/kg bw. Groups of four male and four female beagle dogs received either a vehicle capsule or a capsule containing dantron at 5 or 15 mg/kg bw daily for one year. No adverse effect was observed. The doses employed were reported to be several-fold higher than the usual clinical dose (Case et al., 1977-78).

Apoptosis together with accumulation of lipofuscin pigment in gut wall was noted in guinea-pigs given dantron orally at 25 mg/kg bw (Walker et al., 1988).

Male rats given dantron at 600 or 2400 mg/kg diet for 26 weeks (Sjöberg et al., 1988) had enlarged lymph nodes in the mesocolon, which were brownish due to pigmentation of the accumulated mononuclear phagocytes. In kidney, pigment deposition was seen in the cortical region.

(iii) Effects on reproduction and prenatal toxicity

No data were available to the Working Group.

(iv) Genetic and related effects

Dantron was mutagenic to Salmonella typhimurium TA1537 in the presence and absence of an exogenous metabolic system (Brown & Brown, 1976; Liberman et al., 1982). It was also mutagenic to TA2637 (Tikkanen et al., 1983), TA102 (Levin et al., 1984) and TA104 (Chesis et al., 1984) in the presence of an exogenous metabolic system. In TA104, the results were not significantly changed by the addition of superoxide dismutase and catalase (Chesis et al., 1984). In S. typhimurium TA100, TA1535, TA1538 and TA98, dantron was not mutagenic in the presence or absence of an exogenous metabolic system (Brown & Brown, 1976; Liberman et al., 1982; Tikkanen et al., 1983).

Dantron induced respiration-deficient mutants in yeast (Zetterberg & Swanbeck, 1971).
It induced unscheduled DNA synthesis in hepatocytes from mice (Mori et al., 1984) and rats (Mori et al., 1984; Kawai et al., 1986) but not in another study with rat hepatocytes (Probst et al., 1981). Dantron induced chromosomal aberrations in human peripheral lymphocytes in vitro in the absence of an exogenous metabolic system (Carballo et al., 1981). In some studies, dantron inhibited gap-junctional intercellular communication in Chinese hamster V79 cells (Umeda et al., 1980 [The Working Group noted that the way in which the data were presented precluded statistical analysis.]; Trosko et al., 1982 [one dose]), but in other studies no such effect was found in Chinese hamster V79 cells (Kinsella, 1982; Zeilmaker & Yamasaki, 1986) or in human fibroblasts (Si et al., 1988).

(b) Humans

(i) Pharmacokinetics

Following its administration within 24 h of the induction of labour in 12 women, dantron was found in maternal urine, neonatal urine and amniotic fluid. Most of the drug appeared as a glucuronide in both mothers and babies (Blair et al., 1977).

(ii) Adverse effects

Liver damage was reported in a woman who had used a laxative containing dantron and dioctyl calcium sulfosuccinate for one year. The symptoms disappeared after discontinuation of the medication but reappeared upon resumption; none of the compounds given alone had any effect on the results of hepatic function tests (Tolman et al., 1976).

A woman developed deep discoloration of the skin following ingestion of large amounts of a laxative containing dantron (Darke & Cooper, 1978). Such staining was also found in other studies, predominantly in elderly subjects, and was localized to the buttocks and thighs, with minor inflammatory symptoms (Bunney & Noble, 1974; Cox & Vickers, 1984). Contact of skin with faeces or urine containing the drug seems to be a prerequisite for discoloration. Inflammation, when present, may result from reduction of the parent compound in the colon to the diol derivative, which irritates both the gut and skin (Puschmann, 1983; Ipren, 1974), while the parent compound does not (Green et al., 1988).

Melanosis coli, a state involving apoptosis and lipofuscin pigment accumulation in macrophages in colonic lamina propria, has been described in persons using anthraquinone laxatives (Bockus et al., 1933; Speare, 1951; Wittoesch et al., 1958; Steer & Colin-Jones, 1975; Badiali et al., 1985; Walker et al., 1988).

3.3 Case reports and epidemiological studies of carcinogenicity to humans

No data were available to the Working Group.
4. Summary of Data Reported and Evaluation

4.1 Exposure data

Dantron occurs naturally in several species of plants and in insects. It has been produced and widely used since the beginning of the century as a laxative and, to a lesser extent, as an intermediate for dyes. No data on occupational exposure levels were available.

4.2 Experimental carcinogenicity data

Dantron was tested for carcinogenicity by oral administration in single studies in male mice of one strain and in male rats of one strain. In mice, a small increase in the incidence of hepatocellular carcinomas and a large increase in adenomatous polypoid hyperplasia of the colon were observed; there was also an increased combined incidence of adenomas and adenocarcinomas of the colon and caecum. In rats, dantron increased the incidence of adenocarcinomas of the colon.

4.3 Human carcinogenicity data

No data were available to the Working Group.

4.4 Other relevant data

In one study, dantron caused chromosomal aberrations in human lymphocytes in vitro. It gave contradictory results with respect to the induction of unscheduled DNA synthesis in rodent cells and was mutagenic to yeast in one study and to Salmonella typhimurium. Dantron did not inhibit gap-junctional intercellular communication in human cells, but conflicting results were obtained in Chinese hamster cells. (See Appendix 1.)

4.5 Evaluation\(^1\)

There is sufficient evidence for the carcinogenicity of dantron in experimental animals.

No data were available from studies in humans on the carcinogenicity of dantron.

\(^1\)For definition of the italicized terms, see Preamble, pp. 26–29.
Overall evaluation
Dantron is possibly carcinogenic to humans (Group 2B).

5. References

Anon. (1987) Adria and Hoechst-Roussel Danthron-free OTC Laxatives. FDC Reports Pink Sheet, April 6, T&G-6-T&G-7
DANON

Enviro Control (1981) Anthraquinone Dye Toxicological Profiles (CSPC-Mono-82-2; US NTIS PB83-166033), Rockville, MD


Kinsella, A.R. (1982) Elimination of metabolic co-operation and the induction of sister chromatid exchanges are not properties common to all promoting or co-carcinogenic agents. Carcinogenesis, 3, 499-403


Sigma Chemical Co. (1988) Biochemical and Organic Compounds for Research and Diagnostic Clinical Reagents, St Louis, MO, p. 521


Wurster, D.E. & Upadrashta, S.M. (1986) Simultaneous quantitation of 1,8,9-anthracene-triol, 1,8-dihydroxy-9,10-anthraquinone, and 1,8,1',8'-tetrahydroxy-10,10'-dianthrone by reversed-phase high-performance liquid chromatography. *J. Chromatogr.*, 362, 71-78


FUROSEMIDE (FRUSEMIDE)

1. Chemical and Physical Data

1.1 Synonyms

Chem. Abstr. Services Reg. No.: 54-31-9
Chem. Abstr. Name: 5-(Aminosulfonyl)-4-chloro-2-[(2-furanyl methyl)-amino]-benzoic acid
Synonym: Sulfamoylanthranilic acid, 4-chloro-N-furfuryl-5

1.2 Structural and molecular formulae and molecular weight

\[ \text{C}_{12}\text{H}_{11}\text{ClN}_{2}\text{O}_{5}\text{S} \quad \text{Mol. wt: 330.77} \]

1.3 Chemical and physical properties of the pure substance

(a) Description: White, microcrystalline powder; crystals from aqueous ethanol (Reynolds, 1989)

(b) Melting-point: 206°C dec (Windholz, 1983)

(c) Solubility: Slightly soluble in water; soluble in aqueous solutions above pH 8; slightly soluble in chloroform, ethanol and diethyl ether; soluble in acetone, methanol and dimethylformamide (Windholz, 1983)

(d) Spectroscopy data: Ultraviolet and infrared spectra have been reported (Anon., 1979).
(e) Stability: Discolours on exposure to light (Barnhart, 1989); precipitates with calcium gluconate, ascorbic acid, tetracyclines, urea and adrenaline (Windholz, 1983)

(f) Dissociation constant: $pK_a = 3.9$ (Anon., 1979)

1.4 Technical products and impurities

*Trade names:* Aluzine; Aquamide; Aquasin; Arasemide; Discoid; Diural; Diuresal; Diurolasa; Dryptal; Durafurid; Errolon; Franyl; Frusetic; Furetic; Furix; Furo-basan; Fur-O-Im; Furo-Puren; Furose; Furoside; Fusid; Hydrex; Hydro-rapid; Impugan; Lasiletten; Lasilix; Lasix; Luxor; Min-I-Jet Frusemide; Moilarorin; Neo-Renal; Nicorol; Novosemide; Oedemase; Oedemex; Puresis; Seguril; Sigasalur; SK-Furosemide; Uremide; Urex; Urex-M; Uritol

The following names have been used for multi-ingredient preparations containing furosemide: Diumide-K; Frumil; Frusene; Lasikal; Lasilactone; Lasipressin; Lasix + K; Lasoride

Furosemide is available as tablets (20 mg, 40 mg, 80 mg) with lactose, magnesium stearate, starch and talc (see IARC, 1987), and for injection in 2-, 4- and 10-ml ampoules containing furosemide at 10 mg/ml sterile solution in amber vials (water and sodium hydroxide). It is also available as an oral solution containing furosemide at 10 mg/ml and 11.5% alcohol, D & C Yellow #10, FD & C Yellow #6, glycerine, parabens, sodium hydroxide and sorbitol (Barnhart, 1989).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

Furosemide is prepared from 4,6-dichlorobenzoic acid-3-sulfonylchloride via a multistep synthesis involving the sequential addition of ammonia and 6-furfurylamine (Sturm et al., 1962). It is synthesized in Brazil, Bulgaria, China, Hungary, Israel, Italy, Poland, Switzerland and the USA (Chemical Information Services, 1989-90).

Specific data on production of furosemide are not available, but the number of prescriptions for this drug in the USA increased from 16 million in 1973 to 23 million in 1981. The oral form (Lasix) alone was the eighth most frequently prescribed drug in the USA in 1985 (La Piana Simonsen, 1989). In Sweden, furosemide was sold at a level of 44.08 defined daily doses per 1000 inhabitants in 1988 (Apoteksbolaget, 1988, 1989). In Finland, furosemide sales were 13.87 defined daily doses (40 mg) per 1000 inhabitants in 1987 (Finnish Committee on Drug Information and Statistics, 1987).
Furosemide is not known to occur naturally.

2.2 Use

Furosemide is a potent, short-acting diuretic (Weiner & Mudge, 1985). It is used for the treatment of oedema of cardiac, hepatic or renal origin and in a variety of situations ranging from the control of hypertension to the symptomatic treatment of hypercalcaemia.

Furosemide has a steep dose-effect curve, and therapeutic doses range from 40 to 200 mg daily in adults (Weiner & Mudge, 1985). Treatment of oedema is usually started with an initial oral dose of 40 mg daily; in severe cases, a gradual increase up to 600 mg daily may be required. Intramuscular or slow intravenous injections of furosemide are also used, although the oral route is preferred. In the management of oliguria in acute or chronic renal failure, doses up to 6 g have been given in slow (less than 4 mg per min) intravenous infusions (see Reynolds, 1989).

The usual dose for children is 1-3 mg/kg bw daily given orally and 0.5-1.5 mg/kg bw by injection (Reynolds, 1989).

2.3 Analysis

Furosemide has been determined in biological fluids by high-performance liquid chromatography with detection by spectrofluorimetry (Uchino et al., 1984; Sood et al., 1987) and ultraviolet (Andreasen et al., 1981) and mass spectrometry (Uchino et al., 1984). Analysis of furosemide in pharmaceutical preparations by high-performance liquid chromatography and colorimetric complexation with copper has been reported (Mishra et al., 1989; US Pharmacopeial Convention, Inc., 1989).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

(a) Oral administration

Mouse: Groups of 50 male and 50 female B6C3F1 mice, eight weeks old, were fed furosemide (99% pure, USP grade) at 0, 700 or 1400 mg/kg of diet for 104 weeks. The average amounts of furosemide consumed per day were approximately 100 and 200 mg/kg bw for low- and high-dose groups, respectively. Mean body weights of treated and control mice were comparable. Final survival rates in males were:
control, 31/50; low-dose, 24/50; and high-dose, 26/50; and those in females were: control, 36/50; low-dose, 29/50; and high-dose, 18/50. Survival in high-dose females was significantly lower than that in controls \( (p = 0.003) \). All survivors were killed at weeks 105-107 then necropsied, and about 40 different tissues were examined microscopically. In female mice, a small but statistically significant increase in the incidence of mammary gland carcinomas was observed: control, 0/50; low-dose, 2/50; and high-dose, 5/48 \( (p = 0.01, \) logistic regression test for trend taking account of survival) \cite{national_toxicology_program_1989}.

**Rat:** Groups of 50 male and 50 female F344/N rats, seven weeks old, were fed furosemide (99% pure; USP grade) at 0, 350 or 700 mg/kg of diet for 104 weeks. The average amounts of furosemide consumed per day were approximately 15 and 30 mg/kg bw for low- and high-dose groups, respectively. Mean body weights of treated and control mice were comparable. Survivors at 104-106 weeks in males were: controls, 17/50; low-dose, 17/50; and high-dose, 20/50; those in females were: controls, 35/50; low-dose, 31/50; and high-dose, 34/50. About 40 different tissues were examined microscopically. No statistically significant increase in the incidence of tumours at any site was reported; however, in males, meningiomas of the brain were observed in 3/50 low-dose rats versus 2/1928 in historical controls. The authors noted that these rare tumours occurred early in the study in low-dose animals \cite{national_toxicology_program_1989}.

\( b) \) **Administration with known carcinogens**

**Rat:** Four groups of 25 male Fischer 344 rats, five weeks of age, were given drinking water containing 0.01% or 0.05% \( \text{N-nitrosobutyl-N-(4-hydroxybutyl)} \)amine (NBHBA) for four weeks, followed by no further treatment or administration of furosemide [purity unspecified] dissolved in 0.5% carboxymethyl cellulose by gavage three times per week for 32 weeks (total dose, 250 mg/kg bw). The experiment was terminated at 36 weeks. One group of 25 male rats was treated with furosemide alone. No treatment-related mortality was observed in any group, but body weights of furosemide-treated groups were significantly lower; almost all rats survived to the end of the experiment. Following sacrifice, all bladders were examined histologically. No significant difference in the incidence of bladder lesions (simple, papillary or nodular hyperplasia, papilomas or carcinomas) was seen in furosemide-treated versus other groups. Treatment with furosemide alone did not induce any lesion in the bladder \cite{shibata_et_al_1989}. \cite{the_working_group_noted_the_short_duration_of_the_study_and_the_limited_pathological_examination}.
3.2 Other relevant data

(a) Experimental systems

(i) Absorption, distribution, excretion and metabolism

After oral administration of furosemide to dogs, about 50% of the dose was absorbed (Yakatan et al., 1979). In one study in male Sprague-Dawley rats, the bioavailability of oral furosemide was estimated to be 30% (Lee & Chiou, 1983).

The pharmacokinetics of the disappearance of furosemide from the blood is best described by two- or three-compartment open models, with dose-dependent variations in plasma protein binding (Hammarlund & Paalzow, 1982). In rats, furosemide is cleared from the plasma by the kidneys, is biotransformed by the liver or is excreted unchanged in the bile, with subsequent intestinal reabsorption (Kitani et al., 1988). About 4% of furosemide administered intravenously to rats was recovered from the gut (Lee & Chiou, 1983). In contrast, biliary excretion of furosemide has been reported to be as high as 30% of doses of 50-100 mg/kg bw given to male Swiss mice (Spitznagle et al., 1977). Glucuronidation of furosemide appears to take place in the kidney; removal of the liver did not affect clearance of furosemide in dogs (Lee & Chiou, 1983; Verbeeck et al., 1981).

Covalent binding of furosemide to mouse liver proteins has been shown, and this was enhanced by administration of an inhibitor of epoxide hydrase, suggesting formation of an arene oxide intermediate involving the furan ring (Wirth et al., 1976). In vitro, human liver microsomes can convert furosemide to metabolites that bind irreversibly to microsomal proteins (Dybing, 1977).

Formation of unidentified metabolites was demonstrated after incubation of furosemide with a 9000 × g supernatant fraction of washed stomach homogenates from rats. The apparent metabolism per gram of tissue was greater in the stomach than in the small intestine, large intestine or liver (Lee & Chiou, 1983).

(ii) Toxic effects

The oral LD₅₀ for furosemide was approximately 2700 mg/kg bw in 60-day-old rats (Goldenthal, 1971), 2200 mg/kg bw in mice (Romanova & Rudzit, 1985) and 800 mg/kg bw in rabbits (Horioka et al., 1982). The intravenous LD₅₀ in rabbits was 800 mg/kg (Horioka et al., 1982). Intraperitoneal injection of 400 mg/kg bw into male mice produced massive necrosis in both the midzonal and centrilobular areas of the liver; this damage was prevented by prior administration of cytochrome P450 inhibitors (Mitchell et al., 1974).

Two of five male and three of five female rats that were fed diets containing furosemide at up to 46 g/kg for 14 days died before the end of the studies. Minimal-to-mild nephrosis was found in all rats that received furosemide at 1.3 or 46 g/kg and in one male receiving 5.1 g/kg. Microscopically, the toxic lesion was subcapsular or cortical and was characterized by tubular-cell regeneration;
mineralization was present at the corticomedullary junction. Dose-related nephrosis was also observed in mice in a 14-day study. In a 13-week study, male rats given a diet containing furosemide at 12.5 g/kg or more and females given a diet containing 15 g/kg had increased liver:body weight ratios; dose-related diuresis was also observed. Compound-related minimal-to-moderate nephrosis occurred in male rats given 5 or 10 g/kg and in females given 7.5 or 15 g/kg. Mineralization was observed at the corticomedullary junction in male rats given 0.625 g/kg or more. In mice, dose-related minimal-to-mild nephrosis was also observed in a 13-week study (National Toxicology Program, 1989).

In a two-year study (see section 3.1), nephropathy occurred with greater severity in dosed male rats than in non-dosed rats. In mice, compound-related nephropathy and dilatation of the renal pelvis occurred in males and females; and tubular cysts, suppurative inflammation and epithelial hyperplasia of the renal pelvis were observed. Epithelial hyperplasia and inflammation of the urinary bladder and suppurative inflammation of the prostate were seen in dosed male mice; and suppurative inflammation of the ovary, uterus and adrenal cortex was observed at increased incidence in high-dose female mice (National Toxicology Program, 1989).

Subcutaneous doses of furosemide at 5 or 15 mg/kg bw per day were given to Sprague-Dawley pups from day 4 to day 28 after birth. Increased urinary calcium and magnesium excretion was observed, and the total concentration of calcium and magnesium in bone was lower. The growth of the pups was inhibited in a dose-dependent manner, and bone mineral content was appropriate for the smaller bone mass (Koo et al., 1986).

Furosemide at 0.5 mM reduced the viability of isolated mouse hepatocytes and induced ultrastructural changes related to toxicity (Massey et al., 1987).

Haemodynamic effects include an increase in renal blood flow (Hook et al., 1965) and decreases in mesenteric (Gaffney et al., 1978), hepatic (Gaffney et al., 1979) and splenic (Gaffney & Williamson, 1979) blood flow.

(iii) Effects on reproduction and prenatal toxicity

When CRCD rats were administered furosemide at 37.5, 75, 150 or 300 mg/kg bw twice daily on days 6-17 of gestation [route of administration unspecified], the two highest dose levels, which caused maternal deaths, resulted in increased resorption rates and decreased fetal weights. Dose-related increases in the frequency of wavy ribs occurred in all treatment groups. In addition, five of 176 fetuses in the group receiving 150 mg/kg bw had malformations of the scapula (Robertson et al., 1981).
(iv) Genetic and related effects

Furosemide was not mutagenic to *Salmonella typhimurium* in plate incorporation tests in the presence or absence of an exogenous metabolic system (National Toxicology Program, 1989).

The urine of rats treated *in vivo* with furosemide at 45 mg/kg bw did not induce gene conversion in growing cells of *Saccharomyces cerevisiae* D4-RDII (Marquardt & Siebert, 1971).

Furosemide was reported to induce mutations to trifluorothymidine resistance in L5178Y mouse lymphoma cells in the presence of an exogenous metabolic system only at the highest concentration tested (1500 µg/ml). It was also reported to induce sister chromatid exchange and chromosomal aberrations in Chinese hamster CHO cells at 3750 and 5000 µg/ml in the presence and absence of an exogenous metabolic system (National Toxicology Program, 1989). [The Working Group noted the exceptionally high concentrations used in these studies, surpassing the solubility limits of the test substance, which preclude an assessment of the observed effects.] No sister chromatid exchange was induced in a diploid human fibroblast cell line (HE2144) by concentrations of up to 0.33 mg/ml (Sasaki et al., 1980). Furosemide induced chromosomal damage in Chinese hamster lung fibroblasts *in vitro*, but only in the absence of an exogenous metabolic system (Matsuoka et al., 1979; Ishidate, 1988). A concentration-dependent increase in the frequency of chromosomal aberrations was observed in human lymphocytes exposed *in vitro* to furosemide for 24 and 72 h (Jameela et al., 1979). No such effect was detected in the human fibroblast cell line HE2144 (Sasaki et al., 1980).

In male C3H/HE mice treated intraperitoneally with furosemide at 0.3-50 mg/kg bw, a non-dose-dependent increase in the percentage of meiotic cells with chromosomal aberrations was observed during the whole spermatogenic cycle, i.e., in weeks 1-5 after treatment (Subramanyam & Jameela, 1977). [The Working Group noted that only one mouse per dose per week was apparently used.]

(b) Humans

(i) Pharmacokinetics

In healthy subjects, the bioavailability of furosemide ranges from 60 to 69% (Kelly et al., 1973; Rupp, 1974; Tilstone & Fine, 1978); but in end-stage renal failure its availability is reduced to 43-46% (Rane et al., 1978; Tilstone & Fine, 1978). According to early reports, food does not alter bioavailability, although the rate of absorption is decreased (Kelly et al., 1973). In a recent study, however, a reduction of approximately 30% in bioavailability, accompanied by a reduced diuretic effect, was observed when furosemide was given at 40 mg to ten healthy volunteers with breakfast as compared to when it was given in the fasting state (Beermann & Midskov, 1986).
About 99% of furosemide is bound to plasma proteins (Smith et al., 1980), almost exclusively to albumin (Andreasen & Jacobsen, 1974; Prandota & Pruitt, 1975; Branch, 1983).

Two-compartment models are most often used to describe the kinetics of furosemide (Rupp, 1974; Beermann et al., 1975). The half-time of the α-phase averages 10-15 min and that of the β-phase, 47-90 min (Beermann et al., 1977; Mikkelsen & Andreasen, 1977; Rane et al., 1978; Andreasen et al., 1982). The apparent volume of distribution at steady state is approximately 190 ml/kg (Mikkelsen & Andreasen, 1977; Andreasen et al., 1978). The plasma clearance of furosemide is 2.2-3.0 ml/min per kg (Mikkelsen & Andreasen, 1977; Andreasen et al., 1978). A higher non-renal clearance ratio is seen after oral dosing (15.7 ± 4.8%) than after intravenous administration (11.2 ± 4.0%) (Zhu & Koizumi, 1987). Glucuronide conjugate is the only well documented metabolite of furosemide in man (Beermann et al., 1975; Andreasen & Mikkelsen, 1977; Verbeeck et al., 1982).

About 20% of furosemide is eliminated by renal glucuronidation (Smith et al., 1980); it has been suggested that the remaining 25-30% may be secreted into the gut in unchanged and/or conjugated form (Branch, 1983). However, gastrointestinal elimination amounted to only 2% of renal clearance, and active secretion into the intestinal lumen did not occur in six healthy volunteers given furosemide as a 40-mg bolus followed by a continuous infusion of 0.55 mg/kg per h. Plasma clearance was 223 ± 15, renal clearance, 93.1 ± 21.2 and total clearance by the gastrointestinal tract, 2.1 ± 0.2 ml/min. There was no change in the intestinal clearance of furosemide after administration of probenecid, but plasma and renal clearance decreased by 48 and 70%, respectively. It was also shown that incubation of urine samples with β-glucuronidase increased furosemide levels (Valentine et al., 1986).

The disposition of furosemide during renal insufficiency, nephrotic syndrome, cirrhosis and congestive heart failure has been reviewed (Brater, 1986). The mean plasma half-time of furosemide in patients with nephrosis does not differ from that in normal subjects but is prolonged about three fold in patients with uraemia (Rane et al., 1978). A positive relationship between the renal clearance of creatinine and of furosemide has been shown (Beermann et al., 1977). Liver disease may prolong plasma half-time by up to 4.3 h, depending on the degree of liver failure (Allgulander et al., 1980; Fuller et al., 1981; Verbeeck et al., 1982).

(ii) Adverse effects

The most common adverse effects of furosemide are fluid and electrolyte imbalance, including hyponatraemia, hypokalaemia and hypochloraemic alkalosis. Hyperuricaemia is relatively common, and a variety of uncommon adverse reactions have been reported (see Reynolds, 1989).
Signs of volume depletion and hypokalaemia have been reported in several studies (Greenblatt et al., 1977; Naranjo et al., 1978; Spino et al., 1978; Lowe et al., 1979). Rare adverse effects reported in patients receiving furosemide include skin rash, thrombocytopenia (Lowe et al., 1979), gynaecomastia (Tuzel, 1981), temporary hearing impairment (Naranjo et al., 1978; Spino et al., 1978) and hepatic coma in cirrhotic patients (Naranjo et al., 1978). Elevated serum concentrations of parathyroid hormone and alkaline phosphatase, together with decreased calcium concentration, were shown in 36 patients with congestive heart failure (Elmgreen et al., 1980).

Renal calcification was documented in ten premature infants who had received furosemide in a dose of at least 2 mg/kg bw per day for at least 12 days (Hufnagel et al., 1982).

(iii) Effects on reproduction and prenatal toxicity

No report of pregnancy outcomes following first-trimester use of furosemide has been found. Furosemide has been used extensively for treatment of oedema, hypertension and heart failure in the later stages of pregnancy, with no apparent adverse effect on the fetus or newborn (see review by Briggs et al., 1986).

(iv) Genetic and related effects

No data were available to the Working Group.

3.3 Case reports and epidemiological studies of carcinogenicity to humans

In a hypothesis-generating cohort study designed to screen a large number of drugs for possible carcinogenicity [described in detail in the monograph on ampicillin], 2302 persons to whom at least one prescription for furosemide had been dispensed during 1969-73 were followed up for up to 15 years (Selby et al., 1989). Increased risks were noted for cancer of the lung (50 observed, 25.4 expected; \( p < 0.002 \)) and for cancers at all sites combined (233 observed, 164.5 expected; \( p < 0.002 \)). [The Working Group noted that heart failure and cirrhosis of the liver, both of which are associated directly or indirectly with cigarette smoking, are frequent indications for prescribing furosemide, and confounding by cigarette smoking (which was not analysed in the study) may explain the observed associations.] In an earlier report with up to nine years of follow-up (Friedman & Ury, 1983), there was also an association with cancer of the liver (5 observed, 1.6 expected cases; \( p < 0.05 \)). The medical records indicated that this association was due to underlying liver disease for which furosemide was prescribed. [The Working Group noted, as did the authors, that, since some 12 000 comparisons were made in this study, the associations should be verified independently. Data on duration of use were not provided.]
4. Summary of Data Reported and Evaluation

4.1 Exposure data

Furosemide is a diuretic. It has been used extensively since 1964 in the treatment of oedema and hypertension.

4.2 Experimental carcinogenicity data

Furosemide was tested for carcinogenicity by oral administration in one strain of mice and one strain of rats. A small increase in the incidence of mammary gland carcinomas was observed in female mice. No increase in the incidence of tumours was seen in rats.

4.3 Human carcinogenicity data

In one hypothesis-generating study in which many drugs were screened for possible carcinogenicity, associations with furosemide use were observed for cancers of the lung and of all sites combined, which could have been accounted for by smoking and/or chance.

4.4 Other relevant data

The data are inadequate to assess the effects of furosemide on human reproduction. In rats, the drug induces skeletal anomalies.

Furosemide is metabolized by mouse and human liver microsomes and binds covalently to proteins. Renal tubular hyperplasia and hepatic centrilobular necrosis have been observed after administration of large doses of furosemide to mice.

Studies on the induction by furosemide of chromosomal aberrations in mice were inconclusive. Reports of studies on chromosomal aberrations in human cells in vitro gave conflicting results; it induced chromosomal damage in hamster cells. Furosemide did not induce sister chromatid exchange in human cells in vitro; one study gave questionably positive results for sister chromatid exchange in Chinese hamster cells and for gene mutation in mouse lymphoma cells. The urine of rats treated with this drug did not induce gene conversion in Saccharomyces cerevisiae. It was not mutagenic to Salmonella typhimurium. (See Appendix 1.)
4.5 Evaluation

There is inadequate evidence for the carcinogenicity of furosemide in humans.
There is inadequate evidence for the carcinogenicity of furosemide in experimental animals.

Overall evaluation
Furosemide is not classifiable as to its carcinogenicity to humans (Group 3).

5. References


1For description of the italicized terms, see Preamble, pp. 26-29.


Chemical Information Services (1989-90) *Directory of World Chemical Producers*, Oceanside, NY


Horioka, M., Saito, T., Takagi, K. & Takasugi, M. (1982) *Drugs in Japan (Ethical Drugs)*, Tokyo, Japan Pharmaceutical Information Center


Marquardt, H. & Siebert, D. (1971) Ein neuer host mediated assay (Urinversuch) zum Nachweis mutagener Stoffe mit Saccharomyces cerevisiae. [A new host-mediated assay (urine test) for the detection of mutagenic material with *Saccharomyces cerevisiae* (Ger.).] *Naturwissenschaften*, 58, 568


National Toxicology Program (1989) *Toxicology and Carcinogenesis Studies of Furosemide (CAS No. 54-31-9) in F344/N Rats and B6C3F1 Mice (Feed Studies)* (Technical Report No. 356), Research Triangle Park, NC, US Department of Health and Human Services, pp. 1-90


FUROSEMIDE


HYDROCHLOROTHIAZIDE

1. Chemical and Physical Data

1.1 Synonyms

Chem. Abstr. Name: 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-1,1-dioxide  
Synonyms: 6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-dihydrochlorothiazide; chlorosulfonamidodihydrobenzothiadiazine dioxide; chlorosulthiadiil

1.2 Structural and molecular formula and molecular weight

\[
\begin{align*}
\text{NH}_2\text{SO}_2 & \quad \text{O} \\
\text{S} & \quad \text{O} \\
\text{Cl} & \quad \text{N} \\
\text{H} & \quad \text{N-H} \\
\end{align*}
\]

C\text{\textsubscript{7}}H\text{\textsubscript{8}}ClN\text{\textsubscript{3}}O\text{\textsubscript{4}}S 
Mol. wt: 297.72

1.3 Chemical and physical properties of the pure substance

From Deppeler (1981), unless otherwise specified  
(a) Description: White, fluffy, microcrystalline powder  
(b) Melting-point: 273-275°C (Windholz, 1983)  
(c) Solubility: Practically insoluble in water; soluble in dilute ammonia and sodium hydroxide; soluble in methanol, ethanol, acetone and acetonitrile  
(d) Spectroscopy data: Infrared, ultraviolet, nuclear magnetic resonance and mass spectra have been reported.  
(e) Stability data: Stable in bulk for five years at room temperature; at extremes of pH in aqueous solution, hydrolysed to formaldehyde and 6-chloro-2,4-disulfamoylaniline
Dissociation constant: $\text{pK}_a$ 7.2, 9.2 (Windholz, 1983)

1.4 Technical products and impurities

*Trade names:* Apo-Hydro; Aquarius; Atenadon; Bremil; Caturida; Chlorthia; Chlorzide; Cidrex; Cloredema; Delco-Retic; Dichlorosal; Dichlortride; Dichlotride; Diclotride; Didral; Diidrotiazde; Direma; Disalunil; Diu 25; Diucen-H; Diurex; Diursana-H; Dixidrasi; Edemex; Esidrex; Esidrix; Fluvin; Hidrenox; Hidroronol; Hidrosaluretil; Hydri; Hydro-Aquil; Hydro-Diuril; Hydro-MURIL; Hydrosaluric; Hydrothide; Hydro-Z; Hydrozide; Hypothiazde; Idrodiuvis; Idrofluin; Idroliisin; Ivaugan; Jen-diral; Lexor; Loqua; Maschitt; Mietrin; Natrimax; Nefrix; Neo-Codema; NeoFlumen; Neo-Flumen; Neo Minzil; Newtolide; Novohydrazide; Oretic; Pantemon; Panurin; Ridaq; Ro-Hydrazde; Salupres; Serapres; SK-Hydrochlorothiazide; Tandiur; Thiarietic; Thiuretic; Urirex; Urodiazin; Urozide; Vetidrex

Hydrochlorothiazide is also contained in numerous multi-ingredient preparations.

Hydrochlorothiazide is available as tablets for oral use (25, 50 or 100 mg) containing calcium phosphate, D & C Yellow #6, gelatin, lactose, magnesium stearate, starch and talc (see IARC, 1987) (Barnhart, 1989).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

Hydrochlorothiazide is synthesized by either the reaction of paraformaldehyde with 5-chloro-2,4-disulfamoylaniline in nonaqueous media, or the reaction of formaldehyde with 6-chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine-1,1-dioxide in aqueous alkaline solution (Deppeler, 1981). It is synthesized in China, Hungary, India, Italy, Japan, Romania, Switzerland, the UK, the USA and Yugoslavia (Chemical Information Services, 1989-90).

Hydrochlorothiazide has been used as a diuretic and antihypertensive agent since 1957 (Reynolds, 1989). More prescriptions were written for hydrochlorothiazide/triamterene combination than for any other prescription drug product in the USA in 1984 and 1985 (Chappell, 1985), and hydrochlorothiazide was the sixth most frequently prescribed generic drug in 1987 and 1988 in the USA (La Piana Simonsen, 1989). In 1988, this drug was sold in Sweden at a level of 0.14 defined daily doses per 1000 inhabitants (Apoteksbolaget, 1988, 1989). In 1987, it was sold in Finland at a level of 2.06 defined daily doses per 1000 inhabitants (Finnish Committee on Drug Information and Statistics, 1987).
Hydrochlorothiazide is not known to occur as a natural product.

2.2 Use

Hydrochlorothiazide is a thiazide diuretic (Reynolds, 1989). It is used to reduce oedema associated with heart failure, as an antihypertensive agent, and for special indications such as Ménière's disease (Roydhouse, 1974) and reduction of the formation of renal calculi in patients with hypercalciuria (Yendt et al., 1970; Baggio et al., 1986). The daily dose of hydrochlorothiazide in treating oedema is 25-50 mg after an initial dose of twice this amount. The daily dose for children is 2.5 mg/kg bw and that for infants under six months, 3.5 mg/kg bw. The antihypertensive doses of hydrochlorothiazide vary between 25 and 200 mg daily (Reynolds, 1989).

2.3 Analysis

Hydrochlorothiazide can be analysed in urine and plasma by colorimetry, thin-layer chromatography and high-performance liquid chromatography (Sheppard et al., 1961; Redalieu et al., 1978; Suria, 1978; Koopmans et al., 1984; Alton et al., 1986; Fullinfaw et al., 1987; van der Meer & Brown, 1987). Analysis of hydrochlorothiazide in pharmaceutical preparations has also been reported (Cieri, 1988; US Pharmacopoeial Convention, Inc., 1989).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

(a) Oral administration

Mouse: Groups of 50 male and 50 female B6C3F1 mice, seven to eight weeks of age, were fed hydrochlorothiazide (> 98% pure) at 0, 2500 or 5000 mg/kg of diet for 103-104 weeks (average daily intake, 280 or 575 mg/kg bw), and all survivors were killed at weeks 113-114. Mean body weights were similar in control and treated mice. Survival in males was: control, 43/50; low-dose, 42/50 and high-dose, 43/50; that in females was: control, 38/50; low-dose, 40/50 and high-dose, 35/50. All animals were necropsied, and samples taken from all major organs, tissues and gross lesions were examined histologically. A significant increase in the incidence of hepatocellular adenomas and of combined adenomas and carcinomas (control, 7/48; low-dose, 10/49; high-dose, 21/50 (p = 0.009, incidental tumour test)) but not of carcinoma alone was observed in males. No increase in the incidence of any other neoplasm was observed (National Toxicology Program, 1989).
Rat: A group of 24 male and 24 female Fischer 344 rats, six to eight weeks of age, were fed hydrochlorothiazide [purity unspecified] at 1000 mg/kg of diet for 104 weeks (total intake: males, 21 g; females, 14 g). A control group of 24 male and 24 female rats remained untreated. Over 70% of the rats survived more than two years, with similar survival rates in all groups. All survivors were killed after 130 weeks; complete necropsies were performed on all animals, and major organs were examined histologically. No difference in overall tumour incidence or in the incidence of tumours at any site was observed between treated and control rats (Lijinsky & Reuber, 1987).

Four groups each of 50 male and 50 female Fischer 344/N rats, seven to eight weeks of age, were fed hydrochlorothiazide (> 98% pure) at 0, 250, 500 or 2000 mg/kg of diet for 105-106 weeks (average daily intake, 11, 23 or 89 mg/kg bw), and all survivors were killed at weeks 113-114. Survival was—males: control, 18/50; low-dose, 16/50; mid-dose, 9/50; high-dose, 11/50; females: control, 31/50; low-dose, 25/50; mid-dose, 30/50; high-dose, 27/50. All animals were necropsied, and samples from all major organs, tissues and gross lesions were examined histologically. No increase in either overall tumour incidence or in the incidence of tumours at any site was observed (National Toxicology Program, 1989).

(b) Administration in combination with other compounds

Rat: In the experiment by Lijinsky and Reuber (1987), described above, three groups each of 24 male and 24 female Fischer 344 rats, six to eight weeks of age, were fed diets containing hydrochlorothiazide [purity unspecified] at 1000 mg/kg, sodium nitrite at 2000 mg/kg or hydrochlorothiazide at 1000 mg/kg plus sodium nitrite at 2000 mg/kg for 104 weeks. Over 70% of the rats survived more than two years, with similar survival rates in all groups. All survivors were killed after 130 weeks; complete necropsies were performed on all animals, and major organs were examined histologically. No difference in overall tumour incidence or in the incidence of tumours at any site was observed between treated and control rats.

3.2 Other relevant data

(a) Experimental systems

(i) Absorption, distribution, excretion and metabolism

No data were available to the Working Group.

(ii) Toxic effects

The oral LD$_{50}$ for hydrochlorothiazide in mice was 3080 mg/kg bw (Barnes & Eltherington, 1965).

All 20 dogs receiving hydrochlorothiazide at daily doses of 50-200 mg for up to nine months had enlarged, hyperactive parathyroid glands (Pickleman et al., 1969).
In male (but not female) Syrian golden hamsters receiving hydrochlorothiazide at 1 or 2 mg/kg bw by gavage for six months, increased total cholesterol and high-density lipoprotein cholesterol levels were observed. When a dose of 4 mg/kg bw was administered, a similar increase was seen in animals of each sex (Sarva et al., 1985).

All male and female rats fed diets containing 3.125-50 g/kg (five dose levels) hydrochlorothiazide survived for 15 days. Thymic haemorrhage of slight to moderate severity was observed in animals receiving the highest doses, but no other toxic effect was observed (National Toxicology Program, 1989).

In groups of 24 male and 24 female rats fed hydrochlorothiazide at 1000 mg/kg of diet for two years, the incidence and severity of chronic progressive nephropathy and of lesions secondary to chronic renal disease, polyarteritis and mural thrombosis were increased (Lijinsky & Reuber, 1987).

In a two-year study (see section 3.1), there was a uniform reduction in the body weight of treated rats (male and female) at all doses. Chronic renal disease (cysts of the parenchyma and epithelial hyperplasia of the renal pelvis) was present in all groups of male and female rats, but it was more severe in dosed groups. Secondary signs of chronic renal disease, including parathyroid hyperplasia, mineralization in multiple organs and fibrous osteodystrophy, also occurred at increased frequency in dosed groups. No other lesion in rats appeared to be related to exposure to hydrochlorothiazide. In mice, a two-year exposure had only negligible effects on body weight. No increase in the frequency of non-neoplastic lesions in the kidney, urinary bladder or any other organ was attributed to hydrochlorothiazide administration (National Toxicology Program, 1989).

(iii) Effects on reproduction and prenatal toxicity

Hydrochlorothiazide was administered by gavage to pregnant CD rats at 100, 300 or 1000 mg/kg bw per day and to CD-1 mice at 300, 1000 or 3000 mg/kg bw per day on gestational days 6-15. No dose-related fetal toxicity or significant increase in the incidence of malformations was observed (National Toxicology Program, 1989).

(iv) Genetic and related effects

Hydrochlorothiazide did not induce reversion in an arg strain of *Escherichia coli* (Hs30R) (Fujita, 1985). It was not mutagenic to *Salmonella typhimurium* in the presence or absence of an exogenous metabolic system (Waskell, 1978; Andrews et al., 1984). [The Working Group noted that only one concentration was used in both studies.] In strain TA98, but not in TA1535, TA1537 or TA100, a small, reproducible, concentration-dependent increase in the mean number of revertants was observed in the absence, but not in the presence, of an exogenous metabolic system (Mortelmans et al., 1986).

In a spot test, hydrochlorothiazide induced nondisjunction and mitotic crossing-over in *Aspergillus nidulans* (Bignami et al., 1974).
Hydrochlorothiazide did not induce sex-linked recessive lethal mutations in *Drosophila melanogaster* either fed or injected with solutions of 10 mg/ml (Valencia *et al.*, 1985).

At concentrations above 500 µg/ml, hydrochlorothiazide produced cytotoxic effects and induced mutations to trifluorothymidine resistance in L5178Y mouse lymphoma cells in the absence of an exogenous metabolic system (National Toxicology Program, 1989). Significant, but not concentration-dependent, increases in the frequency of sister chromatid exchange were observed in Chinese hamster CHO cells in the presence and absence of an exogenous metabolic system (Galloway *et al.*, 1987). Chromosomal aberrations were not found in Chinese hamster lung CHL cells, but polyploidy was observed after 48 h treatment (Ishidate, 1988). Chromosomal aberrations were also not detected in Chinese hamster CHO cells in the presence or absence of an exogenous metabolic system at concentrations of up to 2600 µg/ml (Galloway *et al.*, 1987).

(b) Humans

(i) Pharmacokinetics

The pharmacokinetics of hydrochlorothiazide have been reviewed (Welling, 1986).

Hydrochlorothiazide is incompletely absorbed from the duodenum and upper jejunum (Beermann *et al.*, 1976), and plasma concentrations, peaking at about 2-3 h after intake, are proportional to the dose within the range 25-100 mg (Patel *et al.*, 1984). Administration with food either enhances (Beermann & Groschinsky-Grind, 1978) or reduces (Barbhaiya *et al.*, 1982) the absorption of hydrochlorothiazide, as compared with fasting conditions. The discrepancy is partly attributable to differences in fasting states in these experiments. Food might delay passage through the small intestine; patients with intestinal shunt surgery and accelerated intestinal passage have shown reduced absorption of hydrochlorothiazide (Backman *et al.*, 1979).

Hydrochlorothiazide is concentrated in red blood cells (Beermann *et al.*, 1976; Redalieu *et al.*, 1985). It is excreted almost entirely unchanged in urine; its renal clearance rate (about 300 ml/min) indicates combined glomerular filtration and tubular secretion (Barbhaiya *et al.*, 1982). Its plasma elimination half-time is about 6 h initially but up to 15 h terminally (Patel *et al.*, 1984). In patients with decreased renal function, the plasma half-time of hydrochlorothiazide is prolonged to 20 h (Niemeyer *et al.*, 1983).

Concentrations of hydrochlorothiazide in maternal plasma and umbilical cord plasma were similar (Beermann *et al.*, 1980) and were lower than those in amniotic fluid (Mulley *et al.*, 1978). The drug was detected in the milk of nursing mothers
treated with it, but no measurable concentration was found in nursing infants (detection limit, 20 ng/ml) (Miller et al., 1982).

(ii) Adverse effects

Administration of large doses of hydrochlorothiazide often leads to electrolyte imbalance, including hypochloraeamic alkalosis, hyponatraemia, hypokalaemia and hypercalcaemia (Porter et al., 1978; Zalin et al., 1984; Bayer et al., 1986; Reynolds, 1989).

Like other thiazide diuretics, hydrochlorothiazide is known to produce metabolic effects, such as hyperglycaemia and glycosuria, in diabetic and other susceptible patients (Flamenbaum, 1983; Freis, 1986). It produces asymptomatic hyperuricaemia in many patients, although actual attacks of gout are not common (Anon., 1987).

Hyperparathyroidism associated with prolonged intake of thiazides, including hydrochlorothiazide, has been reported (Paloyan & Pickleman, 1969; Christensson et al., 1977; Klimiuk et al., 1981).

A number of skin diseases of an allergic and idiosyncratic nature have been reported among patients treated with thiazide diuretics (Ebstein & Wintroub, 1985; Reed et al., 1985; Hardwick & Saxe, 1986).

Interstitial nephritis (Linton et al., 1980; Scully et al., 1983), idiosyncratic pneumonitis (Piper et al., 1983; Parfrey & Herlong, 1984), thrombocytopenia (Eisner & Crowell, 1971), intravascular haemolysis (Beek et al., 1984) and pancreatitis (Cornish et al., 1961) have been reported in patients treated with thiazide diuretics.

(iii) Effects on reproduction and prenatal toxicity

In the Collaborative Perinatal Project, in which drug intake and pregnancy outcome were studied in a series of 50,282 women in 1959-65, 107 women had been exposed to hydrochlorothiazide during the first trimester of pregnancy. There were nine malformed children in the exposed group, giving a nonsignificant standardized relative risk of 1.2 (Heinonen et al., 1977).

(iv) Genetic and related effects

No data were available to the Working Group.

3.3 Case reports and epidemiological studies of carcinogenicity to humans

In a hypothesis-generating cohort study designed to screen a large number of drugs for possible carcinogenicity (described in detail in the monograph on ampicillin), 12,799 persons to whom at least one prescription for a thiazide diuretic had been dispensed during 1969-73 were followed up for up to 15 years (Selby et al., 1989). Hydrochlorothiazide was the predominant drug used in this group.
Increased risks were noted for cancer of the prostate (53 cases observed, 38.2 expected; $p < 0.05$) during follow-up of up to seven years (Friedman & Ury, 1980) and for cancers at all sites combined (1209 observed, 1132.9 expected; $p < 0.05$) during follow-up of up to 15 years (Selby et al., 1989). The association with prostatic cancer diminished in later follow-up. [The Working Group noted that prostatic cancer may be diagnosed more readily in patients under more intensive medical care. In addition, as also noted by the authors, since some 12000 comparisons were made in this hypothesis-generating study, the associations should be verified independently. Data on duration of use were not provided.]

4. Summary of Data Reported and Evaluation

4.1 Exposure data

Hydrochlorothiazide has been used extensively since 1957 as a diuretic and antihypertensive agent.

4.2 Experimental carcinogenicity data

Hydrochlorothiazide was tested for carcinogenicity by oral administration in one strain of mice and one strain of rats. An increase in the incidence of hepatocellular adenomas was observed in male mice. No increase in the incidence of tumours at any site was observed in two studies in rats.

4.3 Human carcinogenicity data

In one hypothesis-generating study in which many drugs were screened for possible carcinogenicity, associations with hydrochlorothiazide use were observed for cancers of the prostate and of all sites combined, which could be accounted for by chance.

4.4 Other relevant data

One study provided no evidence that use of hydrochlorothiazide in the first trimester of pregnancy is associated with the induction of birth defects. In rats, no teratogenic, embryotoxic or fetotoxic effect was observed.

Hydrochlorothiazide induced gene mutations in mouse lymphoma cells and sister chromatid exchange in Chinese hamster cells. It did not induce chromosomal aberrations in Chinese hamster cells in vitro or sex-linked recessive lethal mutations in Drosophila. Hydrochlorothiazide induced mitotic recombination and nondis-
junction in Aspergillus nidulans. It was not mutagenic to Salmonella typhimurium or Escherichia coli. (See Appendix 1.)

4.5 Evaluation

There is inadequate evidence for the carcinogenicity of hydrochlorothiazide in humans.

There is inadequate evidence for the carcinogenicity of hydrochlorothiazide in experimental animals.

Overall evaluation

Hydrochlorothiazide is not classifiable as to its carcinogenicity to humans (Group 3).

5. References


1For description of the italicized terms, see Preamble, pp. 26-29.


Chappell, S.C. (1985) 1st 6 months of 1985: RPhs are decision-makers in 20% of new Rxs compared with only 17% one year ago. *Pharm. Times*, 51, 122-130

Chemical Information Services (1989-90) *Directory of World Chemical Producers*, Oceanside, NY


HYDROCHLOROTHIAZIDE


National Toxicology Program (1989) *Toxicology and Carcinogenesis Studies of Hydrochlorothiazide (CAS No. 58-93-5) in F344/N Rats and B6C3F1 Mice (Feed Studies)* (Technical Report Series No. 357), Springfield, VA, National Technical Information Service


PARACETAMOL (ACETAMINOPHEN)

1. Chemical and Physical Data

1.1 Synonyms and trade names

Chem. Abstr. Name: Acetamide, N-(4-hydroxyphenyl)-
Synonyms: 4'-Hydroxy-acetanilde; para-acetaminophenol; acetophenum;
para-acetylamidophenol; N-acetyl-para-aminophenol; para-acetylamino-
phenol; para-hydroxyacetanilde; N-para-hydroxyphenylacetamide
A large number of fixed combinations containing paracetamol are available.

1.2 Structural and molecular formula and molecular weight

\[
\text{C}_8\text{H}_9\text{NO}_2 \quad \text{Mol. wt: 151.16}
\]

1.3 Chemical and physical properties of the pure substance

From Fairbrother (1974) and El-Obeid and Al-Badr (1985)
(a) Description: White odourless crystalline powder; large monoclinic prisms
    from water
(b) Melting-point: 169-170.5°C
(c) Solubility: Soluble in water (1:70, 1:20 at 100°C), ethanol (1:7), acetone
    (1:13), chloroform (1:50), glycerol (1:40), methanol (1:10), propylene glycol
    (1:9) and solutions of alkali hydroxides; insoluble in diethyl ether. A
    saturated aqueous solution has a pH of ~6.
(d) Spectroscopy data: Infrared, ultraviolet, nuclear magnetic resonance,
    fluorescence and mass spectra have been reported.
(e) **Stability:** Dry, pure paracetamol is stable to 45°C. Contamination with traces of para-aminophenol, and humid conditions that cause hydrolysis to para-aminophenol, result in further degradation and discoloration. Slightly light-sensitive in solution, and degradation is catalysed by acids or bases.

(f) **Dissociation constant:** $\text{pK}_a = 9.0$-$9.5$

(g) **Partition coefficient:** $P_c = 6.237$ (octanol: pH 7.2 buffer)

### 1.4 Technical products and impurities

Paracetamol is available in pure form as numerous trade-name preparations for oral use. It is also combined in over 200 preparations with other drugs.

**Trade names:** Abensanil; Acamol; Acephen; Acetalgin; Acetamol; Aferadol; Alba-Temp; Alpiny; Alvedon; Amadil; Anacin-3; Anaflon; Anhiba; Anuphen; Apamide; APAP; Atasol; Ben-u-ron; Bickie-mol; Bramcetamol; Calip; Calpol; Calpon; Campain; Capital; Captin; Ceetamol; Cetadol; Cetamol; Cetapon; Claradol; Claratal; Custodial; Dafalgan; Datril; Dial-a-gesix; Dirox; Disprol Paediatric; Dolamin; Dolanex; Doliprane; Doloral; Dolorol; Dolprone; Dorcol Children's Fever and Pain Reducer; Doregrippin; Dymadon; Efferalgan; Enelfa; Eneril; Ennagesic; Eu-Med; Exdol; Fanalgic; Febrigesic; Febrilix; Fendol; Fevamol; Finimal; Fonafor; Gelocatil; Glenpar; Gynospasmine; Hedex; Homoolan; Kinderfinimal; Kinder-Finiweh; Korum; Liquiprin; Lyteca; Malgis; Melabon; Momentum; Napamol; Naprinol; Nebs; Neuridal; Nevral; Nina 120; Nobedon; Ophinal; Orafen; Pacemo; Pacemol; Painamol; Painaway; Paldesic; Pamol; Panado; Panadol; Panaleve; Panamax; Panasorb; Panets; Panex; Panodil; Panofen; Pantalgin; Paracet; Paracetamolum; Paraclear; Paralgin; Parapain; Paraprom; Parasin; Parasp; Paratol; Parmol; Pasolind; Phendex; Pinex; Placemol; Praecimed; Proval; Puermol; Pyragies; Pyralen; Reliv; Repamol; Resolve; Robigesic; Rounox; Salzene; Schmerzex; Sedapyren; Servigesic; Setamol; SK-APAP; Summadol; Tabalgin; Tachipirina; Tapar; Temlo; Tempra; Tenasfen; Ticelgesic; Tralgan; Treupel; Treuphadol; Tricocetamol; Tylan; Tymol; Valadol; Zolben

Paracetamol is available as 325-mg or 500-mg tablets, which may include calcium stearate or magnesium stearate, cellulose, docusate sodium and sodium benzoate or sodium lauryl sulfate, starch, hydroxypropyl methylcellulose, propylene glycol, sodium starch glycolate, polyethylene glycol and Red #40.

It is also available as 500-mg gelatin capsules and as a mint-flavoured liquid containing 500 mg/15 ml solution, which can include 7% ethanol, citric acid, glycerine, polyethylene glycol, sodium benzoate, sorbitol, sucrose, Yellow #6, #10 and Blue #1. For children, drops (80 mg/0.8 ml), chewable tablets (80 mg), elixir (160 mg/5 ml) and coated capsules (160 mg/capsule) are available (Barnhart, 1989).
Characteristic impurities may include *para*-nitrophenol, *para*-aminophenol, *para*-chloroaniline, *ortho*-acetyl paracetamol, azobenzene (see IARC, 1975), azoxybenzene, quinone (see IARC, 1977), quinonimine, inorganic chloride, inorganic sulfate, inorganic sulfide and water (Fairbrother, 1974).

2. Production, Occurrence, Use and Analysis

2.1 Production and occurrence

Paracetamol may be made by acetylation of *para*-aminophenol (obtained by reduction of *para*-nitrophenol) with acetic acid or acetic anhydride. A number of other synthetic routes have been described (Fairbrother, 1974).

Paracetamol is synthesized in Argentina, Brazil, China, Colombia, France, the Federal Republic of Germany, India, Japan, Mexico, Poland, Republic of Korea, Romania, Taiwan, Turkey, the UK and the USA (Chemical Information Services Ltd, 1989-90).

In Sweden, paracetamol sales in 1988 were 20.02 defined daily doses per 1000 inhabitants (Apoteksbolaget, 1988, 1989).

Paracetamol is not known to occur naturally, but it is the major metabolite of phenacetin (see IARC, 1980, 1987).

2.2 Use

Paracetamol is used as an analgesic and antipyretic drug. It is the preferred alternative analgesic-antipyretic to aspirin (acetylsalicylic acid), particularly in patients with coagulation disorders, individuals with a history of peptic ulcer or who cannot tolerate aspirin, as well as in children (American Medical Association, 1986). Paracetamol was first used in clinical medicine in 1893. Following initial use as a prescription product in the USA in 1951, it subsequently became available without prescription in 1955 (Ameer & Greenblatt, 1977). In many countries, it is widely available without prescription.

The conventional oral dose for adults is 500-1000 mg. Dosing may be repeated every 4 h as necessary, but the total daily dose should not exceed 4000 mg. For children, the recommended dose is 10-15 mg/kg bw; no more than five doses should be administered over 24 h. Prolonged use (for more than ten days) and use for young children is not recommended (Flower et al., 1985).

The usual dose for rectal administration is equal to that for oral administration (American Medical Association, 1986).
2.3 Analysis

Methods for the analysis of paracetamol have been reviewed (El-Obeid and Al-Badr, 1985).

Paracetamol and its metabolites can be analysed in biological fluids by high-performance liquid chromatography (HPLC; Manno et al., 1981; Kinney & Kelly, 1987; Aguilar et al., 1988; Meatherall & Ford, 1988), HPLC-mass spectrometry (Betowski et al., 1987) and fluorescence polarization immunoassay (Koizumi et al., 1988). It can be analysed in pharmaceutical preparations by HPLC (Biemer, 1987) and spectrophotometric (US Pharmacopeial Convention, Inc., 1989) methods.

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity studies in animals

Since paracetamol is a metabolite of phenacetin (Reynolds, 1989), carcinogenicity studies of phenacetin result in exposure of animals to paracetamol. For the results of studies on phenacetin, see IARC (1987).

(a) Oral administration

**Mouse:** Groups of 60 male and 60 female young adult IF strain mice were fed paracetamol (>98% pure; dissolved in acetone then evaporated) at 5000 or 10 000 mg/kg of diet for 18 months (approximate daily intake, 250 or 500 mg/kg bw, respectively). A group of 52 males and 52 females fed basal diet served as controls. Shortly after the beginning of treatment, 33 males and seven females in the higher-dose group died from liver necrosis. Subsequent survival in all groups was high. All survivors were killed at 18 months after the beginning of the experiment, and complete necropsy was carried out with histological examination of the liver, lungs, pancreas, kidneys, spleen, bladder and adrenal glands. The effective numbers of animals were 50 male and 48 female controls, 54 males and 57 females in the lower-dose group and 23 males and 47 females in the higher-dose group. The incidences of large, often multiple liver neoplasms (adenomas and carcinomas combined) were 20/23 (87%: 15 adenomas, 5 carcinomas) in higher-dose males, 9/47 (7 adenomas, 2 carcinomas) in higher-dose females, 1/54 (adenoma) in lower-dose males, 0/57 in lower-dose females, 1/50 (adenoma) in control males and 0/48 in control females (Flaks & Flaks, 1983). [The Working Group noted that the high dose produced early lethal hepatotoxicity in half the males.]
Groups of 50 and 55 male or female (C57Bl/6 × C3H/He)F1 (B6C3F1) mice, eight to nine weeks of age, were fed paracetamol (> 98% pure) at 3000 and 6000 mg/kg of diet, respectively. The total intake of paracetamol in the high-dose groups was 863 g/kg bw for males and 675 g/kg bw for females. Two groups of 50 males and females were maintained on basal diet. All survivors were killed at 134 weeks. Survival among males was 43/50 (controls), 39/50 (low-dose) and 45/55 (high-dose), and that among females was 49/50 (controls), 46/50 (low-dose) and 50/55 (high-dose). The numbers of mice scored for tumours were 27/43 control males, 32/49 control females, 21/39 low-dose males, 33/46 low-dose females, 23/45 high-dose males and 33/50 high-dose females. No difference was found in the incidence of tumours at any site between treated and control mice (Aro & Matsuyama, 1985).

Groups of 60 and 120 male B6C3F1 mice, six weeks of age, received paracetamol at 5000 or 10000 mg/kg of diet, respectively, for up to 70 weeks, at which time the remaining animals were killed. A group of 30 mice served as controls. Survival in the high-dose group was less than 50% at 24 weeks and 16% at 72 weeks; in the low-dose group, the survival was greater than 90%. Severe hepatotoxicity was a common finding in mice that died. No increased incidence of neoplasms was observed (Hagiwara & Ward, 1986). [The Working Group noted the poor survival in the high-dose group.]

Rat: Groups of 30 male SPF Sprague-Dawley rats, six weeks of age, were fed paracetamol (99.5-99.7% pure) at 0 or 5350 mg/kg of diet for 117 weeks (total paracetamol intake, 86.5 g per rat). All animals were necropsied, and kidneys, urinary bladder, adrenal glands, liver, stomach, spleen, lungs, heart and any grossly abnormal organs or tissues were examined histologically. No significant difference in survival rates was observed. In the treated group, 4/30 rats developed bladder papillomatosis or tumours versus 2/30 controls (Johansson, 1981). [The Working Group noted the relatively small number of animals used in the study.]

Groups of 50 male and 50 female Fischer 344/DuCrj rats, five weeks of age were fed pharmacopoeial-grade paracetamol at 0, 4500 or 9000 mg/kg (males) and 0, 6500 or 13 000 mg/kg (females) of diet for 104 weeks and were then observed for a further 26 weeks (average daily intakes: lower-dose males, 195 mg/kg bw; lower-dose females, 336 mg/kg bw; higher-dose males, 402 mg/kg bw; higher-dose females, 688 mg/kg bw), at which time all survivors were killed. Survival rates at 104 weeks varied between 86 and 90% in males and 80 and 82% in females, with no significant difference between treated and control rats. All rats were necropsied, and major organs, tissues and gross abnormalities were examined histologically. No difference was seen in tumour incidence between the groups (Hiraga & Fujii, 1985).

Groups of 50 male and 50 female young adult Leeds inbred rats were fed paracetamol (> 98% pure) at 5000 or 10000 mg/kg of diet for up to 18 months (mean
daily intake, 300 and 600 mg/kg bw, respectively), at which time all survivors were killed. A group of 40 males and 40 females fed basal diet alone served as controls. Survival was high: male controls, 40/40; female controls, 40/40; lower-dose males, 48/50; lower-dose females, 49/50; higher-dose males, 45/50; and higher-dose females, 49/50. All animals were necropsied, and samples from each liver lobe, lungs, kidneys, pancreas, mammary glands, spleen, adrenal glands and from grossly visible lesions were examined histologically. No tumour was observed among controls. In treated animals, no hepatocellular carcinoma was observed, but hepatocellular neoplastic nodules occurred in 0/40, 1/48 and 9/45 control, lower-dose and higher-dose males and 0/40, 0/49 and 10/49 control, lower-dose and higher-dose females; and 20-25% of rats in each treated group developed hyperplasia of the bladder epithelium. Bladder calculi were present in about 30% of all treated male animals and in 6% of females; no clear association was seen between hyperplasia and the presence of bladder calculi. Bladder papillomas were observed in 5/49 higher-dose males and bladder carcinomas in 1/49 higher-dose males; the total bladder tumour incidence was significantly higher \( p = 0.02 \), Fisher's exact test] among high-dose males. In the low-dose group, 4/49 females developed bladder papillomas and 1/49 females developed bladder carcinoma. Total bladder tumour incidence was significantly higher in low-dose female rats \( p = 0.045 \), Fisher's exact test] (Flaks et al., 1985). [The Working Group noted that there were increased incidences of calculi, hyperplasia and tumours of the bladder in treated animals but there was no relationship between the presence of calculi and the presence of either hyperplasia or tumours.]

(b) Administration with known carcinogens

**Mouse:** Groups of 30 and 60 male B6C3F1 mice, six weeks of age, received paracetamol at 5000 or 10 000 mg/kg of diet, respectively, continuously for up to 70 weeks following a single intraperitoneal injection of 40 mg/kg bw \( N \)-nitrosodiethylamine at four weeks of age. A group of 30 mice that received \( N \)-nitrosodiethylamine alone served as controls. Mice were sacrificed at either 24 or 72 weeks after injection of the nitrosamine. Survival in the higher-dose group was very poor; severe hepatotoxicity was a common finding in mice that died. No increased incidence of neoplasms was found (Hagiwara & Ward, 1986).

**Rat:** Two groups of 25 or 30 male Fisher 344 rats weighing 150 g were administered \( N \)-nitrosoethyl-\( N \)-hydroxyethylamine (NEHEA) at 0 or 0.1% (v/v) in drinking-water for two weeks and one week later were fed diets containing paracetamol [purity unspecified] at 1.3% for 29 weeks. One group of 25 rats received NEHEA in the drinking-water followed by no further treatment. All animals were killed at the end of week 32, and samples from liver, kidneys and other organs with gross abnormalities were examined histologically.
PARACETAMOL

γ-Glutamyltranspeptidase foci, hyperplastic nodules, hepatocellular carcinomas, renal-cell carcinomas, as well as 'atypical cell foci' and adenomas were measured. Paracetamol inhibited the formation of NEHEA-induced γ-glutamyltranspeptidase foci, hyperplastic nodules and carcinomas in comparison with animals treated with NEHEA only. No liver lesion was found in any animal treated with paracetamol only. In contrast, the incidence and multiplicity of preneoplastic renal lesions and renal-cell adenomas were significantly increased in NEHEA-initiated animals treated with paracetamol in comparison with animals treated with NEHEA only. No such renal lesion was observed in groups treated with paracetamol alone (Tsuda et al., 1984). [The Working Group noted that the progression of the lesions described as preneoplastic to neoplasms was not documented.]

Groups of 25 male Fischer 344 rats, seven weeks old, were administered N-nitrosobutyl-N-(4-hydroxybutyl)amine at 0 or 0.05% (v/v) in the drinking-water for four weeks to initiate bladder carcinogenesis and were then fed paracetamol [purity unspecified] at 13 000 mg/kg of diet for a further 32 weeks, at which time all rats were killed. One group received treatment with the nitrosamine only. Urinary bladders, livers and kidneys were examined histologically. No significant difference in the incidence of bladder tumours was observed between the groups (Kurata et al., 1986).

Groups of male Fischer 344 rats [numbers unspecified], six weeks of age, were subjected to a two-thirds partial hepatectomy and 24 h later received either intragastric intubations of paracetamol (purity, > 99%) at 0 or 1000 mg/kg bw in 0.2% tragacanth gum twice a week for five weeks, or a single intragastric instillation of paracetamol at 500 mg/kg bw. Two weeks after the end of paracetamol treatment, the animals were administered phenobarbital (pharmacopoeial grade) at 0 or 1 mg/ml drinking-water for 12 weeks. The experiment was terminated at the end of phenobarbital treatment (weeks 13 and 18). Livers, kidneys, thyroid glands and any gross lesions were examined histologically. The tumour-initiating activity of paracetamol was evaluated by the formation of placental-type glutathione S-transferase-positive foci in liver cells; treatment with paracetamol did not result in the induction of such foci (Hasegawa et al., 1988). [The Working Group noted that the rate of absorption of paracetamol from the tragacanth suspension was not measured, and the limited reporting of the experiment.]

To examine possible interference with the activation of 2-acetylaminofluorene, groups of 20 female SPF CD rats were given diets containing acetylaminofluorene at 250 mg/kg alone or with paracetamol at 11 000 mg/kg for 20 weeks and were observed for an additional ten weeks. Mammary tumours were seen in 14/20 females given acetylaminofluorene and in 7/20 (p = 0.028, Fisher's exact test) animals given acetylaminofluorene and paracetamol (Weisburger et al., 1973).
Hamster: Groups of 30 male and 30 female Syrian golden hamsters, six weeks old, were given N-hydroxyacetylaminofluorene at 430 mg/kg alone or with paracetamol at 11,000 mg/kg of diet for 39 weeks. The experiment was terminated at 47 weeks. The incidences of liver cholangiomas in animals treated with N-hydroxyacetylaminofluorene were 13/26 in males and 22/25 in females; in the group treated with N-hydroxyacetylaminofluorene and paracetamol, no liver tumour was seen in 24 males but two occurred in 24 females. Similar results were found in groups given acetylaminofluorene at 400 mg/kg alone or with paracetamol at 11,000 mg/kg: with acetylaminofluorene, the incidence of liver cholangiomas was 6/30 males and 28/30 females; in the group treated with acetylaminofluorene and paracetamol, the incidence was 0/29 males ($p = 0.013$, Fisher's exact test) and 4/28 females ($p < 0.001$, Fisher's exact test) (Weisburger et al., 1973).

3.2 Other relevant data

(a) Experimental systems

(i) Absorption, distribution, excretion and metabolism

Dogs receiving a single oral administration of a wide range of doses of paracetamol excreted about 85% of the administered dose within the first 24 h (Savides et al., 1984).

A summary of the proposed metabolic pathways of paracetamol is shown in Figure 1. The major urinary metabolites (the glucuronide, sulfate and 3-mercapto derivatives) are observed in most species, although there is much species variation regarding the percentages of these conjugates excreted in the urine (Davis et al., 1976). Each of the other metabolites shown in Figure 1 has been identified in one species (see Gemborys & Mudge, 1981, for details). In rats, biliary excretion of the various metabolites of paracetamol increased from 20 to 49% as doses were increased from 37.5 to 600 mg/kg bw. The glucuronide conjugate was the major metabolite recovered in the bile at all doses (Hjelle & Klaassen, 1984). The putative reactive intermediates are not known but are thought to include benzoquinone (Hinson et al., 1977).

A minor but important metabolic pathway involves the conversion of paracetamol to a reactive metabolite by the hepatic cytochrome P450-dependent mixed-function oxidase system (Mitchell et al., 1973; Potter et al., 1973). The reactive metabolite is thought to be either $N$-acetyl-$para$-benzoquinoneimine (Corcoran et al., 1980) or the corresponding semiquinone free radical (De Vries, 1981; Nelson et al., 1981). With low doses of paracetamol, a conjugate of reduced glutathione with the reactive metabolite is further transformed to cysteine and mercapturic acid conjugates, which are excreted. As the dose of paracetamol increases, hepatic glutathione stores are diminished and the glucuronidation and sulfation pathways
Fig. 1. Summary of metabolism of paracetamol based on data for different species\(^a\)

\(\text{PARACETAMOL}\)

\(\text{315}\)

\(^a\text{From Jollow et al. (1974), Wong et al. (1976) and Gemborys & Mudge (1981)}\)
become saturated (Galinsky & Levy, 1981). A correlation has been demonstrated between species sensitivity to the hepatotoxicity of paracetamol and the balance between two pathways: (i) formation of glutathione conjugates and the corresponding hydrolysis products (indicative of the ‘toxic’ pathway) and (ii) metabolism via formation of glucuronide and sulfate esters (the ‘detoxification pathway’) (Gregus et al., 1988). Paracetamol-induced liver toxicity and depletion of glutathione may be partially prevented by provision of dietary methionine (Reicks et al., 1988; McLean et al., 1989). At sufficiently high doses of paracetamol, glutathione is depleted and the reactive metabolite binds covalently to cell macromolecules. It has also been noted that paracetamol and N-acetyl-para-benzquinoneimine may exert their cytotoxic effects via disruption of Ca²⁺ homeostasis secondary to the depletion of soluble and protein-bound thiols (Moore et al., 1985). These data indicate that oxidative or free-radical reactions initiated by paracetamol have a role in the hepatotoxicity of this drug (Birge et al., 1988).

Radiolabel was bound covalently to hepatocellular proteins following incubation of mouse, rat, hamster, rabbit or guinea-pig liver microsomes with ³H-paracetamol; the degree of binding was correlated with the susceptibility of the species to hepatotoxicity in vivo (Davis et al., 1974). Similar covalent binding of radiolabel to liver proteins of rats 48 h after administration of [ring-¹⁴C]-paracetamol was proportional to the extent of liver damage (Davis et al., 1976). Covalent binding of radiolabel to liver plasma membranes and microsomes was demonstrated 2.5 h after oral administration of ³H-paracetamol at 2.5 g/kg bw to rats (Tsokos-Kuhn et al., 1988).

Paracetamol is activated in the kidney by an NADPH-dependent cytochrome P450 mechanism to an arylating agent which can bind covalently to cellular macromolecules (McMurty et al., 1978). Studies in several species have suggested that formation of para-aminophenol may be of importance with respect to paracetamol nephrotoxicity. para-Aminophenol was identified as a urinary metabolite in hamsters (Gemborys & Mudge, 1981); the deacetylation of paracetamol to para-aminophenol has also been demonstrated in mouse renal cortical slices (Carpenter & Mudge, 1981). In comparison to acetyl-labelled paracetamol, ring-labelled paracetamol was preferentially bound to renal macromolecules in Fischer rats, which are sensitive to paracetamol nephrotoxicity, whereas binding of ring- and acetyl-labelled paracetamol to renal macromolecules was similar in non-susceptible Sprague-Dawley rats (Newton et al., 1985). This suggests that para-aminophenol may be responsible for paracetamol-induced renal necrosis in Fischer 344 rats (Newton et al., 1982).
(ii) Toxic effects

The single-dose oral LD<sub>50</sub> of paracetamol in male rats was 3.7 g/kg bw (Boyd & Bereczky, 1966); the 100-day LD<sub>50</sub> in rats was 400 mg per day (Boyd & Hogan, 1968).

Hepatic necrosis following administration of paracetamol was first reported in rats (Boyd & Bereczky, 1966). The main signs are hydropic vacuolation, centrilobular necrosis, macrophage infiltration and regenerative activity (Dixon et al., 1971). Paracetamol-induced hepatotoxicity varies considerably among species: hamsters and mice are most sensitive, whereas rats, rabbits and guinea-pigs are resistant to paracetamol-induced liver injury (Davis et al., 1974; Siegers et al., 1978). Toxic effects in dogs and cats given a single oral dose of paracetamol (maximal doses, 500 and 120 mg/kg bw, respectively) included hepatic centrilobular pathology in dogs, while cats, which do not glucuronidate exogenous compounds, had more diffuse liver pathological changes (Savides et al., 1984).

The hepatotoxic effects of paracetamol administered in the diet to mice have been examined histologically. After continuous exposure at 10 000 mg/kg diet for 72 weeks (Hagiwara & Ward, 1986), severe chronic hepatotoxicity was observed, with centrilobular hepatocytomegaly, cirrhosis, lipofuscin deposition and hepatocyte necrosis varying from focal to massive. With the same dose, Ham and Calder (1984) observed macroscopically and microscopically deformed livers with extensive lobular collapse, foci of hepatic necrosis and lymphoid aggregation in portal tracts after 32 weeks. At a lower dose (5000 mg/kg bw) and a shorter exposure time (24 weeks), histological changes were mild. Ultrastructural changes in the livers of rats administered paracetamol at 10 000 mg/kg diet for up to 18 months have been described (Flaks et al., 1985).

Histopathological review of liver sections from B6C3F1 mice of each sex fed paracetamol at 300, 600 or 12 500 mg/kg diet for 41 weeks and from NIH general-purpose mice of each sex fed paracetamol at 11 000 mg/kg diet for 48 weeks indicated severe liver injury, characterized by centrilobular necrosis in animals receiving more than 10 000 mg/kg diet (Maruyama & Williams, 1988).

A single subcutaneous dose of paracetamol at 750 mg/kg bw to male Fischer 344 rats produced renal tubular necrosis restricted to the upper part of the proximal tubule (McMurty et al., 1978). Chronic cortical and medullary damage has been produced in uninephrectomized homozygous Gunn rats by single doses of various analgesic preparations containing paracetamol (Henry & Tange, 1984).

In fasted adult male mice given paracetamol at 600 mg/kg bw orally and killed within 48 h after treatment, degenerative and necrotic changes were detected in the bronchial epithelium and in testicular and lymphoid tissue, in addition to renal and hepatic effects (Placke et al., 1987).
When male rats were given paracetamol at 500 mg/kg bw per day orally for 70 days, a significant decrease in testicular weight was observed (Jacqueson et al., 1984).

(iii) Effects on reproduction and prenatal toxicity

In Sprague-Dawley rats administered paracetamol at 250 mg/kg bw orally on days 8 through 19 of gestation, embryo- and fetotoxic effects were not seen (Lubawy & Burriss Garret, 1977).

(iv) Genetic and related effects

Paracetamol was not mutagenic to Salmonella typhimurium at concentrations of up to 50 mg/plate in the presence or absence of an exogenous metabolic system (King et al., 1979; Wirth et al., 1980; Imamura et al., 1983; Dybing et al., 1984; Oldham et al., 1986; Jasiewicz & Richardson, 1987). It did not induce mutations in a liquid pre-incubation test with Escherichia coli in the presence or absence of an exogenous metabolic system (King et al., 1979). As reported in an abstract, paracetamol exhibited mutagenic activity towards S. typhimurium TA100 in the presence of an exogenous metabolic system (Tamura et al., 1980).

Feeding of male Drosophila melanogaster with a 40-mM solution of paracetamol did not induce sex-linked recessive mutations (King et al., 1979).

Treatment of Chinese hamster V79 cells with low concentrations (0.1-3.0 mM) of paracetamol inhibited DNA synthesis (Holme et al., 1988; Hongslo et al., 1988). Paracetamol at 10 mM had no effect on Reuber H4-II-E rat hepatoma cell DNA, as assayed by alkaline elution, but the toxic metabolite of paracetamol, N-acetyl-para-benzoquinoneimine, induced DNA strand breaks (Dybing et al., 1984). Treatment of Chinese hamster V79 cells induced DNA strand breaks at 3 and 10 mM but not at 1 mM (Hongslo et al., 1988). Analogous results were obtained with Chinese hamster ovary cells (Sasaki, 1986). Species specificity was observed in assays for unscheduled DNA synthesis in vitro. No unscheduled DNA synthesis was detected in Chinese hamster V79 cells (Hongslo et al., 1988), in Syrian hamster or guinea-pig primary hepatocytes (Holme & Soderlund, 1986) or in rat hepatocytes (Milam & Byard, 1985; Sasaki, 1986; Williams et al., 1989); however, a small but significant increase in unscheduled DNA synthesis was seen in rat primary hepatocytes and a marked increase in unscheduled DNA synthesis was observed in mouse hepatocytes (Holme & Soderlund, 1986).

Paracetamol did not induce mutations to ouabain-resistance in C3H/10T½ clone 8 mouse embryo cells (Patierno et al., 1989). It was reported in an abstract that paracetamol did not induce mutations at the hprom locus in Chinese hamster V79 cells (Sawada et al., 1985). It induced sister chromatid exchange in Chinese hamster V79 (Holme et al., 1988; Hongslo et al., 1988) and CHO cells (Sasaki, 1986). Micronuclei were induced by paracetamol in a rat kidney cell line (NRK-49F) at
concentrations above 10 mM (Dunn et al., 1987). Paracetamol induced chromosomal aberrations in three different Chinese hamster cell lines (Sasaki et al., 1980; Sasaki, 1986; Ishidate, 1988) and in human lymphocytes (Watanabe, 1982). It weakly transformed C3H/10T½ clone 8 mouse embryo cells (Patierno et al., 1989).

Paracetamol given twice at a dose of 3 mM (450 mg/kg bw) either intraperitoneally or orally to NMRI mice did not induce micronuclei (King et al., 1979). Oral treatment of female Sprague-Dawley rats with paracetamol at 500 and 1000 mg/kg bw induced aneuploidy in 12-day embryos (Tsuruzaki et al., 1982). Oral treatment of Swiss mice with single or three consecutive daily doses of aqueous solutions of up to 2.5 mg/0.5 ml did not lead to chromatid breaks in bone-marrow cells (Reddy, 1984) or meiotic cells of male Swiss mice (Reddy & Subramanyam, 1985). [The Working Group noted that the description of the doses used in the two last studies was unclear.]

(b) Humans

(i) Pharmacokinetics

Following an oral dose, paracetamol is absorbed rapidly from the small intestine. The rate of absorption depends on the rate of gastric emptying (Clements et al., 1978). First-pass metabolism of paracetamol is dose-dependent: systemic availability ranges from 90% (with 1-2 g) to 68% (with 0.5 g). Plasma concentrations of paracetamol in fasting healthy subjects peaked within 1 h after treatment with 0.5 or 1.0 g but continued to rise up to 2 h after treatment with 2.0 g (Rawlings et al., 1977).

Paracetamol is rapidly and relatively uniformly distributed throughout the body fluids (Gwilt et al., 1963). Binding to plasma proteins is considered insignificant (Gazzard et al., 1973). The apparent volume of distribution of paracetamol in man is about 0.9 l/kg bw (Forrest et al., 1982). The decrease in paracetamol concentrations in plasma is multiphasic both after intravenous injections and after oral dosing with 500 and 1000 mg. When the data from six healthy volunteers were interpreted according to a two-compartment open model, the half-time of the first exponential ranged from 0.15 to 0.53 h and that of the second exponential from 2.24 to 3.30 h. The latter value was in agreement with that found after oral dosing. Mean clearance (± SEM) after intravenous administration of 1000 mg was 352 (± 40) ml/min (Rawlings et al., 1977). Renal excretion of paracetamol involves glomerular filtration and passive reabsorption, and the sulfate conjugate is subject to active renal tubular secretion (Morris & Levy, 1984). Both these metabolites have been shown to accumulate in plasma in patients with renal failure who are taking paracetamol (Lowenthal et al., 1976).
Paracetamol crosses the placenta in unconjugated form, and excretion in the urine of an exposed neonate was similar to that of a two- to three-day-old infant (Collins, 1981).

Paracetamol passes rapidly into milk, and the milk:plasma concentration ratio ranges from 0.7 to 1.1 (Berlin et al., 1980; Notarianni et al., 1987).

Paracetamol is metabolized predominantly to the glucuronide and sulfate conjugates in the human liver. A minor fraction is converted by cytochrome P450-dependent hepatic mixed-function oxidase to a highly reactive arylating metabolite, which is postulated to be N-acetyl-para-benzoquinoneimine (Miner & Kissenger, 1979). This metabolite is rapidly inactivated by conjugation with reduced glutathione and eventually excreted in the urine as acetyl cysteine and mercapturic acid conjugates. Large doses of paracetamol can deplete glutathione stores, and the excess of highly reactive intermediate binds covalently with vital cell elements, which may result in acute hepatic necrosis (Mitchell et al., 1973, 1974). Only 2-5% of a therapeutic dose was excreted unchanged in the urine. In young healthy subjects, about 55, 30, 4 and 4% of a therapeutic dose was excreted after hepatic conjugation with glucuronic acid, sulfuric acid, cysteine and mercapturic acid, respectively (Forrest et al., 1982).

The fractional recovery of mercapturic acid and cysteine conjugates after ingestion of paracetamol at 1500 mg was 9.3% in Caucasians compared with only 4.4-5.2% in Africans (Critchley et al., 1986). This may reflect different susceptibility to paracetamol hepatotoxicity.

(ii) Adverse effects

The toxic effects of paracetamol have been reviewed (Flower et al., 1985).

Reports on the acute toxicity, and in particular hepatotoxicity, of paracetamol have continued to appear since the reporting of the first two cases in 1966 (Davidson & Eastham, 1966). Initial symptoms of overdose are nausea, vomiting, diarrhoea and abdominal pain. Clinical indications of hepatic damage become manifest within two to four days after ingestion of toxic doses; in adults, a single dose of 10-15 g (200-250 mg/kg bw) is toxic. Serum transaminases, lactic dehydrogenase and bilirubin concentrations are elevated, and prothrombin time is prolonged (Koch-Weser, 1976). The severity of hepatic injury increases with the ingested dose and with previous consumption of other drugs that induce liver cytochrome P450 enzymes (Wright & Prescott, 1973). Biopsy of the liver reveals centrilobular necrosis with sparing of the periportal area (James et al., 1975). In nonfatal cases, the hepatic lesions are reversible over a period of months, without development of cirrhosis (Hamlyn et al., 1977).

Heavy alcohol consumption has been stated in several case reports to be related to more severe paracetamol hepatotoxicity than in non- or moderate
drinkers (for review, see Black, 1984). Five cases of combined hepatocellular injury and renal tubular necrosis have been reported among patients with a history of chronic alcohol use who were receiving therapeutic doses of paracetamol (Kaysen et al., 1985).

(iii) Effects on reproduction and prenatal toxicity

No association of paracetamol use with congenital abnormalities or stillbirths was observed in a study on drug use in approximately 10,000 pregnancies in the UK (Crombie et al., 1970). In a case-control study of 458 mothers of malformed babies and 911 controls, there was no association of abnormalities with use of paracetamol during the first trimester (Nelson & Forfar, 1971). In the Collaborative Perinatal Project, in which drug intake and pregnancy outcome were studied in a series of 50,282 women in 1959-65, 226 women had been exposed to paracetamol during the first trimester of pregnancy. There were 17 malformed children in the exposed group, giving a nonsignificant standardized relative risk (RR) of 1.05 (Heinonen et al., 1977).

In a study of 280,000 women belonging to a prepaid health plan in Seattle, WA (USA), all drug prescriptions and all pregnancy outcomes were monitored between July 1977 and December 1979. Among the liveborn babies of 6837 women, 80 (1.2%) had major congenital malformations. Three of the infants born to 493 women for whom paracetamol had been prescribed in the first trimester had major malformations (types not specified), giving a prevalence of 6 per 1000, which was not significantly different from the overall prevalence in the total population studied (12 per 1000). A second group of 328 women were exposed to paracetamol with codeine in the first trimester. Five of these had malformed babies, giving a prevalence of 15 per 1000, which was not significantly different from that in controls (Jick et al., 1981).

In a second study of the same population, covering the period January 1980 to June 1982, 6509 women had pregnancies ending in livebirths; 105 (1.5%) of the infants had major congenital malformations. Two of the infants born to 350 women for whom paracetamol had been prescribed in the first trimester had major malformations (types not specified), giving a prevalence of 6 per 1000 compared with an overall prevalence in the entire group of 16 per 1000. Three of 347 women exposed to paracetamol with codeine had malformed babies, giving a prevalence of 9 per 1000 (not significant) (Aselton et al., 1985).

(iv) Genetic and related effects

Eleven healthy volunteers were given paracetamol at 1000 mg three times over a period of 8 h. The frequency of chromatid breaks in peripheral blood lymphocytes was significantly increased after one day but returned to normal one week later (Kocisova et al., 1988).
3.3 Case reports and epidemiological studies of carcinogenicity to humans

The Working Group considered only studies in which paracetamol was taken directly, either alone or in mixtures. Paracetamol may be taken by analgesic users who previously took phenacetin. Analgesic mixtures containing phenacetin are carcinogenic to humans; and phenacetin is probably carcinogenic to humans (IARC, 1980, 1987).

A population-based case-control study was conducted in Minnesota, USA, involving 495 cases of cancer of the renal parenchyma and 74 cases of cancer of the renal pelvis, diagnosed in 1974-79, and 697 controls (McLaughlin et al., 1983, 1984, 1985). An association between cancer of the renal pelvis and intensity and duration of use of paracetamol-containing drugs was seen in women (p for trend, < 0.05; RR in the highest exposure category, based on three exposed cases and eight exposed controls, 5.8; 95% confidence interval (CI), 0.8-40). [The Working Group noted that the trend test included unexposed cases and controls; if the unexposed are excluded, the trend is not statistically significant.] No other significant association was observed. Four of the five cases in the highest exposure category (two men, three women) who developed renal pelvic cancer had also taken phenacetin-containing analgesics; in the entire study, only two cases of cancer of the renal pelvis and seven controls had taken paracetamol alone.

Another population-based case control study was conducted among women aged 20-49 years in the state of New York (USA) involving 173 cases of bladder cancer diagnosed in 1975-79 and an equal number of controls matched for age and telephone area code (Piper et al., 1985). A history of regular use of analgesics containing paracetamol (and not phenacetin) at least one year before diagnosis yielded a smoking-adjusted RR of 1.5 (95% CI, 0.4-7.2). In contrast, the risk for regular users of phenacetin-containing analgesics was significantly elevated whether they also regularly took paracetamol (RR, 3.8; 95% CI, 1.4-13.0) or not (RR, 6.5; 95% CI, 1.5-59.2).

A series of population-based case-control studies of urinary-tract cancer were conducted in New South Wales, Australia, involving cases identified in 1977-82 (McCredie et al., 1983a,b, 1988; McCredie & Stewart, 1988). Ultimately, there were 360 cases of renal parenchymal cancer, 73 cases of renal pelvic cancer, 55 cases of ureteral cancer and 162 cases (women only) of bladder cancer. Controls (985 for renal parenchymal cancer and 689 for the other sites) were derived from electoral rolls. The only significant increase in risk for regular use of paracetamol (cumulative consumption of at least 0.1 kg) was with ureteral cancer (RR, 2.5; 95% CI, 1.1-5.9); this association was not further elevated in the subgroup with higher exposure (at least 1 kg; RR, 2.0; 95% CI, 0.8-4.5). The RR for cancer of the renal
pelvis was 1.2 (95% CI, 0.6-2.3). These analyses were adjusted for cigarette smoking and the presence of urological disease.

A further population-based case-control study was conducted in Los Angeles County, USA, based on 187 cases of cancer of the renal pelvis or ureter diagnosed in 1978-82 and an equal number of neighbourhood controls (Ross et al., 1989). An association was found with use of nonprescription analgesics in general. The risks for use of analgesics containing paracetamol were nonsignificantly elevated, at 1.3 for use more than 30 days/year ($p = 0.34$) and 2.0 for use more than 30 consecutive days/year ($p = 0.08$). The analyses were controlled for cigarette smoking and history of urinary-tract stones. The authors noted that it was difficult to distinguish the effects of individual compounds in this study.

In a hypothesis-generating cohort study designed to screen a large number of drugs for possible carcinogenicity (described in detail in the monograph on ampicillin), 3238 persons to whom at least one prescription for paracetamol alone and 2612 to whom at least one prescription for paracetamol with codeine had been dispensed during 1969-73 were followed up for up to 15 years (Selby et al., 1989). No significant association with cancer at any site was seen for use of paracetamol with codeine. For paracetamol alone, a positive association was noted for melanoma (seven cases observed, 1.7 expected; RR, 4.1; 95% CI, 1.7-8.5), and negative associations for cancer of the colon (four observed, 12.1 expected; RR, 0.33; 95% CI, 0.1-0.85) and cancer of the uterine corpus (one observed, 6.5 expected; RR, 0.15; 95% CI, 0-0.86); but no association was seen for any cancer of the urinary tract or for all cancers combined (Friedman & Ury, 1980, 1983; Selby et al., 1989). [The Working Group noted that there was no information on non-prescription dispensing of paracetamol, which is the most common way that it is obtained. Since, as also noted by the authors, some 12,000 comparisons were made in this study, the associations should be verified independently. Data on duration of use were not provided.]

4. Summary of Data Reported and Evaluation

4.1 Exposure data

Paracetamol has been used extensively as an analgesic and antipyretic since 1946.

4.2 Experimental carcinogenicity data

Paracetamol was tested for carcinogenicity by oral administration in mice and rats. In one strain of mice, a significant increase in the incidence of multiple liver
carcinomas and adenomas was observed in animals of each sex at a markedly toxic dose; in two studies on another strain, no increase in the incidence of any tumour was observed at a well-tolerated dose that was approximately half that in the preceding study. Administration of paracetamol to two different strains of rats did not increase tumour incidence. In a further strain of rats, the incidence of neoplastic liver nodules was increased in animals of each sex given the higher dose; the combined incidence of bladder papillomas and carcinomas (mostly papillomas) was significantly greater in high-dose male and in low-dose female rats. Although treatment increased the incidence of bladder calculi in treated rats, there was no relationship between the presence of calculi and of either hyperplasia or tumours in the bladder.

Oral administration of paracetamol to rats enhanced the incidence of renal adenomas induced by N-nitrosoethyl-N-hydroxyethylamine.

4.3 Human carcinogenicity data

A positive association between use of paracetamol and cancer of the ureter (but not of other sites in the urinary tract) was observed in an Australian case-control study. None of three other population-based case-control studies showed an association between paracetamol use and cancer in the urinary tract.

4.4 Other relevant data

One study provided no evidence that use of paracetamol in the first trimester of pregnancy is associated with an increase in the incidence of malformations. Paracetamol induced testicular atrophy in rats.

Hepatotoxicity has been reported repeatedly in people taking high doses of paracetamol; chronic alcohol users are particularly sensitive. Paracetamol is metabolized in humans and animals to reactive intermediates that bind to proteins. It is hepatotoxic to experimental animals and causes renal tubular necrosis in rats.

Paracetamol induced chromatid breaks in peripheral human lymphocytes in vivo. It induced aneuploidy in rat embryos treated transplacentally. It gave negative results in the micronucleus test in mice in vivo. It did not induce chromosomal aberrations in bone-marrow cells or spermatocytes of mice.

Paracetamol induced sister chromatid exchange and chromosomal aberrations in Chinese hamster cells, micronuclei in rat kidney cells and chromosomal aberrations in human lymphocytes in vitro. It did not induce point mutations in mouse or Chinese hamster cells. Paracetamol gave positive results in a transformation test in mouse cells in vitro. It induced unscheduled DNA synthesis in mouse and rat cells but not in Chinese or Syrian hamster or guinea-pig cells. Paracetamol did not induce sex-linked recessive lethal mutations in Drosophila and was not mutagenic to Salmonella typhimurium or Escherichia coli. (See Appendix 1.)
4.5 Evaluation

There is *inadequate evidence* for the carcinogenicity of paracetamol in humans. There is *limited evidence* for the carcinogenicity of paracetamol in experimental animals.

**Overall evaluation**

Paracetamol is *not classifiable as to its carcinogenicity to humans* (Group 3).

5. References


Apoteksbolaget (1988) *Svensk Lätemedelsstatistik* [Swedish Drugs Statistics], Stockholm, Pharmaceutical Association of Sweden


---

1For description of the italicized terms, see Preamble, pp. 26-29.


Chemical Information Services Ltd (1989-90) Directory of World Chemical Producers, Oceanside, NY


PARACETAMOL


<table>
<thead>
<tr>
<th>Agent</th>
<th>Evidence for carcinogenicity</th>
<th>Overall evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Humans</td>
<td>Animals</td>
</tr>
<tr>
<td>Ampicillin</td>
<td>Inadequate</td>
<td>Limited</td>
</tr>
<tr>
<td>Azacitidine</td>
<td>No data</td>
<td>Sufficient</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>Limited</td>
<td>Inadequate</td>
</tr>
<tr>
<td>Chlorzotocin</td>
<td>No data</td>
<td>Sufficient</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>Sufficient</td>
<td>Limited</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>Inadequate</td>
<td>Inadequate</td>
</tr>
<tr>
<td>Dantron (Chrysazin; 1,8-Dihydroxy-anthraquinone)</td>
<td>No data</td>
<td>Sufficient</td>
</tr>
<tr>
<td>Furosemide (Frusemide)</td>
<td>Inadequate</td>
<td>Inadequate</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>Inadequate</td>
<td>Inadequate</td>
</tr>
<tr>
<td>Nitrofural (Nitrofurazone)</td>
<td>Inadequate</td>
<td>Limited</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>Inadequate</td>
<td>Limited</td>
</tr>
<tr>
<td>Paracetamol (Acetaminophen)</td>
<td>Inadequate</td>
<td>Limited</td>
</tr>
<tr>
<td>Prednimustine</td>
<td>No data</td>
<td>Inadequate</td>
</tr>
<tr>
<td>Thiotepa</td>
<td>Sufficient</td>
<td>Sufficient</td>
</tr>
<tr>
<td>Trichlormethine (Trimustine hydrochloride)</td>
<td>No data</td>
<td>Sufficient</td>
</tr>
</tbody>
</table>
Appendix 1. Summary table of genetic and related effects

<table>
<thead>
<tr>
<th>Nonmammalian systems</th>
<th>Mammalian systems</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prokaryotes</td>
<td>Eukaryotes</td>
</tr>
<tr>
<td>Lower eukaryotes</td>
<td>Plants</td>
</tr>
<tr>
<td>Plants</td>
<td>Insects</td>
</tr>
<tr>
<td>In vitro</td>
<td>In vivo</td>
</tr>
<tr>
<td>Animal cells</td>
<td>Human cells</td>
</tr>
<tr>
<td>Animal cells</td>
<td>In vivo</td>
</tr>
<tr>
<td>Human cells</td>
<td>Animals</td>
</tr>
<tr>
<td>Humans</td>
<td>Humans</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antineoplastic and immunosuppressive agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azacitidine</td>
</tr>
<tr>
<td>+ +</td>
</tr>
<tr>
<td>Chlorozotocin</td>
</tr>
<tr>
<td>+ +</td>
</tr>
<tr>
<td>Ciclosporin</td>
</tr>
<tr>
<td>+ +</td>
</tr>
<tr>
<td>Thiotepa</td>
</tr>
<tr>
<td>+ +</td>
</tr>
<tr>
<td>Trichloromethine</td>
</tr>
<tr>
<td>+ +</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antimicrobial agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampicillin</td>
</tr>
<tr>
<td>- +</td>
</tr>
<tr>
<td>Chloramphenicol</td>
</tr>
<tr>
<td>- +</td>
</tr>
<tr>
<td>Nitrofurantion</td>
</tr>
<tr>
<td>+ +</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
</tr>
<tr>
<td>+ +</td>
</tr>
</tbody>
</table>
### Appendix 1 (contd)

<table>
<thead>
<tr>
<th>Prokaryotes</th>
<th>Lower eukaryotes</th>
<th>Plants</th>
<th>Insects</th>
<th>In vitro</th>
<th>In vivo</th>
<th>Animal cells</th>
<th>Human cells</th>
<th>Animals</th>
<th>Humans</th>
</tr>
</thead>
<tbody>
<tr>
<td>D G D R G A D G C R G C A</td>
<td>D G S M C A T I D G S M C A T I</td>
<td>D G S M C A T I D G S M C A T I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Other drugs

<table>
<thead>
<tr>
<th>Drugs</th>
<th>D G D R G A D G C R G C A</th>
<th>D G S M C A T I D G S M C A T I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimetidine</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>N-Nitrosocimetidine</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Dantron</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Furosemide</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

A, aneuploidy; C, chromosomal aberrations; D, DNA damage; DL, dominant lethal mutation; G, gene mutation; I, inhibition of intercellular communication; M, micronuclei; R, mitotic recombination and gene conversion; S, sister chromatid exchange; T, cell transformation.

In completing the tables, the following symbols indicate the consensus of the Working Group with regard to the results for each endpoint:

- **+** considered to be positive for the specific endpoint and level of biological complexity
- **+ 1** considered to be positive, but only one valid study was available to the Working Group
- **-** considered to be negative
- **- 1** considered to be negative, but only one valid study was available to the Working Group
- **?** considered to be equivocal or inconclusive (e.g., there were contradictory results from different laboratories; there were confounding exposures; the results were equivocal)

*Cimetidine hydrochloride gave a positive result.*
APPENDIX 2

ACTIVITY PROFILES
FOR GENETIC AND RELATED EFFECTS

Methods

The x-axis of the activity profile (Waters et al., 1987, 1988) represents the bioassays in phylogenetic sequence by endpoint, and the values on the y-axis represent the logarithmically transformed lowest effective doses (LED) and highest ineffective doses (HID) tested. The term 'dose', as used in this report, does not take into consideration length of treatment or exposure and may therefore be considered synonymous with concentration. In practice, the concentrations used in all the in-vitro tests were converted to µg/ml, and those for in-vivo tests were expressed as mg/kg bw. Because dose units are plotted on a log scale, differences in molecular weights of compounds do not, in most cases, greatly influence comparisons of their activity profiles. Conventions for dose conversions are given below.

Profile-line height (the magnitude of each bar) is a function of the LED or HID, which is associated with the characteristics of each individual test system – such as population size, cell-cycle kinetics and metabolic competence. Thus, the detection limit of each test system is different, and, across a given activity profile, responses will vary substantially. No attempt is made to adjust or relate responses in one test system to those of another.

Line heights are derived as follows: for negative test results, the highest dose tested without appreciable toxicity is defined as the HID. If there was evidence of extreme toxicity, the next highest dose is used. A single dose tested with a negative result is considered to be equivalent to the HID. Similarly, for positive results, the LED is recorded. If the original data were analysed statistically by the author, the dose recorded is that at which the response was significant (p < 0.05). If the available data were not analysed statistically, the dose required to produce an effect is estimated as follows: when a dose-related positive response is observed with two or more doses, the lower of the doses is taken as the LED; a single dose resulting in a positive response is considered to be equivalent to the LED.

In order to accommodate both the wide range of doses encountered and positive and negative responses on a continuous scale, doses are transformed
logarithmically, so that effective (LED) and ineffective (HID) doses are represented by positive and negative numbers, respectively. The response, or logarithmic dose unit \( LDU_{ij} \), for a given test system \( i \) and chemical \( j \) is represented by the expressions

\[
LDU_{ij} = -\log_{10} (\text{dose}), \text{ for HID values; } LDU \leq 0 \\
\text{and} \\
LDU_{ij} = -\log_{10} (\text{dose} \times 10^{-6}), \text{ for LED values; } LDU \geq 0.
\]

These simple relationships define a dose range of 0 to \(-5\) logarithmic units for ineffective doses (1–100 000 µg/ml or mg/kg bw) and 0 to \(+8\) logarithmic units for effective doses (100 000–0.001 µg/ml or mg/kg bw). A scale illustrating the LDU values is shown in Figure 1. Negative responses at doses less than 1 µg/ml (mg/kg bw) are set equal to 1. Effectively, an LED value \( \geq 100 000 \) or an HID value \( \leq 1 \) produces an LDU = 0; no quantitative information is gained from such extreme values. The dotted lines at the levels of log dose units 1 and \(-1\) define a ‘zone of uncertainty’ in which positive results are reported at such high doses (between 10 000 and 100 000 µg/ml or mg/kg bw) or negative results are reported at such low dose levels (1 to 10 µg/ml or mg/kg bw) as to call into question the adequacy of the test.

**Fig. 1. Scale of log dose units used on the y–axis of activity profiles**

<table>
<thead>
<tr>
<th>Positive ( (\mu g/ml \text{ or } mg/kg \text{ bw}) )</th>
<th>Log dose units</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.001</td>
<td>8</td>
</tr>
<tr>
<td>0.01</td>
<td>7</td>
</tr>
<tr>
<td>0.1</td>
<td>6</td>
</tr>
<tr>
<td>1.0</td>
<td>5</td>
</tr>
<tr>
<td>10</td>
<td>4</td>
</tr>
<tr>
<td>100</td>
<td>3</td>
</tr>
<tr>
<td>1000</td>
<td>2</td>
</tr>
<tr>
<td>10 000</td>
<td>1</td>
</tr>
<tr>
<td>100 000</td>
<td>0</td>
</tr>
</tbody>
</table>

| Negative \( (\mu g/ml \text{ or } mg/kg \text{ bw}) \)
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>(-1)</td>
</tr>
<tr>
<td>100</td>
<td>(-2)</td>
</tr>
<tr>
<td>1000</td>
<td>(-3)</td>
</tr>
<tr>
<td>10 000</td>
<td>(-4)</td>
</tr>
<tr>
<td>100 000</td>
<td>(-5)</td>
</tr>
</tbody>
</table>

LED and HID are expressed as µg/ml or mg/kg bw.
In practice, an activity profile is computer generated. A data entry program is used to store abstracted data from published reports. A sequential file (in ASCII) is created for each compound, and a record within that file consists of the name and Chemical Abstracts Service number of the compound, a three-letter code for the test system (see below), the qualitative test result (with and without an exogenous metabolic system), dose (LED or HID), citation number and additional source information. An abbreviated citation for each publication is stored in a segment of a record accessing both the test data file and the citation file. During processing of the data file, an average of the logarithmic values of the data subset is calculated, and the length of the profile line represents this average value. All dose values are plotted for each profile line, regardless of whether results are positive or negative. Results obtained in the absence of an exogenous metabolic system are indicated by a bar (−), and results obtained in the presence of an exogenous metabolic system are indicated by an upward-directed arrow (↑). When all results for a given assay are either positive or negative, the mean of the LDU values is plotted as a solid line; when conflicting data are reported for the same assay (i.e., both positive and negative results), the majority data are shown by a solid line and the minority data by a dashed line (drawn to the extreme conflicting response). In the few cases in which the numbers of positive and negative results are equal, the solid line is drawn in the positive direction and the maximal negative response is indicated with a dashed line.

Profile lines are identified by three-letter code words representing the commonly used tests. Code words for most of the test systems in current use in genetic toxicology were defined for the US Environmental Protection Agency's GENE-TOX Program (Waters, 1979; Waters & Auletta, 1981). For IARC Monographs Supplement 6, Volume 44 and subsequent volumes, including this publication, codes were redefined in a manner that should facilitate inclusion of additional tests. If a test system is not defined precisely, a general code is used that best defines the category of the test. Naming conventions are described below.

Data listings are presented with each activity profile and include endpoint and test codes, a short test code definition, results [either with (M) or without (NM) an exogenous activation system], the associated LED or HID value and a short citation. Test codes are organized phylogenetically and by endpoint from left to right across each activity profile and from top to bottom of the corresponding data listing. Endpoints are defined as follows: A, aneuploidy; C, chromosomal aberrations; D, DNA damage; F, assays of body fluids; G, gene mutation; H, host-mediated assays; I, inhibition of intercellular communication; M, micronuclei; P, sperm morphology; R, mitotic recombination or gene conversion; S, sister chromatid exchange; and T, cell transformation.
Dose conversions for activity profiles

Doses are converted to μg/ml for in-vitro tests and to mg/kg bw per day for in-vivo experiments.

1. In-vitro test systems
   
   (a) Weight/volume converts directly to μg/ml.
   
   (b) Molar (M) concentration × molecular weight = mg/ml = 10³ μg/ml; mM concentration × molecular weight = μg/ml.
   
   (c) Soluble solids expressed as % concentration are assumed to be in units of mass per volume (i.e., 1% = 0.01 g/ml = 10 000 μg/ml; also, 1 ppm = 1 μg/ml).
   
   (d) Liquids and gases expressed as % concentration are assumed to be given in units of volume per volume. Liquids are converted to weight per volume using the density (D) of the solution (D = g/ml). Gases are converted from volume to mass using the ideal gas law, PV = nRT. For exposure at 20–37°C at standard atmospheric pressure, 1% (v/v) = 0.4 μg/ml × molecular weight of the gas. Also, 1 ppm (v/v) = 4 × 10⁻⁵ μg/ml × molecular weight.
   
   (e) In microbial plate tests, it is usual for the doses to be reported as weight/plate, whereas concentrations are required to enter data on the activity profile chart. While remaining cognisant of the errors involved in the process, it is assumed that a 2-ml volume of top agar is delivered to each plate and that the test substance remains in solution within it; concentrations are derived from the reported weight/plate values by dividing by this arbitrary volume. For spot tests, a 1-ml volume is used in the calculation.
   
   (f) Conversion of particulate concentrations given in μg/cm² are based on the area (A) of the dish and the volume of medium per dish; i.e., for a 100-mm dish: A = πR² = π × (5 cm)² = 78.5 cm². If the volume of medium is 10 ml, then 78.5 cm² = 10 ml and 1 cm² = 0.13 ml.

2. In-vitro systems using in-vivo activation
   
   For the body fluid–urine (BF–) test, the concentration used is the dose (in mg/kg bw) of the compound administered to test animals or patients.

3. In-vivo test systems
   
   (a) Doses are converted to mg/kg bw per day of exposure, assuming 100% absorption. Standard values are used for each sex and species of rodent, including body weight and average intake per day, as reported by Gold
et al. (1984). For example, in a test using male mice fed 50 ppm of the agent in the diet, the standard food intake per day is 12% of body weight, and the conversion is dose = 50 ppm × 12% = 6 mg/kg bw per day.

Standard values used for humans are: weight – males, 70 kg; females, 55 kg; surface area, 1.7 m²; inhalation rate, 20 l/min for light work, 30 l/min for mild exercise.

(b) When reported, the dose at the target site is used. For example, doses given in studies of lymphocytes of humans exposed in vivo are the measured blood concentrations in μg/ml.

**Codes for test systems**

For specific nonmammalian test systems, the first two letters of the three–symbol code word define the test organism (e.g., SA– for Salmonella typhimurium, EC– for Escherichia coli). If the species is not known, the convention used is –S–. The third symbol may be used to define the tester strain (e.g., SA8 for S. typhimurium TA1538, ECW for E. coli WP2uvrA). When strain designation is not indicated, the third letter is used to define the specific genetic endpoint under investigation (e.g., –D for differential toxicity, –F for forward mutation, –G for gene conversion or genetic crossing–over, –N for aneuploidy, –R for reverse mutation, –U for unscheduled DNA synthesis). The third letter may also be used to define the general endpoint under investigation when a more complete definition is not possible or relevant (e.g., –M for mutation, –C for chromosomal aberration).


For animal (i.e., non–human) test systems in vitro, when the cell type is not specified, the code letters –IA are used. For such assays in vivo, when the animal species is not specified, the code letters –VA are used. Commonly used animal species are identified by the third letter (e.g., –C for Chinese hamster, –M for mouse, –R for rat, –S for Syrian hamster).

For test systems using human cells in vitro, when the cell type is not specified, the code letters –IH are used. For assays on humans in vivo, when the cell type is not specified, the code letters –VH are used. Otherwise, the second letter specifies the cell type under investigation (e.g., –BH for bone marrow, –LH for lymphocytes).

Some other specific coding conventions used for mammalian systems are as follows: BF– for body fluids, HM– for host–mediated, –L for leucocytes or
lymphocytes in vitro (–AL, animals; –HL, humans), –L– for leucocytes in vivo (–LA, animals; –LH, humans), —T for transformed cells.

Note that these are examples of major conventions used to define the assay code words. The alphabetized listing of codes must be examined to confirm a specific code word. As might be expected from the limitation to three symbols, some codes do not fit the naming conventions precisely. In a few cases, test systems are defined by first-letter code words, for example: MST, mouse spot test; SLP, mouse specific locus test, postspermatogonia; SLO, mouse specific locus test, other stages; DLM, dominant lethal test in mice; DLR, dominant lethal test in rats; MHT, mouse heritable translocation test.

The genetic activity profiles and listings that follow were prepared in collaboration with Environmental Health Research and Testing Inc. (EHRT) under contract to the US Environmental Protection Agency; EHRT also determined the doses used. The references cited in each genetic activity profile listing can be found in the list of references in the appropriate monograph.

References


# AZACITIDINE

<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose LED/HID</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA virus, mutation</td>
<td>+</td>
<td>5 µg/ml</td>
<td>Halle (1968)</td>
</tr>
<tr>
<td>PRB, Prophage induction</td>
<td>+</td>
<td>20 µg/ml</td>
<td>Barbe et al. (1986)</td>
</tr>
<tr>
<td>EBC, Escherichia coli, DNA damage (dcm+/recA56)</td>
<td>+</td>
<td>2.0 µg/ml</td>
<td>Bhagwat &amp; Roberts (1987)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA677, forward mutation</td>
<td>+</td>
<td>0.24 µg/ml</td>
<td>Call et al. (1986)</td>
</tr>
<tr>
<td>SMO, Salmonella typhimurium TA100, reverse mutation</td>
<td>-</td>
<td>10 µg/ml</td>
<td>Marquardt &amp; Marquardt (1977)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA100, reverse mutation</td>
<td>-</td>
<td>5 µg/ml</td>
<td>Podger (1983)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA102, reverse mutation</td>
<td>+</td>
<td>6 µg/ml</td>
<td>Schmick et al. (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA104, reverse mutation</td>
<td>+</td>
<td>2.4 µg/ml</td>
<td>Schmuck et al. (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA1535, reverse mutation</td>
<td>+</td>
<td>2.4 µg/ml</td>
<td>Schmuck et al. (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA1538, reverse mutation</td>
<td>+</td>
<td>24 µg/ml</td>
<td>Schmuck et al. (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA98, reverse mutation</td>
<td>-</td>
<td>5 µg/ml</td>
<td>Schmuck et al. (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA98, reverse mutation</td>
<td>-</td>
<td>25 µg/ml</td>
<td>Levin &amp; Ames (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA98, reverse mutation</td>
<td>-</td>
<td>12.5 µg/ml</td>
<td>Podger (1983)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA98, reverse mutation</td>
<td>-</td>
<td>0.5 µg/ml</td>
<td>Schmuck et al. (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA98, reverse mutation</td>
<td>-</td>
<td>2.4 µg/ml</td>
<td>Schmuck et al. (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA92, reverse mutation</td>
<td>-</td>
<td>12 µg/ml</td>
<td>Schmuck et al. (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA92, reverse mutation</td>
<td>-</td>
<td>25 µg/ml</td>
<td>Schmuck et al. (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA92, reverse mutation</td>
<td>-</td>
<td>12.5 µg/ml</td>
<td>Levin &amp; Ames (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA2640, reverse mutation</td>
<td>-</td>
<td>12.5 µg/ml</td>
<td>Levin &amp; Ames (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA2661, reverse mutation</td>
<td>+</td>
<td>12.5 µg/ml</td>
<td>Levin &amp; Ames (1986)</td>
</tr>
<tr>
<td>SAA, Salmonella typhimurium TA4006, reverse mutation</td>
<td>+</td>
<td>12.5 µg/ml</td>
<td>Levin &amp; Ames (1986)</td>
</tr>
<tr>
<td>EBC, Escherichia coli WP2, reverse mutation</td>
<td>-</td>
<td>4 µg/ml</td>
<td>Fucik et al. (1965)</td>
</tr>
<tr>
<td>ECR, Escherichia coli exclusive of strain K12, forward mutation</td>
<td>+</td>
<td>0.1 µg/ml</td>
<td>Lal et al. (1988)</td>
</tr>
<tr>
<td>ECR, Escherichia coli exclusive of strain K12, reverse mutation</td>
<td>+</td>
<td>0.4 µg/ml</td>
<td>Fucik et al. (1965)</td>
</tr>
<tr>
<td>SCH, Saccharomyces cerevisiae, mitotic recombination</td>
<td>+</td>
<td>2500 µg/ml</td>
<td>Zimmermann &amp; Scheel (1984)</td>
</tr>
<tr>
<td>SCA, Saccharomyces cerevisiae, mitotic gene conversion</td>
<td>+</td>
<td>1000 µg/ml</td>
<td>Zimmermann &amp; Scheel (1984)</td>
</tr>
<tr>
<td>SCR, Saccharomyces cerevisiae, reverse mutation</td>
<td>+</td>
<td>1000 µg/ml</td>
<td>Zimmermann &amp; Scheel (1984)</td>
</tr>
<tr>
<td>SCH, Saccharomyces cerevisiae, aneuploidy</td>
<td>-</td>
<td>5000 µg/ml</td>
<td>Zimmermann &amp; Scheel (1984)</td>
</tr>
<tr>
<td>VFC, Vicia faba, chromosomal aberrations</td>
<td>-</td>
<td>24 µg/ml</td>
<td>Fucik et al. (1970)</td>
</tr>
<tr>
<td>DMM, Drosophila melanogaster, wing-spot assay (somatic mutation and recombination)</td>
<td>-</td>
<td>244 µg/ml</td>
<td>Katz (1985)</td>
</tr>
<tr>
<td>GNR, Gene mutation, Chinese hamster lung V79 cells, hprt locus</td>
<td>-</td>
<td>0.7 µg/ml</td>
<td>Landolph &amp; Jones (1982)</td>
</tr>
</tbody>
</table>
### AZACITIDINE (contd)

<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>G90, Gene mutation, Chinese hamster lung V79 cells, ouabain resistance</td>
<td>+</td>
<td>0</td>
<td>1 µg/ml</td>
</tr>
<tr>
<td>G90, Gene mutation, Chinese hamster lung V79 cells, ouabain resistance</td>
<td>-</td>
<td>0</td>
<td>0.7 µg/ml</td>
</tr>
<tr>
<td>GST, Gene mutation, mouse lymphoma L5178Y cells in vitro, tk locus</td>
<td>+</td>
<td>0</td>
<td>0.02 µg/ml</td>
</tr>
<tr>
<td>GST, Gene mutation, mouse lymphoma L5178Y cells in vitro, tk locus</td>
<td>-</td>
<td>0</td>
<td>0.01 µg/ml</td>
</tr>
<tr>
<td>GIA, Gene mutation, mouse C3H/10 T1/2 cells, ouabain resistance</td>
<td>-</td>
<td>0</td>
<td>2.4 µg/ml</td>
</tr>
<tr>
<td>GIA, Gene mutation, BHK cells, hprt locus</td>
<td>-</td>
<td>0</td>
<td>2.4 µg/ml</td>
</tr>
<tr>
<td>GIA, Gene mutation, BHK cells, hprt resistance</td>
<td>-</td>
<td>0</td>
<td>1 µg/ml</td>
</tr>
<tr>
<td>GIA, Gene mutation, primary rat tracheal epithelial cells, ouabain resistance/hprt locus</td>
<td>-</td>
<td>0</td>
<td>1 µg/ml</td>
</tr>
<tr>
<td>GIA, Gene mutation, mouse lymphoma L5178Y cells in vitro, hprt locus</td>
<td>-</td>
<td>0</td>
<td>0.33 µg/ml</td>
</tr>
<tr>
<td>SIT, Sister chromatid exchange, hamster cells in vitro</td>
<td>+</td>
<td>0</td>
<td>1.00 µg/ml</td>
</tr>
<tr>
<td>SIC, Sister chromatid exchange, hamster cells in vitro</td>
<td>+</td>
<td>0</td>
<td>0.24 µg/ml</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster Don cells in vitro</td>
<td>+</td>
<td>0</td>
<td>10 µg/ml</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster embryo fibroblasts</td>
<td>+</td>
<td>0</td>
<td>0.73 µg/ml</td>
</tr>
<tr>
<td>CIT, Chromosomal aberrations, hamster cells in vitro</td>
<td>(+)</td>
<td>0</td>
<td>2.5 µg/ml</td>
</tr>
<tr>
<td>TBM, Cell transformation, BALB/c 3T3 mouse cells</td>
<td>+</td>
<td>0</td>
<td>1.2 µg/ml</td>
</tr>
<tr>
<td>TCM, Cell transformation, C3H 10T1/2 mouse cells</td>
<td>+</td>
<td>0</td>
<td>0.25 µg/ml</td>
</tr>
<tr>
<td>TCL, Cell transformation, Chinese hamster embryo fibroblasts</td>
<td>+</td>
<td>0</td>
<td>0.73 µg/ml</td>
</tr>
<tr>
<td>TCL, Cell transformation, primary rat tracheal epithelial cells</td>
<td>+</td>
<td>0</td>
<td>0.24 µg/ml</td>
</tr>
<tr>
<td>D1M, DNA strand breaks, HeLa cells</td>
<td>+</td>
<td>0</td>
<td>48 µg/ml</td>
</tr>
<tr>
<td>G1H, Gene mutation, human cells in vitro, hprt locus</td>
<td>+</td>
<td>0</td>
<td>0.12 µg/ml</td>
</tr>
<tr>
<td>G1H, Gene mutation, human cells in vitro, tk locus</td>
<td>+</td>
<td>0</td>
<td>0.024 µg/ml</td>
</tr>
<tr>
<td>SHL, Sister chromatid exchange, human lymphocytes in vitro</td>
<td>+</td>
<td>0</td>
<td>1.95 µg/ml</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>0</td>
<td>1.95 µg/ml</td>
</tr>
<tr>
<td>CHF, Chromosomal aberrations, transformed human cells in vitro</td>
<td>+</td>
<td>0</td>
<td>2.4 µg/ml</td>
</tr>
<tr>
<td>DLM, Dominant lethal test, mice</td>
<td>-</td>
<td>0</td>
<td>10 mg/kg x 1, i.p.</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>--------</td>
<td>---------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>PRB, Strand breaks in PM2-CCC DNA</td>
<td>+</td>
<td>0</td>
<td>Low &amp; McLaughlin (1979)</td>
</tr>
<tr>
<td>PRB, Plasmid pBR 322 DNA strand breaks</td>
<td>+</td>
<td>0</td>
<td>Vadi &amp; Reed (1983)</td>
</tr>
<tr>
<td>Plasmid pBR 322 DNA alkylation</td>
<td>+</td>
<td>0</td>
<td>Vadi &amp; Reed (1983)</td>
</tr>
<tr>
<td>PRB, Plasmid pBR 322 DNA interstrand cross-links</td>
<td>+</td>
<td>0</td>
<td>Alexander et al. (1986)</td>
</tr>
<tr>
<td>DNA cross-links, calf thymus</td>
<td>+</td>
<td>1570 μg/ml</td>
<td>Pranpta &amp; Aqul (1986)</td>
</tr>
<tr>
<td>SA0, Salmonella typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>31 μg/ml</td>
<td>Pranpta &amp; Aqul (1986)</td>
</tr>
<tr>
<td>SA5, Salmonella typhimurium TA1535, reverse mutation</td>
<td>+</td>
<td>0</td>
<td>Pranpta &amp; Aqul (1986)</td>
</tr>
<tr>
<td>SA5, Salmonella typhimurium TA1535, reverse mutation</td>
<td>+</td>
<td>50 μg/ml</td>
<td>Pranpta &amp; Aqul (1986)</td>
</tr>
<tr>
<td>SA8, Salmonella typhimurium TA1538, reverse mutation</td>
<td>+</td>
<td>62 μg/ml</td>
<td>Pranpta &amp; Aqul (1986)</td>
</tr>
<tr>
<td>SA9, Salmonella typhimurium TA98, reverse mutation</td>
<td>+</td>
<td>62 μg/ml</td>
<td>Pranpta &amp; Aqul (1986)</td>
</tr>
<tr>
<td>SA8, Salmonella typhimurium hisG46, reverse mutation</td>
<td>+</td>
<td>100 μg/ml</td>
<td>Zimmerman &amp; Bhuyan (1976)</td>
</tr>
<tr>
<td>SCG, Saccharomyces cerevisiae, gene conversion</td>
<td>+</td>
<td>314 μg/ml</td>
<td>Siebert &amp; Eisenbrand (1977)</td>
</tr>
<tr>
<td>DOK, Drosophila melanogaster, sex-linked recessive lethal mutation</td>
<td>+</td>
<td>31.4 μg/ml</td>
<td>Kortelius (1978)</td>
</tr>
<tr>
<td>DLA, DNA cross-links and strand breaks, mouse leukaemia LI210 cells</td>
<td>+</td>
<td>7.85 μg/ml</td>
<td>Ewig &amp; Kohn (1977)</td>
</tr>
<tr>
<td>DLA, DNA strand breaks, Chinese hamster V79 cells</td>
<td>+</td>
<td>15.7 μg/ml</td>
<td>Erickson et al. (1978)</td>
</tr>
<tr>
<td>DLA, DNA strand breaks, mouse leukaemia LI210 cells</td>
<td>+</td>
<td>6.28 μg/ml</td>
<td>Alexander et al. (1986)</td>
</tr>
<tr>
<td>GHK, Gene mutation, Chinese hamster lung V79 cells, hprt locus</td>
<td>+</td>
<td>0.1 μg/ml</td>
<td>Siddiqui et al. (1988)</td>
</tr>
<tr>
<td>SIM, Sister chromatid exchange, mouse leukaemia LI210 cells</td>
<td>+</td>
<td>0.3 μg/ml</td>
<td>Tofilon et al. (1983)</td>
</tr>
<tr>
<td>ZIF, Sister chromatid exchange, 9L rat brain tumour cells</td>
<td>+</td>
<td>15.7 μg/ml</td>
<td>Erickson et al. (1980)</td>
</tr>
<tr>
<td>DIH, DNA cross-links, human cells in vitro</td>
<td>+</td>
<td>31.4 mg/kg x 1, i.p.</td>
<td>Bedford &amp; Eisenbrand (1984)</td>
</tr>
<tr>
<td>DVA, DNA interstrand cross-links, strand breaks, rat bone-marrow cells in vivo</td>
<td>+</td>
<td>24 μg/ml</td>
<td>Panasci et al. (1979)</td>
</tr>
<tr>
<td>BVD, DNA binding in vitro</td>
<td>+</td>
<td>24 μg/ml</td>
<td>Ahlgren et al. (1982)</td>
</tr>
<tr>
<td>BVD, DNA binding in vitro</td>
<td>+</td>
<td>24 μg/ml</td>
<td></td>
</tr>
</tbody>
</table>
CHLOROZOTOCIN

54749-90-5

5-SEP-90

LOG DOSE UNITS

PROKARYOTES | LOWER EUKAR. | PLANTS | INSECT | MAMMALS IN VITRO | HUMANS IN VITRO | F/H | MAMMALS IN VIVO | HUMANS IN VIVO

APPENDIX 2

347
<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose LED/HID</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>With exogenous metabolic system</td>
<td>Without</td>
<td>Exogenous metabolic system</td>
<td></td>
</tr>
<tr>
<td>SAG, Salmonella typhimurium TA100, reverse mutation</td>
<td>–</td>
<td>–</td>
<td>15000 µg/ml</td>
</tr>
<tr>
<td>SAG, Salmonella typhimurium TA1535, reverse mutation</td>
<td>–</td>
<td>–</td>
<td>15000 µg/ml</td>
</tr>
<tr>
<td>SAG, Salmonella typhimurium TA1537, reverse mutation</td>
<td>–</td>
<td>–</td>
<td>15000 µg/ml</td>
</tr>
<tr>
<td>SAG, Salmonella typhimurium TA1538, reverse mutation</td>
<td>–</td>
<td>–</td>
<td>15000 µg/ml</td>
</tr>
<tr>
<td>SAG, Salmonella typhimurium miscellaneous strains, reverse mutation</td>
<td>–</td>
<td>–</td>
<td>15000 µg/ml</td>
</tr>
<tr>
<td>G9H, Gene mutation, Chinese hamster lung V79 cells, hprt locus</td>
<td>–</td>
<td>–</td>
<td>250 µg/ml</td>
</tr>
<tr>
<td>SHL, Sister chromatid exchange, human lymphocytes in vitro (+)</td>
<td>0</td>
<td>1 µg/ml</td>
<td>Tuzawa et al. (1986)</td>
</tr>
<tr>
<td>SHL, Sister chromatid exchange, human lymphocytes in vitro (+)</td>
<td>0</td>
<td>1 µg/ml</td>
<td>Tuzawa et al. (1987)</td>
</tr>
<tr>
<td>UVN, Unscheduled DNA synthesis, mouse cells in vivo</td>
<td>0</td>
<td>0</td>
<td>Matter et al. (1982)</td>
</tr>
<tr>
<td>MTm, Micronucleus test, mice in vivo</td>
<td>0</td>
<td>1500 mg/kg x 1, p.o.</td>
<td>Matter et al. (1982)</td>
</tr>
<tr>
<td>MVC, Micronucleus test, hamsters in vivo</td>
<td>0</td>
<td>1500 mg/kg x 1, p.o.</td>
<td>Matter et al. (1982)</td>
</tr>
<tr>
<td>CBA, Chromosomal aberrations, animal bone-marrow cells in vivo</td>
<td>0</td>
<td>1000 mg/kg x 1, p.o.</td>
<td>Matter et al. (1982)</td>
</tr>
<tr>
<td>DLM, Dominant lethal test, mice</td>
<td>0</td>
<td>0</td>
<td>Matter et al. (1982)</td>
</tr>
<tr>
<td>UVN, Unscheduled DNA synthesis, human lymphocytes in vivo (+)</td>
<td>0</td>
<td>0</td>
<td>Petitjean et al. (1986)</td>
</tr>
<tr>
<td>CLH, Chromosomal aberrations, human lymphocytes in vivo (+)</td>
<td>0</td>
<td>9.5 mg/kg</td>
<td>Pukuda et al. (1988)</td>
</tr>
<tr>
<td>CLH, Chromosomal aberrations, human lymphocytes in vivo (+)</td>
<td>0</td>
<td>9 mg/kg</td>
<td>Pukuda et al. (1988)</td>
</tr>
</tbody>
</table>

\( ^a \) Tapering to 5–6 mg/kg per day; prednisolone was also given at 10 mg/person per day.

\( ^b \) Tapering to 4 mg/kg per day after one year; prednisolone was also given at 50 mg/person/day and tapering to 10 mg/person per day.
<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose LED/HID</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>SA0, S. typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>250 µg/ml</td>
<td>Pak et al. (1979)</td>
</tr>
<tr>
<td>SA5, S. typhimurium TA1535, reverse mutation</td>
<td>+</td>
<td>50 µg/ml</td>
<td>Benedict et al. (1977a)</td>
</tr>
<tr>
<td>SA9, S. typhimurium TA98, reverse mutation</td>
<td>+</td>
<td>250 µg/ml</td>
<td>Bruce &amp; Heddle (1979)</td>
</tr>
<tr>
<td>SA9, S. typhimurium TA98, reverse mutation</td>
<td>+</td>
<td>500 µg/ml</td>
<td>Pak et al. (1979)</td>
</tr>
<tr>
<td>ANF, A. nidulans, forward mutation</td>
<td>+</td>
<td>12.5 µg/ml</td>
<td>Bignami et al. (1982)</td>
</tr>
<tr>
<td>VPS, V. faba, sister chromatid exchange</td>
<td>+</td>
<td>37.8 µg/ml</td>
<td>Kihlman (1975)</td>
</tr>
<tr>
<td>VFC, V. faba, chromosomal aberrations</td>
<td>+</td>
<td>37.8 µg/ml</td>
<td>Kihlman (1975)</td>
</tr>
<tr>
<td>VFC, V. faba, chromosomal aberrations</td>
<td>+</td>
<td>95 µg/ml</td>
<td>Sturelid &amp; Kihlman (1975)</td>
</tr>
<tr>
<td>VFC, V. faba, chromosomal aberrations</td>
<td>+</td>
<td>19 µg/ml</td>
<td>Popa et al. (1976)</td>
</tr>
<tr>
<td>DMX, D. melanogaster, sex-linked recessive lethal mutations</td>
<td>+</td>
<td>0.23 µg/ml</td>
<td>Liers &amp; Rohrborn (1965)</td>
</tr>
<tr>
<td>DGH, G. h. mutagenesis, Chinese hamster V79 lung cells, hprt locus</td>
<td>+</td>
<td>1.9 µg/ml</td>
<td>Fahmy &amp; Fahmy (1970)</td>
</tr>
<tr>
<td>SIC, Sister chromatid exchange, Chinese hamster cells in vitro</td>
<td>+</td>
<td>2 µg/ml</td>
<td>Paschin &amp; Kozachenko (1982)</td>
</tr>
<tr>
<td>SIC, Sister chromatid exchange, Chinese hamster cells in vitro</td>
<td>+</td>
<td>2.5 µg/ml</td>
<td>Chebotarev &amp; Selezneva (1979)</td>
</tr>
<tr>
<td>SIC, Sister chromatid exchange, Chinese hamster cells in vitro</td>
<td>+</td>
<td>0.05 µg/ml</td>
<td>Chebotarev et al. (1980)</td>
</tr>
<tr>
<td>SIT, Sister chromatid exchange, mouse cells in vitro</td>
<td>+</td>
<td>0.06 µg/ml</td>
<td>Selezneva et al. (1982)</td>
</tr>
<tr>
<td>SIT, Sister chromatid exchange, mouse cells in vitro</td>
<td>+</td>
<td>0.2 µg/ml</td>
<td>Andersen (1983)</td>
</tr>
<tr>
<td>STT, Sister chromatid exchange, cloned hamster cells in vitro</td>
<td>+</td>
<td>0.01 µg/ml</td>
<td>Banerjee &amp; Benedict (1979)</td>
</tr>
<tr>
<td>STA, Sister chromatid exchange, rhesus monkey cells in vitro</td>
<td>+</td>
<td>2.5 µg/ml</td>
<td>Kuzin et al. (1987)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster cells in vitro</td>
<td>+</td>
<td>2 µg/ml</td>
<td>Sturelid (1976)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster cells in vitro</td>
<td>+</td>
<td>10 µg/ml</td>
<td>Maier &amp; Schmid (1976)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster cells in vitro</td>
<td>+</td>
<td>3.78 µg/ml</td>
<td>Sturelid &amp; Kihlman (1975)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster cells in vitro</td>
<td>+</td>
<td>0.5 µg/ml</td>
<td>Benedict et al. (1977b)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, rabbit cells in vitro</td>
<td>+</td>
<td>5 µg/ml</td>
<td>Bochkov et al. (1982)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, rhesus monkey cells in vitro</td>
<td>+</td>
<td>2.5 µg/ml</td>
<td>Kuzin et al. (1987)</td>
</tr>
<tr>
<td>TCM, Cell transformation, C3H 10T1/2 mouse cells</td>
<td>+</td>
<td>0.1 µg/ml</td>
<td>Benedict et al. (1977a)</td>
</tr>
<tr>
<td>UHL, Unscheduled DNA synthesis, human lymphocytes in vitro</td>
<td>+</td>
<td>1 µg/ml</td>
<td>Titenko (1983)</td>
</tr>
<tr>
<td>SHL, Sister chromatid exchange, human lymphocytes in vitro</td>
<td>+</td>
<td>2.5 µg/ml</td>
<td>Littlefield et al. (1979)</td>
</tr>
<tr>
<td>SHL, Sister chromatid exchange, human lymphocytes in vitro</td>
<td>+</td>
<td>0.03 µg/ml</td>
<td>Moulalatos (1979)</td>
</tr>
<tr>
<td>SHL, Sister chromatid exchange, human lymphocytes in vitro</td>
<td>+</td>
<td>5 µg/ml</td>
<td>Chebotarev &amp; Listopad (1980)</td>
</tr>
<tr>
<td>SHL, Sister chromatid exchange, human lymphocytes in vitro</td>
<td>+</td>
<td>1 µg/ml</td>
<td>Listopad &amp; Chebotarev (1982)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>2.5 µg/ml</td>
<td>Shcheglova &amp; Chebotarev (1983a)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>3 µg/ml</td>
<td>Hampel et al. (1986)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>1 µg/ml</td>
<td>Bochkov &amp; Kuleshov (1972)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>10 µg/ml</td>
<td>Bochkov et al. (1972)</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>------</td>
<td>-----------</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>8 μg/ml</td>
<td>Chebotarev (1974)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>20 μg/ml</td>
<td>Kirichenko (1974)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>10 μg/ml</td>
<td>Kirichenko &amp; Chebotarev (1976)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>6 μg/ml</td>
<td>Yakovenko &amp; Nazarenko (1977)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>6 μg/ml</td>
<td>Bochkov et al. (1979)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>200 μg/ml</td>
<td>Wolff &amp; Arutyunyan (1979)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>10 μg/ml</td>
<td>Yakovenko &amp; Kagramanyan (1982)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>6.6 μg/ml</td>
<td>Shcheglova &amp; Chebotarev (1983a)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>200 μg/ml</td>
<td>Lee (1973)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>10 μg/ml</td>
<td>Arni et al. (1977)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>6 μg/ml</td>
<td>Devi &amp; Reddy (1980)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>7.5 mg/kg x 1, s.c.</td>
<td>Shcheglova &amp; Chebotarev (1983b)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>12.4 mg/kg x 3, i.p.</td>
<td>Kusin et al. (1987)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>2.5 mg/kg x 2, p.o.</td>
<td>Maier &amp; Schmid (1976)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>2 mg/kg x 1, i.p.</td>
<td>Ioan et al. (1977)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>3 mg/kg x 1, i.v.</td>
<td>Bruce &amp; Reddle (1979)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>1 mg/kg x 2, i.p.</td>
<td>Leonard et al. (1979)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>2 mg/kg x 1, i.p.</td>
<td>Setnikar et al. (1976)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>2 mg/kg x 1, i.p.</td>
<td>Malashenko &amp; Surkova (1974b)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>1.25 mg/kg x 1, i.p.</td>
<td>Malashenko &amp; Surkova (1975)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>2 mg/kg x 1, i.p.</td>
<td>Leonard et al. (1979)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>1 mg/kg x 1, i.p.</td>
<td>Shcheglova &amp; Chebotarev (1983b)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>0.32 mg/kg x 1, i.p.</td>
<td>Devi &amp; Reddy (1980)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>2 mg/kg x 1, i.p.</td>
<td>Meistrich et al. (1982)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>1.25 mg/kg x 1, i.p.</td>
<td>Malashenko &amp; Surkova (1974b)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>1 mg/kg x 1, i.p.</td>
<td>Malashenko et al. (1978)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>1.66 mg/kg x 2, p.o.</td>
<td>Korogodina et al. (1979)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>20 mg/kg x 1, i.p.</td>
<td>Malashenko &amp; Surkova (1978)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>8 mg/kg x 1, i.p.</td>
<td>Malashenko et al. (1978)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>1.25 mg/kg x 1, i.p.</td>
<td>Korogodina et al. (1978)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>2.5 mg/kg x 1, i.p.</td>
<td>Semenov &amp; Malashenko (1979)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>2.5 mg/kg x 1, i.p.</td>
<td>Korogodina &amp; S'yakste (1981)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>3 mg/kg x 1, i.v.</td>
<td>Bochkov et al. (1982)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>5 mg/kg x 1, i.p.</td>
<td>Kusin et al. (1987)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>5 mg/kg x 1, i.p.</td>
<td>Machemer &amp; Hess (1971)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>5 mg/kg x 1, i.p.</td>
<td>Epstein et al. (1972)</td>
</tr>
</tbody>
</table>
THIOTEPA (contd)

<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>LED/HID</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Without</td>
<td>With</td>
<td></td>
</tr>
<tr>
<td></td>
<td>exogenous</td>
<td>exogenous</td>
<td></td>
</tr>
<tr>
<td></td>
<td>metabolic</td>
<td>metabolic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>system</td>
<td>system</td>
<td></td>
</tr>
<tr>
<td>DLM, Dominant lethal test, mice</td>
<td>+</td>
<td>0</td>
<td>0.2 mg/kg x 10, i.p.</td>
</tr>
<tr>
<td>DLM, Dominant lethal test, mice</td>
<td>+</td>
<td>0</td>
<td>1.25 µg/kg x 1, i.p.</td>
</tr>
<tr>
<td>DLM, Dominant lethal test, mice</td>
<td>+</td>
<td>0</td>
<td>2.5 mg/kg x 1, i.p.</td>
</tr>
<tr>
<td>MHT, Mouse heritable translocation test</td>
<td>+</td>
<td>0</td>
<td>5 mg/kg x 1, i.p.</td>
</tr>
<tr>
<td>MHT, Mouse heritable translocation test</td>
<td>+</td>
<td>0</td>
<td>1.25 mg/kg x 1, i.p.</td>
</tr>
<tr>
<td>MHT, Mouse heritable translocation test</td>
<td>+</td>
<td>0</td>
<td>1.25 mg/kg x 1, i.p.</td>
</tr>
<tr>
<td>MHT, Mouse heritable translocation test</td>
<td>+</td>
<td>0</td>
<td>1.25 mg/kg x 1, i.p.</td>
</tr>
<tr>
<td>CLH, Chromosomal aberrations, human lymphocytes in vivo</td>
<td>+</td>
<td>0</td>
<td>0.14 mg/kg x 4 - x 10, i.m.</td>
</tr>
<tr>
<td>SPM, Sperm morphology, mice in vivo</td>
<td>+</td>
<td>0</td>
<td>2.5 mg/kg x 5, i.v.</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose LED/HID</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>-------------</td>
<td>-----------</td>
</tr>
<tr>
<td></td>
<td>Without exogenous metabolic system</td>
<td>With exogenous metabolic system</td>
<td></td>
</tr>
<tr>
<td>C3H, Gene mutation, Chinese hamster lung V79 cells, hppt locus</td>
<td>+ 0</td>
<td>3 µg/ml</td>
<td>Slamnova et al. (1983)</td>
</tr>
<tr>
<td>CIT, Chromosomal aberrations, Walker 256 cells</td>
<td>+ 0</td>
<td>1 mg/kg x 4 - x 10, i.p.</td>
<td>Boyland et al. (1948)</td>
</tr>
<tr>
<td>CIT, Chromosomal aberrations, Walker 256 cells</td>
<td>+ 0</td>
<td>0</td>
<td>Koller (1969)</td>
</tr>
<tr>
<td>DLM, Dominant lethal test, mice</td>
<td>+ 0</td>
<td>5 mg/kg x 1, i.p.</td>
<td>Sykora &amp; Gandalovicova (1978)</td>
</tr>
</tbody>
</table>
## AMPICILLIN

<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose (µg/ml)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRB, <em>Staphylococcus aureus</em>, prophage induction</td>
<td>+</td>
<td>5</td>
<td>Manthey et al. (1975)</td>
</tr>
<tr>
<td>PRB, <em>Escherichia coli</em> PQ37, SOS induction</td>
<td></td>
<td>417</td>
<td>Venier et al. (1989)</td>
</tr>
<tr>
<td>ECB, <em>Escherichia coli</em>, DNA repair</td>
<td>-</td>
<td>100</td>
<td>Tweets et al. (1981)</td>
</tr>
<tr>
<td>SA0, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>-</td>
<td>0.00</td>
<td>Mortelmans et al. (1986)</td>
</tr>
<tr>
<td>SA0, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td></td>
<td>167</td>
<td>De Flora et al. (1984)</td>
</tr>
<tr>
<td>SA0, <em>Salmonella typhimurium</em> TA1535, reverse mutation</td>
<td>-</td>
<td>0.00</td>
<td>Mortelmans et al. (1986)</td>
</tr>
<tr>
<td>SA5, <em>Salmonella typhimurium</em> TA1535, reverse mutation</td>
<td></td>
<td>1</td>
<td>De Flora et al. (1984)</td>
</tr>
<tr>
<td>SA7, <em>Salmonella typhimurium</em> TA1537, reverse mutation</td>
<td>-</td>
<td>0.00</td>
<td>Mortelmans et al. (1986)</td>
</tr>
<tr>
<td>SA7, <em>Salmonella typhimurium</em> TA1537, reverse mutation</td>
<td></td>
<td>1</td>
<td>De Flora et al. (1984)</td>
</tr>
<tr>
<td>SA8, <em>Salmonella typhimurium</em> TA1538, reverse mutation</td>
<td>-</td>
<td>0.00</td>
<td>De Flora et al. (1984)</td>
</tr>
<tr>
<td>SA9, <em>Salmonella typhimurium</em> TA98, reverse mutation</td>
<td>-</td>
<td>0.00</td>
<td>De Flora et al. (1984)</td>
</tr>
<tr>
<td>SA9, <em>Salmonella typhimurium</em> TA98, reverse mutation</td>
<td></td>
<td>167</td>
<td>Mortelmans et al. (1986)</td>
</tr>
<tr>
<td>SA5, <em>Salmonella typhimurium</em> TA97, reverse mutation</td>
<td>-</td>
<td>0.00</td>
<td>De Flora et al. (1984)</td>
</tr>
<tr>
<td>VFC, <em>Vicia faba</em>, aberrant cell division</td>
<td>+</td>
<td>5000</td>
<td>Prasad (1977)</td>
</tr>
<tr>
<td>GST, Gene mutation, mouse lymphoma L5178Y cells, TK locus</td>
<td>-</td>
<td>5000</td>
<td>National Toxicology Program (1987)</td>
</tr>
<tr>
<td>STC, Sister chromatid exchange, Chinese hamster cells in vitro</td>
<td>-</td>
<td>1500</td>
<td>National Toxicology Program (1987)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster cells in vitro</td>
<td>-</td>
<td>1500</td>
<td>National Toxicology Program (1987)</td>
</tr>
<tr>
<td>CHF, Chromosomal aberrations, human fibroblasts in vitro</td>
<td>-</td>
<td>4000</td>
<td>Byarugaba et al. (1975)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>28</td>
<td>Jaju et al. (1984)</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose LED/HID</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>PRB, Prophage induction, SOS repair test, DNA strand breaks</td>
<td>- 0</td>
<td>10 µg/ml</td>
<td>Mantey et al. (1975)</td>
</tr>
<tr>
<td>PRB, Escherichia coli, DNA damage</td>
<td>- -</td>
<td>30 µg/ml</td>
<td>Mamber et al. (1986)</td>
</tr>
<tr>
<td>Salmonella typhimurium, DNA breaks</td>
<td>± 0</td>
<td>0</td>
<td>Jackson et al. (1977)</td>
</tr>
<tr>
<td>Salmonella typhimurium, differential toxicity</td>
<td>+ 0</td>
<td>1615 µg/ml</td>
<td>Jackson et al. (1977)</td>
</tr>
<tr>
<td>Salmonella typhimurium, differential toxicity</td>
<td>- 0</td>
<td>15 µg/ml</td>
<td>Russell et al. (1980)</td>
</tr>
<tr>
<td>ECD, Escherichia coli pol A, differential toxicity (spot test)</td>
<td>- -</td>
<td>5 µg/ml</td>
<td>Nader et al. (1981)</td>
</tr>
<tr>
<td>ECD, Escherichia coli pol A, differential toxicity (spot test)</td>
<td>- -</td>
<td>30 µg/ml</td>
<td>Longmacker et al. (1974)</td>
</tr>
<tr>
<td>ECD, Escherichia coli pol A, differential toxicity (spot test)</td>
<td>- -</td>
<td>30 µg/ml</td>
<td>Nestmann et al. (1979)</td>
</tr>
<tr>
<td>ECD, Escherichia coli, differential toxicity</td>
<td>- -</td>
<td>20 µg/ml</td>
<td>Boyle &amp; Simpson (1980)</td>
</tr>
<tr>
<td>ECD, Escherichia coli, differential toxicity</td>
<td>- -</td>
<td>30 µg/ml</td>
<td>Leifer et al. (1981)</td>
</tr>
<tr>
<td>ECD, Escherichia coli, differential toxicity</td>
<td>- -</td>
<td>0</td>
<td>Slater et al. (1971)</td>
</tr>
<tr>
<td>ECD, Escherichia coli, differential toxicity</td>
<td>- -</td>
<td>0</td>
<td>Venturini &amp; Monti-Bragadin (1978)</td>
</tr>
<tr>
<td>ERO, Escherichia coli, differential toxicity</td>
<td>- -</td>
<td>0</td>
<td>Suter &amp; Jaeger (1982)</td>
</tr>
<tr>
<td>ERO, Escherichia coli, differential toxicity</td>
<td>- -</td>
<td>0</td>
<td>Shimizu &amp; Rosenberg (1973)</td>
</tr>
<tr>
<td>ERO, Escherichia coli rec, differential toxicity</td>
<td>+ 0</td>
<td>0.6 µg/ml</td>
<td>Kada et al. (1972)</td>
</tr>
<tr>
<td>BSD, Bacillus subtilis, differential toxicity</td>
<td>- 0</td>
<td>1000 µg/ml</td>
<td>Sekizawa &amp; Shibamoto (1982)</td>
</tr>
<tr>
<td>BSD, Bacillus subtilis, differential toxicity</td>
<td>- 0</td>
<td>2.5 µg/ml</td>
<td>Suter &amp; Jaeger (1982)</td>
</tr>
<tr>
<td>BSD, Bacillus subtilis, differential toxicity</td>
<td>- 0</td>
<td>20 µg/ml</td>
<td>Adler et al. (1976)</td>
</tr>
<tr>
<td>BSD, Bacillus subtilis, differential toxicity</td>
<td>- 0</td>
<td>500 µg/ml</td>
<td>Leifer et al. (1981)</td>
</tr>
<tr>
<td>BSD, Bacillus subtilis, differential toxicity</td>
<td>- 0</td>
<td>5 µg/ml</td>
<td>Suter &amp; Jaeger (1982)</td>
</tr>
<tr>
<td>BSD, Bacillus subtilis, differential toxicity</td>
<td>- 0</td>
<td>2.5 µg/ml</td>
<td>Slater et al. (1971)</td>
</tr>
<tr>
<td>BSD, Bacillus subtilis, differential toxicity</td>
<td>- 0</td>
<td>30 µg/ml</td>
<td>Nader et al. (1981)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>- 0</td>
<td>0</td>
<td>Jackson et al. (1977)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>0 -</td>
<td>2.5 µg/ml</td>
<td>Benner et al. (1975)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>- -</td>
<td>333 µg/ml</td>
<td>Mortelmans et al. (1986)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>- -</td>
<td>30 µg/ml</td>
<td>Brem et al. (1974)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>- -</td>
<td>5 µg/ml</td>
<td>Albertini &amp; Gocke (1988)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>- -</td>
<td>30 µg/ml</td>
<td>Brem et al. (1974)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>- -</td>
<td>2.5 µg/ml</td>
<td>McCann et al. (1975)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>- -</td>
<td>0</td>
<td>Jackson et al. (1977)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>- -</td>
<td>333 µg/ml</td>
<td>Mortelmans et al. (1986)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>- -</td>
<td>2.5 µg/ml</td>
<td>McCann et al. (1975)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>- -</td>
<td>333 µg/ml</td>
<td>Mortelmans et al. (1986)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA100, reverse mutation</td>
<td>- -</td>
<td>30 µg/ml</td>
<td>Brem et al. (1974)</td>
</tr>
<tr>
<td>SAQ, Salmonella typhimurium TA98, reverse mutation</td>
<td>(+) (+)</td>
<td>9 µg/ml</td>
<td>Mitchell et al. (1980)</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>Without</strong></td>
<td><strong>With</strong></td>
<td><strong>exogenous</strong></td>
<td><strong>exogenous</strong></td>
</tr>
<tr>
<td><strong>Dose</strong></td>
<td><strong>LED/10^6</strong></td>
<td><strong>μg/ml</strong></td>
<td></td>
</tr>
<tr>
<td>SA9, Salmonella typhimurium TA98, reverse mutation</td>
<td>-</td>
<td>333</td>
<td>Mortelmans et al. (1986)</td>
</tr>
<tr>
<td>SA9, Salmonella typhimurium TA98, reverse mutation</td>
<td>-</td>
<td>27</td>
<td>Jackson et al. (1977)</td>
</tr>
<tr>
<td>ECF, Escherichia coli, forward mutation</td>
<td>+</td>
<td>10</td>
<td>Mitchell et al. (1980)</td>
</tr>
<tr>
<td>ECF, Escherichia coli WP2, forward mutation</td>
<td>+</td>
<td>27</td>
<td>Mitchell &amp; Gilbert (1985)</td>
</tr>
<tr>
<td>ECF, Escherichia coli CM91, forward mutation</td>
<td>(+)</td>
<td>27</td>
<td>Mitchell &amp; Gilbert (1985)</td>
</tr>
<tr>
<td>ECF, Escherichia coli WP2, reverse mutation</td>
<td>-</td>
<td>200</td>
<td>Hemmery &amp; Demerec (1955)</td>
</tr>
<tr>
<td>ECF, Escherichia coli CM91, reverse mutation</td>
<td>-</td>
<td>200</td>
<td>Mitchell &amp; Gilbert (1985)</td>
</tr>
<tr>
<td>ECF, Escherichia coli CM91, reverse mutation</td>
<td>+</td>
<td>27</td>
<td>Mitchell &amp; Gilbert (1985)</td>
</tr>
<tr>
<td>SCF, Saccharomyces cerevisiae D1121, petite mutations</td>
<td>(+)</td>
<td>4000</td>
<td>Weislogel &amp; Butow (1970)</td>
</tr>
<tr>
<td>SCF, Saccharomyces cerevisiae D35 and 44, petite mutations</td>
<td>(-)</td>
<td>3000</td>
<td>Carnevali et al. (1971)</td>
</tr>
<tr>
<td>SCF, Saccharomyces cerevisiae, petite mutations</td>
<td>(+)</td>
<td>3000</td>
<td>Williamson et al. (1971)</td>
</tr>
<tr>
<td>ARM, Arabidopsis species, mutation</td>
<td>-</td>
<td>1620</td>
<td>Moller (1965)</td>
</tr>
<tr>
<td>TSI, Tradescantia paludosa, micronuclei</td>
<td>-</td>
<td>1615</td>
<td>Me et al. (1984)</td>
</tr>
<tr>
<td>HSC, Hordeum species, chromosomal aberrations</td>
<td>+</td>
<td>300</td>
<td>Yoshida et al. (1972)</td>
</tr>
<tr>
<td>VFC, Vicia faba, chromosomal aberrations</td>
<td>+</td>
<td>5000</td>
<td>Frasad (1977)</td>
</tr>
<tr>
<td>DEX, Drosophila melanogaster, sex-linked recessive lethal mutation</td>
<td>-</td>
<td>2500</td>
<td>Clark (1963)</td>
</tr>
<tr>
<td>DEX, Drosophila melanogaster, sex-linked recessive lethal mutation</td>
<td>-</td>
<td>100000</td>
<td>Nasrat et al. (1977)</td>
</tr>
<tr>
<td>DNL, Drosophila melanogaster, dominant lethal test</td>
<td>-</td>
<td>100000</td>
<td>Nasrat et al. (1977)</td>
</tr>
<tr>
<td>U1A, Unscheduled DNA synthesis, Syrian hamster cells in vitro</td>
<td>-</td>
<td>1000</td>
<td>Suzuki (1987)</td>
</tr>
<tr>
<td>GST, Gene mutation, mouse lymphoma L5178Y cells, TK locus</td>
<td>+</td>
<td>3000</td>
<td>Mitchell et al. (1988)</td>
</tr>
<tr>
<td>STS, Sister chromatid exchange, Syrian hamster cells in vitro</td>
<td>+</td>
<td>30</td>
<td>Suzuki (1987)</td>
</tr>
<tr>
<td>SCA, Chromosomal aberrations, other animal cells in vitro</td>
<td>+</td>
<td>500</td>
<td>Quinnc et al. (1975)</td>
</tr>
<tr>
<td>TCS, Cell transformation, Syrian hamster embryo cells</td>
<td>-</td>
<td>1000</td>
<td>Suzuki (1987)</td>
</tr>
<tr>
<td>TTS, Cell transformation, SA7/Syrian hamster embryo cells</td>
<td>(-)</td>
<td>3490</td>
<td>Hatch et al. (1986)</td>
</tr>
<tr>
<td>DIN, DNA strand breaks, human lymphocytes in vitro</td>
<td>(+)</td>
<td>664</td>
<td>Yunis et al. (1987)</td>
</tr>
<tr>
<td>DIN, DNA strand breaks, human lymphocytes in vitro</td>
<td>-</td>
<td>258</td>
<td>Isildar et al. (1988)</td>
</tr>
<tr>
<td>DIN, DNA strand breaks, human lymphoblastoid cells in vitro</td>
<td>-</td>
<td>258</td>
<td>Isildar et al. (1988)</td>
</tr>
<tr>
<td>DIN, DNA strand breaks, human bone-marrow cells in vitro</td>
<td>-</td>
<td>258</td>
<td>Isildar et al. (1988)</td>
</tr>
<tr>
<td>SHL, Sister chromatid exchange, human lymphocytes in vitro</td>
<td>-</td>
<td>200</td>
<td>Pant et al. (1976)</td>
</tr>
<tr>
<td>CHF, Chromosomal aberrations, human fibroblasts in vitro</td>
<td>-</td>
<td>625</td>
<td>Byarugara et al. (1975)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>10</td>
<td>Mitis &amp; Coleman (1970)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>-</td>
<td>500</td>
<td>Jensen (1972)</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose LED/HID</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>--------</td>
<td>--------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>100 µg/ml</td>
<td>Sasaki &amp; Tonomura (1973)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>80 µg/ml</td>
<td>Goh (1979)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>200 µg/ml</td>
<td>Pant et al. (1976)</td>
</tr>
<tr>
<td>CBA, Chromosomal aberrations, animal bone-marrow cells in vivo</td>
<td>-</td>
<td>1000 mg/kg x 3, i.m.</td>
<td>Jensen (1972)</td>
</tr>
<tr>
<td>CBA, Chromosomal aberrations, animal bone-marrow cells in vivo</td>
<td>(+)</td>
<td>50 mg/kg x 1, i.m.</td>
<td>Manna &amp; Bhardhan (1973)</td>
</tr>
<tr>
<td>CBA, Chromosomal aberrations, animal bone-marrow cells in vivo</td>
<td>(+)</td>
<td>50 mg/kg x 1, i.m.</td>
<td>Manna &amp; Bhardhan (1977)</td>
</tr>
<tr>
<td>CGG, Chromosomal aberrations, Swiss mouse meiotic cells in vivo</td>
<td>(+)</td>
<td>50 mg/kg x 1, i.m.</td>
<td>Roy &amp; Manna (1981)</td>
</tr>
<tr>
<td>CCG, Chromosomal aberrations, Swiss mouse meiotic cells in vivo</td>
<td>(+)</td>
<td>50 mg/kg x 1, i.m.</td>
<td>Roy &amp; Manna (1981)</td>
</tr>
<tr>
<td>DLM, Dominant lethal test, mice</td>
<td>-</td>
<td>333 mg/kg x 1, i.p.</td>
<td>Epstein &amp; Shafner (1968)</td>
</tr>
<tr>
<td>DLM, Dominant lethal test (1011C3H)F1 mice</td>
<td>-</td>
<td>1500 mg/kg x 1, i.p.</td>
<td>Ehling (1971)</td>
</tr>
<tr>
<td>DLM, Dominant lethal test, mice</td>
<td>-</td>
<td>666 mg/kg x 1, i.p.</td>
<td>Epstein et al. (1972)</td>
</tr>
<tr>
<td>DLM, Dominant lethal test, mice</td>
<td>+</td>
<td>500 mg/kg x 1, i.p.</td>
<td>Sram (1972)</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose LED/HID</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>--------</td>
<td>--------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>FRB, Escherichia coli T44(1), prophage induction</td>
<td>+</td>
<td>1.0 µg/ml</td>
<td>McCalla &amp; Voutsinos (1974)</td>
</tr>
<tr>
<td>ECB, Escherichia coli B/8, DNA strand breaks</td>
<td>+</td>
<td>25 µg/ml</td>
<td>McCalla et al. (1971)</td>
</tr>
<tr>
<td>ECB, Escherichia coli c1256, DNA strand breaks</td>
<td>+</td>
<td>75 µg/ml</td>
<td>Tu &amp; McCalla (1975)</td>
</tr>
<tr>
<td>ECB, Escherichia coli ntr-207, DNA strand breaks</td>
<td>-</td>
<td>50 µg/ml</td>
<td>McCalla et al. (1971)</td>
</tr>
<tr>
<td>SAD, Salmonella typhimurium TA1975, DNA strand breaks</td>
<td>+</td>
<td>50 µg/ml</td>
<td>McCalla et al. (1975)</td>
</tr>
<tr>
<td>SAD, Salmonella typhimurium TA1975, differential toxicity</td>
<td>+</td>
<td>100 µg/ml</td>
<td>Yahagi et al. (1974)</td>
</tr>
<tr>
<td>ERD, Escherichia coli WP100, differential toxicity</td>
<td>+</td>
<td>10 µg/ml</td>
<td>Haveland-Smith et al. (1979)</td>
</tr>
<tr>
<td>ERD, Escherichia coli WP67, differential toxicity</td>
<td>+</td>
<td>100 µg/ml</td>
<td>Yahagi et al. (1974)</td>
</tr>
<tr>
<td>ERD, Escherichia coli, differential toxicity</td>
<td>+</td>
<td>1 µg/ml</td>
<td>Ebringer &amp; Bencova (1980)</td>
</tr>
<tr>
<td>BSD, Bacillus subtilis KLL3g vs M3-15, differential toxicity</td>
<td>+</td>
<td>500 µg/ml</td>
<td>Tanooka (1977)</td>
</tr>
<tr>
<td>BSM, Bacillus subtilis TK35211, mutation</td>
<td>+</td>
<td>500 µg/ml</td>
<td>Tanooka (1977)</td>
</tr>
<tr>
<td>SA0, Salmonella typhimurium TA100, fluctuation test</td>
<td>+</td>
<td>0.0001 µg/ml</td>
<td>National Toxicology Program (1988)</td>
</tr>
<tr>
<td>SA0, Salmonella typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>0.15 µg/ml</td>
<td>Goodman et al. (1977)</td>
</tr>
<tr>
<td>SA0, Salmonella typhimurium TA100, reverse mutation (spot test)</td>
<td>+</td>
<td>0.25 µg/ml</td>
<td>Yahagi et al. (1976)</td>
</tr>
<tr>
<td>SA0, Salmonella typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>1.98 µg/ml</td>
<td>Chin et al. (1978)</td>
</tr>
<tr>
<td>SA0, Salmonella typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>1.98 µg/ml</td>
<td>Rosin &amp; Stich (1978)</td>
</tr>
<tr>
<td>SA0, Salmonella typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>2 µg/ml</td>
<td>Bruce &amp; Heddle (1979)</td>
</tr>
<tr>
<td>SA0, Salmonella typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>2 µg/ml</td>
<td>Ebringer &amp; Bencova (1980)</td>
</tr>
<tr>
<td>SA0, Salmonella typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>0.1 µg/ml</td>
<td>Green et al. (1977)</td>
</tr>
<tr>
<td>SA5, Salmonella typhimurium TA1535, fluctuation test</td>
<td>+</td>
<td>16 µg/ml</td>
<td>National Toxicology Program (1988)</td>
</tr>
<tr>
<td>SA5, Salmonella typhimurium TA1535, reverse mutation</td>
<td>+</td>
<td>16 µg/ml</td>
<td>McCalla et al. (1975)</td>
</tr>
<tr>
<td>SA5, Salmonella typhimurium TA1535, reverse mutation</td>
<td>+</td>
<td>1 µg/ml</td>
<td>Yahagi et al. (1976)</td>
</tr>
<tr>
<td>SA7, Salmonella typhimurium TA1537, reverse mutation</td>
<td>+</td>
<td>1 µg/ml</td>
<td>National Toxicology Program (1988)</td>
</tr>
<tr>
<td>SA7, Salmonella typhimurium TA1537, reverse mutation</td>
<td>+</td>
<td>33 µg/ml</td>
<td>Yahagi et al. (1976)</td>
</tr>
<tr>
<td>SA8, Salmonella typhimurium TA1538, reverse mutation</td>
<td>+</td>
<td>2.5 µg/ml</td>
<td>McCalla et al. (1975)</td>
</tr>
<tr>
<td>SA9, Salmonella typhimurium TA1538, reverse mutation</td>
<td>+</td>
<td>59.4 µg/ml</td>
<td>Yahagi et al. (1976)</td>
</tr>
<tr>
<td>SA9, Salmonella typhimurium TA1538, reverse mutation</td>
<td>+</td>
<td>2.5 µg/ml</td>
<td>Nuclear Toxicology Program (1988)</td>
</tr>
<tr>
<td>SA9, Salmonella typhimurium TA98, reverse mutation</td>
<td>+</td>
<td>1.5 µg/ml</td>
<td>Goodman et al. (1977)</td>
</tr>
<tr>
<td>SA9, Salmonella typhimurium TA98, reverse mutation</td>
<td>+</td>
<td>0.5 µg/ml</td>
<td>Bruce &amp; Heddle (1979)</td>
</tr>
<tr>
<td>SA9, Salmonella typhimurium TA98, reverse mutation</td>
<td>+</td>
<td>2 µg/ml</td>
<td>National Toxicology Program (1988)</td>
</tr>
</tbody>
</table>
## NITROFURAN (NITROFURAZONE) (contd)

<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SAS, Salmonella typhimurium TA98NR, reverse mutation</strong></td>
<td>+</td>
<td>1 µg/ml</td>
<td>Ni et al. (1987)</td>
</tr>
<tr>
<td><strong>SAS, Salmonella typhimurium TA98/1,8-DNP6, reverse mutation</strong></td>
<td>+</td>
<td>1 µg/ml</td>
<td>Ni et al. (1987)</td>
</tr>
<tr>
<td><strong>SAS, Salmonella typhimurium TA1536, reverse mutation</strong></td>
<td>-</td>
<td>59.4 µg/ml</td>
<td>Yahagi et al. (1974)</td>
</tr>
<tr>
<td><strong>SAS, Salmonella typhimurium TA97, reverse mutation (fluct. test)</strong></td>
<td>+</td>
<td>0.32 µg/ml</td>
<td>Obaseiki-Ebor &amp; Akerere (1986)</td>
</tr>
<tr>
<td><strong>ECF, Escherichia coli WP2uvrA, reverse mutation</strong></td>
<td>+</td>
<td>0</td>
<td>Baers et al. (1980)</td>
</tr>
<tr>
<td><strong>ECW, Escherichia coli WP2uvrA, reverse mutation (spot test)</strong></td>
<td>+</td>
<td>40 µg/ml</td>
<td>McCalla &amp; Voutsinos (1974)</td>
</tr>
<tr>
<td><strong>ECW, Escherichia coli WP2uvrA, reverse mutation</strong></td>
<td>+</td>
<td>8 µg/ml</td>
<td>Green et al. (1977)</td>
</tr>
<tr>
<td><strong>EC2, Escherichia coli WP2, reverse mutation (spot test)</strong></td>
<td>(++)</td>
<td>0.01 µg/ml</td>
<td>Haveland-Smith et al. (1979)</td>
</tr>
<tr>
<td><strong>EC2, Escherichia coli WP2, reverse mutation</strong></td>
<td>+</td>
<td>10 µg/ml</td>
<td>McCalla &amp; Voutsinos (1974)</td>
</tr>
<tr>
<td><strong>EC2, Escherichia coli WP2, reverse mutation (fluctuation test)</strong></td>
<td>(+)</td>
<td>0</td>
<td>McCalla &amp; Voutsinos (1974)</td>
</tr>
<tr>
<td><strong>ECR, Escherichia coli nfr 342, reverse mutation</strong></td>
<td>-</td>
<td>100 µg/ml</td>
<td>Obaseiki-Ebor &amp; Akerere (1986)</td>
</tr>
<tr>
<td><strong>ECR, Escherichia coli nfr 343, reverse mutation</strong></td>
<td>-</td>
<td>16 µg/ml</td>
<td>McCalla &amp; Voutsinos (1974)</td>
</tr>
<tr>
<td><strong>ECR, Escherichia coli nfr 345, reverse mutation</strong></td>
<td>-</td>
<td>0.04 µg/ml</td>
<td>McCalla &amp; Voutsinos (1974)</td>
</tr>
<tr>
<td><strong>ECR, Escherichia coli CM61, reverse mutation</strong></td>
<td>-</td>
<td>0</td>
<td>McCalla &amp; Voutsinos (1974)</td>
</tr>
<tr>
<td><strong>ECR, Escherichia coli CM571, reverse mutation</strong></td>
<td>-</td>
<td>10 µg/ml</td>
<td>McCalla &amp; Voutsinos (1974)</td>
</tr>
<tr>
<td><strong>ECR, Escherichia coli CM611, reverse mutation</strong></td>
<td>-</td>
<td>0</td>
<td>McCalla &amp; Voutsinos (1974)</td>
</tr>
<tr>
<td><strong>ECR, Escherichia coli S, Lac, reverse mutation</strong></td>
<td>-</td>
<td>50 µg/ml</td>
<td>Sambiri &amp; Greenberg (1964)</td>
</tr>
<tr>
<td><strong>ECR, Escherichia coli CM611, reverse mutation (fluctuation test)</strong></td>
<td>-</td>
<td>0</td>
<td>Green et al. (1977)</td>
</tr>
<tr>
<td><strong>ECR, Escherichia coli ES97, reverse mutation (fluctuation test)</strong></td>
<td>-</td>
<td>0.02 µg/ml</td>
<td>Obaseiki-Ebor &amp; Akerere (1986)</td>
</tr>
<tr>
<td><strong>ECR, Escherichia coli 343/113/R-9, reverse mutation</strong></td>
<td>-</td>
<td>40 µg/ml</td>
<td>Baers et al. (1980)</td>
</tr>
<tr>
<td><strong>AMP, Aspergillus nidulans, forward mutation</strong></td>
<td>-</td>
<td>1000 µg/ml</td>
<td>Bigiamenti et al. (1982)</td>
</tr>
<tr>
<td><strong>NCR, Neurospora crassa, reverse mutation</strong></td>
<td>+</td>
<td>198 µg/ml</td>
<td>Ong (1977)</td>
</tr>
<tr>
<td><strong>DDM, Drosophila melanogaster, sex-linked recessive lethal mutation</strong></td>
<td>+</td>
<td>990 µg/ml</td>
<td>Kramer (1982)</td>
</tr>
<tr>
<td><strong>DIA, DNA single strand breaks, mouse L929 cells in vitro</strong></td>
<td>+</td>
<td>49.5 µg/ml</td>
<td>Olive &amp; McCalla (1975)</td>
</tr>
<tr>
<td><strong>DIA, DNA single strand breaks, hamster BHK-21 cells in vitro</strong></td>
<td>+</td>
<td>49.5 µg/ml</td>
<td>Olive &amp; McCalla (1975)</td>
</tr>
<tr>
<td><strong>DIA, DNA single strand breaks, mouse L929 cells in vitro</strong></td>
<td>+</td>
<td>39.6 µg/ml</td>
<td>Olive (1978)</td>
</tr>
<tr>
<td><strong>URP, Unscheduled DNA synthesis, rat primary hepatocytes</strong></td>
<td>-</td>
<td>0.011 µg/ml</td>
<td>Mori et al. (1987)</td>
</tr>
<tr>
<td><strong>UTA, Unscheduled DNA synthesis, mouse hepatocytes in vitro</strong></td>
<td>-</td>
<td>0</td>
<td>Mori et al. (1987)</td>
</tr>
<tr>
<td><strong>GCD, Gene mutation, Chinese hamster ovary cells in vitro</strong></td>
<td>-</td>
<td>200 µg/ml</td>
<td>Anderson &amp; Phillips (1985)</td>
</tr>
<tr>
<td><strong>GIA, Gene mutation, Chinese hamster V79 cells, 6-thioguanine res.</strong></td>
<td>-</td>
<td>150 µg/ml</td>
<td>Olive (1981)</td>
</tr>
</tbody>
</table>
## NITROFURAL (NITROFURAZONE) (contd)

<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GST, Gene mutation, mouse lymphoma L5178Y cells, TK locus</strong></td>
<td>+</td>
<td>0</td>
<td>50 µg/ml</td>
</tr>
<tr>
<td><strong>SIC, Sister chromatid exchange, Chinese hamster CHO cells in vitro</strong></td>
<td>+</td>
<td>0</td>
<td>0.83 µg/ml</td>
</tr>
<tr>
<td><strong>CIC, Chromosomal aberrations, Chinese hamster lung cells in vitro</strong></td>
<td>0</td>
<td>+</td>
<td>83.3 µg/ml</td>
</tr>
<tr>
<td><strong>CIC, Chromosomal aberrations, Chinese hamster ovary cells in vitro</strong></td>
<td>+</td>
<td>+</td>
<td>150 µg/ml</td>
</tr>
<tr>
<td><strong>CIC, Chromosomal aberrations, Chinese hamster ovary cells in vitro</strong></td>
<td>+</td>
<td>0</td>
<td>100 µg/ml</td>
</tr>
<tr>
<td><strong>CIC, Chromosomal aberrations, Chinese hamster ovary cells in vitro</strong></td>
<td>0</td>
<td>-</td>
<td>25 µg/ml</td>
</tr>
<tr>
<td><strong>CIC, Chromosomal aberrations, Chinese hamster ovary cells in vitro</strong></td>
<td>0</td>
<td>+</td>
<td>600 µg/ml</td>
</tr>
<tr>
<td><strong>CIC, Chromosomal aberrations, Chinese hamster CHL cells in vitro</strong></td>
<td>+</td>
<td>0</td>
<td>100 µg/ml</td>
</tr>
<tr>
<td><strong>DIH, DNA single strand breaks, human KB cells in vitro</strong></td>
<td>0</td>
<td>0</td>
<td>49.5 µg/ml</td>
</tr>
<tr>
<td><strong>UHF, Unscheduled DNA synthesis, normal human fibroblasts in vitro</strong></td>
<td>-</td>
<td>0</td>
<td>23.8 µg/ml</td>
</tr>
<tr>
<td><strong>UHF, Unscheduled DNA synthesis, human XP fibroblasts in vitro</strong></td>
<td>-</td>
<td>0</td>
<td>23.8 µg/ml</td>
</tr>
<tr>
<td><strong>CHL, Chromosomal aberrations, human lymphocytes in vitro</strong></td>
<td>-</td>
<td>0</td>
<td>23.8 µg/ml</td>
</tr>
<tr>
<td><strong>DNA, DNA strand breaks, mouse tissue in vitro</strong></td>
<td>+</td>
<td>0</td>
<td>120 mg/kg x 25, p.o.</td>
</tr>
<tr>
<td><strong>MMV, Micronucleus test, mice in vivo</strong></td>
<td>-</td>
<td>0</td>
<td>150 mg/kg x 5, i.p.</td>
</tr>
<tr>
<td><strong>MVR, Micronucleus test, Sprague-Dawley rats in vivo</strong></td>
<td>-</td>
<td>0</td>
<td>60 mg/kg x 1, i.p.</td>
</tr>
<tr>
<td><strong>MVR, Micronucleus test, Long-Evans rats in vivo</strong></td>
<td>-</td>
<td>0</td>
<td>60 mg/kg x 1, i.p.</td>
</tr>
<tr>
<td><strong>CBA, Chromosomal aberrations, rat bone-marrow cells in vivo</strong></td>
<td>-</td>
<td>0</td>
<td>400 mg/kg x 1, p.o.</td>
</tr>
<tr>
<td><strong>CBA, Chromosomal aberrations, rat bone-marrow cells in vivo</strong></td>
<td>-</td>
<td>0</td>
<td>150 mg/kg x 5, p.o.</td>
</tr>
<tr>
<td><strong>CBA, Chromosomal aberrations, rat bone-marrow cells in vivo</strong></td>
<td>-</td>
<td>0</td>
<td>150 mg/kg x 5, i.p.</td>
</tr>
<tr>
<td><strong>SPF, Sperm morphology, F1 mice in vivo</strong></td>
<td>-</td>
<td>0</td>
<td>50 µg/ml</td>
</tr>
</tbody>
</table>

- GST: National Toxicology Program (1988)
- SIC: National Toxicology Program (1988)
- CIC: Ishidae (1988)
- CHL: National Toxicology Program (1988)
- MMV: Matsuoka et al. (1979)
- MVR: Olive & McCalla (1975)
- CBA: Olive & Sasaki (1973)
- SPF: Anderson & Phillips (1985)
<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAD, <em>Salmonella typhimurium</em>, differential toxicity</td>
<td>+</td>
<td>+119 μg/ml</td>
<td>Yahagi et al. (1974)</td>
</tr>
<tr>
<td>ECB, <em>Escherichia coli</em> DNA strand breaks</td>
<td>(+)</td>
<td>50 μg/ml</td>
<td>McCalla et al. (1971)</td>
</tr>
<tr>
<td>ECD, <em>Escherichia coli</em> W3110 vs p3478 differential toxicity</td>
<td>+</td>
<td>10 μg/ml</td>
<td>McCarroll et al. (1981a)</td>
</tr>
<tr>
<td>EDD, <em>Escherichia coli</em> WP2 vs WP4246, reverse mutation</td>
<td>+</td>
<td>10 μg/ml</td>
<td>Ehringer &amp; Bencova (1980)</td>
</tr>
<tr>
<td>EDD, <em>Escherichia coli</em> WP2 vs WP4246, reverse mutation</td>
<td>+</td>
<td>3 μg/ml</td>
<td>McCarroll et al. (1981a)</td>
</tr>
<tr>
<td>EDD, <em>Escherichia coli</em> WP2 vs WP4246, reverse mutation</td>
<td>+</td>
<td>3 μg/ml</td>
<td>McCarroll et al. (1981a)</td>
</tr>
<tr>
<td>EDD, <em>Escherichia coli</em> WP2 vs WP4246, reverse mutation</td>
<td>+</td>
<td>0.1 μg/ml</td>
<td>De Flora et al. (1984)</td>
</tr>
<tr>
<td>EDD, <em>Escherichia coli</em> WP2 vs WP4246, reverse mutation</td>
<td>+</td>
<td>0.4 μg/ml</td>
<td>De Flora et al. (1984)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>0.15 μg/ml</td>
<td>Wang &amp; Lee (1976)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>0.025 μg/ml</td>
<td>De Flora (1979)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>0.15 μg/ml</td>
<td>Havorth et al. (1983)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>0.125 μg/ml</td>
<td>Goodman et al. (1977)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>1 μg/ml</td>
<td>Rosenkranz &amp; Speck (1976)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>0.119 μg/ml</td>
<td>Shirai &amp; Wang (1980)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>1 μg/ml</td>
<td>Yahagi et al. (1974)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>1 μg/ml</td>
<td>Ehringer &amp; Bencova (1980)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>16 μg/ml</td>
<td>Havorth et al. (1983)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>71 μg/ml</td>
<td>Yahagi et al. (1974)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>8 μg/ml</td>
<td>Havorth et al. (1983)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>0.15 μg/ml</td>
<td>Yahagi et al. (1974)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>0.15 μg/ml</td>
<td>Yahagi et al. (1974)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>1 μg/ml</td>
<td>Yahagi et al. (1974)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>0.5 μg/ml</td>
<td>Ni et al. (1987)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>1.5 μg/ml</td>
<td>Goodman et al. (1977)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>50 μg/ml</td>
<td>Wang &amp; Lee (1976)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>1 μg/ml</td>
<td>Ni et al. (1987)</td>
</tr>
<tr>
<td>SAD, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>+</td>
<td>1 μg/ml</td>
<td>Ni et al. (1987)</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose LED/MID</td>
<td>Reference</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>--------</td>
<td>--------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>SAS, <em>Salmonella typhimurium</em> TA1536, reverse mutation</td>
<td>-</td>
<td>71 µg/ml</td>
<td>Yahagi et al. (1974)</td>
</tr>
<tr>
<td>SAS, <em>Salmonella typhimurium</em> TA97, reverse mutation (fluct. test)</td>
<td>+</td>
<td>0.32 µg/ml</td>
<td>Obaseki-Ebor &amp; Akerele (1986)</td>
</tr>
<tr>
<td>SAS, <em>Salmonella typhimurium</em> TA100PR1, reverse mutation</td>
<td>-</td>
<td>5 µg/ml</td>
<td>Rosenkranz &amp; Speck (1976)</td>
</tr>
<tr>
<td>ECO, <em>Escherichia coli</em> WP2 uvrA, reverse mutation</td>
<td>-</td>
<td>71 µg/ml</td>
<td>Yahagi et al. (1974)</td>
</tr>
<tr>
<td>ECO, <em>Escherichia coli</em> WP2, reverse mutation (fluctuation test)</td>
<td>+</td>
<td>7.14 µg/ml</td>
<td>Lu et al. (1979)</td>
</tr>
<tr>
<td>EC2, <em>Escherichia coli</em> WP2, reverse mutation</td>
<td>-</td>
<td>0.4 µg/ml</td>
<td>Obaseki-Ebor &amp; Akerele (1986)</td>
</tr>
<tr>
<td>SCG, <em>Saccharomyces cerevisiae</em> D4-RDII, mitotic gene conversion</td>
<td>+</td>
<td>23.8 µg/ml</td>
<td>Siebert et al. (1979)</td>
</tr>
<tr>
<td>SCG, <em>Saccharomyces cerevisiae</em> D4-RDII, mitotic gene conversion</td>
<td>0</td>
<td>238 µg/ml</td>
<td>Callen (1981)</td>
</tr>
<tr>
<td>SCG, <em>Saccharomyces cerevisiae</em> D7, mitotic gene conversion</td>
<td>+</td>
<td>476 µg/ml</td>
<td>Bignami et al. (1974)</td>
</tr>
<tr>
<td>ANG, <em>Aspergillus nidulans</em>, crossing over</td>
<td>+</td>
<td>0</td>
<td>Setnikar et al. (1976)</td>
</tr>
<tr>
<td>DMX, <em>Drosophila melanogaster</em>, sex-linked recessive lethal mutation</td>
<td>+</td>
<td>2.14 µg/ml</td>
<td>Zimmering et al. (1985)</td>
</tr>
<tr>
<td>DTA, DNA single strand breaks, mouse L cells in vitro</td>
<td>+</td>
<td>102 µg/ml</td>
<td>Williams et al. (1989)</td>
</tr>
<tr>
<td>URP, Unscheduled DNA synthesis, rat primary hepatocytes</td>
<td>-</td>
<td>23.8 µg/ml</td>
<td>Shirai &amp; Wang (1980)</td>
</tr>
<tr>
<td>SIC, Sister chromatid exchange, Chinese hamster CHO cells in vitro</td>
<td>+</td>
<td>9.5 µg/ml</td>
<td>Ishidate (1988)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster lung cells in vitro</td>
<td>+</td>
<td>60 µg/ml</td>
<td>Tonomura &amp; Sasaki (1973)</td>
</tr>
<tr>
<td>UHF, Unscheduled DNA synthesis, human fibroblasts in vitro</td>
<td>-</td>
<td>20 µg/ml</td>
<td>Tonomura &amp; Sasaki (1973)</td>
</tr>
<tr>
<td>UHF, Unscheduled DNA synthesis, human XP fibroblasts in vitro</td>
<td>-</td>
<td>20 µg/ml</td>
<td>Sasaki et al. (1980)</td>
</tr>
<tr>
<td>SII, Sister chromatid exchange, human HE2144 cells in vitro</td>
<td>-</td>
<td>20 µg/ml</td>
<td>Tonomura &amp; Sasaki (1973)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>-</td>
<td>2.38 µg/ml</td>
<td>Sasaki et al. (1980)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human HE2144 cells in vitro</td>
<td>-</td>
<td>600 µg/kg x 4, p.o.</td>
<td>Wang &amp; Lee (1976)</td>
</tr>
<tr>
<td>BFA, <em>Salmonella typhimurium</em> TA100, reverse mutation (rat urine)</td>
<td>+</td>
<td>600 µg/kg x 4, p.o.</td>
<td>Wang &amp; Lee (1976)</td>
</tr>
<tr>
<td>BFA, <em>Salmonella typhimurium</em> TA100PR1, reverse mutation (rat urine)</td>
<td>(+)</td>
<td>500 µg/kg x 1, p.o.</td>
<td>Siebert et al. (1979)</td>
</tr>
<tr>
<td>BFA, <em>Saccharomyces cerevisiae</em> D4-RDII, mitotic gene conversion</td>
<td>+</td>
<td>1.6 µg/kg x 1, p.o.</td>
<td>Wang et al. (1977)</td>
</tr>
<tr>
<td>BFA, <em>Saccharomyces cerevisiae</em> D4, reverse mutation (human urine)</td>
<td>+</td>
<td>1.6 µg/kg x 1, p.o.</td>
<td>Wang et al. (1977)</td>
</tr>
<tr>
<td>BFA, <em>Saccharomyces cerevisiae</em> D4, reverse mutation/gene conversion</td>
<td>-</td>
<td>71 µg/kg x 1, p.o.</td>
<td>Siebert et al. (1976)</td>
</tr>
<tr>
<td>BMN, <em>Saccharomyces cerevisiae</em> D4-RDII, mitotic gene conversion</td>
<td>-</td>
<td>500 µg/kg x 1, p.o. 6 h</td>
<td>Siebert et al. (1976)</td>
</tr>
</tbody>
</table>
NITROFURANTOIN (contd)

<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose LED/HID</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMM, Saccharomyces cerevisiae D4-RDII, mitotic gene conversion</td>
<td>+</td>
<td>500 mg/kg x 1, p.o. 8h</td>
<td>Siebert et al. (1979)</td>
</tr>
<tr>
<td>DVA, DNA damage, Sprague-Dawley rats in vivo</td>
<td>+</td>
<td>56 mg/kg x 1, i.p.</td>
<td>Russo et al. (1982)</td>
</tr>
<tr>
<td>DVA, DNA damage, Sprague-Dawley rats in vivo</td>
<td>+</td>
<td>14 mg/kg x 1, i.p.</td>
<td>Parodi et al. (1983)</td>
</tr>
<tr>
<td>DVA, DNA damage, mouse bone-marrow cells in vivo</td>
<td>+</td>
<td>64 mg/kg x 1, i.p.</td>
<td>Parodi et al. (1983)</td>
</tr>
<tr>
<td>MST, Mouse spot test</td>
<td>-</td>
<td>80 mg/kg x 1, i.p.</td>
<td>Gocke et al. (1983)</td>
</tr>
<tr>
<td>STA, Sister chromatid exchange, mouse bone-marrow cells in vivo</td>
<td>+</td>
<td>32 mg/kg x 1, i.p.</td>
<td>Parodi et al. (1983)</td>
</tr>
<tr>
<td>Mvr, Micronucleus test, Sprague-Dawley rats in vivo</td>
<td>-</td>
<td>400 mg/kg x 1, p.o.</td>
<td>Setnikar et al. (1976)</td>
</tr>
<tr>
<td>MVR, Micronucleus test, Sprague-Dawley rats in vivo</td>
<td>-</td>
<td>200 mg/kg x 1, i.p.</td>
<td>Goodman et al. (1977)</td>
</tr>
<tr>
<td>CCC, Chromosomal aberrations, male NMRI mice mitotic cells</td>
<td>0</td>
<td>80 mg/kg x 1, i.p.</td>
<td>Epstein et al. (1972)</td>
</tr>
<tr>
<td>DLM, Dominant lethal test, ICR/Ha Swiss mice</td>
<td>0</td>
<td>17.5 mg/kg x 1, p.o.</td>
<td>Setnikar et al. (1976)</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>------</td>
<td>-----------</td>
</tr>
<tr>
<td>ERD, Escherichia coli, differential toxicity</td>
<td>- 0</td>
<td>60 µg/ml</td>
<td>Pool et al. (1979)</td>
</tr>
<tr>
<td>ERD, Escherichia coli, differential toxicity</td>
<td>- 0</td>
<td>1250 µg/ml</td>
<td>De Flora (1981)</td>
</tr>
<tr>
<td>SA0, Salmonella typhimurium TA100, reverse mutation</td>
<td>- 0</td>
<td>10000 µg/ml</td>
<td>De Flora &amp; Picciotto (1980)</td>
</tr>
<tr>
<td>SA5, Salmonella typhimurium TA1535, reverse mutation</td>
<td>- 0</td>
<td>10000 µg/ml</td>
<td>De Flora &amp; Picciotto (1980)</td>
</tr>
<tr>
<td>SA7, Salmonella typhimurium TA1537, reverse mutation</td>
<td>- 0</td>
<td>10000 µg/ml</td>
<td>De Flora &amp; Picciotto (1980)</td>
</tr>
<tr>
<td>SA8, Salmonella typhimurium TA1538, reverse mutation</td>
<td>- 0</td>
<td>10000 µg/ml</td>
<td>De Flora &amp; Picciotto (1980)</td>
</tr>
<tr>
<td>SA9, Salmonella typhimurium TA98, reverse mutation</td>
<td>- 0</td>
<td>1260 µg/ml</td>
<td>Schwars et al. (1980)</td>
</tr>
<tr>
<td>DIA, DNA strand breaks, transformed mouse epithelial cells in vitro</td>
<td>+ 0</td>
<td>756 µg/ml</td>
<td>Martelli et al. (1983)</td>
</tr>
<tr>
<td>DIA, DNA damage, rat hepatocytes in vitro</td>
<td>+ 0</td>
<td>83 µg/ml</td>
<td>Martelli et al. (1983)</td>
</tr>
<tr>
<td>DIA, Unscheduled DNA synthesis, rat primary hepatocytes</td>
<td>+ 0</td>
<td>2520 µg/ml</td>
<td>Lefèvre &amp; Ashby (1985)</td>
</tr>
<tr>
<td>DIA, Unscheduled DNA synthesis, rat primary hepatocytes</td>
<td>+ 0</td>
<td>25.2 µg/ml</td>
<td>Lefèvre &amp; Ashby (1985)</td>
</tr>
<tr>
<td>DIH, DNA damage, human hepatocytes in vitro</td>
<td>+ 0</td>
<td>2268 µg/ml</td>
<td>Martelli et al. (1986)</td>
</tr>
<tr>
<td>DIH, Unscheduled DNA synthesis, human hepatocytes in vitro</td>
<td>+ 0</td>
<td>2268 µg/ml</td>
<td>Martelli et al. (1986)</td>
</tr>
<tr>
<td>SHL, Sister chromatid exchange, human lymphocytes in vitro</td>
<td>+ 0</td>
<td>252 µg/ml</td>
<td>Inoue et al. (1985)</td>
</tr>
<tr>
<td>DVA, DNA damage, rat liver cells in vivo</td>
<td>+ 0</td>
<td>250 mg/kg × 20 p.o.</td>
<td>Brambilla et al. (1982)</td>
</tr>
<tr>
<td>DVA, DNA damage, rat gastric mucosa in vivo</td>
<td>- 0</td>
<td>250 mg/kg x 1 p.o.</td>
<td>Pino &amp; Robbiano (1983)</td>
</tr>
</tbody>
</table>

a Cimetidine hydrochloride
b With NaN₂, 80 mg/kg
### Table: N-NITROSOCIMETIDINE/CIMETIDINE PLUS NITRITE

<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose (LED/HID)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ERD,</strong> Escherichia coli, differential toxicity</td>
<td>+</td>
<td>6 µg/ml</td>
<td>Pool et al. (1979)</td>
</tr>
<tr>
<td><strong>ERD,</strong> Escherichia coli, differential toxicity</td>
<td>+</td>
<td>1250 µg/ml&lt;sup&gt;a&lt;/sup&gt;</td>
<td>De Flora (1981)</td>
</tr>
<tr>
<td><strong>ERD,</strong> Escherichia coli, differential toxicity</td>
<td>+</td>
<td>6000 µg/ml&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>ERD,</strong> Escherichia coli, differential toxicity</td>
<td>+</td>
<td>200 µg/ml&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>ERD,</strong> Escherichia coli (WP1 trp&lt;sup&gt;-&lt;/sup&gt;) strains, differential toxicity</td>
<td>+</td>
<td>30000 µg/ml&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>ERD,</strong> Escherichia coli (WP1 trp&lt;sup&gt;-&lt;/sup&gt;) strains, differential toxicity</td>
<td>+</td>
<td>300 µg/ml&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Alldrick et al. (1984)</td>
</tr>
<tr>
<td><strong>ECP,</strong> Escherichia coli, forward mutation</td>
<td>+</td>
<td>0</td>
<td>De Flora &amp; Picciotto (1980)</td>
</tr>
<tr>
<td><strong>SAO,</strong> Salmonella typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>0</td>
<td>De Flora (1981)</td>
</tr>
<tr>
<td><strong>SAO,</strong> Salmonella typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>155 µg/ml&lt;sup&gt;d&lt;/sup&gt;</td>
<td>De Flora &amp; Picciotto (1980)</td>
</tr>
<tr>
<td><strong>SAO,</strong> Salmonella typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>10000 µg/ml&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>SAO,</strong> Salmonella typhimurium TA100, reverse mutation</td>
<td>+</td>
<td>50 µg/ml&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>SAO,</strong> Salmonella typhimurium TA1535, reverse mutation</td>
<td>+</td>
<td>0</td>
<td>Pool et al. (1979)</td>
</tr>
<tr>
<td><strong>SAO,</strong> Salmonella typhimurium TA1535, reverse mutation</td>
<td>+</td>
<td>17500 µg/ml&lt;sup&gt;b&lt;/sup&gt;</td>
<td>De Flora &amp; Picciotto (1980)</td>
</tr>
<tr>
<td><strong>SAO,</strong> Salmonella typhimurium TA1535, reverse mutation</td>
<td>+</td>
<td>0</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>SAO,</strong> Salmonella typhimurium TA1537, reverse mutation</td>
<td>+</td>
<td>10000 µg/ml&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>SAO,</strong> Salmonella typhimurium TA1538, reverse mutation</td>
<td>+</td>
<td>0</td>
<td>Pool et al. (1979)</td>
</tr>
<tr>
<td><strong>SAO,</strong> Salmonella typhimurium TA98, reverse mutation</td>
<td>+</td>
<td>10000 µg/ml&lt;sup&gt;d&lt;/sup&gt;</td>
<td>De Flora &amp; Picciotto (1980)</td>
</tr>
<tr>
<td><strong>DIA,</strong> DNA damage, transformed mouse epithelial cells</td>
<td>+</td>
<td>0</td>
<td>De Flora &amp; Picciotto (1980)</td>
</tr>
<tr>
<td><strong>DIA,</strong> DNA damage, transformed mouse epithelial cells</td>
<td>+</td>
<td>252 µg/ml</td>
<td>Schwartz et al. (1980)</td>
</tr>
<tr>
<td><strong>DIA,</strong> DNA damage, transformed mouse epithelial cells</td>
<td>+</td>
<td>5 µg/ml</td>
<td>Barrows et al. (1982)</td>
</tr>
<tr>
<td><strong>SIC,</strong> Sister chromatid exchange, Chinese hamster CHO cells in vitro</td>
<td>+</td>
<td>0</td>
<td>Athanasiou &amp; Kyroupolos (1981)</td>
</tr>
<tr>
<td><strong>SIC,</strong> Sister chromatid exchange, Chinese hamster CHO cells in vitro</td>
<td>+</td>
<td>0.05 µg/ml&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>SIC,</strong> Sister chromatid exchange, Chinese hamster CHO cells in vitro</td>
<td>+</td>
<td>0.23 µg/ml&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>SIC,</strong> Sister chromatid exchange, Chinese hamster CHO cells in vitro</td>
<td>+</td>
<td>0.017 µg/ml&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>CIC,</strong> Chromosomal aberrations, Chinese hamster CHO cells in vitro</td>
<td>+</td>
<td>0</td>
<td>Athanasiou &amp; Kyroupolos (1981)</td>
</tr>
<tr>
<td><strong>CIC,</strong> Chromosomal aberrations, Chinese hamster CHO cells in vitro</td>
<td>+</td>
<td>0.03 µg/ml&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>CIC,</strong> Chromosomal aberrations, Chinese hamster CHO cells in vitro</td>
<td>+</td>
<td>23.18 µg/ml&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>CIC,</strong> Chromosomal aberrations, Chinese hamster CHO cells in vitro</td>
<td>+</td>
<td>0.65 µg/ml&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Ichinosubu et al. (1981)</td>
</tr>
<tr>
<td><strong>TCL,</strong> Cell transformation, BHK-21/C131 hamster cells</td>
<td>+</td>
<td>0.8 µg/ml</td>
<td>Barrows et al. (1982)</td>
</tr>
<tr>
<td><strong>DDH,</strong> DNA damage, human lymphoblastoid cell line in vitro</td>
<td>+</td>
<td>0</td>
<td>Henderson et al. (1981)</td>
</tr>
<tr>
<td><strong>UI3,</strong> Unscheduled DNA synthesis, human leukocytes in vitro</td>
<td>+</td>
<td>0</td>
<td>Henderson et al. (1981)</td>
</tr>
<tr>
<td><strong>UI3,</strong> Unscheduled DNA synthesis, human lymphoblasts in vitro</td>
<td>+</td>
<td>0</td>
<td>Henderson et al. (1981)</td>
</tr>
<tr>
<td><strong>SHL,</strong> Sister chromatid exchange, human lymphocytes in vitro</td>
<td>+</td>
<td>0</td>
<td>Inoue et al. (1985)</td>
</tr>
<tr>
<td><strong>SHL,</strong> Sister chromatid exchange, human lymphocytes in vitro</td>
<td>+</td>
<td>3.28 µg/ml</td>
<td>Inoue et al. (1985)</td>
</tr>
<tr>
<td><strong>HDM,</strong> Host-mediated assay, Salmonella typhimurium in mice</td>
<td>-</td>
<td>350 mg/kg</td>
<td>Baumester (1982)</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose</td>
<td>Reference</td>
</tr>
<tr>
<td>------------</td>
<td>--------</td>
<td>------</td>
<td>-----------</td>
</tr>
<tr>
<td></td>
<td>Without</td>
<td>With</td>
<td>LED/HID</td>
</tr>
<tr>
<td></td>
<td>exogenous</td>
<td>exogenous</td>
<td>LED/HID</td>
</tr>
<tr>
<td></td>
<td>metabolic</td>
<td>metabolic</td>
<td>LED/HID</td>
</tr>
<tr>
<td></td>
<td>system</td>
<td>system</td>
<td>LED/HID</td>
</tr>
<tr>
<td>DVA, DNA damage, rat liver cells in vivo</td>
<td>-</td>
<td>0</td>
<td>250 mg/kg x 1 x 20 p.o.</td>
</tr>
<tr>
<td>DVA, DNA damage, rat gastric mucosa in vivo</td>
<td>-</td>
<td>0</td>
<td>250 mg/kg x 1 p.o.</td>
</tr>
</tbody>
</table>

*With 2.5 mg NaNO₂, pH 3, 1 h
*Mononitrosocimetidine
*Dinitrosocimetidine
*With 5 mg NaNO₂, human gastric juice, pH 1.37, 1 h, 37°C
*With 60/120 mg/kg NaNO₂
*With 80 mg/kg NaNO₂
## DANTRON (1,8-DIHYDROXYANTHRAQUINONE)

<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose LED/HID</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Without</strong></td>
<td><strong>With</strong></td>
<td><strong>exogenous</strong></td>
<td><strong>exogenous</strong></td>
</tr>
<tr>
<td><strong>metabolic</strong></td>
<td><strong>metabolic</strong></td>
<td><strong>system</strong></td>
<td><strong>system</strong></td>
</tr>
<tr>
<td>SA0, Mutation, Salmonella typhimurium TA100</td>
<td>-</td>
<td>1000 µg/ml</td>
<td>Brown &amp; Brown (1976)</td>
</tr>
<tr>
<td>SA0, Mutation, Salmonella typhimurium TA100</td>
<td>-</td>
<td>10 µg/ml</td>
<td>Liberman et al. (1982)</td>
</tr>
<tr>
<td>SA0, Mutation, Salmonella typhimurium TA100</td>
<td>-</td>
<td>50 µg/ml</td>
<td>Tikkanen et al. (1983)</td>
</tr>
<tr>
<td>SA2, Mutation, Salmonella typhimurium TA102</td>
<td>-</td>
<td>15 µg/ml</td>
<td>Levin et al. (1984)</td>
</tr>
<tr>
<td>SA5, Mutation, Salmonella typhimurium TA1535</td>
<td>-</td>
<td>500 µg/ml</td>
<td>Brown &amp; Brown (1976)</td>
</tr>
<tr>
<td>SA5, Mutation, Salmonella typhimurium TA1535</td>
<td>-</td>
<td>10 µg/ml</td>
<td>Liberman et al. (1982)</td>
</tr>
<tr>
<td>SA7, Mutation, Salmonella typhimurium TA1537</td>
<td>+</td>
<td>50 µg/ml</td>
<td>Brown &amp; Brown (1976)</td>
</tr>
<tr>
<td>SA7, Mutation, Salmonella typhimurium TA1537</td>
<td>+</td>
<td>1 µg/ml</td>
<td>Liberman et al. (1982)</td>
</tr>
<tr>
<td>SA8, Mutation, Salmonella typhimurium TA1538</td>
<td>-</td>
<td>1000 µg/ml</td>
<td>Liberman et al. (1982)</td>
</tr>
<tr>
<td>SA8, Mutation, Salmonella typhimurium TA1538</td>
<td>-</td>
<td>50 µg/ml</td>
<td>Liberman et al. (1982)</td>
</tr>
<tr>
<td>SA9, Mutation, Salmonella typhimurium TA98</td>
<td>-</td>
<td>1000 µg/ml</td>
<td>Brown &amp; Brown (1976)</td>
</tr>
<tr>
<td>SA9, Mutation, Salmonella typhimurium TA98</td>
<td>-</td>
<td>10 µg/ml</td>
<td>Liberman et al. (1982)</td>
</tr>
<tr>
<td>SA9, Mutation, Salmonella typhimurium TA98</td>
<td>-</td>
<td>50 µg/ml</td>
<td>Tikkanen et al. (1983)</td>
</tr>
<tr>
<td>SA9, Mutation, Salmonella typhimurium TA98</td>
<td>0</td>
<td>4.8 µg/ml</td>
<td>Chesis et al. (1984)</td>
</tr>
<tr>
<td>SB5, Mutation, Salmonella typhimurium TA2637</td>
<td>0</td>
<td>+</td>
<td>Tikkanen et al. (1983)</td>
</tr>
<tr>
<td>SCB, Saccharomyces cerevisiae, forward mutation</td>
<td>+</td>
<td>0</td>
<td>Zetterberg &amp; Swanbeck (1971)</td>
</tr>
<tr>
<td>URF, Unscheduled DNA synthesis, rat primary hepatocytes</td>
<td>-</td>
<td>120 µg/ml</td>
<td>Probst et al. (1981)</td>
</tr>
<tr>
<td>URF, Unscheduled DNA synthesis, rat primary hepatocytes</td>
<td>+</td>
<td>4.8 µg/ml</td>
<td>Mori et al. (1984)</td>
</tr>
<tr>
<td>URF, Unscheduled DNA synthesis, rat primary hepatocytes</td>
<td>+</td>
<td>12 µg/ml</td>
<td>Kawai et al. (1986)</td>
</tr>
<tr>
<td>ULA, Unscheduled DNA synthesis, mouse hepatocytes</td>
<td>+</td>
<td>4.8 µg/ml</td>
<td>Mori et al. (1984)</td>
</tr>
<tr>
<td>CML, Chromosomal alterations, human lymphocytes in vitro</td>
<td>+</td>
<td>10 µg/ml</td>
<td>Carballo et al. (1981)</td>
</tr>
<tr>
<td>ICR, Inhibition of intercellular communication, animal cells in vitro</td>
<td>-</td>
<td>5 µg/ml</td>
<td>Zeilmaker &amp; Yamasaki (1986)</td>
</tr>
<tr>
<td>ICR, Inhibition of intercellular communication, animal cells in vitro</td>
<td>-</td>
<td>2.4 µg/ml</td>
<td>Si et al. (1988)</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>------</td>
<td>-----------</td>
</tr>
<tr>
<td>SA0, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>-</td>
<td>5000 µg/ml</td>
<td>National Toxicology Program (1989)</td>
</tr>
<tr>
<td>SA5, <em>Salmonella typhimurium</em> TA1535, reverse mutation</td>
<td>-</td>
<td>5000 µg/ml</td>
<td>National Toxicology Program (1989)</td>
</tr>
<tr>
<td>SA7, <em>Salmonella typhimurium</em> TA1537, reverse mutation</td>
<td>-</td>
<td>5000 µg/ml</td>
<td>National Toxicology Program (1989)</td>
</tr>
<tr>
<td>SA9, <em>Salmonella typhimurium</em> TA98, reverse mutation</td>
<td>-</td>
<td>5000 µg/ml</td>
<td>National Toxicology Program (1989)</td>
</tr>
<tr>
<td>G51 Gene mutation mouse lymphoma L5178Y cells</td>
<td>- (+)</td>
<td>1500 µg/ml</td>
<td>National Toxicology Program (1989)</td>
</tr>
<tr>
<td>SIC Sister chromatid exchange, Chinese hamster ovary cells</td>
<td>(+) (+) 750 µg/ml</td>
<td>National Toxicology Program (1989)</td>
<td></td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster lung cells in vitro</td>
<td>(+) 2000 µg/ml</td>
<td>Ishidate (1988)</td>
<td></td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster lung cells in vitro</td>
<td>(+)</td>
<td>500 µg/ml</td>
<td>Matsuoka et al. (1979)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster ovary cells</td>
<td>(+) (+) 3750 µg/ml</td>
<td>National Toxicology Program (1989)</td>
<td></td>
</tr>
<tr>
<td>SHF, Sister chromatid exchange, human fibroblasts in vitro</td>
<td>- 0 1654 µg/ml</td>
<td>Sasaki et al. (1980)</td>
<td></td>
</tr>
<tr>
<td>CHF, Chromosomal aberrations, human fibroblasts in vitro</td>
<td>- 0 1654 µg/ml</td>
<td>Sasaki et al. (1980)</td>
<td></td>
</tr>
<tr>
<td>CHH, Chromosomal aberrations, human leukocytes in vitro</td>
<td>+ 0 200 µg/ml</td>
<td>Jameela et al. (1979)</td>
<td></td>
</tr>
<tr>
<td>CCC, Chromosomal aberrations, <em>C3H/He</em> mouse germ cells in vivo</td>
<td>+ 0 50 mg/kg x 1, i.p.</td>
<td>Subramanyam &amp; Jameela (1977)</td>
<td></td>
</tr>
<tr>
<td>BFA, <em>Saccharomyces cerevisiae</em> D4-RDII, gene conversion mouse urine</td>
<td>- 0 45 mg/kg x 1, i.p.</td>
<td>Marquardt &amp; Siebert (1971)</td>
<td></td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>------</td>
<td>-----------</td>
</tr>
<tr>
<td>SA9, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>Without</td>
<td>0</td>
<td>77.5 µg/ml</td>
</tr>
<tr>
<td>SA9, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td>With</td>
<td></td>
<td>5000 µg/ml</td>
</tr>
<tr>
<td>SA9, <em>Salmonella typhimurium</em> TA100, reverse mutation</td>
<td></td>
<td></td>
<td>2500 µg/ml</td>
</tr>
<tr>
<td>SA9, <em>Salmonella typhimurium</em> TA1535, reverse mutation</td>
<td></td>
<td></td>
<td>500 µg/ml</td>
</tr>
<tr>
<td>SA9, <em>Salmonella typhimurium</em> TA1535, reverse mutation</td>
<td></td>
<td></td>
<td>5000 µg/ml</td>
</tr>
<tr>
<td>SA9, <em>Salmonella typhimurium</em> TA1537, reverse mutation</td>
<td></td>
<td></td>
<td>500 µg/ml</td>
</tr>
<tr>
<td>SA9, <em>Salmonella typhimurium</em> TA1538, reverse mutation</td>
<td></td>
<td></td>
<td>500 µg/ml</td>
</tr>
<tr>
<td>SA9, <em>Salmonella typhimurium</em> TA98, reverse mutation</td>
<td></td>
<td></td>
<td>500 µg/ml</td>
</tr>
<tr>
<td>ANG, <em>Aspergillus nidulans</em>, non-disjunction and mitotic crossing-over</td>
<td>+</td>
<td>0.00</td>
<td>Andrews et al. (1984)</td>
</tr>
<tr>
<td>IMA, <em>Drosophila melanogaster</em>, sex-linked recessive lethal mutation</td>
<td>-</td>
<td>10000 µg/ml</td>
<td>Valencia et al. (1985)</td>
</tr>
<tr>
<td>G51, Gene mutation, mouse lymphoma L5178Y cells</td>
<td>+</td>
<td>500 µg/ml</td>
<td>National Toxicology Program (1989)</td>
</tr>
<tr>
<td>SIC, Sister chromatid exchange, Chinese hamster ovary cells in vitro</td>
<td>+</td>
<td>500 µg/ml</td>
<td>National Toxicology Program (1989)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster ovary cells in vitro</td>
<td>-</td>
<td>2600 µg/ml</td>
<td>National Toxicology Program (1989)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster lung cell</td>
<td>-</td>
<td>500 µg/ml</td>
<td>Ishidate (1988)</td>
</tr>
</tbody>
</table>
### PARACETAMOL

<table>
<thead>
<tr>
<th>Test system</th>
<th>Result</th>
<th>Dose (µg/ml)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SA0, Salmonella typhimurium TA100, reverse mutation</strong></td>
<td>Without exogenous</td>
<td>3576</td>
<td>King et al. (1979)</td>
</tr>
<tr>
<td><strong>SA0, Salmonella typhimurium TA100, reverse mutation</strong></td>
<td>Without exogenous</td>
<td>0</td>
<td>Wirth et al. (1980)</td>
</tr>
<tr>
<td><strong>SA0, Salmonella typhimurium TA100, reverse mutation</strong></td>
<td>With metabolic system</td>
<td>0</td>
<td>Dybing et al. (1984)</td>
</tr>
<tr>
<td><strong>SA0, Salmonella typhimurium TA100, reverse mutation</strong></td>
<td>With metabolic system</td>
<td>3020</td>
<td>Oldham et al. (1986)</td>
</tr>
<tr>
<td><strong>SA2, Salmonella typhimurium TA102, reverse mutation</strong></td>
<td>Without exogenous</td>
<td>5000</td>
<td>Jasiwicz &amp; Richardson (1987)</td>
</tr>
<tr>
<td><strong>SA5, Salmonella typhimurium TA1535, reverse mutation</strong></td>
<td>Without exogenous</td>
<td>3020</td>
<td>Dybing et al. (1984)</td>
</tr>
<tr>
<td><strong>SA5, Salmonella typhimurium TA1535, reverse mutation</strong></td>
<td>With metabolic system</td>
<td>2500</td>
<td>King et al. (1979)</td>
</tr>
<tr>
<td><strong>SA7, Salmonella typhimurium TA1537, reverse mutation</strong></td>
<td>Without exogenous</td>
<td>5000</td>
<td>Oldham et al. (1986)</td>
</tr>
<tr>
<td><strong>SA7, Salmonella typhimurium TA1537, reverse mutation</strong></td>
<td>With metabolic system</td>
<td>3576</td>
<td>Jasiwicz &amp; Richardson (1987)</td>
</tr>
<tr>
<td><strong>SA8, Salmonella typhimurium TA1538, reverse mutation</strong></td>
<td>Without exogenous</td>
<td>3576</td>
<td>King et al. (1979)</td>
</tr>
<tr>
<td><strong>SA9, Salmonella typhimurium TA96, reverse mutation</strong></td>
<td>Without exogenous</td>
<td>3576</td>
<td>Oldham et al. (1986)</td>
</tr>
<tr>
<td><strong>SA9, Salmonella typhimurium TA98, reverse mutation</strong></td>
<td>Without exogenous</td>
<td>2500</td>
<td>Jasiwicz &amp; Richardson (1987)</td>
</tr>
<tr>
<td><strong>SA9, Salmonella typhimurium TA98, reverse mutation</strong></td>
<td>Without exogenous</td>
<td>3576</td>
<td>King et al. (1979)</td>
</tr>
<tr>
<td><strong>SA9, Salmonella typhimurium TA98, reverse mutation</strong></td>
<td>With metabolic system</td>
<td>2500</td>
<td>Oldham et al. (1986)</td>
</tr>
<tr>
<td><strong>SA9, Salmonella typhimurium TA98, reverse mutation</strong></td>
<td>With metabolic system</td>
<td>3576</td>
<td>Jasiwicz &amp; Richardson (1987)</td>
</tr>
<tr>
<td><strong>SAS, Salmonella typhimurium TA97, reverse mutation</strong></td>
<td>Without exogenous</td>
<td>3576</td>
<td>Jasiwicz &amp; Richardson (1987)</td>
</tr>
<tr>
<td><strong>ECK, Escherichia coli K12/343/113, mutation</strong></td>
<td>Without exogenous</td>
<td>8940</td>
<td>King et al. (1979)</td>
</tr>
<tr>
<td><strong>ACC, Allium cepa root cells, chromosomal aberrations</strong></td>
<td>Without exogenous</td>
<td>5000</td>
<td>Reddy &amp; Subramanyam (1981)</td>
</tr>
<tr>
<td><strong>DMX, Drosophila melanogaster, sex-linked recessive lethal mutation</strong></td>
<td>Without exogenous</td>
<td>11920</td>
<td>King et al. (1979)</td>
</tr>
<tr>
<td><strong>DIA, DNA damage, Beber hepatoma cells in vitro</strong></td>
<td>Without exogenous</td>
<td>1510</td>
<td>Dybing et al. (1984)</td>
</tr>
<tr>
<td><strong>DIA, DNA damage, Chinese hamster V79 cells in vitro</strong></td>
<td>With exogenous</td>
<td>1510</td>
<td>Hongisto et al. (1988)</td>
</tr>
<tr>
<td><strong>URP, Unscheduled DNA synthesis, rat hepatocytes in vitro</strong></td>
<td>Without exogenous</td>
<td>1057</td>
<td>Milam &amp; Byard (1985)</td>
</tr>
<tr>
<td><strong>URP, Unscheduled DNA synthesis, rat hepatocytes in vitro</strong></td>
<td>With exogenous</td>
<td>1510</td>
<td>Holme &amp; Soderlund (1986)</td>
</tr>
<tr>
<td><strong>UIA, Unscheduled DNA synthesis, mouse hepatocytes in vitro</strong></td>
<td>With exogenous</td>
<td>755</td>
<td>Dybing et al. (1984)</td>
</tr>
<tr>
<td><strong>UIA, Unscheduled DNA synthesis, mouse hepatocytes in vitro</strong></td>
<td>With exogenous</td>
<td>1510</td>
<td>Holme &amp; Soderlund (1986)</td>
</tr>
<tr>
<td><strong>UIA, Unscheduled DNA synthesis, hamster hepatocytes in vitro</strong></td>
<td>With exogenous</td>
<td>755</td>
<td>Holme &amp; Soderlund (1986)</td>
</tr>
<tr>
<td><strong>UIA, Unscheduled DNA synthesis, guinea-pig hepatocytes in vitro</strong></td>
<td>With exogenous</td>
<td>1510</td>
<td>Holme &amp; Soderlund (1986)</td>
</tr>
<tr>
<td><strong>UIA, Unscheduled DNA synthesis, Chinese hamster V79 cells in vitro</strong></td>
<td>With exogenous</td>
<td>1510</td>
<td>Hongisto et al. (1988)</td>
</tr>
<tr>
<td><strong>GIA, Gene mutation, mouse C3H 10T1/2 clone 8 cells in vitro</strong></td>
<td>With exogenous</td>
<td>1000</td>
<td>Patierno et al. (1989)</td>
</tr>
<tr>
<td>Test system</td>
<td>Result</td>
<td>Dose</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>------</td>
<td>-----------</td>
</tr>
<tr>
<td>SIC, Sister chromatid exchange, Chinese hamster V79 cells in vitro</td>
<td>+</td>
<td>453 µg/ml</td>
<td>Hongslo et al. (1988)</td>
</tr>
<tr>
<td>SIC, Sister chromatid exchange, Chinese hamster V79 cells in vitro</td>
<td>+</td>
<td>151 µg/ml</td>
<td>Holme et al. (1988)</td>
</tr>
<tr>
<td>MIA, Micronucleus test, rat kidney cells in vitro</td>
<td>+</td>
<td>0</td>
<td>Dunn et al. (1987)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster lung cells in vitro</td>
<td>(+)</td>
<td>0</td>
<td>Ishidate et al. (1978)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster Don-6 cells in vitro</td>
<td>+</td>
<td>60 µg/ml</td>
<td>Sasaki et al. (1980)</td>
</tr>
<tr>
<td>CIC, Chromosomal aberrations, Chinese hamster Don-6 cells in vitro</td>
<td>(+)</td>
<td>75 µg/ml</td>
<td>Patierno et al. (1989)</td>
</tr>
<tr>
<td>TCM, Cell transformation, C3H 10T1/2 clone 8 cells in vitro</td>
<td>+</td>
<td>1000 µg/ml</td>
<td>Watanabe (1982)</td>
</tr>
<tr>
<td>CHL, Chromosomal aberrations, human lymphocytes in vitro</td>
<td>+</td>
<td>200 µg/ml</td>
<td>Watanabe (1982)</td>
</tr>
<tr>
<td>MVM, Micronucleus test, NMRI mice in vivo</td>
<td>-</td>
<td>894 mg/kg x 2, i.p.</td>
<td>King et al. (1979)</td>
</tr>
<tr>
<td>CBA, Chromosomal aberrations, Swiss mice bone-marrow cells in vivo</td>
<td>(+)</td>
<td>0</td>
<td>Reddy (1984)</td>
</tr>
<tr>
<td>CCC, Chromosomal aberrations, male Swiss mice germ cells in vivo</td>
<td>?</td>
<td>100 mg/kg x 3, p.o.</td>
<td>Reddy &amp; Subramanyam (1985)</td>
</tr>
<tr>
<td>AVA, Aneuploidy, rat embryos in vivo</td>
<td>+</td>
<td>500 mg/kg x 25, p.o.</td>
<td>Tsuruzaki et al. (1982)</td>
</tr>
<tr>
<td>CLH, Chromosomal aberrations, human lymphocytes in vivo</td>
<td>+</td>
<td>50 mg/kg x 1, p.o.</td>
<td>Kocisova et al. (1988)</td>
</tr>
</tbody>
</table>
SUPPLEMENTARY CORRIGENDA TO VOLUMES 1–49


Volume 47

<table>
<thead>
<tr>
<th>p. 499</th>
<th>G9H</th>
<th>Paschin &amp; Bahitova (1982)</th>
<th>Replace + 0 by 0 +</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SHL</td>
<td>Jansson et al. (1986)</td>
<td>Replace 2.0000 by 188.0000</td>
</tr>
<tr>
<td></td>
<td>SHL</td>
<td>Erexson et al. (1985)</td>
<td>Replace 0.0050 by 0.5000</td>
</tr>
<tr>
<td></td>
<td>SHL</td>
<td>Morimoto et al. (1983)</td>
<td>Replace 3.0000 by 282.0000</td>
</tr>
</tbody>
</table>

-385-
CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS

The volume, page and year are given. References to corrigenda are given in parentheses.

A

A-α-C
Acetaldehyde

Acetaldehyde formylmethylhydrazone (see Gyromitrin)
Acetamide
Acetaminophen (see Paracetamol)
Acridine orange
Acriflavinium chloride
Acrolein

Acrylamide
Acrylic acid
Acrylic fibres
Acrylonitride
Acrylonitrile-butadiene-styrene copolymers
Actinolite (see Asbestos)
Actinomycins

Adriamycin
AF-2
Aflatoxins

Aflatoxin B₁ (see Aflatoxins)
Aflatoxin B₂ (see Aflatoxins)
Aflatoxin G₁ (see Aflatoxins)
Aflatoxin G₂ (see Aflatoxins)
Aflatoxin M₁ (see Aflatoxins)
Agaritine

40, 245 (1986); Suppl. 7, 56 (1987)
36, 101 (1985) (corr. 42, 263);
Suppl. 7, 77 (1987)

7, 197 (1974); Suppl. 7, 389 (1987)

16, 145 (1978); Suppl. 7, 56 (1987)
13, 31 (1977); Suppl. 7, 56 (1987)
19, 479 (1979); 36, 133 (1985);
Suppl. 7, 78 (1987);
39, 41 (1986); Suppl. 7, 56 (1987)
19, 47 (1979); Suppl. 7, 56 (1987)
19, 86 (1979); Suppl. 7, 56 (1987)
19, 73 (1979); Suppl. 7, 79 (1987)
19, 91 (1979); Suppl. 7, 56 (1987)

10, 29 (1976) (corr. 42, 255);
Suppl. 7, 80 (1987)
10, 43 (1976); Suppl. 7, 82 (1987)
31, 47 (1983); Suppl. 7, 56 (1987)
1, 145 (1972) (corr. 42, 251);
10, 51 (1976); Suppl. 7, 83 (1987)

31, 63 (1983); Suppl. 7, 56 (1987)
Alcohol drinking
Aldrin
Allyl chloride
Allyl isothiocyanate
Allyl isovalerate
Aluminium production
Amaranth
5-Aminoacenaphthene
2-Aminoanthraquinone
para-Aminoazobenzene
ortho-Aminoazotoluene
para-Aminobenzoic acid
4-Aminobiphenyl

2-Amino-3,4-dimethylimidazo[4,5-f]quinoline (see MeIQ)
2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (see MeIQx)
3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (see Trp-P-1)
2-Aminodipyrido[1,2-a:3',2'd]imidazole (see Glu-P-2)
1-Amino-2-methylantraquinone
2-Amino-3-methylimidazo[4,5-f]quinoline (see IQ)
2-Amino-6-methylidipyrido[1,2-a:3',2'-d]-imidazole (see Glu-P-1)
2-Amino-3-methyl-9H-pyrido[2,3-b]indole (see MeA-α-C)
3-Amino-1-methyl-5H-pyrido[4,3-b]indole (see Trp-P-2)
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole
4-Amino-2-nitrophenol
2-Amino-5-nitrothiazole
2-Amino-9H-pyrido[2,3-b]indole (see A-α-C)
11-Aminoundecanoic acid
Amitrole

Ammonium potassium selenide (see Selenium and selenium compounds)
Amorphous silica (see also Silica)
Amosite (see Asbestos)
Ampicillin
Anabolic steroids (see Androgenic (anabolic) steroids)
Anaesthetics, volatile
Analgescic mixtures containing phenacetin (see also Phenacetin)
Androgenic (anabolic) steroids
Angelican and some synthetic derivatives (see also Angelicins)
Angelican plus ultraviolet radiation (see also Angelican and some synthetic derivatives)
Angelicins

5, 25 (1974); Suppl. 7, 88 (1987)
36, 39 (1985); Suppl. 7, 56 (1987)
36, 55 (1985); Suppl. 7, 56 (1987)
36, 69 (1985); Suppl. 7, 56 (1987)
34, 37 (1984); Suppl. 7, 89 (1987)
8, 41 (1975); Suppl. 7, 56 (1987)
16, 243 (1978); Suppl. 7, 56 (1987)
27, 191 (1982); Suppl. 7, 56 (1987)
8, 53 (1975); Suppl. 7, 390 (1987)
8, 61 (1975) (corr. 42, 254);
Suppl. 7, 56 (1987)
16, 249 (1978); Suppl. 7, 56 (1987)
1, 74 (1972) (corr. 42, 251);
Suppl. 7, 91 (1987)
Anilne
ortho-Anisidine
para-Anisidine
Anthanthrene
Anthophyllite (see Asbestos)
Anthracene
Anthranilic acid
Antimony trioxide
Antimony trisulfide
ANTU (see 1-Naphthylthiourea)

Aniline
ortho-Anisidine
para-Anisidine
Anthanthrene
Anthophyllite (see Asbestos)
Anthracene
Anthranilic acid
Antimony trioxide
Antimony trisulfide
ANTU (see 1-Naphthylthiourea)

Apholate
Aramite®
Areca nut (see Betel quid)
Arsenic and arsenic compounds
Arsenic pentoxide (see Arsenic and arsenic compounds)
Arsenic sulphide (see Arsenic and arsenic compounds)
Arsenic trioxide (see Arsenic and arsenic compounds)
Arsine (see Arsenic and arsenic compounds)
Asbestos

Apholate
Aramite®
Areca nut (see Betel quid)
Arsenic and arsenic compounds
Arsenic pentoxide (see Arsenic and arsenic compounds)
Arsenic sulphide (see Arsenic and arsenic compounds)
Arsenic trioxide (see Arsenic and arsenic compounds)
Arsine (see Arsenic and arsenic compounds)
Asbestos

Apholate
Aramite®
Areca nut (see Betel quid)
Arsenic and arsenic compounds
Arsenic pentoxide (see Arsenic and arsenic compounds)
Arsenic sulphide (see Arsenic and arsenic compounds)
Arsenic trioxide (see Arsenic and arsenic compounds)
Arsine (see Arsenic and arsenic compounds)
Asbestos

Apholate
Aramite®
Areca nut (see Betel quid)
Arsenic and arsenic compounds
Arsenic pentoxide (see Arsenic and arsenic compounds)
Arsenic sulphide (see Arsenic and arsenic compounds)
Arsenic trioxide (see Arsenic and arsenic compounds)
Arsine (see Arsenic and arsenic compounds)
Asbestos

Atapulgite
Auramine (technical-grade)
Auramine, manufacture of (see also Auramine, technical-grade)
Aurothiogluco
Azacitidine
Azathioprine
Aziridine
2-(1-Aziridinyl)ethanol
Aziridyl benzoquinone
Azobenzene

B

Barium chromate (see Chromium and chromium compounds)
Basic chromic sulphate (see Chromium and chromium compounds)
BCNU (see Bischloroethyl nitrosourea)
Benz[a]acridine
Benz[c]acridine

Benzal chloride (see also α–Chlorinated toluenes)
Benz[a]anthracene

Benzene

Benzidine

Benzidine–based dyes
Benzo[b]fluoranthene

Benzo[j]fluoranthene

Benzo[k]fluoranthene
Benzo[ghi]fluoranthene
Benzo[a]fluorene

Benzo[b]fluorene
Benzo[c]fluorene
Benzo[ghi]perylene
Benzo[c]phenanthrene

Benzo[a]pyrene

Benzo[e]pyrene

para–Benzoquinone dioxime

Benzoquinone (see also α–Chlorinated toluenes)

Benzyl chloride

Benzyl peroxide

Benzyl acetate

Benzyl chloride (see also α–Chlorinated toluenes)

Benzyl violet 4B

Bertrandite (see Beryllium and beryllium compounds)

Beryllium and beryllium compounds

Beryllium acetate (see Beryllium and beryllium compounds)

Beryllium acetate, basic (see Beryllium and beryllium compounds)

Beryllium–aluminium alloy (see Beryllium and beryllium compounds)

Beryllium carbonate (see Beryllium and beryllium compounds)

Beryllium chloride (see Beryllium and beryllium compounds)
Beryllium–copper alloy (see Beryllium and beryllium compounds)
Beryllium–copper–cobalt alloy (see Beryllium and beryllium compounds)
Beryllium fluoride (see Beryllium and beryllium compounds)
Beryllium hydroxide (see Beryllium and beryllium compounds)
Beryllium–nickel alloy (see Beryllium and beryllium compounds)
Beryllium oxide (see Beryllium and beryllium compounds)
Beryllium phosphate (see Beryllium and beryllium compounds)
Beryllium silicate (see Beryllium and beryllium compounds)
Beryllium sulphate (see Beryllium and beryllium compounds)
Beryl ore (see Beryllium and beryllium compounds)
Betel quid
Betel–quid chewing (see Betel quid)
BHA (see Butylated hydroxyanisole)
BHT (see Butylated hydroxytoluene)
Bis(1-aziridinyl)morpholinophosphine sulphide
Bis(2-chloroethyl)ether
N,N-Bis(2-chloroethyl)-2-naphthylamine
Bischloroethyl nitrosourea (see also Chloroethyl nitrosoureas)
1,2-Bis(chloromethoxy)ethane
1,4-Bis(chloromethoxymethyl)benzene
Bis(chloromethyl)ether
Bis(2-chloro-1-methylethyl)ether
Bis(2,3-epoxycyclopentyl)ether
Bitumens
Bleomycins
Blue VRS
Boot and shoe manufacture and repair
Bracken fern
Brilliant Blue FCF

1,3-Butadiene

1,4-Butanediol dimethanesulphonate
n-Butyl acrylate
Butylated hydroxyanisole
Butylated hydroxytoluene
Butyl benzyl phthalate

β-Butyrolactone
γ-Butyrolactone

C

Cabinet–making (see Furniture and cabinet–making)
Cadmium acetate (see Cadmium and cadmium compounds)
Cadmium and cadmium compounds

Cadmium chloride (see Cadmium and cadmium compounds)
Cadmium oxide (see Cadmium and cadmium compounds)
Cadmium sulphate (see Cadmium and cadmium compounds)
Cadmium sulphide (see Cadmium and cadmium compounds)
Calcium arsenate (see Arsenic and arsenic compounds)
Calcium chromate (see Chromium and chromium compounds)
Calcium cyclamate (see Cyclamates)
Calcium saccharin (see Saccharin)
Canthardin
Caprolactam

Captan
Carbaryl
Carbazole
3-Carbethoxypsoralen
Carbon blacks

Carbon tetrachloride
Carmoisine
Carpentry and joinery
Carrageenan

Catechol
CCNU (see 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea)
Ceramic fibres (see Man-made mineral fibres)
Chemotherapy, combined, including alkylating agents
(see MOPP and other combined chemotherapy including alkylating agents)
Chlorambucil

Chloramphenicol

Chlorendic acid
Chlordane (see also Chlordane/Heptachlor)
Chlordane/Heptachlor
Chlordecone
Chlordimeform
Chlorinated dibenzodioxins (other than TCDD)
Chlorinated paraffins

2, 74 (1973); 11, 39 (1976)
(correction: 42, 255);
Suppl. 7, 139 (1987)

10, 79 (1976); Suppl. 7, 59 (1987)
19, 115 (1979) (correction: 42, 258);
39, 247 (1986) (correction: 42, 264);
Suppl. 7, 390 (1987)
30, 295 (1983); Suppl. 7, 59 (1987)
12, 37 (1976); Suppl. 7, 59 (1987)
32, 239 (1983); Suppl. 7, 59 (1987)
40, 317 (1986); Suppl. 7, 59 (1987)
3, 22 (1973); 33, 35 (1984); Suppl.
7, 142 (1987)
1, 53 (1972); 20, 371 (1979);
Suppl. 7, 143 (1987)
8, 83 (1975); Suppl. 7, 59 (1987)
25, 139 (1981); Suppl. 7, 378 (1987)
10, 181 (1976) (correction: 42, 255); 31,
79 (1983); Suppl. 7, 59 (1987)
15, 155 (1977); Suppl. 7, 59 (1987)

9, 125 (1975); 26, 115 (1981);
Suppl. 7, 144 (1987)
10, 85 (1976); Suppl. 7, 145 (1987);
50, 169 (1990)
48, 45 (1990)
20, 45 (1979) (correction: 42, 258)
Suppl. 7, 146 (1987)
20, 67 (1979); Suppl. 7, 59 (1987)
30, 61 (1983); Suppl. 7, 59 (1987)
15, 41 (1977); Suppl. 7, 59 (1987)
48, 55 (1990)
α-Chlorinates toluenes
Chlormadinone acetate (see also Progestins; Combined oral contraceptives)
Chlornaphazine (see N,N-Bis(2-chloroethyl)-2-naphthylamine)
Chlorobenzilate

Chlorodifluoromethane
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (see also Chloroethyl nitrosoureas)
Chloroethyl nitrosoureas
Chlorofluoromethane
Chloroform

Chloromethyl methyl ether (technical-grade) (see also Bis(chloromethyl)ether)
(4-Chloro-2-methylphenoxo)acetic acid (see MCPA)
Chlorophenols
Chlorophenols (occupational exposures to)
Chlorophenoxy herbicides
Chlorphenoxy herbicides (occupational exposures to)
4-Chloro-ortho-phenylenediamine
4-Chloro-meta-phenylenediamine
Chloroprene
Chloropropham
Chloroquine
Chlorothalonil
para-Chloro-ortho-toluidine and its strong acid salts (see also Chlordimeform)
Chlorotrianisene (see also Nonsteroidal oestrogens)
2-Chloro-1,1,1-trifluoroethane
Chlorozotocin
Cholesterol

Chromic acetate (see Chromium and chromium compounds)
Chromic chloride (see Chromium and chromium compounds)
Chromic oxide (see Chromium and chromium compounds)
Chromic phosphate (see Chromium and chromium compounds)
Chromite ore (see Chromium and chromium compounds)
Chromium and chromium compounds

Chromium carbonyl (see Chromium and chromium compounds)
Chromium potassium sulphate (see Chromium and chromium compounds)
Chromium sulphate (see Chromium and chromium compounds)
Chromium trioxide (see Chromium and chromium compounds)
Chrysazin (see Dantron)
Chryse

Chrysoidine
Chrysotile (see Asbestos)
Ciclosporin
CI Disperse Yellow 3
Cimetidine
Cinnamyl anthranilate

Cisplatin
Citrinin
Citrus Red No. 2

Clofibrate
Clomiphene citrate
Coal gasification
Coal–tar pitches (see also Coal–tars)
Coal–tars

Cobalt–chromium alloy (see Chromium and chromium compounds)
Coke production
Combined oral contraceptives (see also Oestrogens, progestins and combinations)

Conjugated oestrogens (see also Steroidal oestrogens)
Contraceptives, oral (see Combined oral contraceptives; Sequential oral contraceptives)

Copper 8–hydroxyquinoline
Coronene
Coumarin
Creosotes (see also Coal–tars)
meta–Cresidine
para–Cresidine
Crocidolite (see Asbestos)
Crude oil
Crystalline silica (see also Silica)
Cycasin

Cyclamates
Cyclamic acid (see Cyclamates)
Cyclochlorotine
Cyclohexanone
Cyclohexylamine (see Cyclamates)
CUMULATIVE CROSS INDEX

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclopropane (see Anaesthetics, volatile)</td>
<td>9, 135 (1975); 26, 165 (1981); Suppl. 7, 182 (1987)</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td></td>
</tr>
</tbody>
</table>

**D**

2,4-D (see also Chlorophenoxy herbicides; Chlorophenoxy herbicides, occupational exposures to)

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dacarbazine</td>
<td>15, 111 (1977)</td>
</tr>
<tr>
<td>Dantron</td>
<td>26, 203 (1981); Suppl. 7, 184 (1987)</td>
</tr>
<tr>
<td>D &amp; C Red No. 9</td>
<td>50, 265 (1990)</td>
</tr>
<tr>
<td>Dapsone</td>
<td>8, 107 (1975); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>Daunomycin</td>
<td>24, 59 (1980); Suppl. 7, 185 (1987)</td>
</tr>
<tr>
<td>DDD (see DDT)</td>
<td>10, 145 (1976); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>DDE (see DDT)</td>
<td></td>
</tr>
<tr>
<td>DDT</td>
<td>5, 83 (1974) (corr. 42, 253); Suppl. 7, 186 (1987)</td>
</tr>
<tr>
<td>Decabromodiphenyl oxide</td>
<td>48, 73 (1990)</td>
</tr>
<tr>
<td>Diacetylaminoaztoluene</td>
<td>8, 113 (1975); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>N,N'-Diacetylbenzidine</td>
<td>16, 293 (1978); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>Diallate</td>
<td>12, 69 (1976); 30, 235 (1983); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>2,4-Diaminoanisole</td>
<td>16, 51 (1978); 27, 103 (1982); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>4,4'-Diaminodiphenyl ether</td>
<td>16, 301 (1978); 29, 203 (1982); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>1,2-Diamino-4-nitrobenzene</td>
<td>16, 63 (1978); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>1,4-Diamino-2-nitrobenzene</td>
<td>16, 73 (1978); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>2,6-Diamino-3-(phenylazo)pyridine (see Phenazopyridine hydrochloride)</td>
<td>16, 83 (1978); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>2,4-Dianitrotoluene (see also Toluene diisocyanates)</td>
<td>16, 97 (1978); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>2,5-Dianitrotoluene (see also Toluene diisocyanates)</td>
<td></td>
</tr>
<tr>
<td>ortho-Dianisidine (see 3,3'-Dimethoxybenzidine)</td>
<td>13, 57 (1977); Suppl. 7, 189 (1987)</td>
</tr>
<tr>
<td>Diazepam</td>
<td>7, 223 (1974); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>Diazomethane</td>
<td>3, 247 (1973); 32, 277 (1983); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>Dibenzo[a,h]acridine</td>
<td>3, 254 (1973); 32, 283 (1983); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>Dibenzo[a,c]anthracene</td>
<td>3, 178 (1973) (corr. 43, 261); 32, 299 (1983); Suppl. 7, 61 (1987)</td>
</tr>
<tr>
<td>Dibenzo[a,h]anthracene</td>
<td></td>
</tr>
</tbody>
</table>
Dibenz[a,j]anthracene
7H-Dibenzo[c,g]carbazole

Dibenzo[a,e]fluoranthene
Dibenzo[h,je]pentaphene
Dibenzo[a,e]pyrene

Dibenzo[a,h]pyrene
Dibenzo[a,i]pyrene
Dibenzo[a,l]pyrene

1,2-Dibromo-3-chloropropane

Dichloroacetylene
ortho-Dichlorobenzene
para-Dichlorobenzene

3,3'-Dichlorobenzidine

trans-1,4-Dichlorobutene
3,3’-Dichloro-4,4’-diaminodiphenyl ether
1,2-Dichloroethane
Dichloromethane

2,4-Dichlorophenol (see Chlorophenols; Chlorophenols, occupational exposures to)
(2,4-Dichlorophenox)acetic acid (see 2,4-D)
2,6-Dichloro-para-phenylenediamine
1,2-Dichloropropane
1,3-Dichloropropene (technical-grade)
Dichlorvos
Dicofol
Dicyclohexylamine (see Cyclamates)
Dieldrin
Dienoestrol (see also Nonsteroidal oestogens)
Diepoxybutane

Diesel and gasoline engine exhausts
Diesel fuels
Diethyl ether (see Anaesthetics, volatile)
<table>
<thead>
<tr>
<th>Chemical Compound</th>
<th>Cross References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Di(2-ethylhexyl) adipate</td>
<td>29, 257 (1982); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>Di(2-ethylhexyl) phthalate</td>
<td>29, 269 (1982); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>1,2-Diethylhydrazine</td>
<td>4, 153 (1974); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>Diethylstilboestrol</td>
<td>6, 55 (1974); 21, 173 (1979); Suppl. 7, 273 (1987)</td>
</tr>
<tr>
<td>Diethylstilboestrol dipropionate (see Diethylstilboestrol)</td>
<td>4, 277 (1974); Suppl. 7, 198 (1987)</td>
</tr>
<tr>
<td>Diethyl sulphate</td>
<td>11, 125 (1976); 36, 181 (1985); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>Diglycidyl resorcino1 ether</td>
<td>1, 170 (1972); 10, 233 (1976); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>Dihydrosaffrole</td>
<td>24, 77 (1980); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>1,8-Dihydroxanthraquinone (see Dantron)</td>
<td>6, 167 (1974); 21, 377 (1979)</td>
</tr>
<tr>
<td>Dihydroxybenzenes (see Catechol; Hydroquinone; Resorcino1)</td>
<td>15, 177 (1977); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>Dihydroxymethylfurtrazin1e</td>
<td>4, 41 (1974); Suppl. 7, 198 (1987)</td>
</tr>
<tr>
<td>Dimethisterone (see also Progestins; Sequential oral contraceptives)</td>
<td>39, 279 (1986); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>Dimethoxane</td>
<td>8, 125 (1975); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>3,3' -Dimethoxybenzidine</td>
<td>8, 147 (1975); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>para-Dimethylaminobenzene</td>
<td>Suppl. 7, 57 (1987)</td>
</tr>
<tr>
<td>para-Dimethylaminobenzenediazo sodium sulphonate</td>
<td>Suppl. 7, 57 (1987)</td>
</tr>
<tr>
<td>trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)-vinyl]-1,3,4-oxadiazole</td>
<td>Suppl. 7, 7, 12 (1976); 36, 181 (1985); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>4,4’-Dimethylangelicin plus ultraviolet radiation (see also Angelicin and some synthetic derivatives)</td>
<td>4, 271 (1974); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>4,5’-Dimethylangelicin plus ultraviolet radiation (see also Angelicin and some synthetic derivatives)</td>
<td>4, 145 (1974) (corr. 42, 253); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>Dimethylarsinic acid (see Arsenic and arsenic compounds)</td>
<td>Suppl. 7, 57 (1987)</td>
</tr>
<tr>
<td>3,3'-Dimethylbenzidine</td>
<td>1, 87 (1972); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>Dimethylcarbamoyl chloride</td>
<td>12, 77 (1976); Suppl. 7, 199 (1987)</td>
</tr>
<tr>
<td>Dimethylformamide</td>
<td>47, 171 (1989)</td>
</tr>
<tr>
<td>1,1-Dimethylhydrazine</td>
<td>4, 137 (1974); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>1,2-Dimethylhydrazine</td>
<td>4, 145 (1974) (corr. 42, 253); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>Dimethyl hydrogen phosphite</td>
<td>48, 85 (1990)</td>
</tr>
<tr>
<td>1,4-Dimethylphenanthrene</td>
<td>32, 349 (1983); Suppl. 7, 62 (1987)</td>
</tr>
<tr>
<td>Dimethyl sulphate</td>
<td>4, 271 (1974); Suppl. 7, 200 (1987)</td>
</tr>
<tr>
<td>3,7-Dinitrofluoranthen</td>
<td>46, 189 (1989)</td>
</tr>
<tr>
<td>3,9-Dinitrofluoranthen</td>
<td>46, 195 (1989)</td>
</tr>
<tr>
<td>1,3-Dinitropyrene</td>
<td>46, 201 (1989)</td>
</tr>
<tr>
<td>1,6-Dinitropyrene</td>
<td>46, 215 (1989)</td>
</tr>
<tr>
<td>1,8-Dinitropyrene</td>
<td>33, 171 (1984); Suppl. 7, 63 (1987); 46, 231 (1989)</td>
</tr>
<tr>
<td>Dinitrosopentamethylenetetramine</td>
<td>11, 241 (1976); Suppl. 7, 63 (1987)</td>
</tr>
</tbody>
</table>
1,4-Dioxane
2,4’-Diphenyldiamine
Direct Black 38 (see also Benzidine-based dyes)
Direct Blue 6 (see also Benzidine-based dyes)
Direct Brown 95 (see also Benzidine-based dyes)
Disperse Blue 1
Disperse Yellow 3
Disulfiram
Dithranol
Divinyl ether (see Anaesthetics, volatile)
Dulcin

E

Endrin
Enflurane (see Anaesthetics, volatile)
Eosin
Epichlorohydrin
1,2-Epoxybutane
1-Epoxyethyl-3,4-epoxycyclohexane
3,4-Epoxy-6-methylcyclohexymethyl-3,4-epoxy-6-methyl-
cyclohexane carboxylate
cis-9,10-Epoxystearic acid
Erionite
Ethynylestradiol (see also Steroidal oestrogens)
Ethionamide
Ethyl acrylate

Ethylene
Ethylene dibromide
Ethylene oxide

Ethylene sulphide
Ethylene thiourea
Ethyl methanesulphonate
N-Ethyl-N-nitrosourea

Ethyl selenac (see also Selenium and selenium compounds)
Ethyl tellurac
Ethynodiol diacetate (see also Progestins; Combined oral
contraceptives)
Eugenol
Evans blue
### F

<table>
<thead>
<tr>
<th>Compound</th>
<th>Years and Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fast Green FCF</td>
<td>16, 187 (1978); Suppl. 7, 63 (1987)</td>
</tr>
<tr>
<td>Ferbam</td>
<td>12, 121 (1976) ( corr. 42, 256); Suppl. 7, 63 (1987)</td>
</tr>
<tr>
<td>Ferric oxide</td>
<td>1, 29 (1972); Suppl. 7, 216 (1987)</td>
</tr>
<tr>
<td>Ferrochromium (see Chromium and chromium compounds)</td>
<td>30, 245 (1983); Suppl. 7, 63 (1987)</td>
</tr>
<tr>
<td>Fluometuron</td>
<td>32, 355 (1983); Suppl. 7, 63 (1987)</td>
</tr>
<tr>
<td>Fluorene</td>
<td>32, 365 (1983); Suppl. 7, 63 (1987)</td>
</tr>
<tr>
<td>Fluorides (inorganic, used in drinking-water)</td>
<td>27, 237 (1982); Suppl. 7, 208 (1987)</td>
</tr>
<tr>
<td>5-Fluorouracil</td>
<td>26, 217 (1981); Suppl. 7, 210 (1987)</td>
</tr>
<tr>
<td>Fluorspar (see Fluorides)</td>
<td>29, 345 (1982); Suppl. 7, 211 (1987)</td>
</tr>
<tr>
<td>Fluosilicic acid (see Fluorides)</td>
<td>7, 151 (1974) ( corr. 42, 253); Suppl. 7, 63 (1987)</td>
</tr>
<tr>
<td>Fluroxene (see Anaesthetics, volatile)</td>
<td>45, 239 (1989) ( corr. 47, 505)</td>
</tr>
<tr>
<td>Formaldehyde</td>
<td>31, 141 (1983); Suppl. 7, 63 (1987)</td>
</tr>
<tr>
<td>Frusemide (see Furosemide)</td>
<td>50, 277 (1990)</td>
</tr>
<tr>
<td>Fuel oils (heating oils)</td>
<td>11, 169 (1976); 31, 153 (1983); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td>Furazolidone</td>
<td>40, 223 (1986); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td>Furniture and cabinet-making</td>
<td>40, 235 (1986); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td>Furosemide</td>
<td>11, 175 (1976); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td>2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide (see AF-2)</td>
<td>47, 237 (1989)</td>
</tr>
<tr>
<td>Fusarenon-X</td>
<td>11, 183 (1976); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td></td>
<td>10, 153 (1976); Suppl. 7, 391 (1987)</td>
</tr>
<tr>
<td></td>
<td>16, 199 (1978); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td></td>
<td>31, 163 (1983); Suppl. 7, 391 (1987)</td>
</tr>
</tbody>
</table>

### G

<table>
<thead>
<tr>
<th>Compound</th>
<th>Years and Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gasoline</td>
<td>45, 159 (1989) ( corr. 47, 505)</td>
</tr>
<tr>
<td>Gasoline engine exhaust (see Diesel and gasoline engine exhausts)</td>
<td>40, 223 (1986); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td>Glass fibres (see Man-made mineral fibres)</td>
<td>40, 235 (1986); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td>Glasswool (see Man-made mineral fibres)</td>
<td>11, 175 (1976); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td>Glass filaments (see Man-made mineral fibres)</td>
<td>47, 237 (1989)</td>
</tr>
<tr>
<td>Glu-P-1</td>
<td>11, 183 (1976); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td>Glu-P-2</td>
<td>11, 187 (1976); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td>L-Glutamic acid, 5-[2-(4-hydroxymethyl)phenylhydrazide] (see Agaramine)</td>
<td>10, 153 (1976); Suppl. 7, 391 (1987)</td>
</tr>
<tr>
<td>Glyceraldehyde</td>
<td>16, 199 (1978); Suppl. 7, 64 (1987)</td>
</tr>
<tr>
<td>Some glycidyl ethers</td>
<td>31, 163 (1983); Suppl. 7, 391 (1987)</td>
</tr>
</tbody>
</table>
IARC MONOGRAPHS VOLUME 50

H

Haematite 1, 29 (1972); Suppl. 7, 216 (1987)
Haematite and ferric oxide Suppl. 7, 216 (1987)
Haematite mining, underground, with exposure to radon 1, 29 (1972); Suppl. 7, 216 (1987)
Halothane (see Anaesthetics, volatile) 1, 29 (1972); Suppl. 7, 216 (1987)
α-HCH (see Hexachlorocyclohexanes) 5, 173 (1974); 20, 129 (1979)
β-HCH (see Hexachlorocyclohexanes) 20, 155 (1979); Suppl. 7, 219 (1987)
γ-HCH (see Hexachlorocyclohexanes) 20, 179 (1979); Suppl. 7, 64 (1987)
Heating oils (see Fuel oils) 5, 47 (1974); 20, 195 (1979)
Hexachlorobenzene (corr. 42, 258); Suppl. 7, 220 (1987)
Hexachlorobutadiene 20, 467 (1979); Suppl. 7, 64 (1987)
Hexachlorocyclohexanes 20, 241 (1979); Suppl. 7, 64 (1987)
Hexachlorocyclohexane, technical-grade (see Hexachlorocyclohexanes) 15, 211 (1977); Suppl. 7, 64 (1987)
Hexachloroethane 20, 467 (1979); Suppl. 7, 64 (1987)
Hexachlorophene 20, 241 (1979); Suppl. 7, 64 (1987)
Hexamethylphosphoramide 15, 211 (1977); Suppl. 7, 64 (1987)
Hexoestrol (see Nonsteroidal oestrogens) 13, 91 (1977 Suppl. 7, 64 (1987)
Hycanthone mesylate 20, 129 (1979)
Hydralazine 24, 85 (1980); Suppl. 7, 222 (1987)
Hydrazine 4, 127 (1974); Suppl. 7, 223 (1987)
Hydrochlorothiazide 50, 293 (1990)
Hydrogen peroxide 36, 285 (1985); Suppl. 7, 64 (1987)
Hydroquinone 15, 155 (1977 Suppl. 7, 64 (1987)
4-Hydroxyazobenzene 8, 157 (1975 Suppl. 7, 64 (1987)
17α-Hydroxyprogesterone caproate (see also Progestins) 21, 399 (1979) (corr. 42, 259)
8-Hydroxyquinoline 10, 265 (1976); Suppl. 7, 64 (1987)
8-Hydroxybenzylkirkine 21, 399 (1979) Suppl. 7, 64 (1987)

I

Indeno[1,2,3-cd]pyrene 3, 229 (1973); 32, 373 (1983); Suppl. 7, 64 (1987)
IQ 46, 261 (1986); Suppl. 7, 64 (1987)
Iron and steel founding 34, 133 (1984); Suppl. 7, 224 (1987)
Iron–dextran complex 2, 161 (1973); Suppl. 7, 226 (1987)
Iron–dextrin complex 2, 161 (1973) (corr. 42, 252); Suppl. 7, 64 (1987)
Iron oxide (see Ferric oxide) 2, 161 (1973); Suppl. 7, 64 (1987)
Iron oxide, saccharated (see Saccharated iron oxide) 2, 161 (1973); Suppl. 7, 64 (1987)
Iron sorbitol–citric acid complex
Isatidine
Isoflurane (see Anaesthetics, volatile)
Isoniazid (see Isonicotinic acid hydrazide)
Isonicotinic acid hydrazide
Isophosphamide
Isopropyl alcohol
Isopropyl alcohol manufacture (strong-acid process)
(see also Isopropyl alcohol)
Isopropyl oils
Isosafrole

J

Jacoline
Jet fuel
Joinery (see Carpentry and joinery)

K

Kaempferol
Kepone (see Chlordecone)

L

Lasiocarpine
Lauroyl peroxide
Lead acetate (see Lead and lead compounds)
Lead and lead compounds

Lead arsename (see Arsenic and arsenic compounds)
Lead carbonate (see Lead and lead compounds)
Lead chloride (see Lead and lead compounds)
Lead chromate (see Chromium and chromium compounds)
Lead chromate oxide (see Chromium and chromium compounds)
Lead naphthenate (see Lead and lead compounds)
Lead nitrate (see Lead and lead compounds)
Lead oxide (see Lead and lead compounds)
Lead phosphate (see Lead and lead compounds)
Lead subacetate (see Lead and lead compounds)
Lead tetroxide (see Lead and lead compounds)
Leather goods manufacture

10, 269 (1976); Suppl. 7, 65 (1987)
4, 159 (1974); Suppl. 7, 227 (1987)
26, 237 (1981); Suppl. 7, 65 (1987)
15, 223 (1977); Suppl. 7, 229 (1987)
Suppl. 7, 229 (1987)
15, 223 (1977); Suppl. 7, 229 (1987)
1, 169 (1972); 10, 232 (1976);
Suppl. 7, 65 (1987)
10, 275 (1976); Suppl. 7, 65 (1987)
45, 203 (1989)
31, 171 (1983); Suppl. 7, 65 (1987)
10, 281 (1976); Suppl. 7, 65 (1987)
36, 315 (1985); Suppl. 7, 65 (1987)
1, 40 (1972) (corr. 42, 251); 2, 52,
150 (1973); 12, 131 (1976);
23, 40, 208, 209, 325 (1980);
Suppl. 7, 230 (1987)
25, 279 (1981); Suppl. 7, 235 (1987)
Leather industries
Leather tanning and processing
Ledate (see also Lead and lead compounds)
Light Green SF
Lindane (see Hexachlorocyclohexanes)
The lumber and sawmill industries (including logging)
Luteokyn
Lyneostrenol (see also Progestins; Combined oral contraceptives)

M

Magenta
Magenta, manufacture of (see also Magenta)
Malathion
Maleic hydrazide
Malonaldehyde
Maneb
Man-made mineral fibres
Mannomustine
MCPS (see also Chlorophenoxy herbicides; Chlorophenoxy herbicides, occupational exposures to)
MeA-O-C
Medphalan
Medroxyprogesterone acetate

Megestrol acetate (see also Progestins; Combined oral contraceptives)
MeIQ
MeIQx
Melamine
Melphalan
6-Mercaptopurine
Merphalan
Mestranol (see also Steroidal oestrogens)

Methanearsonic acid, disodium salt (see Arsenic and arsenic compounds)
Methanearsonic acid, monosodium salt (see Arsenic and arsenic compounds)
Methotrexate
Methoxsalen (see 8-Methoxypsoralen)
Methoxychlor
CUMULATIVE CROSS INDEX

Methoxyflurane (see Anaesthetics, volatile)
5-Methoxypsoralen
8-Methoxypsoralen (see also 8-Methoxypsoralen plus ultraviolet radiation)
8-Methoxypsoralen plus ultraviolet radiation
Methyl acrylate

5-Methylangelicin plus ultraviolet radiation (see also Angelicin and some synthetic derivatives)
2-Methylaziridine
Methylazoxymethanol acetate

Methyl bromide

Methyl carbanate
Methyl–CCNU [see 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea]
Methyl chloride
1-, 2-, 3-, 4-, 5- and 6-Methylchrysenes
N-Methyl-N,4-dinitroaniline
4,4'-Methylene bis(2-chloroaniline)

4,4'-Methylene bis(N,N-dimethyl)benzenamine
4,4'-Methylene bis(2-methylaniline)
4,4'-Methyleneedianiline

4,4'-Methylenediphenyl diisocyanate
2-Methylfluoranthenone
3-Methylfluoranthenone
Methyl iodide

Methyl methacrylate
Methyl methanesulphonate
2-Methyl-1-nitroantraquinone
N-Methyl-N'-nitro-N-nitrosoguanidine
3-Methylnitrosaminopropionaldehyde (see 3-(N-Nitrosomethylamino)propionaldehyde)
3-Methylnitrosaminopropionitrile (see 3-(N-Nitrosomethylamino)propionitrile)
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanal (see 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanal)
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butaneone (see 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butaneone)

N-Methyl-N-nitrosourea
IARC MONOGRAPHS VOLUME 50

404

N-Methyl-N-nitrosourethane

Methyl parathion

1-Methylphenanthrene

7-Methylpyrido[3,4-c]psoralen

Methyl red

Methyl selenac (see also Selenium and selenium compounds)

Methylthiouracil

Metronidazole

Mineral oils

Mirex

Mitomycin C

MNNG (see N-Methyl-N’-nitro-N-nitrosoguanidine)

MOCA (see 4,4’-Methylene bis(2-chloroaniline))

Modacrylic fibres

Monocrotaline

Monuron

MOPP and other combined chemotherapy including alkylation agents

Morpholine

5-(Morpholinomethyl)-3-[(5-nitrofururylidene)amino]-2-oxazolidinone

Mustard gas

Myleran (see 1,4-Butanediol dimethanesulphonate)

N

Nafenopin

1,5-Naphthalenediamine

1,5-Naphthalene diisocyanate

1-Naphthylamine

2-Naphthylamine

1-Naphthylthiourea

Nickel acetate (see Nickel and nickel compounds)

Nickel ammonium sulphate (see Nickel and nickel compounds)

Nickel and nickel compounds

Nickel carbonate (see Nickel and nickel compounds)

Nickel carbonyl (see Nickel and nickel compounds)

Nickel chloride (see Nickel and nickel compounds)

Nickel–gallium alloy (see Nickel and nickel compounds)
Nickel hydroxide (see Nickel and nickel compounds)
Nickelocene (see Nickel and nickel compounds)
Nickel oxide (see Nickel and nickel compounds)
Nickel subsulphide (see Nickel and nickel compounds)
Nickel sulphate (see Nickel and nickel compounds)

Niridazole
Nifiazide
Nitrilotriacetic acid and its salts
5-Nitroacenaphthene
5-Nitro-ortho-anisidine
9-Nitroanthracene
7-Nitrobenz[a]anthracene
6-Nitrobenzo[a]pyrene

4-Nitrobiphenyl
6-Nitrochrysene

Nitrofen (technical-grade)
3-Nitrofluoranthene
2-Nitrofluorene
Nitrofural

5-Nitro-2-furaldehyde semicarbazone (see Nitrofural)
Nitrofurantoin
Nitrofurazone (see Nitrofural)
1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone
N-[4-(5-Nitro-2-furyl)-2-thiazoyl]acetamide

Nitrogen mustard
Nitrogen mustard N'-oxide
1-Nitronaphthalene
2-Nitronaphthalene
3-Nitroperylene
2-Nitropropane
1-Nitropyrene

2-Nitropyrene
4-Nitropyrene
N'-Nitrosatable drugs
N'-Nitrosatable pesticides
N'-Nitrosoanabasine
N'-Nitrosoanatabine
N-Nitrosodi-n-butylamine
N'-Nitrosodiethanolamine

13, 123 (1977); Suppl. 7, 67 (1987)
31, 179 (1983); Suppl. 7, 67 (1987)
48, 181 (1990)
16, 319 (1978); Suppl. 7, 67 (1987)
27, 133 (1982); Suppl. 7, 67 (1987)
33, 179 (1984); Suppl. 7, 67 (1987)
46, 247 (1989)
33, 187 (1984); Suppl. 7, 67 (1987);
46, 255 (1989)
4, 113 (1974); Suppl. 7, 67 (1987)
33, 195 (1984); Suppl. 7, 67 (1987);
46, 267 (1989)
30, 271 (1983); Suppl. 7, 67 (1987)
33, 201 (1984); Suppl. 7, 67 (1987)
46, 277 (1989)
7, 171 (1974); Suppl. 7, 67 (1987);
50, 195 (1990)
7, 181 (1974); Suppl. 7, 67 (1987)
1, 181 (1972); 7, 185 (1974);
Suppl. 7, 67 (1987)
9, 193 (1975); Suppl. 7, 269 (1987)
9, 209 (1975); Suppl. 7, 67 (1987)
46, 291 (1989)
46, 303 (1989)
46, 313 (1989)
29, 331 (1982); Suppl. 7, 67 (1987)
33, 209 (1984); Suppl. 7, 67 (1987);
46, 321 (1989)
46, 359 (1989)
46, 367 (1989)
24, 297 (1980) (corr. 42, 260)
30, 359 (1983)
37, 225 (1985); Suppl. 7, 67 (1987)
37, 233 (1985); Suppl. 7, 67 (1987)
4, 197 (1974); 17, 51 (1978);
Suppl. 7, 67 (1987)
17, 77 (1978); Suppl. 7, 67 (1987)
N-Nitrosodiethylamine
1, 107 (1972) (corr. 42, 251); 17, 83 (1978) (corr. 42, 257); Suppl. 7, 67 (1987)

N-Nitrosodimethylamine
1, 95 (1972); 17, 125 (1978) (corr. 42, 257); Suppl. 7, 67 (1987)

N-Nitrosodiphenylamine
27, 213 (1982); Suppl. 7, 67 (1987)

*para*-Nitrosodiphenylamine

N-Nitrosodi-n-propylamine
17, 177 (1978); Suppl. 7, 68 (1987)

N-Nitroso-N-ethylurea (see N-Ethyl-N-nitrosourea)
17, 217 (1978); Suppl. 7, 68 (1987)

N-Nitrosoguacoline
37, 263 (1985); Suppl. 7, 68 (1987)

N-Nitrosoguvacine
37, 263 (1985); Suppl. 7, 68 (1987)

N-Nitrosohydroxyproline
17, 304 (1978); Suppl. 7, 68 (1987)

3-(N-Nitrosomethylamino)propionaldehyde
37, 263 (1985); Suppl. 7, 68 (1987)

3-(N-Nitrosomethylamino)propionitrile
37, 263 (1985); Suppl. 7, 68 (1987)

4-(N-Nitrosomethylamino)-4-(3-pyridyl)-1-butanal
37, 205 (1985); Suppl. 7, 68 (1987)

4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butaneone
37, 209 (1985); Suppl. 7, 68 (1987)

N-Nitrosomethylethylamine
17, 221 (1978); Suppl. 7, 68 (1987)

N-Nitroso-N-methylurea (see N-Methyl-N-nitrosourea)
17, 257 (1978); Suppl. 7, 68 (1987)

N-Nitroso-N-methylurethane (see N-Methyl-N-methylurethane)
17, 263 (1978); Suppl. 7, 68 (1987)

N-Nitrosomorpholine
17, 281 (1978); 37, 241 (1985); Suppl. 7, 68 (1987)

N-Nitrosopyrrolidine
17, 303 (1978); Suppl. 7, 68 (1987)

N-Nitrososarcosine
17, 313 (1978); Suppl. 7, 68 (1987)

Nitrosoureas, chloroethyl (see Chloroethyl nitrosoureas)
48, 169 (1990)

5-Nitro-o|ntho|toluidine
31, 185 (1983); Suppl. 7, 68 (1987)

Nitrous oxide (see Anaesthetics, volatile)

Nitrovin
NNA (see 4-(N-Nitrosomethylamino)-4-(3-pyridyl)-1-butanal)

NNK (see 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butaneone)
Nonsteroidal oestrogens (see also Oestrogens, progestins and combinations)

Norethisterone (see also Progestins; Combined oral contraceptives)
6, 179 (1974); 21, 461 (1979)

Norethynodrel (see also Progestins; Combined oral contraceptives)
6, 191 (1974); 21, 461 (1979) (corr. 42, 259)

Norgestrel (see also Progestins, Combined oral contraceptives)
6, 201 (1974); 21, 479 (1979)

Nylon 6
19, 120 (1979); Suppl. 7, 68 (1987)
CUMULATIVE CROSS INDEX

O


Oestradiol-17β (see also Steroidal oestro gens) 6, 99 (1974); 21, 279 (1979)

Oestradiol 3-benzoate (see Oestradiol-17β) 9, 217 (1975)

Oestradiol dipropionate (see Oestradiol-17β) 6, 117 (1974); 21, 327 (1979)

Oestradiol mustard 9, 217 (1975)

Oestradiol-17β-valerate (see Oestradiol-17β) Suppl. 7, 308 (1987)

Oestriol (see also Steroidal oestrogens) Suppl. 7, 280 (1987)

Oestrogen-progestin combinations (see Oestrogens, progestins and combinations) 6 (1974); 21 (1979);

Oestrogen-progestin replacement therapy (see also Oestrogens, progestins and combinations) Suppl. 7, 272 (1987)

Oestrogens (see Oestrogens, progestins and combinations) 6, 123 (1974); 21, 343 (1979) (corr. 42, 259)

Oestrogens, nonsteroidal (see Nonsteroidal oestrogens) Suppl. 7, 69 (1987)

Oestrogens, progestins and combinations 8, 165 (1975); Suppl. 7, 69 (1987)

Oestrone (see also Steroidal oestrogens) 8, 173 (1975); Suppl. 7, 69 (1987)

Oestrone benzoate (see Oestrone) 8, 181 (1975); Suppl. 7, 69 (1987)

Oil Orange SS Suppl. 7, 230 (1987)

Oral contraceptives, combined (see Combined oral contraceptives) 13, 58 (1977); Suppl. 7, 69 (1987)

Oral contraceptives, investigational (see Combined oral contraceptives) 13, 131 (1977)

Oral contraceptives, sequential (see Sequential oral contraceptives) 13, 185 (1977); Suppl. 7, 69 (1987)

Orange I 47, 329 (1989)

Orange G 24, 77 (1980); Suppl. 7, 69 (1987)

Organolead compounds (see also Lead and lead compounds) 50, 307 (1990)

Oxazepam 10, 199 (1976) (corr. 42, 255); Suppl. 7, 69 (1987)


Oxetholone (see also Androgenic (anabolic) steroids) 24, 77 (1980); Suppl. 7, 69 (1987)

Oxybutynine (see also Androgenic (anabolic) steroids) 50, 307 (1990)

Oxyphenbutazone 10, 199 (1976) (corr. 42, 255); Suppl. 7, 69 (1987)

Paint manufacture and painting (occupational exposures in) 47, 329 (1989)

Panfuran S (see also Dihydroxymethylfurazidine) 24, 77 (1980); Suppl. 7, 69 (1987)

Paper manufacture (see Pulp and paper manufacture) 50, 307 (1990)

Paracetamol 10, 199 (1976) (corr. 42, 255); Suppl. 7, 69 (1987)
Parathion
Patulin

Penicillic acid
Pentachloroethane
Pentachloronitrobenzene (see Quinotroozene)
Pentachlorophenol (see also Chlorophenols; Chlorophenols, occupational exposures to)
Perylene
Petasitenine
Petasites japonicus (see Pyrrolizidine alkaloids)
Petroleum refining (occupational exposures in)
Some petroleum solvents
Phenacetin
Phenanthrene
Phenazopyridine hydrochloride

Phenelzine sulphate
Phenicarbazide
Phenobarbital
Phenol
Phenoxyacetic acid herbicides (see Chlorophenoxy herbicides)
Phenoxybenzamine hydrochloride

Phenylbutazone
meta–Phenylenediamine
para–Phenylenediamine
N–Phenyl–2–naphthylamine

ortho–Phenylphenol
Phenytoin
Piperazine oestrone sulphate (see Conjugated oestrogens)
Piperonyl butoxide
Pitches, coal–tar (see Coal–tar pitches)
Polyacrylic acid
Polybrominated biphenyls

Polybrominated biphenyls
Polychlorinated camphenes (see Toxaphene)
Polychloroprene
Polyethylene

30, 153 (1983); Suppl. 7, 69 (1987)
10, 205 (1976); 40, 83 (1986);
Suppl. 7, 69 (1987)
10, 211 (1976); Suppl. 7, 69 (1987)
41, 99 (1986); Suppl. 7, 69 (1987)
20, 303 (1979)
32, 411 (1983); Suppl. 7, 69 (1987)
31, 207 (1983); Suppl. 7, 69 (1987)
45, 39 (1989)
47, 43 (1989)
13, 141 (1977); 24, 135 (1980);
Suppl. 7, 310 (1987)
32, 419 (1983); Suppl. 7, 69 (1987)
8, 117 (1975); 24, 163 (1980)
(corr. 42, 260); Suppl. 7, 312 (1987)
24, 175 (1980); Suppl. 7, 312 (1987)
12, 177 (1976); Suppl. 7, 70 (1987)
13, 157 (1977); Suppl. 7, 313 (1987)
47, 263 (1989)
9, 223 (1975); 24, 185 (1980);
Suppl. 7, 70 (1987)
13, 183 (1977); Suppl. 7, 316 (1987)
16, 111 (1978); Suppl. 7, 70 (1987)
16, 125 (1978); Suppl. 7, 70 (1987)
16, 325 (1978) (corr. 42, 257);
Suppl. 7, 318 (1987)
30, 329 (1983); Suppl. 7, 70 (1987)
13, 201 (1977); Suppl. 7, 319 (1987)
30, 183 (1983); Suppl. 7, 70 (1987)
19, 62 (1979); Suppl. 7, 70 (1987)
18, 107 (1978); 41, 261 (1986);
Suppl. 7, 321 (1987)
7, 261 (1974); 18, 43 (1978) (corr.
42, 258);
Suppl. 7, 322 (1987)
19, 141 (1979); Suppl. 7, 70 (1987)
19, 164 (1979); Suppl. 7, 70 (1987)
<table>
<thead>
<tr>
<th>Compound</th>
<th>Reference 1</th>
<th>Reference 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polymethylene polyphenyl isocyanate</td>
<td>19, 314 (1979); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Polymethyl methacrylate</td>
<td>19, 195 (1979); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Polyoctadriadi phosphate (see Oestradiol-17β)</td>
<td>19, 218 (1979); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Polypropylene</td>
<td>19, 245 (1979); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Polystyrene</td>
<td>19, 288 (1979); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Polytetrafluoroethylene</td>
<td>19, 320 (1979); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Polyurethane foams</td>
<td>19, 346 (1979); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Polyvinyl alcohol</td>
<td>8, 189 (1975); Suppl. 7, 70 (1987)</td>
<td>12, 183 (1976); Suppl. 7, 70 (1987)</td>
</tr>
<tr>
<td>Polyvinyl pyrrolidone</td>
<td>8, 199 (1975); Suppl. 7, 70 (1987)</td>
<td>40, 207 (1986); Suppl. 7, 70 (1987)</td>
</tr>
<tr>
<td>Ponceau MX</td>
<td>8, 207 (1975); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Ponceau 3R</td>
<td>12, 183 (1976); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Ponceau SX</td>
<td>12, 183 (1976); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Potassium arsenate (see Arsenic and arsenic compounds)</td>
<td>12, 183 (1976); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Potassium arsenite (see Arsenic and arsenic compounds)</td>
<td>12, 183 (1976); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Potassium bis(2-hydroxyethyl)dithiocarbamate</td>
<td>12, 183 (1976); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Potassium bromate</td>
<td>12, 183 (1976); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Potassium chromate (see Chromium and chromium compounds)</td>
<td>12, 183 (1976); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Potassium dichromate (see Chromium and chromium compounds)</td>
<td>12, 183 (1976); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Prednimustine</td>
<td>50, 115 (1990)</td>
<td></td>
</tr>
<tr>
<td>Prednisone</td>
<td>26, 293 (1981); Suppl. 7, 326 (1987)</td>
<td></td>
</tr>
<tr>
<td>Procarbazine hydrochloride</td>
<td>26, 311 (1981); Suppl. 7, 327 (1987)</td>
<td></td>
</tr>
<tr>
<td>Proflavine salts</td>
<td>24, 195 (1980); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>Progesterone (see also Progestins; Combined oral contraceptives)</td>
<td>6, 135 (1974); 21, 491 (1979) (corr. 42, 259)</td>
<td>Suppl. 7, 289 (1987)</td>
</tr>
<tr>
<td>Progestins (see also Oestrogens, progestins and combinations)</td>
<td>13, 227 (1977) (corr. 42, 256); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>1,3-Propane sultone</td>
<td>12, 189 (1976); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>β-Propiolactone</td>
<td>12, 201 (1976); Suppl. 7, 70 (1987)</td>
<td></td>
</tr>
<tr>
<td>n-Propyl carbamate</td>
<td>19, 213 (1979); Suppl. 7, 71 (1987)</td>
<td></td>
</tr>
<tr>
<td>Propylene</td>
<td>11, 191 (1976); 36, 227 (1985) (corr. 42, 263); Suppl. 7, 328 (1987)</td>
<td></td>
</tr>
<tr>
<td>Propythiouracil</td>
<td>40, 55 (1986); Suppl. 7, 71 (1987)</td>
<td></td>
</tr>
<tr>
<td>Plaquilloside (see also Bracken fern)</td>
<td>25, 157 (1981); Suppl. 7, 385 (1987)</td>
<td></td>
</tr>
<tr>
<td>Pulp and paper manufacture</td>
<td>32, 431 (1983); Suppl. 7, 71 (1987)</td>
<td></td>
</tr>
<tr>
<td>Pyrene</td>
<td>40, 349 (1986); Suppl. 7, 71 (1987)</td>
<td></td>
</tr>
<tr>
<td>Pyrido[3,4-c]psoralen</td>
<td>13, 233 (1977); Suppl. 7, 71 (1987)</td>
<td></td>
</tr>
<tr>
<td>Pyrimethamine</td>
<td>13, 233 (1977); Suppl. 7, 71 (1987)</td>
<td></td>
</tr>
</tbody>
</table>
Pyrolizidine alkaloids (see Hydroxynkirkine; Isatidine; Jacobine; Lasiocarpine; Monocrotaline; Retrorsine; Riddelliine; Seneciphylline; Senkirkine)

Q

Quercetin (see also Bracken fern)
para-Quinone
Quintozene

R

Radon
Reserpine

Resorcinol
Retrorsine
Rhodamine B
Rhodamine 6G
Riddelliine
Rifampicin
Rockwool (see Man-made mineral fibres)
The rubber industry

Rugulosin

S

Saccharated iron oxide
Saccharin

Safrrole

The sawmill industry (including logging) (see The lumber and sawmill industry (including logging))

Scarlet Red

Selenium and selenium compounds

Selenium dioxide (see Selenium and selenium compounds)
Selenium oxide (see Selenium and selenium compounds)
Semicarbazide hydrochloride

Senecio jacobaea L. (see Pyrolizidine alkaloids)
Senecio longilobus (see Pyrolizidine alkaloids)
<table>
<thead>
<tr>
<th>Term</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seneciphylline</td>
<td>10, 319, 335 (1976); Suppl. 7, 71 (1987)</td>
</tr>
<tr>
<td>Senkirkine</td>
<td>10, 327 (1976); 31, 231 (1983); Suppl. 7, 71 (1987)</td>
</tr>
<tr>
<td>Sepiolite</td>
<td>42, 175 (1987); Suppl. 7, 71 (1987)</td>
</tr>
<tr>
<td>Sequential oral contraceptives</td>
<td>Suppl. 7, 296 (1987)</td>
</tr>
<tr>
<td>(see also Oestrogens, progestins and combinations)</td>
<td></td>
</tr>
<tr>
<td>Shikimic acid (see also Bracken fern)</td>
<td>40, 55 (1986); Suppl. 7, 71 (1987)</td>
</tr>
<tr>
<td>Shoe manufacture and repair</td>
<td>42, 39 (1987)</td>
</tr>
<tr>
<td>(see Boot and shoe manufacture and repair)</td>
<td></td>
</tr>
<tr>
<td>Silica (see also Amorphous silica; Crystalline silica)</td>
<td></td>
</tr>
<tr>
<td>Slagwool (see Man-made mineral fibres)</td>
<td></td>
</tr>
<tr>
<td>Sodium arsenate (see Arsenic and arsenic compounds)</td>
<td></td>
</tr>
<tr>
<td>Sodium arsenite (see Arsenic and arsenic compounds)</td>
<td></td>
</tr>
<tr>
<td>Sodium cacodylate (see Arsenic and arsenic compounds)</td>
<td></td>
</tr>
<tr>
<td>Sodium chromate (see Chromium and chromium compounds)</td>
<td></td>
</tr>
<tr>
<td>Sodium cyclamate (see Cyclamates)</td>
<td></td>
</tr>
<tr>
<td>Sodium dichromate (see Chromium and chromium compounds)</td>
<td></td>
</tr>
<tr>
<td>Sodium diethylidithiocarbamate</td>
<td>12, 217 (1976); Suppl. 7, 71 (1987)</td>
</tr>
<tr>
<td>Sodium equilin sulphate (see Conjugated oestrogens)</td>
<td></td>
</tr>
<tr>
<td>Sodium fluoride (see Fluorides)</td>
<td></td>
</tr>
<tr>
<td>Sodium monofluorophosphate (see Fluorides)</td>
<td></td>
</tr>
<tr>
<td>Sodium oestrone sulphate (see Conjugated oestrogens)</td>
<td></td>
</tr>
<tr>
<td>Sodium ortho-phenylphenate (see also ortho-Phenylphenol)</td>
<td></td>
</tr>
<tr>
<td>Sodium saccharin (see Saccharin)</td>
<td>30, 329 (1983); Suppl. 7, 392 (1987)</td>
</tr>
<tr>
<td>Sodium selenate (see Selenium and selenium compounds)</td>
<td></td>
</tr>
<tr>
<td>Sodium selenite (see Selenium and selenium compounds)</td>
<td></td>
</tr>
<tr>
<td>Sodium silicofluoride (see Fluorides)</td>
<td></td>
</tr>
<tr>
<td>Soots</td>
<td>3, 22 (1973); 35, 219 (1985); Suppl. 7, 343 (1987)</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>24, 259 (1980); Suppl. 7, 344 (1987)</td>
</tr>
<tr>
<td>Stannous fluoride (see Fluorides)</td>
<td></td>
</tr>
<tr>
<td>Steel founding (see Iron and steel founding)</td>
<td></td>
</tr>
<tr>
<td>Sterigmatocystin</td>
<td>1, 175 (1972); 10, 245 (1976); Suppl. 7, 72 (1987)</td>
</tr>
<tr>
<td>Steroidal oestrogens (see also Oestrogens, progestins and combinations)</td>
<td></td>
</tr>
<tr>
<td>Streptozotocin</td>
<td>4, 221 (1974); 17, 337 (1978); Suppl. 7, 72 (1987)</td>
</tr>
<tr>
<td>Strobane® (see Terpene polychlorinates)</td>
<td></td>
</tr>
<tr>
<td>Strontium chromate (see Chromium and chromium compounds)</td>
<td></td>
</tr>
<tr>
<td>Styrene</td>
<td>19, 231 (1979) (corr. 42, 258); Suppl. 7, 345 (1987)</td>
</tr>
<tr>
<td>Styrene–acrylonitrile copolymers</td>
<td>19, 97 (1979); Suppl. 7, 72 (1987)</td>
</tr>
</tbody>
</table>
Styrene–butadiene copolymers
Styrene oxide
Succinic anhydride
Sudan I
Sudan II
Sudan III
Sudan Brown RR
Sudan Red 7B
Sulfafurazole
Sulfallate
Sulfamethoxazole
Sulphisoxazole (see Sulfafurazole)
Sunset Yellow FCF
Symphytine

T

2,4,5–T (see also Chlorophenoxy herbicides; Chlorophenoxy herbicides, occupational exposures to)
Talc
Tannic acid
Tannins (see also Tannic acid)
TCDD (see 2,3,7,8–Tetrachlorodibenzo–para–dioxin)
TDE (see DDT)
Terpene polychlorinates
Testosterone (see also Androgenic (anabolic) steroids)
Testosterone oenanthate (see Testosterone)
Testosterone propionate (see Testosterone)
2,2',5,5'–Tetrachlorobenzidine
2,3,7,8–Tetrachlorodibenzo–para–dioxin
1,1,1,2–Tetrachloroethane
1,1,2,2–Tetrachloroethane
Tetrachloroethylene
2,3,4,6–Tetrachlorophenol (see Chlorophenols; Chlorophenols, occupational exposures to)
Tetrachlorvinphos
Tetraethyllead (see Lead and lead compounds)
Tetrafluoroethylene
Tetrakis(hydroxymethyl) phosphonium salts
Tetramethyllead (see Lead and lead compounds)
Textile manufacturing industry, exposures in
Thioacetamide

19, 252 (1979); Suppl. 7, 72 (1987)
11, 201 (1976); 19, 275 (1979);
36, 245 (1985); Suppl. 7, 72 (1987)
15, 265 (1977); Suppl. 7, 72 (1987)
8, 225 (1975); Suppl. 7, 72 (1987)
8, 233 (1975); Suppl. 7, 72 (1987)
8, 241 (1975); Suppl. 7, 72 (1987)
8, 249 (1975); Suppl. 7, 72 (1987)
8, 253 (1975); Suppl. 7, 72 (1987)
24, 275 (1980); Suppl. 7, 347 (1987)
30, 283 (1983); Suppl. 7, 72 (1987)
24, 285 (1980); Suppl. 7, 348 (1987)

8, 257 (1975); Suppl. 7, 72 (1987)
31, 239 (1983); Suppl. 7, 72 (1987)

15, 273 (1977)
42, 185 (1987); Suppl. 7, 349 (1987)
10, 253 (1976) (corr. 42, 255);
Suppl. 7, 72 (1987)
10, 254 (1976); Suppl. 7, 72 (1987)

5, 219 (1974); Suppl. 7, 72 (1987)
6, 209 (1974); 21, 519 (1979)

27, 141 (1982); Suppl. 7, 72 (1987)
15, 41 (1977); Suppl. 7, 350 (1987)
41, 87 (1986); Suppl. 7, 72 (1987)
20, 477 (1979); Suppl. 7, 354 (1987)
20, 491 (1979); Suppl. 7, 355 (1987)

30, 197 (1983); Suppl. 7, 72 (1987)
19, 285 (1979); Suppl. 7, 72 (1987)
48, 95 (1990)

48, 215 (1990)
7, 77 (1974); Suppl. 7, 72 (1987)
CUMULATIVE CROSS INDEX

4,4’-Thiodianiline

Thiotepa

Thiouracil

Thiourea

Thiram

Titanium dioxide

Tobacco habits other than smoking (see Tobacco products, smokeless)

Tobacco products, smokeless

Tobacco smoke

Tobacco smoking (see Tobacco smoke)

ortho-Toluidine (see 3,3’-Dimethylbenzidine)

2,4-Toluene diisocyanate (see also Toluene diisocyanates)

2,6-Toluene diisocyanate (see also Toluene diisocyanates)

Toluene

Toluene diisocyanates

Toluenes, α-chlorinated (see α-Chlorinated toluenes)

ortho-Toluenesulphonamide (see Saccharin)

ortho-Toluidine

Toxaphene

Tremolite (see Asbestos)

Trolesulphan

Triaziquone (see Tris(aziridinyl)-para-benzoquinone)

Trichlorfon

Trichlormethine

1,1,1-Trichloroethane

1,1,2-Trichloroethane

Trichloroethylene

2,4,5-Trichlorophenol (see also Chlorophenols; Chlorophenols occupational exposures to)

2,4,6-Trichlorophenol (see also Chlorophenols; Chlorophenols, occupational exposures to)

(2,4,5-Trichlorophenoxy)acetic acid (see 2,4,5-T)

Trichlorortriethylamine hydrochloride (see Trichlormethine)

T₂-Trichothecene

Triethylene glycol diglycidyl ether

16, 343 (1978); 27, 147 (1982); Suppl. 7, 72 (1987)

9, 85 (1975); Suppl. 7, 368 (1987); 50, 123 (1990)

7, 85 (1974); Suppl. 7, 72 (1987)

7, 95 (1974); Suppl. 7, 72 (1987)

12, 225 (1976); Suppl. 7, 72 (1987)


37 (1985) (corr. 42, 263); Suppl. 7, 357 (1987)

38 (1986) (corr. 42, 263); Suppl. 7, 357 (1987)

19, 303 (1979); 39, 287 (1986)

19, 303 (1979); 39, 289 (1986)


16, 349 (1978); 27, 155 (1982); Suppl. 7, 362 (1987)

20, 327 (1979); Suppl. 7, 72 (1987)

26, 341 (1981); Suppl. 7, 363 (1987)

30, 207 (1983); Suppl. 7, 73 (1987)

9, 229 (1975); Suppl. 7, 73 (1987); 50, 143 (1990)

20, 515 (1979); Suppl. 7, 73 (1987)

20, 533 (1979); Suppl. 7, 73 (1987)

11, 263 (1976); 20, 545 (1979); Suppl. 7, 364 (1987)

20, 349 (1979)

20, 349 (1979)

31, 265 (1983); Suppl. 7, 73 (1987)

11, 209 (1976); Suppl. 7, 73 (1987)
<table>
<thead>
<tr>
<th>Substance</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4',6-Trimethylangelicin plus ultraviolet radiation (see also Angelicin and some synthetic derivatives)</td>
<td>Suppl. 7, 57 (1987)</td>
</tr>
<tr>
<td>2,4,5-Trimethylaniline</td>
<td>27, 177 (1982); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>2,4,6-Trimethylaniline</td>
<td>27, 178 (1982); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>4,5',8-Trimethylpsoralen</td>
<td>40, 357 (1986); Suppl. 7, 366 (1987)</td>
</tr>
<tr>
<td>Trimustine hydrochloride (see Trichlormethine)</td>
<td></td>
</tr>
<tr>
<td>Triphenylene</td>
<td>32, 447 (1983); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>Tris(aziridinyl)-para-benzoquinone</td>
<td>9, 67 (1975); Suppl. 7, 367 (1987)</td>
</tr>
<tr>
<td>Tris(1-aziridinyl)phosphine oxide</td>
<td>9, 75 (1975); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>Tris(1-aziridinyl)phosphine sulphide (see Thiotepa)</td>
<td>9, 95 (1975); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>2,4,6-Tris(1-aziridinyl)-s-triazine</td>
<td>48, 109 (1990)</td>
</tr>
<tr>
<td>Tris(2-chloroethyl)phosphate</td>
<td>15, 301 (1977); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>1,2,3-Tris(chloromethoxy)propane</td>
<td>20, 575 (1979); Suppl. 7, 369 (1987)</td>
</tr>
<tr>
<td>Tris(2,3-dibromopropyl)phosphate</td>
<td>9, 107 (1975); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>Tris(2-methyl-1-aziridinyl)phosphine oxide</td>
<td>31, 247 (1983); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>Trp-P-1</td>
<td>31, 255 (1983); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>Trp-P-2</td>
<td>8, 267 (1975); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>Trypan blue</td>
<td></td>
</tr>
<tr>
<td>Tussilago farfara L. (see Pyrrolizidine alkaloids)</td>
<td></td>
</tr>
<tr>
<td><strong>U</strong></td>
<td></td>
</tr>
<tr>
<td>Ultraviolet radiation</td>
<td>40, 379 (1986)</td>
</tr>
<tr>
<td>Underground haematite mining with exposure to radon</td>
<td>1, 29 (1972); Suppl. 7, 216 (1987)</td>
</tr>
<tr>
<td>Uracil mustard</td>
<td>9, 235 (1975); Suppl. 7, 370 (1987)</td>
</tr>
<tr>
<td>Urethane</td>
<td>7, 111 (1974); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td><strong>V</strong></td>
<td></td>
</tr>
<tr>
<td>Vat Yellow 4</td>
<td>48, 161 (1990)</td>
</tr>
<tr>
<td>Vincristine sulphate</td>
<td>26, 365 (1981); Suppl. 7, 372 (1987)</td>
</tr>
<tr>
<td>Vinyl acetate</td>
<td>19, 341 (1979); 39, 113 (1986); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>Vinyl bromide</td>
<td>19, 367 (1979); 39, 133 (1986); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>Vinyl chloride</td>
<td>7, 291 (1974); 19, 377 (1979) (corr. 42, 258); Suppl. 7, 373 (1987)</td>
</tr>
<tr>
<td>Vinyl chloride–vinyl acetate copolymers</td>
<td>7, 311 (1976); 19, 412 (1979) (corr. 42, 258); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>4-Vinylcyclohexene</td>
<td>11, 277 (1976); 39, 181 (1986); Suppl. 7, 73 (1987)</td>
</tr>
<tr>
<td>Vinyl fluoride</td>
<td>39, 147 (1986); Suppl. 7, 73 (1987)</td>
</tr>
</tbody>
</table>
Vinylidene chloride

Vinylidene chloride-vinyl chloride copolymers

Vinylidene fluoride

N-Vinyl-2-pyrrolidone

W

Welding

Wollastonite

Wood industries

X

Xylene

2,4-Xyldine

2,5-Xyldine

Y

Yellow AB

Yellow OB

Z

Zearalenone

Zectran

Zinc beryllium silicate (see Beryllium and beryllium compounds)

Zinc chromate (see Chromium and chromium compounds)

Zinc chromate hydroxide (see Chromium and chromium compounds)

Zinc potassium chromate (see Chromium and chromium compounds)

Zinc yellow (see Chromium and chromium compounds)

Zineb

Ziram
PUBLICATIONS OF THE INTERNATIONAL
AGENCY FOR RESEARCH ON CANCER
Scientific Publications Series
(Available from Oxford University Press through local bookshops)

No. 1 Liver Cancer
1971; 176 pages (out of print)

No. 2 Oncogenesis and Herpesviruses
Edited by P.M. Biggs, G. de-Thé and L.N. Payne
1972; 515 pages (out of print)

No. 3 N-Nitroso Compounds: Analysis and Formation
Edited by P. Bogovski, R. Preussman and E.A. Walker
1972; 140 pages (out of print)

No. 4 Transplacental Carcinogenesis
Edited by L. Tomatis and U. Mohr
1973; 181 pages (out of print)

No. 5/6 Pathology of Tumours in Laboratory Animals, Volume I, Tumours of the Rat
Edited by V.S. Tsurusov
1973/1976; 533 pages; £50.00

No. 7 Host Environment Interactions in the Etiology of Cancer in Man
Edited by R. Doll and I. Vodopija
1973; 464 pages; £32.50

No. 8 Biological Effects of Asbestos
Edited by P. Bogovski, J.C. Gilson, V. Timbrell and J.C. Wagner
1973; 346 pages (out of print)

No. 9 N-Nitroso Compounds in the Environment
Edited by P. Bogovski and E.A. Walker
1974; 243 pages; £21.00

No. 10 Chemical Carcinogenesis Essays
Edited by R. Montesano and L. Tomatis
1974; 230 pages (out of print)

No. 11 Oncogenesis and Herpesviruses II
Edited by G. de-Thé, M.A. Epstein and H. zur Hausen
1975; Part I: 511 pages
Part II: 403 pages; £65.00

No. 12 Screening Tests in Chemical Carcinogenesis
Edited by R. Montesano, H. Bartsch and L. Tomatis
1976; 666 pages; £45.00

No. 13 Environmental Pollution and Carcinogenic Risks
Edited by C. Rosenfeld and W. Davis
1975; 441 pages (out of print)

No. 14 Environmental N-Nitroso Compounds. Analysis and Formation
Edited by E.A. Walker, P. Bogovski and L. Griciute
1976; 512 pages; £37.50

No. 15 Cancer Incidence in Five Continents, Volume III
Edited by J.A.H. Waterhouse, C. Muir, P. Correa and J. Powell
1976; 584 pages; (out of print)

No. 16 Air Pollution and Cancer in Man
Edited by U. Mohr, D. Schmähl and L. Tomatis
1977; 328 pages (out of print)

No. 17 Directory of On-going Research in Cancer Epidemiology 1977
Edited by C.S. Muir and G. Wagner
1977; 599 pages (out of print)

No. 18 Environmental Carcinogens. Selected Methods of Analysis. Volume 1: Analysis of Volatile Nitrosamines in Food
Editor-in-Chief: H. Egan
1978; 212 pages (out of print)

No. 19 Environmental Aspects of N-Nitroso Compounds
Edited by E.A. Walker, M. Castegnaro, L. Griciute and R.E. Lyle
1978; 561 pages (out of print)

No. 20 Nasopharyngeal Carcinoma: Etiology and Control
Edited by G. de-Thé and Y. Ito
1978; 606 pages (out of print)

No. 21 Cancer Registration and its Techniques
Edited by R. MacLennan, C. Muir, R. Steinitz and A. Winkler
1978; 235 pages; £35.00

Editor-in-Chief: H. Egan
1978; 142 pages (out of print)

No. 23 Pathology of Tumours in Laboratory Animals, Volume II: Tumours of the Mouse
Editor-in-Chief: V.S. Tsurusov
1979; 669 pages (out of print)

Prices, valid for January 1990, are subject to change without notice
List of IARC Publications

No. 24 Oncogenesis and Herpesviruses III
Edited by G. de-Thé, W. Henle and F. Rapp
1978; Part I: 580 pages, Part II: 512 pages (out of print)

No. 25 Carcinogenic Risk. Strategies for Intervention
Edited by W. Davis and C. Rosenfeld
1979; 280 pages (out of print)

No. 26 Directory of On-going Research in Cancer Epidemiology 1978
Edited by C.S. Muir and G. Wagner
1978; 550 pages (out of print)

No. 27 Molecular and Cellular Aspects of Carcinogen Screening Tests
Edited by R. Montesano, H. Bartsch and L. Tomatis
1980; 372 pages; £29.00

No. 28 Directory of On-going Research in Cancer Epidemiology 1979
Edited by C.S. Muir and G. Wagner
1979; 672 pages (out of print)

No. 29 Environmental Carcinogens. Selected Methods of Analysis. Volume 3: Analysis of Polycyclic Aromatic Hydrocarbons in Environmental Samples
Editor-in-Chief: H. Egan
1979; 240 pages (out of print)

No. 30 Biological Effects of Mineral Fibres
Editor-in-Chief: J.C. Wagner
1980; Volume 1: 494 pages; Volume 2: 513 pages; £65.00

No. 31 N-Nitroso Compounds: Analysis, Formation and Occurrence
Edited by E.A. Walker, L. Griciute, M. Castegnaro and M. Bősziö尼
1980; 835 pages (out of print)

By N.E. Breslow and N.E. Day
1980; 338 pages; £20.00

No. 33 Handling Chemical Carcinogens in the Laboratory
Edited by R. Montesano et al.
1979; 32 pages (out of print)

No. 34 Pathology of Tumours in Laboratory Animals. Volume III. Tumours of the Hamster
Editor-in-Chief: V.S. Turusov
1982; 461 pages; £39.00

No. 35 Directory of On-going Research in Cancer Epidemiology 1980
Edited by C.S. Muir and G. Wagner
1980; 660 pages (out of print)

No. 36 Cancer Mortality by Occupation and Social Class 1851-1971
Edited by W.P.D. Logan
1982; 253 pages; £22.50

No. 37 Laboratory Decontamination and Destruction of Carcinogens in Laboratory Wastes: Some N-Nitrosamines
Edited by M. Castegnaro et al.
1982; 73 pages; £7.50

No. 38 Directory of On-going Research in Cancer Epidemiology 1981
Edited by C.S. Muir and G. Wagner
1981; 696 pages (out of print)

No. 39 Host Factors in Human Carcinogenesis
Edited by H. Bartsch and B. Armstrong
1982; 583 pages; £46.00

Edited by L. Fishbein, M. Castegnaro, I.K. O'Neill and H. Bartsch
1981; 347 pages; £29.00

No. 41 N-Nitroso Compounds: Occurrence and Biological Effects
Edited by H. Bartsch, I.K. O'Neill, M. Castegnaro and M. Okada
1982; 755 pages; £48.00

No. 42 Cancer Incidence in Five Continents, Volume IV
Edited by J. Waterhouse, C. Muir, K. Shanmugaratnam and J. Powell
1982; 811 pages (out of print)

No. 43 Laboratory Decontamination and Destruction of Carcinogens in Laboratory Wastes: Some N-Nitrosamines
Edited by M. Castegnaro et al.
1982; 73 pages; £7.50

No. 44 Environmental Carcinogens. Selected Methods of Analysis. Volume 5: Some Mycotoxins
Edited by L. Stoloff, M. Castegnaro, P. Scott, I.K. O'Neill and H. Bartsch
1983; 455 pages; £29.00

No. 45 Environmental Carcinogens. Selected Methods of Analysis. Volume 6: N-Nitroso Compounds
Edited by R. Preussmann, I.K. O'Neill, G. Eisenbrand, B. Spiegelhalder and H. Bartsch
1983; 508 pages; £29.00

No. 46 Directory of On-going Research in Cancer Epidemiology 1982
Edited by C.S. Muir and G. Wagner
1982; 722 pages (out of print)
List of IARC Publications

No. 47 Cancer Incidence in Singapore 1968–1977
Edited by K. Shanmugaratnam, H.P. Lee and N.E. Day
1983; 171 pages (out of print)

No. 48 Cancer Incidence in the USSR (2nd Revised Edition)
Edited by N.P. Napalkov, G.F. Tserkovny, V.M. Merabishvili, D.M. Parkin, M. Smans and C.S. Muir
1983; 75 pages; £12.00

No. 49 Laboratory Decontamination and Destruction of Carcinogens in Laboratory Wastes: Some Polycyclic Aromatic Hydrocarbons
Edited by M. Castegnaro, et al.
1983; 87 pages; £9.00

No. 50 Directory of On-going Research in Cancer Epidemiology 1983
Edited by C.S. Muir and G. Wagner
1983; 731 pages (out of print)

No. 51 Modulators of Experimental Carcinogenesis
Edited by V. Turusov and R. Montesano
1983; 307 pages; £22.50

No. 52 Second Cancers in Relation to Radiation Treatment for Cervical Cancer: Results of a Cancer Registry Collaboration
Edited by N.E. Day and J.C. Boice, Jr
1984; 207 pages; £20.00

No. 53 Nickel in the Human Environment
Editor-in-Chief: F.W. Sunderman, Jr
1984; 529 pages; £41.00

No. 54 Laboratory Decontamination and Destruction of Carcinogens in Laboratory Wastes: Some Hydrazines
Edited by M. Castegnaro, et al.
1983; 87 pages; £9.00

No. 55 Laboratory Decontamination and Destruction of Carcinogens in Laboratory Wastes: Some N-Nitrosoamides
Edited by M. Castegnaro et al.
1984; 66 pages; £7.50

No. 56 Models, Mechanisms and Etiology of Tumour Promotion
Edited by M. Börzsönyi, N.E. Day, K. Lapis and H. Yamasaki
1984; 532 pages; £42.00

No. 57 N-Nitroso Compounds: Occurrence, Biological Effects and Relevance to Human Cancer
1984; 1013 pages; £80.00

No. 58 Age-related Factors in Carcinogenesis
Edited by A. Likhachev, V. Anisimov and R. Montesano
1985; 288 pages; £20.00

No. 59 Monitoring Human Exposure to Carcinogenic and Mutagenic Agents
Edited by A. Berlin, M. Draper, K. Hemminki and H. Vainio
1984; 457 pages; £27.50

No. 60 Burkitt’s Lymphoma: A Human Cancer Model
Edited by G. Lenoir, G. O’Conor and C.L.M. Olweny
1985; 484 pages; £29.00

No. 61 Laboratory Decontamination and Destruction of Carcinogens in Laboratory Wastes: Some Haloethers
Edited by M. Castegnaro et al.
1985; 55 pages; £7.50

No. 62 Directory of On-going Research in Cancer Epidemiology 1984
Edited by C.S. Muir and G. Wagner
1984; 717 pages (out of print)

No. 63 Virus-associated Cancers in Africa
Edited by A.O. Williams, G.T. O’Conor, G.B. de-Thé and C.A. Johnson
1984; 773 pages; £22.00

No. 64 Laboratory Decontamination and Destruction of Carcinogens in Laboratory Wastes: Some Aromatic Amines and 4-Nitrobiphenyl
Edited by M. Castegnaro et al.
1985; 84 pages; £6.95

No. 65 Interpretation of Negative Epidemiological Evidence for Carcinogenicity
Edited by N.J. Wald and R. Doll
1985; 232 pages; £20.00

No. 66 The Role of the Registry in Cancer Control
Edited by D.M. Parkin, G. Wagner and C.S. Muir
1985; 152 pages; £10.00

No. 67 Transformation Assay of Established Cell Lines: Mechanisms and Application
Edited by T. Kakunaga and H. Yamasaki
1985; 225 pages; £20.00

No. 68 Environmental Carcinogens. Selected Methods of Analysis. Volume 7. Some Volatile Halogenated Hydrocarbons
Edited by L. Fishbein and I.K. O’Neill
1985; 479 pages; £42.00

No. 69 Directory of On-going Research in Cancer Epidemiology 1985
Edited by C.S. Muir and G. Wagner
1985; 745 pages; £22.00
List of IARC Publications

No. 70 The Role of Cyclic Nucleic Acid Adducts in Carcinogenesis and Mutagenesis
Edited by B. Singer and H. Bartsch
1986; 467 pages; £40.00

No. 71 Environmental Carcinogens. Selected Methods of Analysis. Volume 8: Some Metals: As, Be, Cd, Cr, Ni, Pb, Se Zn
Edited by I.K. O'Neill, P. Schuller and L. Fishbein
1986; 485 pages; £42.00

Edited by I. Kemp, P. Boyle, M. Smans and C.S. Muir
1985; 285 pages; £35.00

No. 73 Laboratory Decontamination and Destruction of Carcinogens in Laboratory Wastes: Some Antineoplastic Agents
Edited by M. Castegnaro et al.
1985; 163 pages; £10.00

No. 74 Tobacco: A Major International Health Hazard
Edited by D. Zardide and R. Peto
1986; 324 pages; £20.00

No. 75 Cancer Occurrence in Developing Countries
Edited by D.M. Parkin
1986; 339 pages; £20.00

No. 76 Screening for Cancer of the Uterine Cervix
Edited by M. Hakama, A.B. Miller and N.E. Day
1986; 315 pages; £25.00

No. 77 Hexachlorobenzene: Proceedings of an International Symposium
Edited by C.R. Morris and J.R.P. Cabral
1986; 668 pages; £50.00

No. 78 Carcinogenicity of Alkylationg Cytostatic Drugs
Edited by D. Schmähl and J.M. Kaldor
1986; 337 pages; £25.00

By J.J. Gart, D. Krewski, P.N. Lee, R.E. Tarone and J. Wahrendorf
1986; 213 pages; £20.00

No. 80 Directory of On-going Research in Cancer Epidemiology 1986
Edited by C.S. Muir and G. Wagner
1986; 805 pages; £22.00

No. 81 Environmental Carcinogens: Methods of Analysis and Exposure Measurement. Volume 9: Passive Smoking
Edited by I.K. O'Neill, K.D. Brunnnemann, B. Dodet and D. Hoffmann
1987; 383 pages; £35.00

No. 82 Statistical Methods in Cancer Research. Volume II: The Design and Analysis of Cohort Studies
By N.E. Breslow and N.E. Day
1987; 404 pages; £30.00

No. 83 Long-term and Short-term Assays for Carcinogens: A Critical Appraisal
Edited by R. Montesano, H. Bartsch, H. Vainio, J. Wilbourn and H. Yamasaki
1986; 575 pages; £48.00

No. 84 The Relevance of N-Nitroso Compounds to Human Cancer: Exposure and Mechanisms
Edited by H. Bartsch, I.K. O'Neill and R. Schulte-Hermann
1987; 671 pages; £50.00

No. 85 Environmental Carcinogens: Methods of Analysis and Exposure Measurement. Volume 10: Benzene and Alkylated Benzenes
Edited by L. Fishbein and I.K. O'Neill
1988; 327 pages; £35.00

No. 86 Directory of On-going Research in Cancer Epidemiology 1987
Edited by D.M. Parkin and J. Wahrendorf
1987; 676 pages; £22.00

No. 87 International Incidence of Childhood Cancer
Edited by D.M. Parkin, C.A. Stillier, C.A. Bieber, G.J. Draper, B. Terracini and J.L. Young
1988; 401 pages; £35.00

No. 88 Cancer Incidence in Five Continents Volume V
Edited by C. Muir, J. Waterhouse, T. Mack, J. Powell and S. Whelan
1987; 1004 pages; £50.00

No. 89 Method for Detecting DNA Damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention
Edited by H. Bartsch, K. Hemminki and I.K. O'Neill
1988; 518 pages; £45.00

No. 90 Non-occupational Exposure to Mineral Fibres
Edited by J. Bignon, J. Peto and R. Saracci
1989; 500 pages; £45.00

No. 91 Trends in Cancer Incidence in Singapore 1968–1982
Edited by H.P. Lee, N.E. Day and K. Shanmugaratnam
1988; 160 pages; £25.00

No. 92 Cell Differentiation, Genes and Cancer
Edited by T. Kakunaga, T. Sugimura, L. Tomatis and H. Yamasaki
1988; 204 pages; £25.00
List of IARC Publications

No. 93 Directory of On-going Research in Cancer Epidemiology 1988
Edited by M. Coleman and J. Währendorf
1988; 662 pages (out of print)

No. 94 Human Papillomavirus and Cervical Cancer
Edited by N. Muñoz, F.X. Bosch and O.M. Jensen
1989; 154 pages; £19.00

No. 95 Cancer Registration: Principles and Methods
Edited by O.M. Jensen, D.M. Parkin, R. MacLennan, C.S. Muir and R. Skeet
Publ. due 1990; approx. 300 pages

No. 96 Perinatal and Multigeneration Carcinogenesis
Edited by N.P. Napalkov, J.M. Rice, L. Tomatis and H. Yamazaki
1989; 436 pages; £48.00

No. 97 Occupational Exposure to Silica and Cancer Risk
Edited by L. Simonato, A.C. Fletcher, R. Saracci and T. Thomas
1990; 124 pages; £19.00

No. 98 Cancer Incidence in Jewish Migrants to Israel, 1961–1981
Edited by R. Steinitz, D.M. Parkin, J.L. Young, C.A. Bieber and L. Katz
1989; 320 pages; £30.00

No. 99 Pathology of Tumours in Laboratory Animals, Second Edition, Volume I, Tumours of the Rat
Edited by V.S. Turusov and U. Mohr
Publ. due 1990; 740 pages; £85.00

No. 100 Cancer: Causes, Occurrence and Control
Editor-in-Chief L. Tomatis
1990; 352 pages; £24.00

No. 101 Directory of On-going Research in Cancer Epidemiology 1989–90
Edited by M. Coleman and J. Währendorf
1989; 818 pages; £36.00

No. 102 Patterns of Cancer in Five Continents
Edited by S.L. Whelan and D.M. Parkin
1990; 162 pages; £25.00

No. 103 Evaluating Effectiveness of Primary Prevention of Cancer
Edited by M. Hakama, V. Beral, J.W. Cullen and D.M. Parkin
1990; 250 pages; £32.00

No. 104 Complex Mixtures and Cancer Risk
Edited by H. Vainio, M. Sorsa and A.J. McMichael
1990; 442 pages; £38.00

No. 105 Relevance to Human Cancer of N-Nitroso Compounds, Tobacco Smoke and Mycotoxins
Publ. due 1990; approx. 600 pages

No. 108 Environmental Carcinogens: Methods of Analysis and Exposure Measurement. Volume 11:
Polychlorinated Dioxins and Dibenzofurans
Edited by C. Rappe, H.R. Buser, B. Dodet and I.K. O’Neill
Publ. due 1991; approx. 400 pages; £45.00

No. 109 Environmental Carcinogens: Methods of Analysis and Exposure Measurement. Volume 12:
Indoor Air Contaminants
Edited by B. Seifert, B. Dodet and I.K. O’Neill
Publ. due 1991; approx. 400 pages

No. 110 Directory of On-going Research in Cancer Epidemiology 1991
Edited by M. Coleman and J. Währendorf
1991; approx. 720 pages; £36.00
List of IARC Publications

IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS
(Available from booksellers through the network of WHO Sales Agents*)

Volume 1 Some Inorganic Substances, Chlorinated Hydrocarbons, Aromatic Amines, N-Nitroso Compounds, and Natural Products
1972; 184 pages (out of print)

Volume 2 Some Inorganic and Organometallic Compounds
1973; 181 pages (out of print)

Volume 3 Certain Polycyclic Aromatic Hydrocarbons and Heterocyclic Compounds
1973; 271 pages (out of print)

Volume 4 Some Aromatic Amines, Hydrazine and Related Substances, N-Nitroso Compounds and Miscellaneous Alkylation Agents
1974; 286 pages; Sw. fr. 18.-/US $14.40

Volume 5 Some Organochlorine Pesticides
1974; 241 pages (out of print)

Volume 6 Sex Hormones
1974; 243 pages (out of print)

Volume 7 Some Anti-Thyroid and Related Substances, Nitrofurans and Industrial Chemicals
1974; 326 pages (out of print)

Volume 8 Some Aromatic Azo Compounds
1975; 375 pages; Sw. fr. 36.-/US $28.80

Volume 9 Some Aziridines, N-, S- and O-Mustards and Selenium
1975; 268 pages; Sw.fr. 27.-/US $21.60

Volume 10 Some Naturally Occurring Substances
1976; 353 pages (out of print)

Volume 11 Cadmium, Nickel, Some Epoxydes, Miscellaneous Industrial Chemicals and General Considerations on Volatile Anaesthetics
1976; 306 pages (out of print)

Volume 12 Some Carbamates, Thiocarbamates and Carbazides
1976; 282 pages; Sw fr. 34.-/US $27.20

Volume 13 Some Miscellaneous Pharmaceutical Substances
1977; 255 pages; Sw. fr. 30.-/US$ 24.00

Volume 14 Asbestos
1977; 106 pages (out of print)

Volume 15 Some Fumigants, The Herbicides 2,4-D and 2,4,5-T, Chlorinated Dibenzoioxins and Miscellaneous Industrial Chemicals
1977; 354 pages; Sw. fr. 50.-/US $40.00

Volume 16 Some Aromatic Amines and Related Nitro Compounds - Hair Dyes, Colouring Agents and Miscellaneous Industrial Chemicals
1978; 400 pages; Sw. fr. 50.-/US $40.00

Volume 17 Some N-Nitroso Compounds
1987; 365 pages; Sw. fr. 50.-/US $40.00

Volume 18 Polychlorinated Biphenyls and Polybrominated Biphenyls
1978; 140 pages; Sw. fr. 20.-/US $16.00

Volume 19 Some Monomers, Plastics and Synthetic Elastomers, and Acrolein
1979; 513 pages; Sw. fr. 60.-/US $48.00

Volume 20 Some Halogenated Hydrocarbons
1979; 609 pages (out of print)

Volume 21 Sex Hormones (II)
1979; 583 pages; Sw. fr. 60.-/US $48.00

Volume 22 Some Non-Nutritive Sweetening Agents
1980; 208 pages; Sw. fr. 25.-/US $20.00

Volume 23 Some Metals and Metallic Compounds
1980; 438 pages (out of print)

Volume 24 Some Pharmaceutical Drugs
1980; 337 pages; Sw. fr. 40.-/US $32.00

Volume 25 Wood, Leather and Some Associated Industries
1981; 412 pages; Sw. fr. 60.-/US $48.00

Volume 26 Some Antineoplastic and Immunosuppressive Agents
1981; 411 pages; Sw. fr. 62.-/US $49.60

Volume 27 Some Aromatic Amines, Anthraquinones and Nitroso Compounds, and Inorganic Fluorides Used in Drinking Water and Dental Preparations
1982; 341 pages; Sw. fr. 40.-/US $32.00

Volume 28 The Rubber Industry
1982; 486 pages; Sw. fr. 70.-/US $56.00

Volume 29 Some Industrial Chemicals and Dyestuffs
1982; 416 pages; Sw. fr. 60.-/US $48.00
List of IARC Publications

Volume 30 Miscellaneous
Pesticides
1983; 424 pages;
Sw. fr. 60.-/US $48.00

Volume 31 Some Food Additives, Feed Additives and Naturally Occurring Substances
1983; 314 pages;
Sw. fr. 60.-/US $48.00

Volume 32 Polynuclear Aromatic Compounds, Part 1: Chemical, Environmental and Experimental Data
1984; 477 pages;
Sw. fr. 60.-/US $48.00

Volume 33 Polynuclear Aromatic Compounds, Part 2: Carbon Blacks, Mineral Oils and Some Nitroarenes
1984; 245 pages;
Sw. fr. 50.-/US $40.00

Volume 34 Polynuclear Aromatic Compounds, Part 3: Industrial Exposures in Aluminium Production, Coal Gasification, Coke Production, and Iron and Steel Founding
1984; 219 pages;
Sw. fr. 48.-/US $38.40

Volume 35 Polynuclear Aromatic Compounds: Part 4: Bitumens, Coal-tars and Derived Products, Shale-oils and Soots
1985; 271 pages;
Sw. fr. 70.-/US $56.00

Volume 37 Tobacco Habits Other than Smoking: Betel-quid and Areca-nut Chewing; and some Related Nitrosamines
1985; 291 pages;
Sw. fr. 70.-/US $56.00

Volume 38 Tobacco Smoking
1986; 421 pages;
Sw. fr. 75.-/US $60.00

Volume 39 Some Chemicals Used in Plastics and Elastomers
1986; 403 pages;
Sw. fr. 60.-/US $48.00

Volume 40 Some Naturally Occurring and Synthetic Food Components, Furocoumarins and Ultraviolet Radiation
1986; 444 pages;
Sw. fr. 65.-/US $52.00

Volume 41 Some Halogenated Hydrocarbons and Pesticide Exposures
1986; 434 pages;
Sw. fr. 65.-/US $52.00

Volume 42 Silica and Some Silicates
1987; 289 pages;
Sw. fr. 65.-/US $52.00

Volume 43 Man-Made Mineral Fibres and Radon
1988; 300 pages;
Sw. fr. 65.-/US $52.00

Volume 44 Alcohol Drinking
1988; 416 pages;
Sw. fr. 65.-/US $52.00

Volume 45 Occupational Exposures in Petroleum Refining; Crude Oil and Major Petroleum Fuels
1989; 322 pages;
Sw. fr. 65.-/US $52.00

Volume 46 Diesel and Gasoline Engine Exhausts and Some Nitroarenes
1989; 458 pages;
Sw. fr. 65.-/US $52.00

Volume 47 Some Organic Solvents, Resin Monomers and Related Compounds, Pigments and Occupational Exposures in Paint Manufacture and Painting
1990; 536 pages;
Sw. fr. 85.-/US $68.00

Volume 48 Some Flame Retardants and Textile Chemicals, and Exposures in the Textile Manufacturing Industry
1990; 345 pages;
Sw. fr. 65.-/US $52.00

Volume 49 Chromium, Nickel and Welding
1990; 677 pages;
Sw. fr. 95.-/US $76.00

Volume 50 Pharmaceutical Drugs
1990; 415 pages;
Sw. fr. 65.-/US $52.00

Supplement No. 1
Chemicals and Industrial Processes Associated with Cancer in Humans (IARC Monographs, Volumes 1 to 20)
1979; 71 pages; (out of print)

Supplement No. 2
Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal
1980; 426 pages;
Sw. fr. 40.-/US $32.00

Supplement No. 3
Cross Index of Synonyms and Trade Names in Volumes 1 to 26
1982; 199 pages (out of print)

Supplement No. 4
Chemicals, Industrial Processes and Industries Associated with Cancer in Humans (IARC Monographs, Volumes 1 to 29)
1982; 292 pages (out of print)

Supplement No. 5
Cross Index of Synonyms and Trade Names in Volumes 1 to 36
1985; 259 pages;
Sw. fr. 46.-/US $36.80

Supplement No. 6
Genetic and Related Effects: An Updating of Selected IARC Monographs from Volumes 1 to 42
1987; 729 pages;
Sw. fr. 80.-/US $64.00

Supplement No. 7
Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1-42
1987; 434 pages;
Sw. fr. 65.-/US $52.00

Supplement No. 8
Cross Index of Synonyms and Trade Names in Volumes 1 to 46 of the IARC Monographs
1990; 260 pages;
Sw. fr. 60.-/US $48.00
List of IARC Publications

IARC TECHNICAL REPORTS*

No. 1 Cancer in Costa Rica
Edited by R. Sierra, R. Barrantes, G. Muñoz Leiva, D.M. Parkin, C.A. Bieber and N. Muñoz Calero
1988; 124 pages; Sw. fr. 30.-/US $24.00

No. 2 SEARCH: A Computer Package to Assist the Statistical Analysis of Case-control Studies

No. 3 Cancer Registration in the European Economic Community
Edited by M.P. Coleman and E. Démaret
1988; 188 pages; Sw. fr. 30.-/US $24.00

No. 4 Diet, Hormones and Cancer: Methodological Issues for Prospective Studies
Edited by E. Riboli and R. Saracci
1988; 156 pages; Sw. fr. 30.-/US $24.00

No. 5 Cancer in the Philippines
Edited by A.V. Laudico, D. Esteban and D.M. Parkin
1989; 186 pages; Sw. fr. 30.-/US $24.00

No. 6 La genèse du Centre International de Recherche sur le Cancer
Par R. Sohier et A.G.B. Sutherland
1990; 104 pages; Sw. fr. 30.-/US $24.00

No. 7 Epidémiologie du cancer dans les pays de langue latine
1990; 310 pages; Sw. fr. 30.-/US $24.00

No. 8 Comparative Study of Anti-smoking Legislation in Countries of the European Economic Community
Edited by A. Sasco
1990; c. 80 pages; Sw. fr. 30.-/US $24.00
(English and French editions available) (in press)

DIRECTORY OF AGENTS BEING TESTED FOR CARCINOGENICITY
(Until Vol. 13 Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity)*

No. 8 Edited by M.-J. Ghess, H. Bartsch and L. Tomatis
1979; 604 pages; Sw. fr. 40.-

No. 9 Edited by M.-J. Ghess, J.D. Wilbourn, H. Bartsch and L. Tomatis
1981; 294 pages; Sw. fr. 41.-

No. 10 Edited by M.-J. Ghess, J.D. Wilbourn and H. Bartsch
1982; 362 pages; Sw. fr. 42.-

No. 11 Edited by M.-J. Ghess, J.D. Wilbourn, H. Vainio and H. Bartsch
1984; 362 pages; Sw. fr. 50.-

No. 12 Edited by M.-J. Ghess, J.D. Wilbourn, A. Tossavainen and H. Vainio
1986; 385 pages; Sw. fr. 50.-

No. 13 Edited by M.-J. Ghess, J.D. Wilbourn and A. Aito
1988; 404 pages; Sw. fr. 43.-

No. 14 Edited by M.-J. Ghess, J.D. Wilbourn and H. Vainio
1990; c. 370 pages; Sw. fr. 45.-

NON-SEGIAL PUBLICATIONS †

Alcool et Cancer
By A. Tuyys (in French only)
1978; 42 pages; Fr. fr. 35.-

Cancer Morbidity and Causes of Death Among Danish Brewery Workers
By O.M. Jensen 1980;
143 pages; Fr. fr. 75.-

Directory of Computer Systems Used in Cancer Registries
By H.R. Menck and D.M. Parkin 1986; 236 pages;
Fr. fr. 50.-

* Available from booksellers through the network of WHO sales agents.
†Available directly from IARC